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Abstract 
Plasma clot structure/function is a major determinant in cardiovascular disease risk 
and severity. Plasma proteins are incorporated into plasma clots via binding and 
factor XIII-dependent cross-linking, with complement C3 and factor H previously 
identified as plasma clot components using proteomics. The aim of this current 
project was to validate the role of C3 and factor H in fibrin structure and function 
and to establish a proteomics method for the identification of novel factor XIII 
substrates.  C3 did not affect fibrin structure; however C3 induced a concentration-
dependent prolongation of fibrinolysis. C3 was cross-linked to fibrin within purified 
and plasma clots and bound to plasma clot components. C3 was a substrate for 
plasmin, with cleavage occurring in the presence and absence of fibrin. C3 also 
influenced angiostatin production and t-PA and plasminogen interactions within 
fibrin clots to prevent plasminogen cleavage and plasmin generation. All of these 
interactions were found to influence fibrinolysis. Whereas factor H was confirmed to 
be a plasma clot component, was associated with inflammation and fibrin structure 
and function but was not associated with complement activation in individuals at risk 
of cardiovascular disease. Further in vitro analyses found that factor H did not affect 
fibrin structure or fibrinolysis. Factor H was not cross-linked to fibrin in purified and 
plasma clots, but did form homodimers in the presence and absence of fibrin and 
factor H was a substrate for thrombin and plasmin, with cleavage occurring within 
fibrin clots. The proteomic techniques were established for the identification of 
factor XIII substrates however no novel proteins were identified using these 
methods, suggesting the sensitivity of the technique may be insufficient to detect 
novel proteins. This study has added to the growing body of evidence which suggests 
complement and coagulation pathways interact for the purposes of preventing blood 
loss and pathogen invasion.    
 
 
iii 
 
Table of Contents 
Acknowledgments .......................................................................................................... i 
Abstract   ............................................................................................................ ii 
Table of Contents ......................................................................................................... iii 
List of Figures  ........................................................................................................... xi 
List of Tables  ......................................................................................................... xiv 
Abbreviations  .......................................................................................................... xv 
Chapter 1      Introduction .............................................................................................. 1 
1.1. Cardiovascular disease .................................................................................. 1 
1.1.1. Risk factors for Cardiovascular Disease ................................................ 2 
1.2. Pathogenesis of Cardiovascular Disease ....................................................... 4 
1.2.1. Atherosclerosis ....................................................................................... 4 
1.3. The coagulation cascade ................................................................................ 6 
1.3.1. Platelet plug formation ........................................................................... 6 
1.3.2. Coagulation cascade activation and inhibition ....................................... 7 
1.3.3. Fibrin formation ................................................................................... 11 
1.3.4. FXIII activation and mechanism of cross-link formation .................... 11 
1.3.5. Cross-linking of fibrin by FXIIIa ......................................................... 14 
1.3.6. Fibrinolysis ........................................................................................... 18 
1.4. The influence of fibrin structure in CVD .................................................... 19 
1.5. The influence of inflammation in CVD ...................................................... 20 
1.6. Complement ................................................................................................ 22 
1.6.1. Complement Cascade ........................................................................... 22 
1.6.2. Complement C3 ................................................................................... 27 
1.6.3. Factor H ................................................................................................ 31 
1.7. Clinical studies of complement activation and CVD .................................. 32 
iv 
 
1.7.1. Associations between complement C3, CVD and T2DM ................... 32 
1.7.2. Associations between factor H, CVD and T2DM ................................ 34 
1.8. In vitro studies of complement activation and CVD ................................... 35 
1.8.1. The influence of complement in atherosclerosis .................................. 35 
1.8.2. The influence of complement in thrombosis ........................................ 37 
1.9. In vivo models of complement activation and CVD ................................... 41 
1.9.1. The influence of complement on atherosclerosis in in vivo mouse 
models  .............................................................................................................. 41 
1.9.2. Influence of complement on thrombosis in in vivo mouse models ..... 42 
1.10. Proteomics ............................................................................................... 44 
1.10.1. Use of proteomic technologies in CVD research ............................. 45 
1.10.2. The use of proteomic technologies in thrombosis ............................ 46 
Chapter 2 Aims ................................................................................................. 48 
2.1. To evaluate the influence of C3 on fibrin structure and function................ 48 
2.2. To evaluate the influence of factor H on CVD risk and fibrin structure and 
function .................................................................................................................. 49 
2.3. Determination of novel FXIII substrates using a functional proteomics 
approach ................................................................................................................. 49 
Chapter 3 Methods ............................................................................................ 51 
3.1. Protein Purification ...................................................................................... 51 
3.1.1. C3 Purification ..................................................................................... 51 
3.1.1.1. Polyethylene glycol Precipitation .......................................................... 51 
3.1.1.2. Lysine sepharose chromatography and plasminogen purification ......... 52 
3.1.1.3. DEAE Chromatography ......................................................................... 52 
3.1.1.4. Gel Filtration Chromatography .............................................................. 53 
3.1.1.5. Hydroxylapatite Chromatography .......................................................... 53 
3.1.1.6. Analysis of C3 purification products ..................................................... 54 
3.1.2. Fibrinogen Purification ........................................................................ 55 
3.1.3. Factor XIII Purification ........................................................................ 55 
v 
 
3.1.4. Analysis of fibrinogen, FXIII and plasminogen purification products 56 
3.2. Gel Electrophoresis and Immunoblotting .................................................... 57 
3.2.1. Gel Electrophoresis .............................................................................. 57 
3.2.2. Coomassie staining of gels ................................................................... 57 
3.2.3. Immunoblotting .................................................................................... 57 
3.3. C3 ELISA .................................................................................................... 61 
3.3.1. Evidence for the absence of a blocking step in the C3 ELISA ............ 62 
3.4. Evaluation of the influence of C3 on fibrin structure and function ............. 63 
3.4.1. Turbidimetric analyses ......................................................................... 63 
3.4.1.1. Turbidity Assay ...................................................................................... 63 
3.4.1.2. Lysis Overlay Assay .............................................................................. 65 
3.4.1.3. Concurrent Turbidity and Lysis Assay .................................................. 65 
3.4.2. Concurrent turbidity and lysis assay modifications ............................. 66 
3.4.2.1. Plasminogen and t-PA dose response .................................................... 66 
3.4.3. Plasma concurrent turbidity and lysis assay with spiked C3 ............... 66 
3.5. Analysis of FXIII-dependent cross-linking of C3 to 5-
(biotinamido)pentylamine and fibrin ..................................................................... 67 
3.5.1. Analysis of FXIII-dependent cross-linking of 5-
(biotinamido)pentylamine to C3 ........................................................................ 67 
3.5.1.1. FXIII-dependent cross-linking of 5-(biotinamido)pentylamine into 
immobilised C3 in a plate based assay ....................................................................... 67 
3.5.1.2. Cross-linking of BP into C3 in solution using a plate based assay ........ 68 
3.5.1.3. Cross-linking of BP into C3 in solution analysed by SDS-PAGE ......... 68 
3.5.2. Cross-linking of C3 to fibrin in a purified system ............................... 69 
3.5.3. Cross-linking of C3 to plasma clot components .................................. 70 
3.5.4. Cross-linking of C3 in a plasma based system over a time-course ...... 70 
3.6. Time dependent cleavage of C3 .................................................................. 72 
3.7. Thrombin and plasmin cleavage of C3 ........................................................ 72 
3.8. Analysis of the C3 cleavage products by MALDI-MS/MS and LC-MS/MS . 
  ..................................................................................................................... 74 
vi 
 
3.8.1. Endoproteinase Asp-N and trypsin digestion of C3 cleavage products74 
3.8.2. MALDI-MS/MS analysis of Asp-N and tryptic peptides .................... 75 
3.8.3. LC-MS/MS analysis of Asp-N and trypsin peptides............................ 76 
3.8.4. MASCOT analysis ............................................................................... 76 
3.9. Plasmin Generation Assay ........................................................................... 77 
3.9.1. Plate based plasmin generation assay .................................................. 77 
3.9.1.1. Optimisation of the plate based plasmin generation assay ..................... 78 
3.9.1.2. Final reaction conditions for the plate based plasmin generation assay..... 
  ................................................................................................................ 79 
3.9.2. Clot based plasmin generation assay ................................................... 80 
3.9.2.1. Optimisation of the clot based plasmin generation assay ...................... 81 
3.9.2.2. Final conditions for the clot based plasmin generation assay ................ 81 
3.10. Relationship between factor H, measures of fibrin structure and function 
and family history of T2DM in South Asians ........................................................ 83 
3.10.1. Subjects ............................................................................................ 83 
3.10.2. Blood sampling and analysis of complement factors ....................... 83 
3.11. Evaluation of the influence of factor H on fibrin structure and function 84 
3.11.1. Incorporation of Factor H in plasma clots ........................................ 84 
3.12. Factor H ELISA ....................................................................................... 84 
3.12.1. Optimisation of the Factor H ELISA ............................................... 85 
3.12.1.1. Antibody Optimisation ........................................................................... 85 
3.12.1.2. Blocking step optimisation ..................................................................... 86 
3.12.1.3. Standard Curve Optimisation ................................................................. 89 
3.12.2. Final conditions for the factor H ELISA .......................................... 89 
3.12.2.1. Spiking and Recovery of Factor H ......................................................... 90 
3.12.2.2. Effect of freeze/thaw cycles on Factor H levels ..................................... 90 
3.13. Concurrent turbidity and lysis in the presence of factor H ...................... 91 
3.14. Cross-linking of factor H to fibrin ........................................................... 92 
3.14.1. Cross-linking of factor H in a purified system ................................. 92 
3.14.2. Cross-linking of factor H in plasma based system ........................... 92 
vii 
 
3.15. Thrombin and plasmin cleavage of factor H ........................................... 92 
3.16. Identification of novel factor XIII substrates ........................................... 92 
3.16.1. Incorporation of BP into plasma proteins ......................................... 93 
3.16.2. Removal of excess BP ...................................................................... 93 
3.16.2.1. Removal of excess BP by dialysis ......................................................... 93 
3.16.2.2. Removal of excess BP by gel filtration .................................................. 93 
3.16.3. Factor XIII activity assay to monitor BP elutions from the gel 
filtration column ................................................................................................. 93 
3.17. Purification of biotinylated plasma proteins by monomeric avidin affinity 
chromatography...................................................................................................... 94 
3.17.1. The manufacturers recommended protocol for the purification of BP 
containing proteins by monomeric avidin affinity chromatography .................. 94 
3.17.2. The in-house modified method for the purification of BP containing 
proteins by monomeric avidin affinity chromatography .................................... 95 
3.17.3. Optimisation of the monomeric avidin affinity chromatography 
method using biotinylated BSA ......................................................................... 95 
3.17.3.1. Comparison of the elution profiles using the manufacturers 
recommended protocol and an in-house modified method for monomeric avidin 
purificationof BP containing proteins ........................................................................ 95 
3.17.3.2. Identification of the monomeric avidin affinity column binding capacity . 
  ................................................................................................................ 96 
3.18. Acetone Precipitation ............................................................................. 100 
3.18.1. Acetone precipitation of proteins following monomeric avidin 
affinity chromatography ................................................................................... 100 
3.18.2. Optimisation of the acetone precipitation method ......................... 100 
3.18.2.1. Buffer compatibility with the acetone precipitation method ................ 100 
3.18.2.2. Protein recoveries after acetone precipitation ...................................... 100 
3.19. Identification of Factor XIII substrates by SDS-PAGE ........................ 102 
3.19.1. Silver staining of plasma clot components ..................................... 102 
3.20. Statistical Analysis ................................................................................. 102 
3.20.1. Analysis of clinical data ................................................................. 102 
viii 
 
3.20.2. Analysis of in vitro functional study data....................................... 103 
Chapter 4 Evaluation of the influence of C3 on fibrin structure and function 104 
4.1. Influence of C3 on fibrin formation and fibrinolysis ................................ 104 
4.1.1. Influence of C3 on fibrin clot formation and lysis assessed by 
turbidimetric assay ........................................................................................... 104 
4.2. Evaluation of C3 as a substrate for activated FXIII .................................. 111 
4.2.1. Analysis of cross-linking of BP to purified C3 .................................. 111 
4.2.2. Evaluation of cross-linking of complement C3 to fibrin in a purified 
system  ............................................................................................................ 116 
4.2.3. Influence of plasma C3 incorporation into plasma clots on fibrinolysis 
and cross-linking .............................................................................................. 122 
4.3. The influence of C3 on protein-protein interactions involved in fibrinolysis . 
  ................................................................................................................... 128 
4.3.1. Proteolysis of C3 within cross-linked fibrin clots .............................. 128 
4.3.2. Proteolysis of complement C3 by thrombin....................................... 132 
4.3.3. Proteolysis of complement C3 by plasmin......................................... 133 
4.3.4. Time-dependent cleavage of purified C3 and fibrin clots containing C3 
by plasmin generated as a result of t-PA cleavage of plasminogen ................. 138 
4.3.5. The influence of C3 on t-PA and plasminogen interactions involved in 
plasmin generation ........................................................................................... 145 
4.3.5.1. Analysis of the influence of C3 on plasminogen cleavage .................. 146 
4.3.5.2. The influence of C3 on fibrin structure and fibrinolysis dependent on t-
PA and plasminogen concentration .......................................................................... 153 
4.3.6. The influence of C3 on the interactions between t-PA and plasminogen 
on a fibrin surface involved in plasmin generation .......................................... 157 
4.3.6.1. The influence of C3 on plasmin generation on the surface of fibrin clots 
incubated with t-PA and plasminogen ..................................................................... 163 
Chapter 5 Evaluating the influence of factor H on CVD risk and fibrin structure 
and function  ........................................................................................................ 168 
5.1. Incorporation of factor H into plasma clots ............................................... 168 
ix 
 
5.2. Relationship between factor H and family history of T2DM in South Asians 
  ................................................................................................................... 169 
5.2.1. Relationship between factor H and conventional risk factors for T2DM 
and CVD in South Asian relatives and controls............................................... 169 
5.2.2. Relationship between factor H and complement components in South 
Asian relatives and controls ............................................................................. 170 
5.2.3. Relationship between factor H and fibrin structure and function in 
South Asian relatives and controls ................................................................... 172 
5.3. Evaluating the influence of factor H on fibrin formation and lysis ........... 175 
5.4. Evaluation of factor H cross-linking to fibrin ........................................... 176 
5.4.1. Cross-linking of factor H to fibrin in a purified system ..................... 176 
5.4.2. Cross-linking of factor H to plasma clot components ........................ 179 
5.5. Analysis of factor H cleavage by thrombin and plasmin .......................... 179 
5.6. Discussion ................................................................................................. 184 
Chapter 6 Identification of novel FXIII substrates using a functional proteomics 
approach  ........................................................................................................ 191 
6.1. FXIII-dependent cross-linking of BP into plasma proteins ....................... 192 
6.1.1. Optimisation of the BP cross-linking reaction in normal pool plasma .... 
  ............................................................................................................ 192 
6.1.2. Optimisation of the incubation time for the BP cross-linking reaction in 
fibrinogen depleted plasma .............................................................................. 194 
6.1.3. Establishment of the positive and negative controls for mass 
spectrometry analysis. ...................................................................................... 196 
6.2. Purification of BP labelled plasma proteins by monomeric avdin affinity 
chromatography.................................................................................................... 198 
6.2.1. Removal of free BP by dialysis .......................................................... 198 
6.2.2. Removal of free BP by gel filtration .................................................. 200 
6.2.3. Purification of BP labelled proteins and negative control by gel 
filtration and monomeric avidin affinity chromatography ............................... 202 
x 
 
6.3. Identification of BP labelled proteins by mass spectrometry .................... 204 
6.4. Further optimisation of the monomeric avidin purification method ......... 205 
6.4.1. Establishment of the column size for the purification of BP labelled 
proteins  ............................................................................................................ 205 
6.4.2. Optimisation of the initial protein concentration ............................... 207 
6.4.3. Establishment of BP concentration to reduce human serum albumin 
labelling ............................................................................................................ 209 
6.5. Identification of plasma FXIII substrates by SDS-PAGE ......................... 212 
6.6. Discussion ................................................................................................. 215 
Chapter 7 Conclusions .................................................................................... 227 
Chapter 8 References ...................................................................................... 238 
Chapter 9 Appendices ..................................................................................... 274 
9.1. Appendix A: Identification of complement proteins in perfused, solubilised 
plasma clots .......................................................................................................... 274 
9.2. Appendix B: Buffers and Solutions ........................................................... 275 
9.3. Appendix C: Letter of ethical approval ..................................................... 278 
9.4. Appendix D: Binding of C3 to fibrin ........................................................ 279 
9.5. Appendix E: Turbidity and lysis measurements in South Asian first degree 
relatives of patients with T2DM and South Asian controls with no family history .. 
  ................................................................................................................... 280 
xi 
 
List of Figures 
Figure 1: The coagulation cascade and fibrinolytic pathway..................................... 10 
Figure 2: The formation of fibrin fibres ..................................................................... 12 
Figure 3: Mechanism for the identification of FXIII substrates ................................ 14 
Figure 4: Schematic representation of fibrin degradation products ........................... 19 
Figure 5: The complement cascade ............................................................................ 25 
Figure 6: Schematic representation of the role C3 fragments play in immunity. ...... 30 
Figure 7: Analysis of C3 purification products by SDS-PAGE and Western blot .... 54 
Figure 8: Analysis of fibrinogen, FXIII and plasminogen purification products by 
SDS-PAGE ................................................................................................................. 56 
Figure 9: Preparation of the transfer cassette for immunoblotting. ........................... 58 
Figure 10: Illustration of the turbidity and lysis variables. ........................................ 64 
Figure 11: Method for perfusing plasma clots. .......................................................... 71 
Figure 12: Optimisation of the concentration of t-PA in the plate based plasmin 
generation assay. ........................................................................................................ 79 
Figure 13: Optimisation of the amount of t-PA required for the clot based plasmin 
generation assay. ........................................................................................................ 82 
Figure 14: Grid experiment for the optimisation of the factor H antibodies ............. 88 
Figure 15: Factor H levels after repeat freeze/thaw cycles. ....................................... 91 
Figure 16: Purification of biotinylated BSA by monomeric avidin affinity 
chromatography.......................................................................................................... 99 
Figure 17: Influence of C3 in the turbidimetric clotting assay followed by overlay of 
t-PA and plasminogen to assess fibrinolysis. ........................................................... 105 
Figure 18: Evaluation of the influence of C3 in fibrin formation and lysis using the 
turbidity and lysis overlay assay. ............................................................................. 109 
Figure 19: Evaluating the influence of C3 in fibrin formation and lysis using the 
concurrent turbidity and lysis assay. ........................................................................ 110 
Figure 20: Cross-linking of BP into purified C3. ..................................................... 114 
Figure 21: Formation of enzymatic and non-enzymatic cross-links. ....................... 115 
Figure 22: Analysis of C3 homodimer formation in the presence of FXIIIa. .......... 119 
Figure 23: Cross-linking of C3 to fibrin over a time course. ................................... 120 
Figure 24: Cross-linking of hydrolysed C3 to fibrin over a time course ................. 121 
xii 
 
Figure 26: Cross-linking of C3 to plasma clot components. .................................... 127 
Figure 27: Concentration dependent cleavage of C3 within fibrin clots. ................ 130 
Figure 28: Thrombin cleavage of complement C3 .................................................. 133 
Figure 29: Plasmin cleavage of purified complement C3 ........................................ 136 
Figure 30: Diagrammatic representation of C3 cleavage by plasmin and thrombin 137 
Figure 31: Time-dependent cleavage of purified C3 in the absence of fibrin by 
plasmin generated as a result of t-PA cleavage of plasminogen. ............................. 139 
Figure 33: Time dependent cleavage of cross-linked fibrin clots containing C3 by 
plasmin generated as a result of t-PA cleavage of plasminogen. ............................. 144 
Figure 34: Densitometry analysis of C3 α and β chain cleavage over time. ............ 145 
Figure 35: Time dependent t-PA mediated generation of plasmin in the presence and 
absence of C3, fibrin and FXIII. .............................................................................. 151 
Figure 36: Densitometry analysis of plasmin generation over a 24 hour time course
 .................................................................................................................................. 152 
Figure 37: The effect of t-PA dose response on the influence of C3 in fibrin structure 
and lysis .................................................................................................................... 155 
Figure 38: The effect of a plasminogen dose response on the influence of C3 in fibrin 
structure and lysis ..................................................................................................... 156 
Figure 39: Plasmin generation in a plate based assay. ............................................. 160 
Figure 40: The interactions between C3 and t-PA that influence plasmin generation 
in the plate based assay ............................................................................................ 161 
Figure 41: The interactions between C3 and plasminogen that influence plasmin 
generation in the plate based assay .......................................................................... 162 
Figure 42: Plasmin generation in the presence of C3 and FXIII within a solid fibrin 
clot containing t-PA. ................................................................................................ 165 
Figure 43: Plasmin generation in the presence of C3 and FXIII within a solid clot 
containing plasminogen. .......................................................................................... 166 
Figure 44: Incorporation of complement factor H into ex vivo plasma clots. .......... 169 
Figure 45: Complement factor H in South Asian relatives of subjects with T2DM 
compared with South Asian controls with no family history. .................................. 171 
Figure 46: Role of factor H in plasma fibrin formation and lysis. ........................... 173 
Figure 47: Evaluating the influence of factor H on fibrin formation and lysis. ....... 177 
Figure 48: Analysis of factor H cross-linking to fibrin in a purified system. .......... 178 
Figure 49: Analysis of factor H cross-linking in plasma clots. ................................ 181 
xiii 
 
Figure 50: Concentration dependent cleavage of factor H within purified fibrin clots.
 .................................................................................................................................. 182 
Figure 51: Cleavage of factor H by thrombin and plasmin. ..................................... 183 
Figure 52: Proposed method for the identification of novel FXIII substrates in plasma
 .................................................................................................................................. 191 
Figure 53: Concentration dependent cross-linking of BP to plasma proteins .......... 193 
Figure 54: Depletion of fibrinogen in fibrinogen depleted plasma .......................... 194 
Figure 56: Evaluation of the positive and negative controls for mass spectrometry.
 .................................................................................................................................. 197 
Figure 57: Removal of free BP by dialysis. ............................................................. 199 
Figure 58: Removal of free BP by gel filtration. ..................................................... 201 
Figure 59: Purification of BP labelled plasma proteins, positive and negative controls 
by monomeric avidin affinity chromatography........................................................ 203 
Figure 60: Evaluation of binding capacity of the monomeric avidin column after a 
reduction in column volume..................................................................................... 206 
Figure 61: Purification of negative control and BP labelled plasma proteins by 
monomeric avidin affinity chromatography after an increase in the inital protein 
concentration. ........................................................................................................... 208 
Figure 62: Purification of pooled BP labelled plasma reactions by monomeric avidin 
affinity chromatography. .......................................................................................... 210 
Figure 63: Identification of BP labelling of albumin at reduced BP concentrations 211 
Figure 64: SDS-PAGE of a silver stained, perfused, solubilised plasma clots. ....... 212 
Figure 65: Temperature dependent reduction of solubilised plasma clots ............... 214 
Figure 66: Stages representing the loss of protein in the proteomics approach ....... 223 
Figure 67: Interaction between C3, factor H and components of the 
coagulation/fibrinolytic cascades. ............................................................................ 232 
Figure 68: Identification of complement proteins in perfused, solubilised plasma 
clots. ......................................................................................................................... 274 
Figure 69: Binding interactions between C3 and fibrinogen. .................................. 279 
 
 
 
xiv 
 
List of Tables 
Table 1: Substrates of activated FXIII ....................................................................... 16 
Table 2: Regulators of the complement system ......................................................... 26 
Table 3: Primary and secondary antibodies used in immunoblotting. ....................... 60 
Table 4: C3 ELISA performed in the presence and absence of a blocking step to 
determine non-specific binding to the ELISA plate ................................................... 62 
Table 5: Reaction conditions used to analyse the time dependent cleavage of C3. ... 73 
Table 6: Reaction conditions for the plate based plasmin generation assay. ............. 80 
Table 7: Factor H ELISA performed in the presence and absence of a blocking step 
to determine non-specific binding to the ELISA plate. ............................................. 87 
Table 8: Spiking and recovery of factor H into quality control normal pool plasma. 90 
Table 9: Advantages and disadvantages of avidin affinity chromatography ............. 97 
Table 10: Protein recoveries after acetone precipitation .......................................... 101 
Table 11: Characterisation of complement C3 lysis products analysed by MALDI-
TOF-MS peptide mass fingerprinting ...................................................................... 131 
Table 12 : Age and sex adjusted correlation coefficients between factor H and 
conventional risk factors for T2DM and CVD in South Asian controls and relatives
 .................................................................................................................................. 170 
Table 13: Age and sex adjusted correlation coefficients between factor H and 
complement components in South Asian controls and relatives. ............................. 172 
Table 14: Age and sex adjusted correlation coeffcients between factor H and 
turbidimetric parameters in South Asian relatives and controls .............................. 175 
Table 15: Characterisation of BP labelled plasma proteins analysed by LC-MS/MS 
peptide mass fingerprinting ...................................................................................... 204 
Table 16: Methods evaluated for the purification of BP labelled plasma proteins by 
monomeric avidin affinity chromatography............................................................. 226 
Table 17: The mode of exploitation of the fibrinolytic system by pathogens ......... 233 
Table 18: Plasma clot turbidity and lysis measurements in South Asian first degree 
relatives of patients with T2DM and South Asian controls with no family history 280 
xv 
 
Abbreviations 
α2-AP   α2-antiplasmin 
ADP   Adenosine diphosphate 
aHUS   atypical haemolytic uraemic syndrome 
BMI   Body mass index 
BP   5-(biotinamido)pentylamine 
BSA   Bovine serum albumin 
C3aR   C3a Receptor 
C3(H2O)  Hydrolysed C3 
C5aR   C5a Receptor 
CAD   Coronary artery disease 
COAT platelet Collagen and thrombin activated platelet 
CR   Complement receptor 
CRP   C reactive protein 
CV   Column volume 
CVD   Cardiovascular disease 
DAF   Decay acceleration factor 
DCDR   Division of Cardiovascular and Diabetes Research 
DEAE   Diethylaminoethanol 
DTT   Dithiothreitol 
εACA   ε-aminocaproic acid 
EDTA   Ethylenediaminetetraacetic acid 
xvi 
 
ELISA   Enzyme linked immunosorbant assay 
FP   Fibrinopeptide 
FXIII   Factor XIII 
FXIII-A  Factor XIII A subunit 
FXIII-B  Factor XIII B subunit 
FXIIIa   Activated factor XIII 
FXIII-A2B2  Plasma factor XIII 
gC1qR   C1q receptor 
HOMA  Homeostasis model assessment 
HRP   Horseradish peroxidase 
ICAM-1  Intracellular adhesion molecule-1 
IFG   Impaired fasting glucose 
IL   Interleukin 
KCl   Potassium chloride 
LC-MS/MS  Liquid chromatography tandem MS 
ldlr   Low density lipoprotein receptor 
LOX-1   Oxidized low density lipoprotein receptor-1 
MALDI-MS/MS         Matrix assisted laser desorption/ionisation tandem MS 
MASP MBL-associated proteins 
MBL Mannose-binding lectin 
MES 2-(N-morpholino)ethanesulfonic acid 
MI Myocardial infarction 
MMP Matrix metalloproteinase 
xvii 
 
MS   Mass spectrometry 
NaCl   Sodium chloride 
NO   Nitric oxide 
OPD   o-Penylenediamine 
Ox-LDL  Oxidised low density lipoprotein 
PAI-1   Plasminogen activator inhibitor-1 
PBS   Phosphate buffered saline 
PBS-T   PBS-Tween 
PEG   Polyethylene glycol 
PMSF   Phenylmethanesulfonylfluoride 
PVD   Peripheral vascular disease 
PVDF   Polyvinylidene fluoride 
SCR   Short consensus repeats 
SDS   Sodium dodecyl sulphate 
SDS-PAGE  SDS-polyacrylamide gel electrophoresis 
T2DM   Type 2 diabetes mellitus 
TAFI   Thrombin activatable fibrinolysis inhibitor 
TBS   Tris buffered saline 
TBS-T   TBS-Tween 
TF   Tissue factor 
TG2   Tissue transglutaminase 
TNFα   Tumor necrosis factor α 
t-PA   Tissue-type plasminogen activator 
xviii 
 
TRAP   Thrombin receptor activating peptide 
u-PA   Urokinase plasminogen activator 
VCAM-1  Vascular cell adhesion molecule-1
1 
 
Chapter 1  Introduction 
1.1.  Cardiovascular disease 
Cardiovascular disease (CVD), an illness of the heart and circulation encompasses a 
number of syndromes including ischaemic heart disease, coronary artery disease 
(CAD), myocardial infarction (MI), cerebrovascular disease (stroke), hypertensive 
heart disease, inflammatory heart disease, rheumatic heart disease and peripheral 
vascular disease (PVD).  
A recent World Health Organisation report, indicated CVD was one of the 
leading causes of mortality across the world, with 17 million deaths during 2008, 
with low to middle income countries suffering particularly badly (Anon 2011). A 
2010 British Heart Foundation report found that mortality from CVD has fallen by 
44% over the last ten years in the UK; however, deaths from CVD still remained 
high at around 191,000 each year with 50,000 premature deaths (before the age of 75 
years). In England alone, 101,000 individuals have an MI and 125,000 have a stroke 
every year, placing enormous pressure on health service resources. These include 
266 million prescriptions for anti-platelet, cholesterol-lowering and anti-hypertensive 
drugs, 80,000 angioplasties and 453,000 in-patient episodes, costing the UK 
economy £30 billion every year, with this level likely to increase with the ever 
growing older population (Scarborough et al. 2010b). In developed countries, Black 
and South Asian ethnic groups are at particular risk of CVD with 15% and 27% of 
deaths resulting from CAD in men respectively in the UK (Scarborough et al. 
2010a). 
 CVD was originally considered a disease of developed countries; however, 
the prevalence of CVD is rapidly increasing in developing countries, with deaths as a 
result of CVD estimated to reach 9 million by 2020. Changes to a Westernized diet 
are one of the major causes for this increase (Reddy 2004).   
 
 
2 
 
1.1.1. Risk factors for Cardiovascular Disease  
CVD is a multi-factorial disease, with numerous behavioural, medical, genetic and 
inflammatory factors influencing disease pathogenesis and outcome. Behavioural 
risk factors for CVD include smoking, poor diet, physical inactivity and alcohol 
consumption (Scarborough et al. 2010b). Smoking was a strong risk factor for PVD 
and CAD in a prospective study (Price et al. 1999); additionally smoking is 
associated with an increase in intima thickening and atherosclerotic plaque 
development (Wallenfeldt et al. 2001). Smoking also increases the risk for 
thrombosis, by promoting platelet aggregation, fibrin accumulation and increasing 
clot strength (Barua et al. 2010). Poor diet is associated with an increased CVD risk. 
A western diet of high fat, highly processed foods was associated with un-favourable 
biomarkers of CVD such as reduced high density lipoprotein, increased plasma 
cholesterol, insulin resistance and C-reactive protein (CRP) (Fung et al. 2001), 
whereas an increase in fruit and vegetable intake was found to have a protective 
effect for CVD (Liu et al. 2000).  
Poor diet and physical inactivity can lead to the development of several other 
CVD risk factors, including increased blood pressure, increased blood cholesterol, 
obesity and type 2 diabetes mellitus (T2DM). Obesity is a major risk factor for both 
T2DM and CVD (Wilson et al. 2002), whereas weight loss of >5% was associated 
with a reduced CVD risk (Wing et al. 2011). Deposits of adipose tissue in the 
abdominal region has been shown to be a stronger risk factor for MI measured by 
computed tomography compared with total adipose tissue measured by body mass 
index (BMI) (Nicklas et al. 2004). Obesity is also associated with other traditional 
risk factors for CVD including increased blood pressure, cholesterol and triglycerides 
(Wilson et al. 2002). The age of T2DM onset determines the increased CVD risk; 
individuals who develop T2DM before 60 years of age have the highest CVD risk 
(Wannamethee et al. 2011). Insulin resistance in T2DM individuals is also associated 
with a pro-coagulant (increase in plasminogen activator inhibitor 1 (PAI-1) and 
fibrinogen) and a pro-atherogenic (increase triglycerides and cholesterol) state, 
suggesting insulin resistance contributes to CVD risk (Haffner et al. 1999).  
The genetic component of CVD risk was highlighted by twin studies. In a 
large prospective study in Sweden, the risk of coronary heart disease was increased 
8.1% in male monozygotic and 3.8% in male dizygotic twins if one twin died before 
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the age of 55 years, whereas in female monozygotic twins the risk was 15.0% and in 
dizygotic twins was 2.6% if one twin died before the age of 65 years, which suggests 
that the genetic component of CVD risk is particularly significant if one twin dies 
young (Marenberg et al. 1994). In the Stockholm Heart Epidemiology Program, 
family history of coronary heart disease was a risk factor for MI, after accounting for 
conventional CVD risk factors. In women who had a family history of coronary heart 
disease and who were current smokers the increased risk for MI was synergistic 
(Leander et al. 2001). Recent genome wide association studies suggest that the 
genetic component of CAD, T2DM and blood pressure are likely to be due to small 
effects of many different genetic variants involved in disease pathogenesis (Burton et 
al. 2007;Ehret et al. 2011). 
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1.2.   Pathogenesis of Cardiovascular Disease 
1.2.1. Atherosclerosis 
Atherosclerosis is the term used to describe hardening of the artery wall, which 
occurs due to the build up of fats, cholesterol and inflammatory cells in the formation 
of a plaque in the subendothelium. Atherosclerosis occurs early in life with increased 
intima thickening observed in children as young as 7 years that are overweight or 
with type 1 diabetes (Jarvisalo et al. 2004;Woo et al. 2004).  
The endothelium is regulated by vasodilators (nitric oxide [NO], prostacyclin, 
bradykinin) vasoconstrictors (endothelin, angiotensin II) and by cellular adhesion 
molecules, which prevent cell adhesion and suppression of coagulation. During the 
initial stages of atherosclerosis, endothelial dysfunction, caused by a variety of CVD 
risk factors, leads to alterations in the balance between vasoconstriction and 
vasodilation and in endothelial cell expression of cellular adhesion molecules 
(Davignon and Ganz 2004). The main candidate for endothelial dysfunction is low 
density lipoprotein (LDL), which when mildly oxidised, forms oxidised LDL (Ox-
LDL). Ox-LDL increases the permeability of the endothelium (Essler et al 1999) 
allowing LDL to be transported across the endothelium through porous pathways 
between adjacent endothelial cells into the subendothelium (Rutledge et al 1990). 
Once inside the subendothelium LDL is converted to Ox-LDL by reactive oxygen 
species released from the endothelium in response to increased glucose and free fatty 
acids (Inoguchi et al 2000). Ox-LDL binds and activates the up-regulated endothelial 
receptor, oxidized low density lipoprotein receptor-1 (LOX-1). LOX-1  promotes 
endothelial abnormalities such as superoxide generation, nuclear factor κB 
activation, increases adhesion molecule numbers, endothelial cell apoptosis (Chen et 
al. 2002) and matrix metalloproteinase (MMP) 1 and 3 expression (Li et al. 2003). 
One of the main effects of endothelial dysfunction is impaired endothelial relaxation, 
as a result of dysfunction within the NO synthase pathway, which under normal 
circumstances produces NO, however during endothelial dysfunction produces 
superoxide instead of NO due to the uncoupling of  endothelial NO synthase by 
tetrahydrobiopterin, thus preventing bioavailability of NO for vasodilation 
(Kawashima and Yokoyama 2004).. 
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 Dysfunctional endothelial cells also up-regulate a number of adhesion 
molecules including vascular cell adhesion molecule-1 (VCAM-1), intracellular 
adhesion molecule-1 (ICAM-1), P-selectin and E-selectin by Interleukin (IL) 1 and 
tumor necrosis factor α (TNFα) (Eppihimer et al. 1996;Pober et al. 1986). The 
selectins are responsible for the initial rolling and tethering of monocytes and T cells 
to the endothelium through interactions with sialylated carbohydrates, P-selectin 
glycoprotein-1 and E-selectin ligand-1, whilst firm adhesion to the endothelium is 
mediated by VCAM-1 and ICAM-1 interactions with α4β1 and leukocyte specific β2 
integrin respectively (Blankenberg et al. 2003). Once adhered to endothelial cells, the 
monocytes migrate to the arterial intima, promoted by the cytokine monocyte 
chemoattractant protein-1 where they differentiate into macrophages with the aid of 
macrophage colony-stimulating factor  (Linton and Fazio 2003) which is 
produced/expressed by endothelial cells following a decrease in NO (Peng et al. 
1995). The scavenger receptor CD36 is up-regulated on the macrophage surface and 
internalises Ox-LDL, resulting in the formation of foam cells and ultimately fatty 
streaks (Huh et al. 1996;Podrez et al. 2002). Foam cells produce a number of 
inflammatory mediators (IL1β, IL6, TNFα) which promote expression of monocyte 
chemotactic factor by endothelial cells, which in turn recruit additional monocytes, 
thus contributing to the growth of the atherosclerotic plaque and to intima thickening 
(Strieter et al. 1989). As the plaque increases in complexity, vascular smooth muscle 
cells are recruited and secrete collagen due to the stimulation from cytokines 
(transforming growth factor-β, IL-1, platelet derived growth factor), which forms a 
major component of the fibrous cap (Amento et al. 1991). The thickness of the 
fibrous cap is critical to the overall stability of the plaque, with thin fibrous caps 
particularly prone to rupture due to the stresses applied to the cap within narrowed 
arteries (Li et al. 2006). The fibrous cap is weakened by the secretion of MMP’s, 
which break down collagen (Shah et al. 1995), thus increasing susceptibility to 
plaque rupture.  
 Plaque rupture exposes collagen, collagen-bound von Willebrand factor and 
tissue factor (TF) to flowing blood, allowing binding of platelets via GPIb-IX-V, 
GPVI and α2β1 receptors (discussed in more detail in section 1.3.1) and activation of 
the extrinsic pathway of the coagulation cascade (Figure 1) (as discussed in more 
detail in section 1.3.2). Activation of the coagulation cascade leads to the generation 
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of the serine protease thrombin, which cleaves and activates fibrinogen and factor 
XIII (FXIII) to form a stable cross-linked fibrin clot (discussed in more detail in 
section 1.3.3). In some cases the thrombus is incorporated into the atherosclerotic 
plaque (Bini et al. 1989), furthering its development by promoting smooth muscle 
cell migration into the fibrin gel (Kodama et al. 2002), in other cases thrombus 
formation continues until complete vessel occlusion occurs leading to acute MI.  
 
1.3.   The coagulation cascade 
1.3.1. Platelet plug formation 
Following vascular wall damage, platelets adhere to the damaged tissue via 
interactions between platelet receptors glycoprotein VI and α2β1 which binds 
directly to collagen (Kehrel et al. 1998) or via glycoprotein Ib which binds to the 
multimeric protein von Willebrand factor (Kroll et al. 1991), forming a bridge 
between the collagen and the platelet. FXIII also binds platelets via αIIbβ3 and αVβ3 
under flow, leading to platelet adhesion and spreading, additionally when activated 
FXIII (FXIIIa) is bound to collagen platelet adhesion is synergistic (Magwenzi et al. 
2011). Thrombin also activates platelets via protease activating receptors 1 and 4 
leading to rapid platelet aggregation and secretion of granular contents (Kahn et al. 
1999). Activation of platelets by thrombin, results in several morphological changes 
leading to the formation of filapodia, this is due to structural changes which occur in 
the cytoskeleton (Jennings et al. 1981). Whereas conformational changes in the 
glycoprotein receptor IIb-IIIa exposes binding sites for fibrinogen, von Willebrand 
factor and fibronectin (Sims et al. 1991), which results in a network of proteins 
which bridges the platelet aggregates. In a small subset of collagen and thrombin 
activated platelets (COAT platelets) this network of proteins is the result of FXIII-
dependent cross-linking of serotonin to α-granule proteins which bind to an unknown 
serotonin binding site on platelet bound fibrinogen and thrombospondin (Dale et al. 
2002;Szasz and Dale 2002). 
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1.3.2. Coagulation cascade activation and inhibition 
The coagulation cascade is a series of proteolytic cleavages split into two pathways 
(Figure 1) the first is the extrinsic pathway which is activated following damage to 
the vascular wall. The extrinsic pathway is initiated when TF present on the 
membranes of cells around the vascular bed is exposed to flowing blood. TF forms a 
complex with factor VII in the presence of Ca
2+
 to produce the active serine protease 
TF/VIIa. The TF/VIIa complex cleaves factor X  (Silverberg et al. 1977) and factor 
IX (Osterud and Rapaport 1977) to form the active serine proteases factor Xa and 
IXa.  
The second pathway is the intrinsic pathway which is initiated when factor 
XII, high molecular weight kininogen and prekallikrein come into contact with 
charged surfaces in a process known as the contact activation pathway. In plasma 
high molecular weight kininogen and prekallikrein are present as a complex (Mandle 
et al. 1976), which once bound to the negatively charged surface along with factor 
XII results in the cleavage and activation of factor XII to form factor XIIa. Factor 
XIIa cleaves prekallikrein into kallikrein, which in turn cleaves more factor XII 
(Mandle and Kaplan 1976) and digests high molecular weight kininogen to form 
bradykinin (Thompson et al. 1978). Factor XIIa cleaves and activates factor XI 
(Brunnee et al. 1993), which in turn cleaves and activates factor IX (Sun and Gailani 
1996). Following the activation of factor IX the intrinsic pathway converges with the 
extrinsic pathway at the stage of factor X activation.  
Factor Xa forms a complex with the activated cofactor Va bound to 
phosphatidylserine on the surface of platelets to form the prothrombinase complex 
(Krishnaswamy 1990). Factor V can be activated by factor Xa directly or by the first 
amounts of thrombin generated. The prothrombinase complex cleaves prothrombin at 
Arg271 and Arg320 to form thrombin (Orcutt and Krishnaswamy 2004). Thrombin 
forms several feedback mechanisms to further activate the coagulation cascade, 
firstly thrombin amplifies coagulation by cleaving and activating factor V (Suzuki et 
al. 1982). Thrombin activates factor VIII and liberates the bound von Willebrand 
factor (Saenko et al. 1996), allowing binding of factor VIIIa to the platelet surface 
and the formation of the tenase complex with activated factor IX. Thrombin also 
cleaves factor XI in the presence of negatively charged surfaces to form factor XIa 
(Naito and Fujikawa 1991). Thrombin cleaves fibrinopeptides (FP) A and B from 
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fibrinogen to initiate fibrin polymer formation (as described in section 1.3.3) and 
cleaves and activates FXIII to initate cross-linking of the fibrin polymer (as 
described in section 1.3.4). Thrombin also activates platelets via protease activating 
receptors 1 and 4 (as described in section 1.3.1).  
The coagulation cascade is regulated at several stages, firstly TF pathway 
inhibitor regulates TF/VIIa complex formation and inhibits factor Xa via kunitz 
domains (Bajaj et al. 2001). Secondly antithrombin III a serine protease inhibitor is 
responsible for the inhibition of components of the intrinsic and extrinsic pathway 
including factor IX (Mauray et al. 1998), X (Choay et al. 1983), and thrombin 
(Maaroufi et al. 1997). As shown by these studies antithrombin III is a poor serpin 
when free in solution, however in the presence of heparins antithrombin III inhibitory 
activity is increased. Finally coagulation is regulated by protein C. Protein C is a 
vitamin K dependent protein which is activated by thrombin and thrombomodulin 
present on endothelial cells (Esmon and Owen 1981). Activated protein C in the 
presence of its cofactor free protein S proteolytically inactivates factor V or activated 
factor Va and factor VIIIa (Dahlback 1991), however factor VIIIa bound to von 
Willebrand factor is protected from activated protein C cleavage. In plasma protein S 
can be found bound to complement C4 binding protein (Dahlback 1991), however it 
is only the free form of protein S which can act as a cofactor for protein C.  
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Figure 1: The coagulation cascade and fibrinolytic pathway. 
In the extrinsic pathway, exposed tissue factor (TF) forms a complex with factor VII, which cleaves and activates factor X and factor IX. In the 
intrinsic pathway, contact between high molecular weight kininogen (HMWK), prekallikrein (PK) and factor XII with a negatively charged 
surface results in the activation of factor XII (XIIa), which in turn cleaves and activates factor XI. Activated factor XI (XIa) then cleaves and 
activates factor IX. The intrinsic and extrinsic pathways converge at the stage of factor X activation. Activated factor X (Xa) forms a complex 
with activated V (Va) to form the prothrombinase complex which cleaves and activated prothrombin to generate thrombin. Thrombin cleaves and 
activates fibrinogen and  FXIII to form a stable cross-linked fibrin clot. Thrombin also activates factor V, factor XI and cleaves factor VIII bound 
to von Willebrand factor (vWF) to aid the generation of more thrombin. During fibrin formation the fibrinolytic pathway is activated by tissue 
plasminogen activator (t-PA) binding to fibrin and activating plasminogen to form plasmin. Plasmin cleaves fibrin to form fibrin degradation 
products (FDP). Fibrinolysis inhibitors target t-PA (plasminogen activator inhibitor (PAI) 1 and 2), plasminogen (thrombin activatable 
fibrinolysis inhibitor (TAFI)) and plasmin (α2-antiplasmin and α2-macroglobulin). 
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1.3.3. Fibrin formation 
Fibrin is formed by thrombin-mediated cleavage of fibrinogen in the final stages of 
activation of the coagulation cascade (Figure 1) to prevent blood loss and promote 
wound healing. Fibrinogen is a six-chain (Aα2, Bβ2, γ2) polypeptide arranged into 
two outer D domains joined to the central E domain via a coiled coil region and an 
αC domain which begins at residue 111 in the D domain and is tethered to the E 
domain (Mosesson et al. 1998). Fibrinogen is present in plasma at ~ 2.5 mg/ml. 
During coagulation the serine protease thrombin sequentially cleaves the short N-
terminal fibrinopeptides (FP)A and FPB from fibrinogen Aα and Bβ chains, 
respectively, to initiate polymerisation and the formation of half-staggered double 
stranded fibrin protofibrils. Protofibrils undergo lateral aggregation when they reach 
600-800 nm in length to form fibrin fibres with the aid of αC intermolecular 
interactions (Weisel 2005). Fibrin fibres branch through binding of fibrin monomers 
to divergent fibrin monomers to form trimolecular and tetramolecular branch points, 
which ultimately lead to formation of a complex fibrin network (Figure 2) (Mosesson 
et al. 1993;Weisel et al. 1993). Fibrin fibres are strengthened by FXIII mediated 
cross-linking (described in section 1.3.5).  
 
1.3.4. FXIII activation and mechanism of cross-link formation 
FXIII is a member of the transglutaminase family, which catalyses the formation of 
covalent ε-(γ-glutamyl)lysine cross-links between plasma, extracellular matrix and 
intracellular substrates (Table 1). Plasma FXIII (FXIII-A2B2) has a heterotetrameric 
structure, composed of pairs of A subunits (83 kDa) and B subunits (80 kDa) 
(Komaromi et al. 2011;Schwartz et al. 1973) and is present in plasma at a 
concentration of ~ 22μg/ml. The structure of cellular FXIII is an A subunit 
homodimer (Henriksson et al. 1985;Schwartz et al. 1973). The FXIII-A subunit 
contains the active site of the enzyme and is synthesised by the following cell types: 
monocyte/macrophage, megakaryocyte/platelet, chondrocyte, osteoblast/osteocyte 
and hepatocytes (Kappelmayer et al. 1995;Komaromi et al. 2011;Nurminskaya and 
Kaartinen 2006). The FXIII-B subunit acts as a carrier protein in plasma for the 
hydrophobic A subunit and is synthesised and secreted by liver hepatocytes (Nagy et 
al. 1986). 
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Figure 2: The formation of fibrin fibres 
Thrombin cleaves fibrinopeptide A (FPA) from fibrinogen to initiate protofibril 
formation and activates FXIII to form cross-links between the fibrin γ-chains (red 
lines between D domains). Following thrombin cleavage of FPB the αC domains 
(green) are released to allow the formation of α-chain cross-link formation between 
protofibrils (red lines between αC domains). Fibrin branching occurs when fibrin 
monomers bind to divergent fibrin monomers.  
 
 
During FXIII activation, FXIII-A2B2 binds to fibrin via the B subunit thus 
promoting the correct orientation for cleavage of the peptide bond between Arg37 
and Gly38 of FXIII-A by thrombin, leading to the release of the 37 amino acid 
activation peptide (Hornyak and Shafer 1992;Takagi and Doolittle 1974). In the 
presence of calcium and fibrin thrombin-cleaved FXIII undergoes several 
conformational changes; initially FXIII-B dissociates from FXIII-A and then 
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reorientation of FXIII-A leads to exposure of the active site, forming FXIIIa (Lorand 
et al. 1974;Moaddel et al. 2000). FXIII-A activation is downregulated following γ-
dimer formation, suggesting fibrin plays an activatory and regulatory role in FXIII-A 
activation (Lewis et al. 1985). Cellular FXIII in comparison is activated by an 
increase in cellular Ca
2+
 above 2 mM (Kristiansen and Andersen 2011). Following 
dissociation of the FXIII-B subunit the FXIII-A subunit catalytic triad (Cys314, 
His373, Asp 396) is exposed to allow substrate cross-linking (Lewis et al. 1985).  
FXIIIa uses a double displacement mechanism to form covalent ε-(γ-glutamyl)lysine 
cross-links between the γ-carboxy-amine group of a glutamine (amine acceptor) and 
the ε-amino group of a lysine (amine donor) residue. In stage 1, Cys314 within 
FXIII-A attacks the glutamine γ-carboxyamide group of an amine acceptor protein, 
displacing a molecule of ammonia to form a thioester intermediate. In stage 2, the 
reactive thioester intermediate is attacked by the lysine ε-amino group of the amine 
donor protein, displacing FXIII-A resulting in the formation of an isopeptide bond 
between the two substrate proteins and the release of FXIIIa (Loewy et al. 
1961;Lorand et al. 1966). Alternatively in the absence of a lysine donor protein, 
water reacts with the thioester intermediate converting glutamine into glutamic acid. 
Based on this reaction FXIII substrates have previously been identified using 
molecular probes such as putrescine, dansylcadaverine and 5-
(biotinamido)pentylamine (BP), which are cross-linked by FXIII to glutamine 
residues, whereas labelled synthetic peptides based on α2-antiplasmin are cross-
linked into lysine residues of FXIII substrates. In these studies the glutamine and 
lysine residues within the FXIII substrate(s) were characterised by mass 
spectrometry or Edman sequencing analysis as outlined in Figure 3 and the identified 
substrates can be found in Table 1. 
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Figure 3: Mechanism for the identification of FXIII substrates 
FXIII-A forms a thioester intermediate between a glutamine acceptor (α2-
antiplasmin (α2-AP)) and a lysine donor, displacing a molecule of ammonia, water 
and with the release of FXIII-A. FXIII substrates and their reactive glutamine and 
lysine residues are identified by mass spectrometry and edman sequencing 
(Richardson et al. 2013).  
 
 
1.3.5. Cross-linking of fibrin by FXIIIa 
During fibrin formation the fibrin clot is stabilised by FXIIIa-induced cross-linking 
of the fibrin α and γ-chains as shown in Figure 2. FXIIIa rapidly forms cross-links 
between γ-chains of two fibrin molecules to form γ-dimers (Siebenlist et al. 
2001;Standeven et al. 2007). Cross-link formation occurs between Lys406 on one γ-
chain and either Gln399 or Gln398 on the neighbouring γ-chain (Gorman and Folk 
1980). The fibrin α-chain is cross-linked by FXIIIa to form α-polymers, albeit at a 
much slower rate compared to γ-γ cross-links (Siebenlist et al. 2001). Cross-link 
formation occurs between Gln223 and either Lys508 or Lys539; between Gln237 and 
either Lys418, Lys508, Lys539 or Lys556; between Gln366 and Lys539; and 
between Gln563 and either Lys539 or Lys601 (Wang 2011). A number of additional 
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lysine donor sites in the α-chain have been identified by their ability to incorporate 
an N terminal peptide of α2-antiplasmin, including Lys580, Lys448, Lys606, 
Lys427, Lys429, Lys208, Lys224 and Lys219 (Matsuka et al. 1996;Sobel and 
Gawinowicz 1996). The multiple lysine donor sites identified in the α-chain provide 
the opportunity for the formation of a complex fibrin polymer whilst retaining the 
possibility of cross-linking numerous other plasma proteins such as α2-antiplasmin, 
thrombin activatable fibrinolysis inhibitor (TAFI), PAI-2, fibronectin and von 
Willebrand factor to fibrin (Table 1).  
Cross-linking increases the stiffness and reduces the stretch of the fibrin 
network (Liu et al. 2010). Analyses of the elastic modulus of individual fibrin fibres, 
using optical tweezers, showed that cross-linked fibrin fibres were stiffer compared 
to non-cross-linked fibrin fibres (Collet et al. 2005), specifically fibrin α-chain cross-
linking increased clot stability and rigidity by promoting protofibril aggregation and 
the formation of thicker fibres (Shen and Lorand 1983;Shen et al. 1974;Standeven et 
al. 2003).  Using site directed mutagenesis of Lys406, Gln399 and Gln398 within the 
fibrinogen γ-chain, it was demonstrated that α-polymers produced an increase in clot 
stiffness of 2.5 fold, whereas γ-α-heteropolymers produced an increase in clot 
stiffness of 1.5 fold, compared to a 3.5 fold increase in clot stiffness in the presence 
of un-mutated fibrin (Standeven et al. 2007). This suggests that all forms of cross-
links contribute to fibrin stiffness; however the formation of α-polymers contributes 
to the greatest extent. 
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Table 1: Substrates of activated FXIII 
FXIII substrates including their reactive glutamine (Gln) and lysine (Lys) residues (Richardson et al. 2013)  
Protein Cross-link sites Cross-link substrates References 
Fibrin α chain Gln221, Gln237, Gln328 Gln366, 
Lys556, Lys539, Lys508, Lys580, 
Lys583, Lys418, Lys448, Lys601, 
Lys606, Lys427, Lys446, Lys429, 
Lys208, Lys224 Lys219 
Fibrin α and Fibrin γ chains (Cottrell et al. 1979;Matsuka et al. 
1996;Siebenlist et al. 2001;Sobel et 
al. 1996;Wang 2011) 
Fibrin γ chains Gln399, Gln398, Lys406 Fibrin α and Fibrin γ chains (Gorman et al. 1980;Siebenlist et al. 
2001;Standeven et al. 2007) 
Factor V --- Factor V (Francis et al. 1986;Huh et al. 1988) 
Thrombospondin-1 --- Thrombospondin-1 and Fibrin α 
chain 
(Bale et al. 1985;Bale and Mosher 
1986;Lynch et al. 1987) 
α2-antiplasmin Gln2, Gln21, Gln419, Gln447 Fibrin α chain Lys303 (Lee et al. 2000;Lee et al. 2001) 
Thrombin activatable fibrinolysis 
inhibitor (TAFI) 
Gln2, Gln5, Gln292 TAFI and Fibrin α chain Lys77, 
Lys79, Lys212 
(Mutch et al. 2003;Mutch et al. 
2007;Valnickova and Enghild 1998) 
Vitronectin Gln93, Gln73, Gln84, Gln86 Vitronectin (Sane et al. 1988;Skorstengaard et al. 
1990) 
α2-macroglobulin Gln670, Gln669 Unknown (Mosher 1976;Sottrup-Jensen et al. 
1983) 
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Fibronectin Gln3, Gln4, Gln16 Fibrin α chain and Collagen (Corbett et al. 1997;Matsuka et al. 
1997;McDonagh et al. 1981;Piercy-
Kotb et al. 2012;Procyk and 
Blomback 1988) 
Collagen --- Fibronectin and von Willebrand 
factor 
(Mosher et al. 1980;Mosher 
1984;Mosher and Schad 1979;Piercy-
Kotb et al. 2012) 
Von Willebrand Factor Gln313, Gln560 Fibrin α chain, Collagen and Laminin (Bockenstedt et al. 1986;Takagi et al. 
1995;Usui et al. 1993) 
Plasminogen Lys298, Gln322 Plasminogen and Fibronectin (Bendixen et al. 1993;Bendixen et al. 
1995) 
Plasminogen activator inhibitor 2 
(PAI-2) 
Gln83, Gln84, Gln86 Fibrin α chain Lys148, Lys176, 
Lys230, Lys413 
(Jensen et al. 1994;Ritchie et al. 
1999;Ritchie et al. 2000;Ritchie et al. 
2001) 
Platelet Actin Gln41 Fibrin α chain (Cohen et al. 1980) 
Platelet Myosin --- Platelet myosin (Cohen et al. 1979) 
Vinculin --- Unknown (Serrano and Devine 2002) 
Filamin --- Unknown (Serrano et al. 2002) 
Angiotensin type 1 
receptor 
Gln315 Angiotensin type 1 receptor (AbdAlla et al. 2004) 
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1.3.6. Fibrinolysis 
Fibrin clot formation is a temporary response to wound healing and, as such, 
mechanisms involved in the breakdown of fibrin are important in preventing 
thrombosis. Fibrin is cleaved by plasmin, a serine protease produced upon cleavage 
of the inactive precursor plasminogen by tissue-type plasminogen activator (t-PA) or 
urokinase plasminogen activator (uPA) (Figure 1). Fibrin forms a surface for 
enhanced plasminogen cleavage as t-PA and plasminogen both bind to the αC 
domains (Tsurupa and Medved 2001) and D regions (Bosma et al. 1988;Schielen et 
al. 1991) of fibrin to enable production of the enzyme/substrate complex and the 
generation of plasmin. Fibrin is degraded by plasmin within the coiled coil located 
between regions D and E to form the following fibrin degradation products D-D:E1, 
D-D dimer, E3 and remnants of the αC domain (Figure 4). Degradation of fibrin also 
generates C terminal lysine and arginine residues which act as high affinity binding 
sites for plasminogen, thus promoting plasmin generation and acceleration of fibrin 
cleavage (Suenson et al. 1984;Tran-Thang et al. 1986).  Resistance of the fibrin clot 
to plasmin-mediated fibrinolysis was found to be dependent on the formation of γ-
dimers or highly complex α-multimers which conferred increased resistance to 
fibrinolysis (Siebenlist and Mosesson 1994). 
To prevent uncontrolled fibrin breakdown fibrinolysis is controlled at 
numerous levels. Firstly t-PA is inhibited by the plasminogen activator inhibitors 
(PAI)-1 and 2. PAI-1 and 2 form complexes with free PA, preventing plasmin 
generation and therefore fibrinolysis and proteolysis (Ritchie et al. 1999). PAI-2 and 
not PAI-1 is cross-linked to the fibrin α chain by FXIIIa (Ritchie et al. 2000;Ritchie 
et al. 2001). Cross-linked PAI-2 was also functionally active to inhibit uPA and t-PA 
(Ritchie et al. 1999;Ritchie et al. 2001). Secondly, plasmin is directly inhibited by the 
serine protease inhibitor α2-antiplasmin (α2-AP) which forms a covalent bond with 
the active site serine of plasmin, thus inhibiting plasmin-induced breakdown of fibrin 
(Longstaff and Gaffney 1991). FXIIIa-dependent cross-linking of Gln 2 of α2-AP to 
fibrin Lys 303 during clot formation is important in providing localised protection 
from plasmin-mediated lysis (Fraser et al. 2011). Alternatively TAFI cleaves the C 
terminal lysine and arginine residues of plasmin digested fibrin thus preventing 
plasminogen binding, activation and therefore plasmin generation. Physiological 
concentrations (70 – 250 nM) of activated TAFI also inhibit plasmin directly, to 
19 
 
further inhibit fibrinolysis (Wang et al. 1998). The activation peptide of TAFI is 
cross-linked to the fibrin α chain by FXIIIa (Mutch et al. 2003), with cross-linking of 
TAFI prolonging fibrinolysis in plasma and whole blood thrombi (Mutch et al. 
2007). Inhibition of fibrinolysis is dependent on FXIII-dependent cross-linking of 
fibrinolysis inhibitors to fibrin and supports the incorporation of numerous plasma 
proteins during clot formation. 
 
 
 
Figure 4: Schematic representation of fibrin degradation products 
Plasmin cleaves cross-linked fibrin in the coiled coil region between domains D and 
E resulting in fibrin degradation products D-D:E1, D-D dimer, E3 and αC-domain 
remnants. 
 
1.4.   The influence of fibrin structure in CVD 
Thrombosis is the formation of fibrin clots in the blood vessel resulting in impaired 
blood flow and ultimately leading to MI and stroke. In prospective studies, 
fibrinogen and PAI-1 were associated with an increased risk of MI, CAD and stroke 
(Danesh et al. 2005;Thogersen et al. 1998), additionally fibrinogen was positively 
associated with established risk factors for CVD including age and smoking (Danesh 
et al. 2005). Fibrin clots from MI patients have altered fibrin architecture with stiffer 
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fibrin clots containing fibres which are shorter and increased in number, with smaller 
pores and are susceptible to slower lysis times and reduced permeability (Collet et al. 
2006;Fatah et al. 1996). Individuals with a number of metabolic risk factors for 
T2DM are at increased risk of CVD and as such also contain altered fibrin clot 
structure with reduced clot density and increased clot lysis times, with an increase in 
the number of metabolic risk factors associated with an increase in clot density and 
fibrinolysis times (Carter et al. 2007). Marchi-Cappelletti (2010) further showed that 
fibrin clot permeation was reduced and fibrin compaction was increased in 
individuals with T2DM (Marchi-Cappelletti and Suarez-Nieto 2010). The change in 
fibrin structure as a result of T2DM was previously found to be the result of 
fibrinogen concentration rather than fibrinogen glycation (Pieters et al. 2006). 
Increased fibrinolysis times are also associated with venous thrombosis (Lisman et 
al. 2005). Changes in fibrin architecture pre-date CVD symptoms, as relatives of 
CAD patients produce ex vivo plasma clots with reduced permeability and shorter 
fibrin fibres (Mills et al. 2002). These studies suggest that fibrin structure is a risk 
factor for future CVD development. Furthermore, fibrin clots formed from platelet 
poor plasma form slower and contain fibrin fibres 2-4 times larger than fibrin clots 
formed from purified fibrinogen (Carr 1988), suggesting other plasma proteins 
contribute to fibrin structure and therefore CVD development.  
 
1.5.   The influence of inflammation in CVD 
Inflammation occurs as a response to tissue damage or infection. In CVD 
inflammation occurs at all stages of development from early atheroma formation 
through to plaque rupture and thrombosis. During early atheroma formation 
inflammation occurs via monocyte infiltration of the endothelial surface to form 
macrophages and foam cells. Foam cells release inflammatory cytokines IL1β, IL6 
and TNFα, which recruite additional immune cells (T cells and mast cells) and 
vascular smooth muscle cells to the endothelium (Barillari et al. 2001) and promote 
up-regulation of vascular adhesion molecules. T cells and mast cells secrete a 
number of cytokines (IFNγ, IL2 and TNFα) which promote the continued immune 
cell infiltration (Strieter et al. 1989)  and collagen secretion from vascular smooth 
muscle cells (Amento et al. 1991). Inflammation also promotes a prothrombotic 
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environment, for example IL6 stimulates production of fibrinogen and C-reactive 
protein (CRP) in hepatocytes (Castell et al. 1990), whereas mast cells, macrophages 
and vascular smooth muscle cells synthesise and secrete tissue factor, t-PA, uPA and 
PAI-1 (Mach et al. 1997;Wojta et al. 1993;Wojta et al. 2003).  
In CVD localised cytokine production may lead to systemic inflammation 
due to the synthesis of inflammatory proteins by the liver during the acute phase 
response. In recent years systemic inflammatory proteins have been measured as a 
marker of CVD risk. Of these proteins CRP has been measured in a number of 
prospective studies, with CRP a predictor of a future CVD event (MI and/or stroke), 
in men and women with high baseline levels (Ridker 1998;Ridker et al. 1998).  CRP 
is also a predictor of future CVD mortality (Kaptoge et al. 2010;Strandberg and 
Tilvis 2000). CRP concentrations of <1, 1-3, >3 mg/L are associated with a low, 
medium and high risk of developing CVD (Ridker et al. 2003). Furthermore, 
systemic CRP levels are associated with atherosclerotic plaque severity with 3.2 
mg/L, 2.9 mg/L and 2.5 mg/L associated with ruptured, eroded and stable 
atherosclerotic plaques respectively (Burke et al. 2002). In a prospective study, 
Hashimoto et al (2001) found that high systemic CRP levels were associated with 
increased plaque number and plaque severity after a 1 year follow-up, even after 
accounting for conventional CVD risk factors (Hashimoto et al. 2001). Using 
immunohistochemistry, CRP has been positively stained within atherosclerotic 
plaques, with increased systemic CRP associated with increased staining of CRP 
within atherosclerotic plaques (Burke et al. 2002). Within atherosclerotic plaques 
CRP co-localises with macrophages (Burke et al. 2002;Eisenhardt et al. 2009) and 
the terminal complement complex, C5b-9 (Torzewski et al. 1998a).  
CRP also activates another inflammatory response in the form of the 
complement cascade. CRP binds to microbial surfaces via phosphocholine and 
recruits C1q of the classical pathway of complement to initiate complement 
activation, however CRP also regulates complement activation by binding 
complement inhibitors C4 binding protein and factor H, thus halting complement 
activation at the point of C3 (Mihlan et al. 2011). For this reason the role of 
complement in CVD is a rapidly emerging area of research in the context of CVD 
risk and pathogenesis.  
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1.6.   Complement 
1.6.1. Complement Cascade  
The complement system forms a critical component of the innate immune response 
and consists of plasma and membrane associated proteins, which form three 
pathways of activation, the classical, lectin and alternative pathways (Figure 5). The 
classical pathway is initiated when antibodies or CRP binds to foreign surfaces 
initiating binding of C1q of the C1 complex (C1q, C1r and C1s) which promotes 
conformational changes in C1r and C1s required for their activation (Golan et al. 
1982;Mihlan et al. 2011). C1s cleaves both C2 and C4 to form the classical pathway 
C3 convertase (C4bC2a) (Nagasawa and Stroud 1977). The lectin pathway is 
activated by mannose on the surface of pathogens interacting with mannose binding 
lectin (MBL) (Neth et al. 2000), which binds the MBL associated proteins (MASPs) 
1, 2 and 3 initiating a conformational change in MASP2 which cleaves C4 (Moller-
Kristensen et al. 2007;Thiel et al. 1997). C4b generated as a result of this cleavage 
binds to the pathogen surface along with C2 which is then cleaved by MASP1 and 2 
to form the C3 convertase (C4bC2a) (Moller-Kristensen et al. 2007). The alternative 
pathway unlike the classical and lectin pathways is constitutively activated at low 
levels (tick over) by the hydrolysis of C3 to form C3(H2O) (Pangburn et al. 1981). 
C3(H2O) recruits factor B and factor D to form a soluble C3 convertase 
(C3(H2O)Bb) which cleaves C3 to form C3a and C3b deposited on the pathogen 
surface (Pangburn et al. 1981). The alternative pathway is also activated by C3b 
generated as a result of the classical and lectin pathways. On the pathogen surface, 
C3b recruits factor B forming C3bB in an open conformation. Factor D binds to the 
factor B portion of this complex and cleaves the factor B to form C3bBb with the 
release of Ba (Forneris et al. 2010). The C3 convertase is stabilised by properdin 
(Hourcade 2006), preventing its cleavage by factor I in the presence of factor H. The 
C3 convertase produced via the three pathways cleaves C3 to form C3a and C3b. 
C3b combines with the C3 convertase to form the C5 convertase (C4bC2aC3b or 
C3bBbC3b), which is responsible for cleaving C5 into C5a and C5b (Pangburn and 
Rawal 2002). C5b binds to the pathogen surface and recruits C6, C7, C8 and 
numerous C9 molecules to form the membrane attack complex C5b-9 (Kolb and 
Mullereberhard 1975), which is responsible for forming pores in the cell membranes 
of pathogens resulting in cell lysis (Bhakdi and Tranumjensen 1986). Following 
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complement activation a number of potent anaphylatoxins are produced including 
C3a and C5a. Anaphylatoxins are responsible for chemotaxis of phagocytes and 
degranulation of granulocytes. These effects are mediated by the binding of C3a and 
C5a to the analphylatoxin receptors C3a receptor (C3aR) and C5a receptor (C5aR) 
expressed on the surfaces of inflammatory cells (Werfel et al. 2000;Zwirner et al. 
1999).    
 To prevent uncontrolled complement activation causing tissue damage, 
complement is regulated by soluble and membrane associated inhibitors as outlined 
in Table 2. Complement is tightly regulated at three points including initiation, C3 
convertase formation and membrane attack complex formation. To prevent 
complement initiation, C1 inhibitor binds and inactivates the serine proteases (C1r, 
C1s, MASP1 and MASP2) responsible for initiating the classical (Chesne et al. 
1982) and lectin (Presanis et al. 2004) pathways of complement. To prevent 
continuation of the complement cascade at the point of C3 convertase formation 
several proteins and processes are involved; firstly cofactor inactivation/cleavage of 
C3b and C4b by factor I with cofactors including membrane cofactor protein which 
binds C3b and C4b on host cells (Liszewski et al. 2000), C4 binding protein which 
binds C4b (Fujita et al. 1978) and factor H which binds C3b (Wu et al. 2009b). 
Secondly dissociation of the already formed C3 convertase (C4b2a and C3bBb) by 
decay accelerating factor (DAF) resulting in the release of C2a and Bb (Fujita et al. 
1987); C4 binding protein resulting in the release of C2a (Gigli et al. 1979) and 
factor H resulting in the release of Bb (Wu et al. 2009b). Finally to prevent the 
formation of the membrane attack complex, protectin prevents C9 polymerisation by 
preventing C9 insertion into the lipid bilayers of host cells (Meri et al. 1990). 
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Figure 5: The complement cascade 
The classical pathway is activated when the C1 complex (C1q, C1r, C1s) bind to antibodies and/or CRP bound to foreign surfaces. The C1s 
component of the C1 complex cleaves C2 and C4 to form the C3 convertase (C4bC2a). The lectin pathway is activated by the binding of 
mannose binding lectin (MBL) to mannose on the pathogen surface, which recruites MBL-associated serine proteases (MASP) 1, 2, 3. MASP2 
cleaves C2 and C4 to also form the C3 convertase. The C3 convertase cleaves C3 to form C3a and C3b, with C3b recruited to form the C5 
convertase (C4bC2aC3b) or recruited to the alternative pathway activation. The alternative pathway is activated by the hydrolysis of C3, with 
hydrolysed C3 recruiting factor B which is cleaved by factor D to form soluble and membrane bound C3 convertase (C3bBb). Membrane bound 
C3 convertase is stabilised by properdin. Factor H (FH) inhibits fluid and surface bound C3b by acting as a cofactor for factor I cleavage of C3b. 
Factor H also aids the dissociation of Bb from C3b, thus inhibiting C3 convertase formation. The C3 convertase cleaves C3 into C3a and C3b, 
with C3b recuited to the C5 convertase (C3bBbC3b). The C5 convertase from all three pathways cleaves C5 to form C5a and C5b. C5b binds to 
the pathogen surface and recuits C6, C7, C8 and numerous C9 molecules to form the membrane attack complex (MAC).
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Table 2: Regulators of the complement system 
Name Soluble/membrane Role 
C1 Inhibitor Soluble Binds and inactivates C1r and C1s 
of the classical pathway and 
MASP1 and 2 of the lectin 
pathway 
C4 Binding Protein Soluble Cofactor for factor I cleavage of 
C4b, Accelerates the classical and 
lectin pathway C3 convertase 
(C4b2a) decay with the release of 
C2a 
Factor H Soluble Cofactor for factor I cleavage of 
C3b, Accelerates the alternative 
pathway C3 convertase (C3bBb) 
decay with the release of Bb 
Membrane Cofactor 
Protein (CD46) 
Membrane Cofactor for factor I cleavage of 
C3b and C4b 
Decay Accelerating 
Factor (CD55) 
Membrane Prevents C3bBb assembly, aids 
dissociation of C3bBb and C4bC2a 
with the release of C2a and Bb 
Protectin (CD59) Membrane Prevents formation of the 
membrane attack complex by 
preventing C9 polymerisation 
27 
 
1.6.2. Complement C3 
Complement C3 is a two chain (α chain 110 KDa; β chain 75 KDa) polypeptide 
connected by a disulphide bond, which is present in plasma at a concentration of 
~1.2 mg/ml. Complement C3 is cleaved by all three pathways of complement in the 
generation of C3a and C3b which function in many roles within immunity as 
highlighted in Figure 6. C3a is an anaphylotoxin which recruits phagocytic cells 
(neutrophils and monocytes) via chemotaxis to the injury site (Sarma and Ward 
2011), causes degranulation of eosinophils (Daffern et al. 1995) and the proliferation 
and differentiation of T cells (Strainic et al. 2008). These effects are mediated by the 
binding of C3a to C3aR expressed on the surfaces of these inflammatory cells 
(Werfel et al. 2000;Zwirner et al. 1999).  
C3b binds and is covalently attached to cell surfaces and recruits factor B 
forming C3bB in an open conformation which is cleaved by factor D to produce the 
alternative pathway C3 convertase (C3bBb) with the release of Ba (Forneris et al. 
2010) to initiate the alternative pathway. C3b is also recruited to the C3 convertase to 
form the C5 convertase allowing completion of the complement cascade and in the 
generation of the membrane attack complex (C5b-9) as described in section 1.6.1. 
Alternatively the C3 convertase amplifies the complement response by cleaving C3 
molecules to generate more C3a and C3b. C3b is also an opsonin and binds to 
nucleophilic groups and carbohydrates on cell surfaces via its thioester domain 
forming an intramolecular acyl-imidizole bond (Law and Dodds 1997;Sahu et al. 
1994). The thioester domain is exposed as a result of C3 cleavage to form C3b 
(Janssen et al. 2005).  The C3b α chain is cleaved by factor I in the presence of the 
cofactor factor H between residues 1281/1282 and 1298/1299 to form iC3b with the 
release of C3f (Sahu and Lambris 2001), this process is sufficient to prevent the 
formation of the alternative pathway C3 convertase (Sahu et al. 1998). C3b and iC3b 
are opsonins and deposit on bacteria such as S. aureus, with conversion of C3b to 
iC3b occurring by factor I in the absence of factor H (Cunnion et al. 2004). 
Complement receptor (CR) 1 on eosinophils (Hatano et al. 2009) and neutrophils 
(Gros et al. 2008) and C3Ig receptors on macrophages bind foreign particles 
opsonised with C3b and iC3b, whereas CR3 and CR4 on leukocytes bind foreign 
particles opsonised with iC3b to initiate phagocytosis of pathogens (Gros et al. 
2008).  
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The iC3b α chain is further cleaved by factor I at a third site between residues 
932/933 to form C3c and C3dg (Sahu et al. 2001). The activation products iC3b and 
C3d/C3dg immobilised to a cell surface or in solution bind to CR2 (Sarrias et al. 
2001) mainly expressed on B cells.  Antigen particles coated in the opsonin C3dg 
stimulate B cell proliferation and differentiation 1000-fold, due to the combined 
binding of C3dg to CR2 and the antigen to the B cell antigen receptor (Morgan et al. 
2005), thus enhancing the adaptive immune response.  
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Figure 6: Schematic representation of the role C3 fragments play in immunity.  
C3 is made up of the following domains; macroglobulin domains 1-8, thioester containing domain (TED), complement C1r/C1s Uegf,Bmpl 
(CUB) and C3a domain. C3 is cleaved by the C3 convertase to form the anaphylotoxin C3a and the opsonin C3b. In the presence of factor B, 
factor D and C3b the alternative pathway C3 convertase is formed, cleaving more C3 into C3a and C3b.  C3b combines with the C3 convertase 
to form the C5 convertase with completion of the complement cascade in the formation of the membrane attack complex. The alternative 
pathway C3 convertase is broken down in a process known as decay acceleration to form C3b. C3b is further cleaved by factor I in the presence 
of factor H to initially form the opsonin iC3b and finally C3dg and C3c. C3b and iC3b promote phagocytosis by binding to complement 
receptors (CR) 1, 3 and 4, whereas iC3b and C3dg promote B cell activation by binding to CR2.  Figure adapted from (Gros et al. 2008).
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1.6.3. Factor H 
Factor H is a single polypeptide chain of 155 KDa, made up of 20 short consensus 
repeats (SCR) and is present in plasma at 110-615 µg/ml. Factor H is important for 
cofactor activity and decay acceleration activity. In decay acceleration the SCR 1 and 
2 of factor H bind macroglobulin domains 2, 6 and 7 of C3b, thus dislodging Bb and 
therefore resulting in decay of the alternative pathway C3 convertase (Wu et al. 
2009b). Alternatively during cofactor activity the SCR 1-4 bind the CUB domain of 
C3b; this interaction is essential in allowing the generation of an interface for factor I 
binding and subsequent cleavage of C3b to iC3b (Wu et al. 2009b). Factor H 
regulates both C3b in the fluid phase and membrane bound C3b, whilst inactivation 
of C3b in the fluid phase is rapid, inactivation of membrane bound C3b is dependent 
on the composition of the cell surface. Cell surfaces containing sialic acids, 
glycosaminoglycans or sulphated polysaccharides (heparins) increase the affinity of 
factor H for C3b as simultaneous recognition of both the cell surface and C3b is 
required for effective inactivation of C3b (Rodriguez de et al. 2004). This process is 
highlighted by the large amount of C3b and iC3b opsonisation on surfaces in the 
absence of sialic acids, glycosaminoglycans or sulphated polysaccharides (Rodriguez 
de et al. 2004). Alternatively polyanion binding sites in the SCR 19-20 are 
responsible for protecting host cells from alternative pathway complement activation 
(Morgan et al. 2011). This was highlighted using sheep red blood cells whereby cell 
lysis occurred in the presence of recombinant factor H lacking SCR 19-20 (Pangburn 
2002). SCR 7 and SCR 12-14 also contribute to host cell defence, albeit to a lesser 
extent compared to SCR 19-20 (Pangburn 2002). Host cell protection by factor H is 
achieved by binding of SCR 19-20, 7 and 12-14 to the polyanions on host surfaces, 
thus preventing C3b deposition (Pangburn 2002). In the absence of factor H, the 
alternative pathway is uncontrolled, with consumption of C3 and components of the 
membrane attack complex. 
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1.7.   Clinical studies of complement activation and CVD 
As CRP is a strong predictor of CVD risk and CRP is known to activate the 
complement system, activated components of the complement system including 
soluble C5b-9, C5a and the central effector in complement activation, C3 have been 
investigated for an association with CVD risk. In a prospective study, patients with 
pre-existing atherosclerosis, followed for 22 months, had an increased CVD risk in 
the presence of increased C5a, with a 37% increased risk in the highest quartile 
(Speidl et al. 2005). In stroke patients, levels of soluble C5b-9 increased until day 7 
and remained high until day 12 following a stroke, with soluble C5b-9 levels 
correlating with the infarction size (Pedersen et al. 2004). In a case control study 
soluble C5b-9 was increased in stroke patients compared to controls with 
atherosclerosis, with an increase in soluble C5b-9 correlating with stroke severity 
(Szeplaki et al. 2009). In a case-control study soluble C5b-9, C4d, C3 activation 
products (iC3b, C3a and C3d) and Bb were all found to be increased in acute MI 
patients compared with controls (Yasuda et al. 1990). Martel et al (2012) further 
found that levels of C5a and soluble C5b-9 increased 37% and 96% respectively at 
24 hours following MI compared with controls (Martel et al. 2012), suggesting 
complement activation following MI may lead to tissue damage and further CVD 
risk. Siezenga et al (2009) further showed that soluble C5b-9 and C3 were 
significantly higher in South Asian diabetics and non-diabetics compared with 
healthy Caucasian controls. When the diabetic South Asian group was compared 
with the non-diabetic South Asian group the levels of soluble C5b-9 and C3 
remained significantly higher (Siezenga et al. 2009). These studies suggest that 
complement activation products are a marker of current inflammation and disease 
severity in CVD patients. 
 
1.7.1. Associations between complement C3, CVD and T2DM  
Complement C3 is the central effector in complement activation and as such many 
studies have focused specifically on the association between C3 and CVD and 
T2DM development. In prospective studies, individuals in the highest C3 tertile had 
a 5.8-fold increased risk of an MI (Muscari et al. 1995). Onat et al. (2005) found that 
C3 levels above 1.6 g/L gave a 1.9-fold increase in coronary heart disease prevalence 
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(Onat et al. 2005). Whereas analysis of C3 levels following acute ischaemic stroke 
showed that levels increased to a peak at 3-5 days, after which levels steadily 
decreased, however C3 levels remained significantly higher than healthy controls 
(Tamam et al. 2005). Measuring the C3/C4 ratios in acute coronary syndrome 
patients over a year showed that it was a strong predictor of future cardiovascular 
events compared to measuring C3 or C4 alone, with half the individuals in the 
highest C3/C4 ratio likely to have a cardiovascular event during the follow up period 
(Palikhe et al. 2007). 
In case-control studies levels of C3 were significantly higher in South Asian 
stroke patients and relatives with a family history of stroke compared to healthy 
white controls (Somani et al. 2006), suggesting that C3 may be a marker of CVD 
development and that this development may pre-date disease presentation. In patients 
with coronary artery disease, including those with undetectable, minimal or extensive 
stenosis on angiogram, C3 levels were significantly higher than healthy controls 
(Ajjan et al. 2005). C3 levels were also increased in both male and female patients 
with coronary heart disease and C3 was associated with previous MI and stroke 
(Muscari et al. 2000;Onat et al. 2005). C3 was also found to be elevated in patients 
with MI compared to healthy controls even after adjusting for conventional CVD risk 
factors (Carter et al. 2009), suggesting C3 is also a marker of current inflammation in 
CVD patients. Within these patient groups, individuals with T2DM or impaired 
fasting glucose (IFG) had significantly higher C3 levels compared with patients 
without T2DM or IFG (Ajjan et al. 2005;Carter et al. 2009) and C3 was also found to 
predict future development of T2DM (Engstrom et al. 2005). In relatives with a 
family history of diabetes, levels of C3 were significantly higher than healthy 
controls, with a significant association of C3 with prolonged fibrinolysis times 
observed in these individuals (Schroeder et al. 2010), suggesting C3 is pro-
thrombotic and may contribute to increased CVD risk. C3 also significantly 
correlated with conventional cardiovascular risk factors (cholesterol, triglycerides, 
fibrinogen, CRP, BMI and waist to hip ratio, fasting glucose, HbA1c, insulin and 
homeostatic model assessment (HOMA)) in a number of these studies (Ajjan et al. 
2005;Carter et al. 2009;Onat et al. 2005;Onat et al. 2010).  
 Obesity is a known risk factor for the development of diabetes and CVD. In 
non-diabetic healthy individuals, C3 predicts the risk of future weight gain, with 
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higher levels of C3 associated with higher BMI and weight (Engstrom et al. 2005). In 
obese patients undergoing a six week low calorie diet, weight loss coincided with a 
decrease in C3 (Hernandez-Mijares et al. 2012). Weight loss and increased physical 
activity was responsible for a reduction in C3 levels, with little influence of drugs 
towards diabetes and hypertension on C3 levels (Muscari et al. 2005). These results 
are understandable as adipocytes contribute to the C3 plasma pool, by producing 
10% of the amount produced by the liver (Gabrielsson et al. 2003). 
 
1.7.2. Associations between factor H, CVD and T2DM  
Factor H is a regulator of complement, and as such alterations in factor H may 
therefore play a role in inflammatory aspects of T2DM and CVD. People with 
T2DM have increased factor H and factor B levels, with factor H being negatively 
associated with insulin sensitivity. Improvements in insulin sensitivity as a result of 
treatments with rosiglitazone or weight loss were also shown to decrease factor H 
levels in these individuals (Moreno-Navarrete et al. 2010). The up-regulation of 
factor H in this study as a result of insulin sensitivity may be important in combating 
the up-regulation observed in C3 as a result of T2DM as discussed in section 1.7.1 
A number of studies have looked at the role of the factor H polymorphism 
Y402H in determining risk of CVD. The factor H Y402H polymorphism involves the 
substitution of a tyrosine residue for a histidine in the SCR 7. This mutation was 
found to affect binding of factor H to CRP, but not heparin (Laine et al. 2007). In 
two case control studies looking at Caucasian males and relatives with a family 
history of MI, the Y402H polymorphism was not associated with any ischemic event 
(Stark et al. 2007;Zee et al. 2006). In a similar study looking at both male and female 
Caucasians, the same observation was noted in men; however, in females the HH 
genotype was inversely associated with coronary heart disease when onset was 
before 65 years (Pai et al. 2007). Caucasians in a prospective study had a greater 
incidence of the HH genotype compared to African Americans, and this genotype 
was a significant predictor of ischemic stroke, with a significant increase in 
hypertension and carotid artery thickening in these individuals (Volcik et al. 2008). 
In a prospective study looking at an elderly population (>85 years) the YH and HH 
genotypes had a 1.23 and 1.51 fold increase in cardiovascular mortality compared to 
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the YY genotype. This study also found that individuals with the HH genotype had 
increased CRP and IL-6 levels during the follow-up period of the study (Mooijaart et 
al. 2007).  The Rotterdam study showed that individuals with the HH genotype and 
no history of CHD had an increased risk of MI (Kardys et al. 2006). As highlighted 
by these few studies, the role of factor H in CVD and T2DM is limited with currently 
contradictory findings. As discussed in section 1.7 complement activation is an 
important contributor to CVD risk, since complement activation is regulated by 
complement inhibitors it suggests the down-regulation of inhibitors such as factor H 
as a risk factor for CVD.  
 
1.8.    In vitro studies of complement activation and CVD 
1.8.1. The influence of complement in atherosclerosis 
The role of complement in CVD is a rapidly developing area of research with 
evidence suggesting a role for complement in both atherosclerosis and thrombosis as 
highlighted in the following sections. Complement components have been observed 
in atherosclerotic plaques at all stages of development. During the initial stages of 
atherosclerotic plaque development, the classical pathway of complement is 
activated as a result of binding between C1q and gC1qR receptor on vascular 
endothelial cells. In response to increased sheer stress, endothelial cell expression of 
gC1qR is upregulated leading to deposition of activated complement components 
C3b and C5b-9, suggesting endothelial cells can support classical pathway activation 
and full complement activation (Yin et al. 2007). In a study by Yasojima et al. (2001) 
atherosclerotic plaque tissue was found to contain mRNA and protein relating to 
classical pathway components from C1r, C1s to C8. Interestingly this study did not 
show up regulation of mRNA or protein relating to complement inhibitors C1-
inhibitor, DAF, C4 binding protein or CD59, suggesting ongoing synthesis of 
complement components within the plaque, with uncontrolled complement activation 
(Yasojima et al. 2001). Oksjoki et al. (2003) further found that in the superficial layer 
of early atherosclerotic plaques factor H bound to proteoglycans, thus limiting 
complement activation to C3 convertase stage, whereas deeper in the intima factor H 
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was absent enabling full activation of the complement cascade and the generation of 
C5b-9 (Oksjoki et al. 2003).  
 Complement activation within atherosclerotic plaques has been observed by a 
number of studies using immunohistochemistry. In early atherosclerotic plaques 
C5b-9 was found to co-localise with CRP (Torzewski et al. 1998a) and enzymatically 
modified low density lipoproteins (Torzewski et al. 1998b), due to binding between 
C1q and enzymatically modified low density lipoprotein resulting in the activation of 
the C1 complex (Biro et al. 2007). Ruptured and non-ruptured atherosclerotic 
plaques removed from the coronary arteries of individuals who died of acute MI 
were examined for complement components and inflammatory cells. 
Immunostaining identified C5b-9 present in the intima of both ruptured and non-
ruptured plaques with iC3b present at the rupture site only (Laine et al. 2002). These 
observations support the suggestion that deep in the intima complement inhibitors are 
absent allowing uncontrolled complement activation, whereas at the rupture site C3 
is cleaved by plasma factor I in the presence of plasma factor H to form inactivated 
iC3b.  
Complement activation also results in the production of anaphylatoxins C3a 
and C5a, which are responsible for inflammatory cell recruitment. In ruptured 
plaques high concentrations of T cells, macrophages and mast cells were observed, 
suggesting that anaphylotoxins may contribute to plaque instability (Laine et al. 
2002). Histological staining and mRNA analysis of atherosclerotic plaques shows 
that expression of the anaphylotoxin receptors C3aR and C5aR were increased 5 
fold, with expression occurring on macrophages, T cells, endothelial cells and 
smooth muscle cells (Oksjoki et al. 2007). Speidl et al. (2011) further showed that 
C5a production within the lipid rich regions of the atherosclerotic plaques were 
increased, with co-localisation of C5a with C5aR on macrophages. In vitro binding 
between C5a and C5aR on macrophages was found to promote the expression and 
production of the MMP-1 and 9, with an anti-C5aR antibody preventing the 
expression and production of MMP-1 and 9 (Speidl et al. 2011). Taken together the 
evidence fom these studies suggest that the complement system is active within 
atherosclerotic plaques; that complement promotes atherosclerotic plaque 
development and may aid in atherosclerotic plaque rupture.   
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1.8.2. The influence of complement in thrombosis 
There is increasing evidence to suggest that complement plays a role in thrombosis 
through interactions with platelets and coagulation proteins. Complement activation 
is initiated following platelet activation. In a subset of platelets, rapid (within 30 
seconds) C5b-9 formation was found following platelet activation by adenosine 
diphosphate (ADP), thrombin receptor activating peptide (TRAP) or collagen 
independent of P-selectin expression on the platelet surface (P-selectin binds C3b). 
Formation of C5b-9 in this subset of platelets was thrombin dependent as hirudin 
blocked C5b-9 formation, and these platelets were found to specifically interact only 
with collagen fibres, with upregulation of C3aR and C5aR as a result of this 
interaction (Martel et al. 2011). It is currently unknown why only subsets of platelets 
form C5b-9 upon activation; however this subset may form an important role along 
with the previously identified pro-coagulant subset of COAT activated platelets 
(Dale et al. 2002). Platelets treated with C5b-9 also promote FVa and FXa binding to 
the platelet surface which in turn promotes the prothrombin converting activity of the 
platelet. C5b-9 was also found to stimulate α granule release of FV (Wiedmer et al. 
1986).  
 Platelet activation results in activation of the alternative and classical 
pathway of complement on the platelet surface. Platelets activated by sheer stress, 
ADP or TRAP, contained complement C3 deposition, with deposition occurring as a 
result of P-selectin-mediated binding of C3b. Once bound C3b was able to recruit 
factor B to form the alternative pathway C3 convertase, with the increased generation 
of C3a and deposition of C5b-9 on the platelet surface (Del, I et al. 2005). Hamad et 
al. (2010) also found that C3(H2O) deposition on TRAP-activated platelets was 
independent of complement activation; however, unlike in the previous study, C3 
was cleaved by factor I in the presence of factor H to generate iC3b, which in turn 
bound soluble CR1 (Hamad et al. 2010). This might suggest that platelets are a target 
for phagocytosis as a result of C3 opsonisation (Flaumenhaft 2006). Factor H binds 
to resting and activated platelets, with activation by thrombin and ADP increasing 
factor H deposition by 22% and 89% respectively (Vaziri-Sani et al. 2005). 
Recombinant constructs of the factor H SCR incubated with heparin confirmed that 
binding to platelets took place within the heparin binding region in SCR 19-20 via 
GPIIb/IIIa and thrombospondin-1 receptors present on the platelet surface (Vaziri-
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Sani et al. 2005). On normal platelets, 47% of plasma factor H is present on their 
surface; however, this level is reduced to 18% in patients with atypical haemolytic 
uraemic syndrome (aHUS), which is caused by a mutation in SCR 20. As a result of 
this mutation, surface levels of complement components, C3 and C9 and the platelet 
receptor P-selectin are all increased, with increased platelet microparticle release 
(Stahl et al. 2008). As platelet microparticles are known to be pro-thrombotic 
(Keuren et al. 2006), this study in aHUS patients suggests a protective role of factor 
H in thrombosis. Similar to platelets, complement activation and regulation also 
occurs on platelet microparticles, with expression of gC1qR, IgG, C1-inhibitor, 
CD55 and CD59 (Yin and Peerschke 2007). Platelet microparticles incubated in 
plasma undergo full complement activation with iC3b and C5b-9 deposition 
occurring within 30-60 minutes (Yin et al. 2007). 
Alternatively, platelets activated by TRAP or sheer stress, can also activate 
the classical pathway of complement, with deposition of C1q and C4b on the platelet 
surface.Deposition coincided with increased gC1qR expression, with deposition 
inhibited by antibodies against gC1qR. Classical pathway component deposition also 
resulted in complement activation with the generation of soluble C3a (Peerschke et 
al. 2006). The C3 activation products C3a and C3 desArg promote platelet 
aggregation and serotonin release, and these effects are synergistic in the presence of 
ADP (Polley and Nachman 1983). These studies suggest that complement activation 
on the surface of platelets results in increased inflammation by the production of 
complement dependent inflammatory mediators and promotes thrombosis via platelet 
aggregation at the site of vascular damage. Platelets also influence the complement 
response. Platelet casein kinase is responsible for phosphorylating the C3 α chain 
(Ekdahl and Nilsson 1995;Ekdahl and Nilsson 1999)  and phosphorylation of C3b 
prevents its cleavage by factor I in the presence of factor H (Ekdahl et al. 1995) as a 
result of decreased binding of factor H to phosphorylated C3b (Ekdahl and Nilsson 
2001). Phosphorylated C3b produced by the C3 convertase, binds more readily to 
CR1 on cell surfaces (Ekdahl et al. 1999;Ekdahl et al. 2001). This suggests that 
platelet phosphorylation is responsible for promoting C3 opsonisation instead of 
complement inactivation. 
Recent investigations into the lectin pathway have highlighted the role of 
complement in thrombus formation. Recombinant MASP1 directly cleaves the 
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FXIII-A chain to release the activation peptide and FPB from the fibrinogen β chain, 
with a catalytic efficiency 650-fold slower than thrombin; however, amino terminal 
sequencing confirmed that cleavage occurs at the same sites as thrombin. MASP1 
cleavage of FXIII and fibrinogen resulted in γ dimer and a small amount of α 
polymer formation; however, the majority of the α chain was degraded, suggesting 
MASP1 cleaves at numerous sites within fibrinogen (Krarup et al. 2008). A recent 
study by Hess et al. (2012) confirmed cleavage and activation of FXIII by MASP1. 
MASP1 was also found to cleave TAFI, prothrombin, and FPA from the fibrinogen α 
chain; however, FPA cleavage required the presence of prothrombin for its actions, 
suggesting MASP1 cleaves prothombin first to form thrombin, which then cleaves 
FPA. Analysis of fibrin fibres by scanning electron microscopy in the presence of 
MASP1 showed that the fibrin network contains large pores and coarse fibres 
compared to thrombin (Hess et al. 2012), suggesting MASP1 is protective for CVD 
in this result, however cleavage of prothrombin by MASP1 may promote a pro-
thrombotic state for CVD. Comparable to MASP1, MASP2 is also capable of 
cleaving prothrombin, with thrombin generation by MASP2 enhanced in the 
presence of FXa (Krarup et al. 2007). MASP2, in complex with MBL, generated 
thrombin from prothrombin in the presence of Ca
2+
, with thrombin generation 
resulting in polymerisation of fibrin; this process also occurred when the MBL-
MASP2 complex was bound to S.aureus, suggesting fibrin deposition occurs on 
bacterial surfaces following MASP2 activation (Krarup et al. 2007). In enzyme-
linked immunosorbant assays (ELISA)-based binding assays, MBL has also been 
shown to bind the α and β chains of fibrin, with fibrin binding promoting MBL 
binding to S.aureus (Endo et al. 2010), suggesting fibrin plays a role in promoting 
complement activation via the lectin pathway. The anticoagulant antithrombin III 
inhibits MASP1 and MASP2 and therefore C4 activation in the presence of heparin 
(Presanis et al. 2003). These studies suggest that when the lectin pathway is activated 
it promotes thrombosis by activating/cleaving prothrombin, fibrinogen and FXIII, 
however in the presence of an anticoagulant (antithrombin III), lectin pathway 
activation and thrombosis are inhibited.   
Although extensive work has been performed on the lectin pathway, several 
interactions between components of the classical and alternative pathways with 
components of coagulation have also been observed. The initiating component of the 
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classical pathway, C1q, has been shown to bind the FPA and B on fibrinogen via two 
high affinity sites on C1q (collagen-like and globular domains) (Entwistle and Furcht 
1988), suggesting localisation of complement activation to sites of injury. Similarly, 
Lu et al. (1999) found that the endothelial cell C1q receptor (gC1qR) also bound to 
fibrinogen via the D domain. This binding interaction was found to prevent fibrin 
polymerisation with an increase in clotting time and a decrease in fibrin monomer 
formation (Lu et al. 1999).  Alternatively, in zymosan treated plasma (treatment 
activates the alternative pathway of complement) clots, fibrin fibres were found to be 
thinner with increased clot strength and reduced clot permeability, additionally 
following clot formation complement activation continued with the generation of 
C3a (Shats-Tseytlina et al. 1994). This study suggests a component of the alternative 
pathway is involved in altering fibrin clot structure, although none were specified in 
this study. This study also suggests that fibrin clots can support complement 
activation. Factor B, a component of the alternative pathway, was also found to 
cleave and activate plasminogen similar to the actions of uPA; the resulting plasmin 
was functionally active demonstrated by effective cleavage of radioactively labelled 
fibrin (Sundsmo and Wood 1981) suggesting factor B is pro-fibrinolytic. The 
anaphylatoxin C5a generated by all three complement pathways, promotes PAI-1 
expression and reduces uPA expression and production in macrophages as a result of 
signalling through the C5aR. Incubations with C3a had no effect, suggesting a C5a 
specific effect on PAI-1 expression (Kastl et al. 2006). Additionally C5a promotes 
increased expression and production of PAI-1 in mast cells, PAI-1 production in 
mast cells was capable of inhibiting t-PA produced by the resting mast cells (Wojta 
et al. 2002). P-selectin expressed on endothelial cells, binds C3 and activates the 
alternative pathway of complement resulting in increased C3a generation (Morigi et 
al. 2011). C3a once bound to C3aR results in thrombomodulin shedding, thrombus 
formation and platelet aggregation (Morigi et al. 2011) and therefore microvascular 
thrombosis. These studies highlight the pro-thrombotic actions of the anaphylatoxins 
C3a and C5a. To prevent uncontrolled anaphylatoxin production the fibrinolysis 
inhibitor TAFI cleaves and inactivates C3a and C5a resulting in C3desArg and 
C5desArg, a product with no ability to activate neutrophils (Myles et al. 2003), with 
inactivation occurring within 5 minutes when incubated in serum or plasma 
(Campbell et al. 2001). These studies further support the important interactions 
between complement and coagulation in controlling thrombosis and inflammation.  
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1.9.   In vivo models of complement activation and CVD 
1.9.1. The influence of complement on atherosclerosis in in vivo mouse 
models 
The importance of complement in atherosclerosis progression is highlighted in 
complement deficient animals. During the early stages of atherosclerosis 
development, in ApoE mice Shields et al. (2011) found that C3 and C4 produced by 
perivascular adipose tissue bound to collagen and elastin within the adventitia, thus 
promoting vascular stiffness and future atherosclerotic plaque development. (Shields 
et al. 2011). Whereas in ApoE 
-/-
 CD59 
-/-
 double knockout mice formation of C5b-9 
led to damage of the endothelium as assessed by increased staining for von 
Willebrand factor and increased endothelial cell membrane permeability. Cobra 
factor venom activation of the alternative pathway confirmed C5b-9 produced by the 
alternative pathway was responsible for endothelial dysfunction (Wu et al. 2009a). 
Wu et al (2009a) further showed that macrophages, T cells and apoptotic cells 
accumulate at the site of atherosclerosis, with C5b-9 promoting the formation of 
foam cells with increased cholesteryl ester and Ox-LDL accumulation inside the 
foam cell. In a study by Sakuma et al (2010) DAF 
-/-
 mice were monitored following 
induced endothelial injury, with increased thickening of the neointima and increased 
recruitment of leukocytes observed compared to wildtype mice. Combined knockout 
of DAF with either C3aR or C5aR produced the opposite effects on the neointima 
and leukocytes, suggesting the development of atherosclerosis is dependent on 
complement activation and in particular anaphylatoxin signalling (Sakuma et al. 
2010). DAF 
-/-
 and low density lipoprotein receptor (ldlr) 
-/-
 double knockout mice 
fed either a low fat or high fat diet had increased lipid deposition and increased 
plaque area compared to ldlr 
-/-
 littermates. Immunostaining of the plaques found 
extensive complement activation with increased C3d and C5b-9 deposition in DAF 
-/-
 
ldlr 
-/-
 mice only (Leung et al. 2009). These studies highlight the athero-protective 
role of complement inhibitors in atherosclerosis development.    
Several studies have also investigated in vivo knockout models of 
components of the alternative pathway of complement. Malik et al. (2010) showed 
that factor B 
-/-
 and ldlr 
-/-
 double knockout mice had smaller plaques with decreased 
complement activation compared to ldlr 
-/-
 littermates, suggesting a role for factor B 
in atherosclerosis. This study further showed that chronic infection as a result of 
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bacterial lipopolysaccharide administration increased atherosclerotic plaque size in 
ldlr 
-/-
 mice but not factor B 
-/-
 ldlr 
-/-
 mice, which suggests that the alternative 
pathway of complement contributes to atherosclerosis development especially during 
chronic infection (Malik et al. 2010). However in a factor B 
-/-
, ldlr 
-/-
, ApoE 
-/-
 triple 
knockout mice atherosclerotic plaque size and serum triglyceride levels did not differ 
from ldlr 
-/-
 and ApoE 
-/-
 littermates (Persson et al. 2004), this may suggest that 
ApoE
-/-
 is less dependent on complement. Alternatively C3 
-/-
 and ldlr 
-/-
 double 
knockout mice have increased lipid and macrophage deposition within the 
atherosclerotic plaque with decreased collagen and smooth muscle cell deposition 
(Buono et al. 2002), suggesting C3 is important in the formation of the fibrous cap 
and the continual development of the atherosclerotic plaque. Persson et al (2004) 
found that in C3 
-/-
, ldlr 
-/-
, ApoE 
-/-
 triple knockout mice atherosclerotic plaque size 
was larger with increased serum triglyceride levels compared to ldlr 
-/-
, ApoE 
-/-
 
littermates, this finding is consistent with an increase in lipid and macrophage 
deposition observed by Buono et al. (2002). These studies in both human and mouse 
atherosclerotic plaques have highlighted the role complement and in particular 
complement activation plays in both the development and instability of 
atherosclerotic plaques. 
 
1.9.2. Influence of complement on thrombosis in in vivo mouse models 
The in vitro data determining the role of the lectin pathway in thrombosis suggests 
that MBL and MASPs are pro-thrombotic, which is confirmed in the following 
studies using MBL and MASP1/3 knockout mice.  In MBL and MASP1/3 knockout 
mice tail tip bleeding times were prolonged compared to wildtype mice, with clotting 
times decreased after the addition of recombinant MBL into MBL knockout mice. 
Analysis of bleeding times in C3 knockout mice were the same as those of wildtype 
mice, thus confirming activation of the lectin pathway is important in thrombus 
formation (Takahashi et al. 2011). In MBL and MASP1/3 knockout mice no 
occlusion of blood flow or thrombi formation were observed after FeCl3 induced 
endothelial injury compared to wildtype mice and C2/Factor B knockout mice which 
showed occlusion of blood flow and thrombi formation by 10 minutes and 20 
minutes respectively, with occlusion of blood flow restored to the MBL knockout 
mice following the addition of recombinant MBL. Immunostaining of MBL within 
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wildtype and MBL knockout thrombi after restoring MBL confirmed a strong 
presence of MBL within the thrombi. Additionally, wildtype whole blood was able to 
promote platelet aggregation due to the presence of MBL and MASPs, however 
using MBL knockout whole blood no difference in platelet aggregation was 
observed.  Using a thrombin substrate cleavage assay, MBL or MASP1/3 knockout 
plasma was unable to cleave thrombin however after the addition of recombinant 
MASP1 to MASP1/3 knockout plasma thrombin generation was restored to that of a 
wildtype mouse (La Bonte et al. 2012). These studies show that the lectin pathway 
was important in thrombi formation, as a result of thrombin generation. Although 
downstream complement activation products were found to be less important in the 
inital thrombi formation, no conclusive evidence has been shown to suggest that 
downstream complement components do not play a role in fibrin structure and 
function in vivo.  
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1.10. Proteomics 
More recent evidence for the influence of complement in CVD has been derived 
from proteomic studies. Proteomics is the study of proteins expressed at a given 
period in time by cells or tissues (the proteome). Proteomics can be used in protein 
identification, quantification, protein modification and interactions. Mass 
spectrometry (MS) uses the mass-to-charge ratio of proteins to determine its identity 
and any potential modifications, making it a widely used tool in proteomics. To 
allow the effective identification of proteins by MS, proteomes or subproteomes are 
separated either by two-dimensional gel electrophoresis or by one or more 
chromatography steps (Polkinghorne et al. 2009). Two-dimensional gel 
electrophoresis has been used extensively in the past in the identification of large, 
complex mixtures of proteins according to their isoelectric point and molecular mass, 
as it can separate up to 2000 proteins simultaneously and detect protein as low as 1 
ng per spot. Two-dimensional gel electrophoresis is particularly useful in monitoring 
protein expression and changes in molecular weight associated with post-
transcriptional modifications (Gorg et al. 2005). Liquid chromatography separates 
proteins/peptides based on their size, affinity, ion exchange or reversed-phase, with 
the efficiency of these methods based on the packing material (particle size, pore size 
and surface area). Reversed-phase high performance liquid chromatography has been 
used extensively in proteomics due to its ability to flow peptides directly into the 
mass spectrometer (Neverova and Van Eyk 2005). Separated proteins are 
proteolytically digested by enzymes (e.g trypsin), resulting in peptides that are 
ionised by either electrospray ionisation or matrix–assisted laser desorption 
ionisation (MALDI) within the mass spectrometer. The mass-to-charge ratio is 
determined for each peptide and is compared to known peptide masses in an 
extensive protein database. Information regarding the peptide sequence can be 
generated from further fragmentation of the peptide by collision induced dissociation 
and analysed by tandem MS/MS (Aebersold and Mann 2003;Arrell et al. 2001).  
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1.10.1. Use of proteomic technologies in CVD research 
Within the last 10 years the use of proteomics in cardiovascular research has 
expanded rapidly, with numerous studies looking to identify biomarkers of disease 
and therefore future disease progression. The largest of these studies is the HUPO 
plasma proteome project, which looked to extending the knowledge of the plasma 
proteome. The HUPO project identified 3020 proteins in plasma and by comparing 
the proteins analysed and the current literature they assigned proteins related to 
CVD. Of these, 345 proteins with known cardiovascular functions were identified 
and assigned to the following protein groups: inflammatory and cardiovascular 
markers, vascular and coagulation, signalling, growth and differentiation, 
transcription factors, channels and receptors, heart failure and remodelling (Berhane 
et al. 2005). By comparing plasma from patients with CAD with healthy age and sex 
matched controls, 95 proteins were differentially expressed, the majority (75 
proteins) of which were up-regulated in the CAD patients, including proteins from 
the following protein groups: complement (C1, C3, C4, C5a and factor B), 
coagulation (fibrinogen γ chain, prothrombin) and fibrinolysis (α2-antiplasmin) 
(Donahue et al. 2006). Alternatively, MI patients have a distinctive peptide pattern 
with regards to C3f and FpA, which were found to be amino terminally cleaved by 
endopeptidases (Marshall et al. 2003). Proteins associated with the known 
cardiovascular risk factor high density lipoprotein, analysed from CAD patients and 
healthy controls, saw 48 proteins involved in cholesterol/lipoprotein metabolism, 
inflammation, peptidase inhibitors and heparin binding proteins (Vaisar et al. 2007). 
These few studies have highlighted the importance of inflammation (in particular 
complement) and coagulation proteins in CVD. 
Proteomics has also been used to characterise the proteins which make up 
atherosclerotic plaques. Several studies have compared stable atherosclerotic plaques 
to unstable atherosclerotic plaques. In a study by Lepedda et al (2009) unstable 
atherosclerotic plaques were found to contain increased concentrations of fibrinogen 
fragment D, ferritin, and superoxide dismutase 2 compared to stable atherosclerotic 
plaques (Lepedda et al. 2009). Donners et al (2005) further showed that 71 spots 
(relating to angiotensin I, lactoferin, lipocalin-1 and proline rich lacrimal protein) 
were unique for stable atherosclerotic plaques with 29 spots (relating to vinexin β 
and α1-antitrypsin) unique for atherosclerotic plaques containing thrombi (Donners 
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et al. 2005). A recent study comparing systemic plasma to plasma from an 
atherosclerotic plaque rupture site from MI patients, found that the latter contained 9 
proteins which were differentially expressed including an increase in complement 
factor H related protein 2 and a decrease in complement factor B, C5, C7, 
carboxypeptidase N, plasminogen, protein S, pigment epithelial derived factor and 
matrix metalloprotease 9 (Distelmaier et al. 2012). This study has highlighted the 
local complement activation and potential regulation (complement factor H related 
protein 2) that occurs at coronary atherosclerotic plaque rupture sites. Additionally 
the results from these studies confirm the pro-coagulant environment associated with 
atherosclerotic plaques.  
 
1.10.2. The use of proteomic technologies in thrombosis 
Fibrinogen is a major determinant of clot density and susceptibility to fibrinolysis; 
however, numerous other plasma proteins are incorporated into plasma clots by 
binding or FXIII-dependent cross-linking, suggesting other plasma proteins may play 
a role in thrombosis. This is highlighted in plasma clots, where fibrin formation is 
slower and fibre diameter is larger than in fibrin clots produced from purified fibrin 
(Carr 1988). For this reason, several proteomic studies have looked at identifying the 
components of plasma clots. Comparisons between systemic plasma and plasma 
derived from thrombi after acute MI found that C3c α chain fragment 1, C3a, C5a 
and CRP are all increased in the latter, and complement activation within the thrombi 
was further confirmed by immunohistological staining for CRP, C3d and C5b-9 
(Distelmaier et al. 2009). Complement activation and the generation of C5a also 
resulted in the recruitment of neutrophils to the thrombus (Distelmaier et al. 2009). 
Several studies have compared plasma to plasma derived serum, with components of 
the coagulation cascade found to be depleted in serum compared to plasma. 
Interestingly, C3 and clusterin were found to have molecular weights matching 
cleavage products in serum with C3 cleavage resulting in C3b and C3dg (Misek et al. 
2005). Analysis of the serum peptidome (low molecular weight peptides) found 
fibrinogen, prothrombin, albumin, apolipoprotein A1, collagen, C4, C3 and several 
cellular components (Tammen et al. 2005). Niessen et al (2011) initiated coagulation 
in plasma and whole blood by the addition of TF and calcium, removed the fibrin 
clot, and then monitored cleavage products of coagulation and complement proteins 
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(changes in molecular weight) in the supernatant compared to plasma controls. This 
method observed the majority of coagulation and complement proteins, however 
cleavage only occurring in FX, FV, prothrombin, protein S, fibrinogen, FXIII, 
complement C1r, C5, C6 and C9 (Niessen et al. 2011). These studies have 
highlighted the importance of complement and coagulation in plasma clot formation, 
in particular cleavage of coagulation and complement proteins as a result of plasma 
clot formation. These finding are relevant in the context of complement and 
coagulation cascades, which are derived form common ancestral genes  (Krem and 
Di Cera 2002) and are activated to prevent blood loss and pathogen invasion and as a 
result are required to co-localise at the site of plasma clot formation.  
In previous work carried out by Dr Howes within the Division of 
Cardiovascular and Diabetes Research (DCDR), perfused, solubilised plasma clots 
were analysed to determine the protein components of plasma clots. Although fibrin 
α, β and γ chains accounted for the majority of protein within the plasma clot; 20 
additional proteins were identified, including proteins involved in haemostasis 
(FXIII, α2-macroglobulin, kininogen), inflammation (C3, factor H, carboxypeptidase 
N), protease inhibition (inter-alpha-trypsin inhibitor) and binding proteins 
(fibronectin) (Howes et al. 2012). Complement C3 and factor H identified within the 
FXIII deficient plasma clots were absent at their known molecular weights in plasma 
clots containing FXIII, suggesting they are cross-linked by FXIIIa during clot 
formation forming higher molecular weight complexes (Howes et al. 2012). These 
findings support a role for complement C3 and factor H within fibrin clots and were 
therefore selected for further functional in vitro analyses.  
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Chapter 2 Aims 
Complement proteins C3 and factor H have been shown to play a role in T2DM, 
CVD risk and atherosclerosis progression. In previous work performed within the 
DCDR, complement proteins C3 and factor H were identified as novel plasma clot 
components using a proteomics based technique (Appendix A) (Howes et al. 2012). 
This study highlighted the potential of proteomics to reveal novel proteins involved 
in thrombosis. The aims of this study were therefore: to evaluate the influence of C3 
and factor H on fibrin structure and function and to determine novel FXIII substrates 
using functional proteomics.  
 
2.1.  To evaluate the influence of C3 on fibrin structure and 
function 
The influence of complement C3 on fibrin structure and function was evaluated by 
(a) a turbidimetric assay in a purified and plasma system to determine the effect of 
C3 on fibrin formation and fibrin density. (b) A turbidimetric assay in a purified and 
plasma system to determine the effect of C3 on time to 50% lysis. (c) Plate based BP 
incorporation assays and gel based cross-linking assays using purified proteins and 
plasma to determine whether C3 was a substrate for FXIII and undergoes FXIII-
dependent cross-linking to fibrin during clot formation. (d) Gel based analysis of 
cleavage of purified C3 and C3 within purified fibrin clots to determine whether C3 
was a substrate for thrombin and plasmin and was responsible for substrate 
competition with fibrin. (e) Gel based analysis of plasminogen cleavage in the 
presence of C3 and/or fibrin to determine whether C3 influences plasminogen 
cleavage. (f) Turbidimetric assays using purified proteins in the presence of either a 
t-PA or plasminogen dose response to determine whether the C3 influence on 
fibrinolysis was due to the concentration of t-PA and/or plasminogen. (g) Two 
chromogenic plate based plasmin generation asays to determine whether C3 
influences t-PA and/or plasminogen binding and to determine whether FXIII-
dependent cross-linking of C3 influences plasmin generation.  
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2.2.  To evaluate the influence of factor H on CVD risk and fibrin 
structure and function 
(1) The influence of complement factor H on CVD risk, evaluated in 119 healthy 
South Asian first degree relatives of patients with T2DM compared with 119 healthy 
South Asian control subjects with no personal or family history of T2DM by (a) 
analysing the relationship between factor H concentration measured by ELISA and 
conventional CVD risk factors. (b) The relationship between factor H concentration 
and zymogen and activated complement components. (c) The relationship between 
factor H concentration and ex vivo plasma fibrin structure and function measured by 
turbidimetric assay. (2) The influence of complement factor H on fibrin structure and 
function was evaluated by (a) measuring factor H in plasma and plasma-derived 
serum samples by ELISA to determine the percentage of factor H incorporated into 
plasma clots during fibrin clot formation. (b) A turbidimetric assay in a purified 
system to determine the effect of factor H on fibrin formation and fibrin density. (c) 
A turbidimetric assay in a purified system to determine the effect of factor H on time 
to 50% lysis. (d) Gel based cross-linking assays using purified proteins and plasma to 
determine whether factor H was a substrate for FXIII and undergoes FXIII-
dependent cross-linking to fibrin during clot formation. (e) Gel based analysis of 
cleavage of purified factor H and factor H within purified fibrin clots to determine 
whether factor H was a substrate for thrombin and plasmin and was able to be 
cleaved during fibrin formation/lysis.  
 
2.3.  Determination of novel FXIII substrates using a functional 
proteomics approach 
A functional proteomics technique has previously been used to identify the cellular 
substrates of tissue transglutaminase (Orru et al. 2003;Ruoppolo et al. 2003). In the 
present study this technique was adapted for the identification of potential novel 
substrates of FXIII in plasma. Based on (a) FXIII-dependent cross-linking of BP to 
plasma proteins. (b) Removal of excess BP from plasma. (c) Affinity 
chromatography of BP incorporated proteins using monomeric avidin and (d) MS 
analysis of BP incorporated protein. (e) Gel based analysis of perfused solubilised 
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plasma clots were performed as an alternative method for the identification of 
potential novel FXIII substrates.  
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Chapter 3 Methods 
Unless stated otherwise, details of all buffers described in the following sections are 
provided in appendix B.  
3.1.   Protein Purification 
The majority of functional analyses were carried out using purified proteins from 
whole blood. C3, plasminogen and fibrinogen were purified from blood samples 
from volunteers recruited from the LIGHT Laboratories. All volunteers gave 
informed consent according to a protocol approved by the University 
LIGHT/LIHS/LIMM research ethics committee (Appendix C). On each occasion, 
whole blood was taken from three healthy volunteers who had not receieved any 
anti-inflammatory or anti-platelet drugs. Sixty mls of whole blood from each 
volunteer was taken with a 19-guage needle into ethylenediaminetetraacetic acid 
(EDTA) on ice (C3 and plasminogen) or citrate (fibrinogen) and centrifuged at 3000 
g at 4°C for 30 minutes. EDTA plasma from all three volunteers was removed, 
pooled and used immediately for C3 and plasminogen purification. Citrate pooled 
plasma, aliquoted and stored at -80°C for fibrinogen purification.  
 
3.1.1. C3 Purification 
C3 purification was performed based on method previously described (Tack and 
Prahl 1976).  
3.1.1.1. Polyethylene glycol Precipitation 
To the pooled EDTA plasma, 100 mM phenylmethylsulphonyl fluoride (PMSF) in 
isopropanol was added to a final concentration of 0.5 mM, along with polyethylene 
glycol (PEG) 4000 buffer I, to a final PEG concentration of 5%. The plasma sample 
was stirred for 30 minutes at 4°C, followed by centrifugation at 10,000 g, 4°C for 30 
minutes (Sorvall). The supernatant was removed, PEG 4000 buffer II was added to a 
final PEG concentration of 12% and the sample was stirred at 4°C for 30 minutes 
prior to a second centrifugation at 10,000 g, 4°C for 30 minutes (Sorvall). The 
supernatant was discarded and the pellet was re-suspended in 20 ml of lysine 
sepharose buffer I by gentle agitation.  
52 
 
3.1.1.2. Lysine sepharose chromatography and plasminogen 
purification 
Plasminogen was removed by passing the sample through a lysine sepharose (GE 
Healthcare Life Sciences) column (3 cm width by 8 cm height) equilibrated in lysine 
sepharose buffer I using an automated chromatography system (BioCad Sprint, 
Applied Biosystems). The sample was injected at a flow rate of 1 ml/min and the 
column was washed with three column volumes (CV) of lysine sepharose buffer I. 
The flow through was retained for diethylaminoethanol (DEAE) chromatography 
(section 3.1.1.3).  
 Plasminogen was eluted from the column using two CV of lysine sepharose 
buffer II. Five ml fractions were collected and the absorbance was monitored at 280 
nm. The column was regenerated in lysine sepharose buffer I over two CV. 
Plasminogen containing fractions were pooled and concentrated in a 3 KDa 
molecular weight cut off Vivaspin column (Sartorius Stedim) at 5000g, 4°C until ~ 2 
mls remained. The purity was determined by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) (section 3.2). Purified plasminogen 
was stored at -80°C in 20 μl aliquots. 
 
3.1.1.3. DEAE Chromatography 
The lysine sepharose flow-through (section 3.1.1.2) was diluted with 5 mM EDTA to 
a conductance of 3 mmho/cm using a conductance meter (Omega), before loading 
onto a DEAE cellulose column (3 cm width by 21 cm height, Sigma) equilibrated in 
ion exchange buffer I using the BioCad Sprint (Applied Biosystems). The sample 
was loaded at a flow rate of 2 ml/min and washed with one CV of ion exchange 
buffer I. C3 was eluted from the column using ion exchange buffers II containing 25 
mM NaCl and ion exchange buffer III containing 300 mM NaCl, which produced a 
linear NaCl concentration gradient over 10 CV. Ten ml fractions were collected and 
the absorbance was monitored at 280 nm. The column was regenerated in ion 
exchange buffer I over two CV. The elution profile of C3 was established by C3 
ELISA and shown to be reproducible between runs. C3 was pooled, solid PEG 4000 
(Fisher) was added to a final concentration of 16% and the sample was stirred for 30 
minutes at 4°C and underwent centrifugation at 10,000 g, 4°C for 30 minutes. The 
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supernatant was removed and the pellet was re-suspended in 5 ml of gel filtration 
buffer.  
 
3.1.1.4. Gel Filtration Chromatography 
The re-suspended C3 positive fraction (section 3.1.1.3) was injected onto a sepharose 
6B column (3 cm width by 37 cm height, Sigma) equilibrated in gel filtration buffer 
using the BioCad sprint (Applied Biosystems). The sample was injected at a flow 
rate of 0.5 ml/min and fractions were eluted with one CV of gel filtration buffer. Five 
ml fractions were collected and the absorbance was monitored at 280 nm. The 
elution profile of C3 was established by C3 ELISA and shown to be reproducible 
between runs. C3 positive fractions were pooled. 
 
3.1.1.5.   Hydroxylapatite Chromatography 
The pooled C3 positive fractions were dialysed using a 3 KDa molecular weight cut 
off dialysis membrane (Sigma) twice for 1 hour and then overnight in a total of two 
litres of potassium phosphate dialysis buffer with each buffer exchange. The dialysed 
sample was injected onto a hydroxylapatite column (3 cm width by 8 cm height, 
BioRad) equilibrated in potassium phosphate dialysis buffer using the BioCad Sprint 
(Applied Biosystems) at a flow rate of 0.9 ml/min and washed in one CV of 
potassium phosphate dialysis buffer. C5 eluted from the column over five CV using 
potassium phosphate dialysis buffer and C5 elution buffer I, which produced a linear 
potassium chloride gradient of 100 mM to 2 M. The column was washed with one 
CV of potassium phosphate dialysis buffer. C3 eluted from the column over six CV 
using potassium phosphate dialysis buffer and C3 elution buffer I, which produced a 
linear potassium phosphate gradient of 25 mM to 250 mM. Five ml fractions were 
collected and the absorbance was monitored at 280 nm.  The column was washed in 
two CV of C3 elution buffer II, to remove any non-eluted proteins and regenerated in 
potassium phosphate dialysis buffer over two CV. C3 containing fractions were 
pooled and dialysed using a 3 KDa molecular weight cut off dialysis membrane 
(Sigma) overnight followed by two, one hour dialysis steps each in a total of 2 litres 
of tris buffered saline (TBS). The dialysed samples were concentrated in a 100 KDa 
molecular weight cut off Vivaspin column (Sartorius Stedim) at 5000g, 4°C until ~2 
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mls remained. Final C3 concentration was determined by ELISA (see section 3.3) 
and purity was determined by SDS-PAGE and immunoblotting for C3 and C5 (see 
section 3.2). Purified C3 was stored in 50 μl aliquots at -80°C.   
 
3.1.1.6. Analysis of C3 purification products 
A total of three C3 purifications were performed with each C3 purification resulting 
in ~10-30 mg of total protein. Following the C3 purification procedure the C3 and 
C5 containing fractions were analysed by SDS-PAGE and Western blotting to assess 
purity. Figure 7, Panels A and B show that the C3 fractions were pure with small 
amounts of C3 cleavage products. Panel C confirms there was no C5 contamination 
within the C3 preparation. 
 
 
Figure 7: Analysis of C3 purification products by SDS-PAGE and Western blot 
C3 purification products from the hydroxylapatite column were analysed by 
Coomassie stained SDS-PAGE (Panel A) and immunoblotting with anti-C3c 
antibody (Panel B) and anti-C5 antibodies (Panel C). * indicates contamination 
from other plasma proteins. Immunoblots show that the C3 is pure and contains no 
C5 contamination. Gels and Western blots representative of all C3 purifications 
performed. 
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3.1.2. Fibrinogen Purification 
One aliquot (1.5 mls) of citrated plasma was defrosted at 37°C and mixed with 15 
U/ml of heparin (Sigma). Fifty μl of 1 M CaCl2 was added along with IF-1 
equilibration buffer to a final volume of 5 mls. The plasma sample was filtered with 
a 0.2 μm syringe filter prior to injection onto an IF-1 column (1.5 cm width by 3 cm 
height) equilibrated in IF-1 equilibration buffer using the BioCad Sprint (Applied 
Biosystems). The IF-1 column is a calcium dependent monoclonal antibody (IF-1) 
coupled to sepharose 4B, previously described (Takebe et al. 1995). The IF-1 column 
was washed with IF-1 wash buffer I for six CV followed by a second wash with IF-
1wash buffer II for six CV. Fibrinogen was eluted from the column using three CV 
of IF-1 elution buffer. Five ml fractions were collected and the absorbance was 
monitored at 280 nm. Fibrinogen positive fractions were concentrated using a 100 
KDa molecular weight Vivaspin column (Sartorius Stedim) at 3000g, 4°C until ~ 5 
ml remained. The concentration of fibrinogen positive fractions was determined by 
Nanodrop (Labtech International) using the extinction coefficient 15.1 M
-1
cm
-1
. 
Purified fibrinogen was assessed for purity by SDS-PAGE (see section 3.2) and 50 μl 
aliquots stored at -80°C.  
 
3.1.3. Factor XIII Purification 
Fibrogammin P (CSL Behring) contains a large number of contaminants including 
albumin that were removed by gel filtration. Two vials of fibrogammin P were 
reconstituted in 2 ml of water, giving an initial protein content of 5.48 mg/ml. This 
sample was injected onto a sepharose 6B column (3 cm diameter by 37 cm high, 
Sigma) equilibrated in TBS using the BioCad Sprint (Applied Biosystems) at a flow 
rate of 0.5 ml/min. The FXIII-A2B2 was eluted over one CV of TBS. Five ml 
fractions were collected and the absorbance was monitored at 280 nm. Purified 
FXIII-A2B2 was concentrated using a 100 KDa molecular weight cut off Vivaspin 
column (Sartorius Stedim) at 3000g, 4°C until ~ 3 ml remained. The purity of FXIII 
was assessed by SDS-PAGE (see section 3.2). The concentration of FXIII was 
determined by Nanodrop (Labtech International) using the extinction coefficient 13.8 
M
-1
cm
-1
. Purified FXIII was stored at -80 °C in 20 μl aliquots. 
 
56 
 
3.1.4. Analysis of fibrinogen, FXIII and plasminogen purification 
products 
As shown in Figure 8 fibrinogen and plasminogen were pure. Alternatively the FXIII 
purification products contain albumin (60 KDa) and a small amount of high 
molecular weight contaminants, therefore when determining the FXIII concentration 
the amount of albumin and high molecular weight contaminants were taken into 
consideration by dividing the total concentration by the percentage of FXIII within 
the sample as determined by densitometry.  
 
  
 
Figure 8: Analysis of fibrinogen, FXIII and plasminogen purification products 
by SDS-PAGE 
Fibrinogen (Fbg) and plasminogen (Plg) were pure. Factor XIII (FXIII) contained 
contamination from albumin (Alb) and from high molecular weight contaminants. 
Coomassie stained SDS-PAGE were representative of all purifications performed. 
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3.2.  Gel Electrophoresis and Immunoblotting 
Gel electrophoresis and immunoblotting were used to assess purity of purified 
proteins, protein cleavage and protein cross-linking. Reduced proteins were run on 
either NuPAGE 4-12% Bis-Tris gels (Invitrogen) in 1x 2(N-
morpholino)ethanesulfonic acid (MES) sodium dodecyl sulfate (SDS) running buffer 
(Invitrogen) or NuPAGE 3-8% Tris-Acetate gels (Invitrogen) in 1x Tris Acetate 
running buffer (Invitrogen).   
 
3.2.1. Gel Electrophoresis 
Samples were mixed with appropriate volumes of 4x loading buffer and 10x 
reducing agent (Invitrogen) and incubated at 95°C for 10 minutes in a heat block. 
Two NuPAGE gels were placed into Invitrogen gel running tanks and surrounded by 
1x running buffer appropriate to the gel. Twenty μl of the sample were loaded into 
each well along with 3 μl of WesternC™ standard (BioRad). 4-12% Bis-Tris gels 
were run for 45 minutes at 200 volts, whereas 3-8% Tris-Acetate gels were run for 
60 minutes at 150 volts using a PowerEase® 500 power supply (Invitrogen).  
 
3.2.2.  Coomassie staining of gels 
To visualise proteins, NuPAGE gels were stained with coomassie. The NuPAGE gels 
were removed from their plastic covers and washed with distilled water three times 
each for 10 minutes. The water was removed and either ~50 mls of GelCode® Blue 
Stain Reagent (Pierce) or Coomassie stain reagent (BioRad) (Mass spectrometry gels 
only) were added to completely cover the gel. The gels were left in the stain reagents 
for 1 hour and de-stained by gentle agitation in distilled water until the bands became 
clear. An image was captured using a MultiImage™ Light Cabinet (Alpha Innotech 
Corporation).  
 
3.2.3. Immunoblotting 
For detection of specific proteins, proteins were transferred from non-stained gels 
onto a polyvinylidene fluoride (PVDF) membrane (Millepore) by conventional 
Western blotting. Prior to transfer, a 8 cm x 7.5 cm PVDF membrane was cut in the 
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top left hand corner to indicate orientation. The membrane was soaked in 100% 
methanol for 12 seconds, distilled water for 2 minutes and transfer buffer for 2 
minutes. The Bio-Rad transfer cassette was prepared as shown in Figure 9, with filter 
paper placed on a sponge soaked in transfer buffer. The NuPAGE gel was removed 
from its plastic covers and washed in transfer buffer before placing on top of the 
filter paper. The PVDF membrane was positioned on-top of the gel with the cut 
corner to the top left hand side of the gel. Filter paper was placed on top of the PVDF 
membrane and the stack was finished with a sponge soaked in transfer buffer. The 
transfer cassette was clamped closed and transferred to a tank containing transfer 
buffer at 4°C and an ice block to maintain the temperature throughout the transfer.  
The tank was run at 100 volts for 60 minutes using a BioRad power pack.  
 
 
 
 
Figure 9: Preparation of the transfer cassette for immunoblotting. 
The transfer cassette was prepared by placing filter paper on top of a sponge, 
followed by the gel. The PVDF membrane was placed on top of the gel with the cut 
corner to the top left hand side of the gel. Filter paper was placed on top of PVDF 
membrane and the stack was finished with a sponge. All components were soaked in 
transfer beffer before forming the stack.  
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After the transfer was complete, the filter paper and sponge on top of the PVDF 
membrane were removed. The resulting PVDF membrane was washed in TBS-
Tween (TBS-T) three times each for 5 minutes followed by blocking in 5% non-fat 
dried milk in TBS-T for 1 hour or 3% BSA in TBS-T for 1 hour (For streptavidin 
HRP immunoblots only). The membrane was washed twice with TBS-T and 
incubated for one hour, unless specified otherwise, with the primary antibody at the 
appropriate dilution (See Table 3), whilst shaking. Following the incubation with the 
primary antibody the PVDF membrane was washed in TBS-T five times each for 10 
minutes. The PVDF membrane was then incubated for one hour whilst shaking with 
a horseradish peroxidase (HRP)-conjugated secondary antibody at the appropriate 
dilution (See Table 3) and a 1 in 5000 dilution of Strep Tactin (Bio-Rad) to develop 
the marker. Following the incubation with the secondary antibody the PVDF 
membrane was washed in TBS-T five times each for 10 minutes. The PVDF 
membrane was developed by adding a 1 to 1 mix of Supersignal West Pico Luminol 
(Thermo scientific) and Supersignal West Pico Stable (Thermo scientific) onto the 
protein side of the membrane (cut corner to the right) and incubated for 5 minutes. 
Chemiluminescence was captured using an Image Station 2000R (Kodak).  
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Table 3: Primary and secondary antibodies used in immunoblotting. 
Primary Antibody Secondary Antibody 
Antibody 
Dilution & 
incubation time 
Antibody 
Dilution & 
incubation time 
Streptavidin HRP 
(Sigma) 
1:500                     
1 hour 
  
Rabbit anti-human 
C3c (DAKO) 
1:5000     
Overnight 
Goat anti-rabbit 
HRP (DAKO) 
1:10000                 
1 hour 
Mouse anti-human 
C3a (Technoclone) 
1:2500                   
1 hour 
Rabbit anti-mouse 
HRP (DAKO) 
1:5000                     
1 hour 
Goat anti-human 
α2-antiplasmin 
HRP (Enzyme 
Research Labs) 
1:5000                   
1 hour 
  
Rabbit anti-human 
fibrinogen (DAKO) 
1:5000                   
1 hour 
Goat anti-rabbit 
HRP (DAKO) 
1:2000                   
1 hour 
Sheep anti-human 
factor XIII A 
subunit HRP 
(Enzyme Research 
Labs) 
1:4000                   
1 hour 
  
Goat anti-human 
plasminogen HRP 
(Enzyme Research 
Labs) 
1:5000                    
1 hour 
  
Goat anti-human 
Factor H (Quidel) 
1:10000                 
1 hour 
Rabbit anti-goat 
HRP (SIGMA) 
1:10000                 
1 hour 
Goat anti-human 
C5 (Quidel) 
1:1000        
Overnight 
Rabbit anti-goat 
HRP (SIGMA) 
1:2000                             
1 hour 
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3.3.  C3 ELISA 
An in-house sandwich ELISA established in the DCDR by Mrs May Boothby and 
Mrs Jane Brown (Technicians) was used to assess the concentration of C3 following 
C3 purification. A 96 well microtitre plate (Nunc) was coated with 100 μl of 1 in 
10,000 diluted rabbit anti-human C3c antibody (DAKO) in phosphate buffered saline 
(PBS) for 1 hour at room temperature whilst shaking, before storing overnight at 
4°C. On the day of assay the microtitre plate was brought to room temperature and 
washed four times with 200 μl of PBS-Tween (PBS-T) (No blocking step was 
included as described in section 3.3.1). A quality control sample (pooled normal 
human citrated plasma) and all test samples were diluted 1:100,000 in PBS-T using a 
MICROLAB 500 diluter. A standard curve was set up by diluting a different pooled 
normal human plasma sample calibrated against Liquichek immunology control level 
3 (BioRad). Samples (100 μl) were added to the wells in duplicate before incubating 
for 2 hours at room temperature on a plate shaker. The microtitre plate was washed 
four times with 200 μl of PBS-T and 100 μl of 1 in 10000 diluted goat anti-human 
C3 antibody (Quidel) in PBS-T was added. The plate was incubated for 1 hour at 
room temperature whilst shaking and then washed four times with 200 μl of PBS-T. 
A 1 in 2000 diluted HRP conjugated rabbit anti-sheep (DAKO) in PBS-T (100 μl) 
was added and incubated for 1 hour at room temperature whilst shaking. The 
microtitre plate was washed four times with 200 μl of PBS-T. Activated o-
Phenylenediamine (OPD) substrate was prepared by dissolving 4 OPD tablets 
(DAKO) in 12 ml of deionised water with the addition of 5 μl of 30% hydrogen 
peroxide (Sigma). The activated OPD substrate (100 μl) was added to the wells at 10 
second intervals and allowed to develop for ~4 minutes whilst shaking. Once a 
suitable colour developed, the reaction was stopped by the addition of 100 μl of 
1.5M sulphuric acid (Fisher) at 10 second intervals. The absorbance was measured at 
490 nm on the DYNEX MRX microtitre plate reader and C3 concentrations in the 
samples were automatically read from the standard curve using Revelations software 
(version 2.02).  
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3.3.1. Evidence for the absence of a blocking step in the C3 ELISA 
Previous optimisation steps including the need for a blocking step was performed by 
Mrs May Boothby and Mrs Jane Brown (Technicians). To determine whether C3 
bound non-specifically to the ELISA plate in the absence of a blocking agent, a 
blocking step with 3% BSA in PBS-T was compared with no blocking step. As 
shown in Table 4 the background (PBS-T blank) absorbance and normal pooled 
plasma absorbances were higher in the presence of a blocking step compared to the 
absence of a blocking step, suggesting C3 does not bind non-specifically to the 
ELISA plate. These results suggest a blocking step was not required in the final 
optimised protocol. 
 
Table 4: C3 ELISA performed in the presence and absence of a blocking step to 
determine non-specific binding to the ELISA plate  
The ELISA plate was blocked with either PBS-T only or 3% BSA in PBS-T. The 
absorbance at 490 nm was measured in wells incubated with a PBS-T blank or 
normal pooled plasma. The PBS-T blank absorbance and normal pooled plasma 
absorbance was higher in the blocked compared to the non-blocked wells.   
 No Blocking Blocking 
PBS-T Blank 0.179 0.206 
Normal pooled plasma 0.629 0.770 
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3.4.  Evaluation of the influence of C3 on fibrin structure and 
function 
3.4.1.   Turbidimetric analyses 
The turbidimetric clotting assay is an optical method for monitoring fibrin formation 
and lysis. Parameters derived from turbidimetric measurements include lag time, 
maximum absorbance and 50% lysis time. Lag time represents the time required for 
sufficient formation of fibrin protofibrils to allow lateral aggregation (Figure 10, 
Panels A & C).  Lateral aggregation of the fibrin protofibrils results in exponential 
increases in absorbance which plateaus at the maximum absorbance (Figure 10, 
Panels A & C) (Wolberg 2007). In plasma, maximum absorbance is a measure of 
clot density, whereas in a purified system, maximum absorbance is a measure of 
fibrin fibre thickness and pore size. 50% lysis time represents the time taken from the 
addition of the lysis activation mix (t-PA and plasminogen) to half the maximum 
absorbance, which in the concurrent turbidimetric assay is the time taken from the 
beginning of the assay period to half the maximum absorbance, whereas in the 
overlay turbidimetric assay it is from addition of t-PA and plasminogen after clot 
formation to half the maximum absorbance (Figure 10, Panels B & C). 
 
3.4.1.1. Turbidity Assay 
To a 96 well plate (Greiner), purified fibrinogen (final concentration of 0.5 mg/ml) 
was added in the presence and absence of purified FXIII (final concentration 0.0055 
mg/ml). Purified complement C3 was added in duplicate at the following final 
concentrations: 0, 0.15, 0.35, 0.55 and 0.75 mg/ml along with TBS to a final reaction 
volume of 100 μl. Fifty μl of an activation mix containing 0.025 U/ml final 
concentration of thrombin and 5 mM final concentration of CaCl2 in TBS were added 
to the fibrinogen mix to initiate fibrin clot formation. Immediately after the addition 
of the activation mix the plate was shaken for 2 seconds (intensity setting 3). The 
absorbance was measured every 12 seconds at 340 nm at 37°C for 1 hour in a 
ELx808 spectrophotometer (Bio-Tek). The resulting data was analysed for lag times 
and the maximum absorbance using customised software program (Carter et al. 
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2007) as illustrated in Figure 10, Panel A. Three independent experiments were 
carried out.  
 
 
 
Figure 10: Illustration of the turbidity and lysis variables.  
Panel A. Turbidimetric clotting assay parameters. Panel B. Lysis overlay assay 
parameters Panel C. Concurrent turbidity and lysis assay parameters: Lag time 
(Lag), Maximum Absorbance (Max Abs), Time to 50% Lysis (Lysis50), Complete 
Lysis (Lysisc). 
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3.4.1.2. Lysis Overlay Assay 
Clots formed at the end of the turbidity assay (section 3.4.1.1) were overlaid with 
100 μl of a lysis mix containing 100 ng/ml final concentration of t-PA (Technoclone) 
and 50 μg/ml final concentration of purified plasminogen in TBS. Following the 
addition of the lysis mix the plate was shaken on a plate shaker for 30 seconds and 
left to incubate for 1 hour. The plate was then placed into a ELx808 
spectrophotometer (Bio-Tek), where the absorbance was measured every 108 
seconds at 340 nm at 37°C for 9 hours. The resulting data was analysed for time to 
50% lysis as illustrated in Figure 10, panel B. A minimum of 3 independent 
experiments were carried out. 
 Lysis products produced by the lysis overlay were stored in 4X loading and 
10X reducing buffer at -20°C for analysis by gel electrophoresis and immunoblotting 
as described in section 3.2 and identification by MALDI-MS (see section 3.8).   
 
3.4.1.3.  Concurrent Turbidity and Lysis Assay 
To a 96 well plate (Greiner), purified fibrinogen (final concentration of 0.5 mg/ml) 
and purified plasminogen (final concentration of 20 μg/ml) were added in the 
presence and absence of purified FXIII (final concentration of 0.0055 mg/ml). 
Purified complement C3 was added in duplicate to the following final 
concentrations: 0, 0.15, 0.35, 0.55 and 0.75 mg/ml, and TBS added to a final reaction 
volume of 100 μl. Fifty μl of an activation mix containing 0.025 U/ml final 
concentration of thrombin, 5 mM final concentration of CaCl2 and 12.5 ng/ml final 
concentration of t-PA in TBS were added to the fibrinogen and plasminogen mix to 
initiate fibrin clot formation and lysis. The absorbance was measured every 12 
seconds at 340 nm at 37°C for 2 hours in a ELx808 spectrophotometer (Bio-Tek). 
The resulting data was analysed for lag time, maximum absorbance and time to 50% 
lysis (Figure 10, Panel C) using a customised software program (Carter et al. 2007). 
A minimum of 3 independent experiments were carried out.  
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3.4.2. Concurrent turbidity and lysis assay modifications 
3.4.2.1. Plasminogen and t-PA dose response  
In some concurrent turbidity and lysis experiments the concentration of plasminogen 
and t-PA were modified to determine the influence of modified lysis time on the 
effect of C3 on fibrin structure and lysis. To a 96 well plate (Greiner), purified 
fibrinogen (final concentration of 0.5 mg/ml), purified C3 (final concentration of 0.5 
mg/ml) were added in the presence of purified FXIII (final concentration 0.0055 
mg/ml). Purified plasminogen was added in duplicate to the following final 
concentrations: 20, 2 and 0.2 μg/ml along with TBS to a final reaction volume of 100 
μl.  The activation mix (50 μl) containing 0.025 U/ml final concentration of 
thrombin, 5 mM final concentration of CaCl2 and either 50, 10 or 5 ng/ml final 
concentration of t-PA in TBS was added to the fibrinogen mix to initiate fibrin clot 
formation and lysis. The absorbance was measured every 12 seconds at 340 nm at 37 
°C for 2 hours in a ELx808 spectrophotometer (Bio-Tek). Three independent 
experiments were performed. 
 
3.4.3. Plasma concurrent turbidity and lysis assay with spiked C3  
To a 96 well plate, 25 μL of plasma, spiked with additional purified C3 to equivalent 
plasma concentrations of 0, 0.5, 1, 1.5 and 2 mg/ml. TBS was added to a final 
volume of 50 μL. Fifty μL of 12.5 ng/ml of t-PA in TBS were added at 10 second 
intervals to each column, followed by 50 μL of an activation mix containing 0.03 
U/ml thrombin and 7.5 mM CaCl2 in TBS at 10 second intervals for each column. 
The absorbance was measured every 12 seconds at 340 nm at 32°C for 1 hour in a 
ELx808 spectrophotometer (Bio-Tek). The resulting data was analysed for lag time 
and maximum absorbance using a customised software program (Carter et al. 2007). 
At the end of the turbidity run, the plate remained in the ELx808 
spectrophotometer (Bio-Tek) and the absorbance was measured every 108 seconds at 
340 nm at 32°C for 9 hours. The resulting data was analysed for time to 50% lysis 
using a customised software program (Carter et al. 2007). Three independent 
experiments were carried out. 
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3.5.  Analysis of FXIII-dependent cross-linking of C3 to 5-
(biotinamido)pentylamine and fibrin 
3.5.1. Analysis of FXIII-dependent cross-linking of 5-
(biotinamido)pentylamine to C3 
3.5.1.1. FXIII-dependent cross-linking of 5-
(biotinamido)pentylamine into immobilised C3 in a plate based 
assay 
To determine whether C3 is a substrate of FXIIIa, BP was cross-linked to 
immobilised C3.  In a 96 well microtitre plate (Nunc), 100 μl of purified C3 (50 
μg/ml) in TBS1, or 100 μl of purified fibrinogen in TBS1 (40 μg/ml) as a positive 
control, were incubated at room temperature whilst shaking for 1 hour. The plate was 
blocked with 200 μl of 1% BSA in TBS1 for 1 hour at room temperature whilst 
shaking. Wells were washed three times with 200 μl of TBS1-T. Purified FXIII (30 
μl at final concentrations of 0, 0.5, 1 and 2 μg/ml) were added in duplicate. BP cross-
linking was initiated by the addition of 70 μl of an activation mix containing final 
concentrations of 1 U/ml thrombin (Calbiochem), 10 mM CaCl2, 1 mM BP (Pierce) 
and 0.5 mM dithiothreitol (DTT). As a negative control the activation mix contained 
final concentrations of 1 mM BP and 0.5 mM DTT only. The activation mixes were 
added to each well at 10 second intervals, the plate was incubated for 20 minutes at 
37 °C and 200 μl of 200 mM EDTA were added to each well at 10 second intervals 
to stop the reaction. The plate was washed three times with 200 μl of TBS1-T and 
100 μl of 2 μg/ml streptavidin-alkaline phosphatase (Sigma) in TBS1 were added to 
the plate and incubated at room temperature for 1 hour whilst shaking. The plate was 
washed with 200 μl of TBS1-T and 100 μl of 1 mg/ml p-nitrophenyl phosphate 
(Sigma) in 1M diethanolamine containing 0.5 mM MgCl2, pH 9.8 were added to 
each well at 10 second intervals and incubated at 37°C until a suitable colour 
developed. The reaction was stopped by the addition of 100 μl of 4M NaOH at 10 
second intervals. The plates were read at 405 nm on a DYNEX MRX microtitre plate 
reader. Three independent experiments were carried out.  
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3.5.1.2. Cross-linking of BP into C3 in solution using a plate based 
assay 
To determine whether C3 is cross-linked to BP when incubated in solution, an 
alternative plate based assay was performed which captured C3 cross-linked products 
using a C3 antibody and detected BP cross-linking using streptavidin HRP. In a 96 
well microtitre plate (Nunc) 100 μl of 1 in 10,000 rabbit anti-human C3c antibody 
(Dako) in TBS1 were incubated overnight at 4°C. The plate was brought to room 
temperature on the day of assay and was blocked with 200 μl of 1% BSA in TBS1 
for 1 hour at room temperature whilst shaking followed by three washes with 200 μl 
TBS1-T. In separate eppendorf tubes 0.5 mg/ml final concentration of purified C3 
was incubated with final concentrations of 5 mM BP, 0.022 mg/ml FXIII in the 
presence and absence of 1.0 U/ml thrombin and 5 mM CaCl2. TBS1 was added to a 
final reaction volume of 110 μl. The above reactions were incubated at 37°C for 0, 5, 
10, 30 and 60 minutes. At each time point the reactions were stopped by the addition 
of 110 μl of 200 mM EDTA. The reactions were transferred to the microtitre plate, 
100 μl per well in duplicate, and incubated at room temperature for one hour whilst 
shaking. The plate was washed three times with 200 μl of TBS1-T. One hundred μl 
of 2 μg/ml streptavidin-alkaline phosphatase (Sigma) in TBS1 were added to the 
plate, which was incubated at room temperature for 1 hour whilst shaking prior to 
washing with 200 μl of TBS1-T. One hundred μl of 1 mg/ml p-nitrophenyl phosphate 
(Sigma) in 1M diethanolamine containing 0.5 mM MgCl2, pH 9.8 were added to 
each column at 10 second intervals and incubated at 37°C until a suitable colour 
developed. The reaction was stopped in each column at 10 second intervals with 100 
μl of 4M NaOH. The plates were read at 405 nm on a DYNEX MRX microtitre plate 
reader. Three independent experiments were carried out.  
 
3.5.1.3. Cross-linking of BP into C3 in solution analysed by SDS-
PAGE 
To determine which chains of C3 become cross-linked by FXIIIa, BP was cross-
linked to C3 in solution. Purified C3 (final concentration 0.5 mg/ml), FXIII (final 
concentration 0.022 mg/ml) and BP (final concentration 5 mM) were added to a 1.5 
ml Eppendorf tube. Cross-linking was initiated by the addition of thrombin (final 
concentration 1 U/ml) and CaCl2 (final concentration 5 mM) in TBS. The final 
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volume was 1 mls and the reactions were incubated at 37°C. Cross-linking was 
stopped by the addition of 5 μl of 200 mM EDTA at 30 minutes, 1 and 4 hours. As 
negative controls purified C3 was incubated in the absence of FXIII, thrombin, and 
CaCl2 for 4 hours only. As a positive control purified fibrinogen (final concentration 
0.5 mg/ml) was incubated with BP and pre-activated FXIII (to allow cross-link 
formation but prevent fibrin clot formation). FXIII was pre-activated with thrombin 
and CaCl2 (concentrations as above) for 1 hour at 37°C. Thrombin was inactivated 
by the addition of 10 μl of 10 U/μl of hirudin at 37°C for 10 minutes. Pre-activated 
FXIII was incubated with purified fibrinogen for 4 hours at 37°C. Cross-link 
formation was stopped by the addition of 5 μl of 200 mM EDTA. The resulting BP 
cross-link products underwent gel electrophoresis under reduced conditions and were 
analysed by streptavidin HRP Western blot as described in section 3.2.  
 
3.5.2. Cross-linking of C3 to fibrin in a purified system 
Gel based cross-linking assays were performed to determine whether C3 is cross-
linked to itself to form homodimers and cross-linked to fibrin during clot formation. 
To a 0.5 ml eppendorf, purified C3 (final concentration 0.5 mg/ml) or hydrolysed C3 
(purified C3 dialysed in 1 litre of water each for 2 one hour incubations and a further 
week), purified fibrinogen (final concentration 1 mg/ml), purified FXIII (final 
concentration 0.022 mg/ml) and TBS were added to a final volume of 100 μl. Fibrin 
cross-linking was initiated upon the addition of 20 μl of an activation mix containing 
thrombin (final concentration of 0.025 U/ml), CaCl2 (final concentration of 5 mM) 
and TBS. The reaction mixtures were vortex mixed and incubated at 37°C for the 
following time points; 0, 5, 10, 30, 60, 240 minutes and 24 hours. Cross-linking was 
stopped by the addition of 4x loading buffer (Invitrogen) and 10x reducing agent 
(Invitrogen) and incubation of the samples at 95°C for 10 minutes in a heat block. 
Twenty μl of the sample were loaded onto a NuPAGE 3-8% Tris-acetate gels 
(Invitrogen). The SDS-PAGE gels were either stained with GelCode® Blue Stain 
Reagent (Pierce) or immunoblotted, as described in section 3.2 with rabbit anti-
human C3c antibody and rabbit anti-fibrinogen antibody (see Table 3).  
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3.5.3. Cross-linking of C3 to plasma clot components  
Plasma clots were formed by the addition of 10 μl of an activation mix containing 5 
U/ml thrombin, 15 mM CaCl2 (final concentration) in TBS to 100 μl of human 
plasma. One hundred μl of the mix were pipetted into a burette and incubated in a 
humidified chamber for 4 hours at room temperature. Burettes were attached by 
tubing to a buffer reservoir (Figure 11). The plasma clots were washed by perfusing 
with either 2 M NaCl followed by a TBS wash each for 2 hours or a wash with TBS 
only for 4 hours. Cross-link formation was stopped by the addition of 4x loading 
buffer (Invitrogen) and 10x reducing agent (Invitrogen) as described in section 3.5.2 
and clots were run on NuPAGE 3-8% Tris-Acetate gels, stained with GelCode Blue 
or immunoblotted as described in section 3.2 with rabbit anti-human C3c antibody 
and goat anti-human α2-antiplasmin antibody (see Table 3).  
 
3.5.4. Cross-linking of C3 in a plasma based system over a time-course 
Plasma clots were formed by the addition of 10 μl of activation mix containing 5 
U/ml thrombin, 15 mM CaCl2 (final concentration) in TBS to 100 μl of human 
plasma. Plasma clots were incubated at 37°C for 0, 5, 10, 30 minutes and 1, 2 and 4 
hours. Plasma clot formation was stopped by the addition of 4x loading buffer 
(Invitrogen) and 10x reducing agent (Invitrogen) as described in section 3.5.2 and 
clots were run on NuPAGE 3-8% Tris-Acetate gels, stained with GelCode Blue or 
immunoblotted as described in section 3.2 with rabbit anti-human C3c antibody and 
rabbit anti-fibrinogen antibody (see Table 3). 
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Figure 11: Method for perfusing plasma clots.  
Plasma clots were formed in the end of a burette whilst the other end was filled with 
buffer and attached to the tubing containing buffer without the addition of any air 
bubbles. Buffer was added to the buffer reservoir until it reached the 4 cm mark.  
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3.6.  Time dependent cleavage of C3 
To evaluate the effect of t-PA mediated plasmin cleavage of C3 in the presence and 
absence of fibrin on the C3 cleavage products, a time course was set up. To a 0.5 ml 
eppendorf tube the reagents summarised in Table 5 were added (at final 
concentrations) to a total volume of 100 μL. Reactions 1-4 were incubated at 37°C 
for either 0, 30 minutes, 1, 2, 4 or 24 hours. Reactions 5-8 were initially allowed to 
form a clot by the addition of thrombin and calcium to fibrinogen in the presence and 
absence of C3 and FXIII for 1 hour at 37°C in a water bath. Plasminogen and t-PA 
were subsequently incubated on top of the clots at 37°C for either 0, 30 minutes, 1, 2, 
4 or 24 hours. At each time point the reaction was stopped by the addition of 4x 
loading buffer (Invitrogen) and 10x reducing agent (Invitrogen) and heated to 95°C 
for 10 minutes in a heat block. Gel electrophoresis and immunoblotting were 
performed according to the methods described in section 3.2.  Immunoblots were 
analysed for C3, fibrinogen and plasminogen (see Table 3). 
 
3.7.  Thrombin and plasmin cleavage of C3 
To a 0.5 ml Eppendorf tube, purified C3 to a final concentration of 0.5 mg/ml was 
incubated with 0.025, 1, 5 or 18 U/ml final concentration of thrombin (Calbiochem) 
or 10, 22 or 44 μg/ml final concentration of plasmin (Calbiochem) for 4 hours at 
37°C. TBS was added giving a final reaction volume of 60 μl. After 4 hours the 
reactions were stopped by the addition of 4x loading buffer (Invitrogen) and 10x 
reducing agent (Invitrogen) and heated to 95°C for 10 minutes in a heat block. C3 
cleavage products were analysed by gel electrophoresis and immunoblotting as 
described in section 3.2. In addition, plasmin cleavage products of C3 were analysed 
by gel electrophoresis and coomassie stained for MS analysis (section 3.8).  
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Table 5: Reaction conditions used to analyse the time dependent cleavage of C3.  
Reaction C3 (0.5 mg/ml) Fbg (0.5 mg/ml) FXIII (5.5 µg/ml) 
Thr (0.025 U/ml) 
Ca
2+
 (5 mM) 
Plg (50 μg/ml) 
tPA (100 ng/ml) 
1     √ 
2 √    √ 
3  √   √ 
4 √ √   √ 
5  √  √ √ 
6 √ √  √ √ 
7  √ √ √ √ 
8 √ √ √ √ √ 
Included in the reaction (√). Fibrinogen (Fbg), plasminogen (Plg), tissue plasminogen activator (t-PA), thrombin (Thr). 
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3.8.  Analysis of the C3 cleavage products by MALDI-MS/MS 
and LC-MS/MS 
Lysis products obtained in section 3.4.1.2 were run on 4-12% Bis Tris NuPAGE gels 
(section 3.2) and stained with Coomassie blue (section 3.2.2). Cleavage products of 
C3 were assessed by matrix assisted laser desorption/ionisation mass spectrometry 
(MALDI-MS) in the proteomics facility, University of Leeds, by Dr Jeffrey N Keen, 
employing standardised methods (Gage et al. 2009) or by MALDI-MS/MS and 
liquid chromatography tandem mass spectrometry (LC-MS/MS) in the proteomics 
facility, York University by Dr Adam Dowle. 
 
3.8.1. Endoproteinase Asp-N and trypsin digestion of C3 cleavage 
products 
Protein bands were manually excised from a Coomassie stained 4-12% Bis-Tris gel 
using a razor blade. Protein bands were cut into 2 mm
2 
pieces and were washed and 
de-stained in 200 μL 50 mM ammonium bicarbonate (v/v) in acetonitrile for 10 
minutes in a 37°C water bath. This process was repeated three times. The resulting 
gel pieces were dehydrated in 200 μL 100% acetonitrile for 5 minutes and allowed to 
completely dry in air (approximately 30 minutes). The dehydrated gel pieces were 
rehydrated with 2 μL 25 mM ammonium bicarbonate containing 0.02 mg/ml trypsin 
(Promega). Eight μL of 25 mM ammonium bicarbonate was added to cover the gel 
piece and digestion was allowed to proceed for 18 hours at 37°C. 
In-gel combined Asp-N and trypsin digestion were performed after reduction 
with DTT and S-carbamidomethylation with iodoacetamide. Gel pieces were washed 
two times with 50% (v:v) aqueous acetonitrile containing 25 mM ammonium 
bicarbonate, then once with acetonitrile and dried in a vacuum concentrator for 20 
min.  Lyophilized Endoproteinase Asp-N from Pseudomonas fragi mutant strain 
(Sigma) was dissolved in the 100 μL 50 mM ammonium bicarbonate to give a final 
enzyme concentration of 0.02 μg/μL. Gel pieces were rehydrated by adding 10 μL of 
Asp-N solution and after 10 min enough 50 mM ammonium bicarbonate solution 
was added to cover the gel pieces.  Digests were incubated overnight at 37°C. A 5 L 
aliquot was taken for subsequent tryptic digestion. Sequencing-grade, modified 
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porcine trypsin (Promega) was dissolved in the 50 mM acetic acid supplied by the 
manufacturer, then diluted 5-fold by adding 25 mM ammonium bicarbonate to give a 
final trypsin concentration of 0.02 g/L.  A 10 L aliquot of trypsin solution was 
added to the peptide mixture. Digestion was allowed to proceed overnight at 37
o
C. 
Peptide mixtures were desalted and concentrated using 0.2 μL C18 ZipTips 
(Millipore) with elution into 3 mL 50% (v:v) aqueous acetonitrile containing 0.1% 
(v:v) trifluoroacetic acid. A 1 μL aliquot of the desalted peptide mixture was applied 
directly to a ground steel MALDI target plate, followed immediately by an equal 
volume of a freshly-prepared 5 mg/mL solution of 4-hydroxy-α-cyano-cinnamic acid 
(Sigma) in 50% aqueous (v:v) acetonitrile containing 0.1%  trifluoroacetic acid (v:v).   
 
3.8.2. MALDI-MS/MS analysis of Asp-N and tryptic peptides 
Positive-ion MALDI mass spectra were obtained using a MALDI L/R mass 
spectrometer (Waters) in reflectron mode, equipped with a N2 laser beam.  MS 
spectra were acquired over a mass range of m/z 800-5000.  Final mass spectra were 
externally calibrated against alcohol dehydrogenase and internally calibrated against 
trypsin autolysis products (m/z 2211.105 or 1045.564).  
Positive-ion MALDI mass spectra were obtained using a Bruker ultraflex III 
in reflectron mode, equipped with a Nd:YAG smart beam laser.  MS spectra were 
acquired over a mass range of m/z 800-5000.  Final mass spectra were externally 
calibrated against des-Arg1-Bradykinin (m/z 904.681); Angiotensin I (m/z 
1296.685); Glu1-Fibrinopeptide B (m/z 1750.677); ACTH (1-17 clip) (m/z 
2093.086); ACTH (18-39 clip) (m/z 2465.198); ACTH (7-38 clip) (m/z 3657.929). 
Monoisotopic masses were obtained using a SNAP averaging algorithm (C 4.9384, N 
1.3577, O 1.4773, S 0.0417, H 7.7583) and a signal to noise threshold of 2. For each 
sample the ten strongest peaks of interest with a signal to noise greater than 30 were 
selected for MS/MS fragmentation. Further peaks were manually selected for 
fragmentation as required.  Fragmentation was performed in LIFT mode without the 
introduction of a collision gas. Bruker flexAnalysis software (version 3.3) was used 
to perform the spectral processing and peak list generation for both the MS and 
MS/MS spectra. 
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3.8.3. LC-MS/MS analysis of Asp-N and trypsin peptides 
The trypsin only and trypsin and Asp-N digested samples were loaded onto a 
nanoAcquity UPLC system (Waters) equipped with a nanoAcquity Symmetry C18, 5 
µm trap (180 µm x 20 mm Waters) and a nanoAcquity BEH130 1.7 µm C18 capillary 
column (75 m x 250 mm, Waters). The trap wash solvent was 0.1% (v/v) aqueous 
formic acid and the trapping flow rate was 10 µL/min. The trap was washed for 5 
min before switching flow to the capillary column which had a flow rate of  300 
nL/min and a column temperature of 60°C.  The peptide separation used a gradient 
elution of two solvents (solvent A: 0.1% (v/v) formic acid; solvent B: acetonitrile 
containing 0.1% (v/v) formic acid). Initial conditions used 5% solvent B (2 min), 
followed by a linear gradient to 35% solvent B over 20 min and a wash with 95% 
solvent B for 2.5 min. The column was returned to initial conditions and re-
equilibrated for 25 min before subsequent injections.  
The nanoLC system was interfaced with a maXis LC-MS/MS System 
(Bruker Daltonics) with a nano-electrospray source fitted with a steel emitter needle 
(180 µm O.D. x 30 µm I.D., Proxeon). Positive ESI- MS & MS/MS spectra were 
acquired using AutoMS/MS mode. Instrument control, data acquisition and 
processing were performed using Compass 1.3 SP1 software (microTOF control, 
Hystar and DataAnalysis, Bruker Daltonics). Instrument settings were: ion spray 
voltage= 1,500 V; dry gas= 6 L/min; dry gas temperature= 160 °C; ion acquisition 
range= m/z 50-2,200. AutoMS/MS settings were: MS= 0.5 s (acquisition of survey 
spectrum); MS/MS= Collision induced dissociation with N2 as collision gas; ion 
acquisition range= m/z 350-1,400   
 
3.8.4. MASCOT analysis 
Tandem mass spectral data were submitted to database (Swissprot or NCBI) 
searching using a locally-running copy of the Mascot program (Matrix Science Ltd., 
version 2.3). Search criteria included: Enzyme= trypsin and Asp-N; Fixed 
modifications= Carbamidomethyl; Variable modifications= Oxidation, Deamidation. 
Peptide tolerance= 250 ppm; MS/MS tolerance= 0.5 Da; Instruments= MALDI-TOF, 
MALDI-TOF-TOF or ESI-MS/MS. 
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3.9.  Plasmin Generation Assay 
Plasmin generation assays were performed to determine whether C3 influenced the 
amount and rate of plasmin generated, using a plate based method previously 
described (Dunn et al. 2006) and a clot based method previously described  
(Longstaff and Whitton 2004).  
 
3.9.1. Plate based plasmin generation assay 
Plasmin generation was examined using a plate based assay monitoring absorbance 
at 405 nm as a result of S-2251 cleavage to form pNA (Chemical formula: H-D-Val-
Leu-Lys-OH+pNA) production, which provides information relating to the final 
amount of plasmin and the rate of plasmin generation. The amount of t-PA required 
to allow complete plasmin generation within the two hour incubation period was 
optimised as described in section 3.9.1.1. A 96 well microtitre plate (Nunc) was 
coated with 100 μl of fibrinogen per well at a final concentration of 80 μg/ml in 
TBS2 for 40 minutes at room temperature. The coating solution was removed and the 
plate was washed 3 times with 300 μl per well TBS2-T. The wells were blocked with 
300 μl of TBS2-blocking buffer for 90 minutes at 37°C. The blocking buffer was 
removed and the plate was washed 3 times with 300 μl per well with TBS2-T. The 
plate was incubated for 45 minutes at room temperature with 100 μl of 1 U/ml 
thrombin, 5 mM CaCl2 in TBS2. Following incubation, the plate was initially washed 
3 times with 300 μl per well with high salt buffer then 3 times with 300 μl per well of 
wash buffer. The plate was incubated for 90 minutes at 37°C with 50 μl per well of 
0-700 ng/ml t-PA. Following incubation the plate was washed 3 times with 300 μl 
per well with TBS2-T. To the plate, 100 μl of 600 nmol/L plasminogen in the 
presence of 0.8 mmol/L S-2251 in TBS were added per well. The plate was 
incubated at 37°C for 60 minutes, during which time the increase in absorbance 
(monitoring cleavage of S-2251) was measured at 405 nm using an ELx808 
spectrophotometer (Bio-Tek). The quantity of plasmin generated in each well was 
determined by calculating the rate of change in absorbance (production of pNA) 
between the start of the assay and the maximum absorbance and applying the 
standardisation provided by the manufacturer (Chromogenix): The increase in 
absorbance at 405 nm is proportional to the amount of plasmin generated. An 
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increase in absorbance of 0.05 units per minute at 37°C when S-2251 is 2x Km (0.8 
mmol/L) of the reaction between S-2251 and plasmin equals a plasmin concentration 
of 0.4 mg/L (equation 1). Rate of plasmin generation between 0 and 2 hours was 
determined using equation 2. 
 
Equation 1 
Plasmin (mg/L) = (Abs change per minute / 0.05) x 0.4 
 
Equation 2 
Rate of plasmin generation = Plasmin generated  
 (mg/L/min)                                Time taken  
 
 
3.9.1.1. Optimisation of the plate based plasmin generation assay 
The concentration of t-PA was optimised to determine the amount required to reach 
plateau in the presence of 600 mol/L plasminogen, and therefore the maximum 
plasmin generation. As shown in Figure 12 only t-PA concentrations above 350 
ng/ml were capable of reaching plateau over the 2 hour incubation period. A t-PA 
concentration of 500 ng/ml was chosen for future experiments as the plateau was 
reached well within the 2 hour incubation and produced curves similar to those seen 
with 700 ng/ml t-PA.  
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Figure 12: Optimisation of the concentration of t-PA in the plate based plasmin 
generation assay. 
At higher t-PA concentrations the faster the maximum absorbance was reached. 
However only in the presence of 350 μg/ml or higher was the maximum absorbance 
reached within the assay period.  
 
 
3.9.1.2. Final reaction conditions for the plate based plasmin 
generation assay 
A 96 well microtitre plate (Nunc) was coated with fibrinogen, blocked with TBS2-
blocking buffer and the fibrinogen was cleaved to form fibrin in the presence of 1 
U/ml thrombin and 5 mM CaCl2 as described in section 3.9.1. Following fibrin 
formation, the plate was initially washed 3 times with 300 μl per well with high salt 
buffer then 3 times with 300 μl per well of wash buffer. The plate was incubated for 
90 minutes at 37°C with 50 μl per well of either TBS2, 500 ng/ml tPA, 0.5 mg/ml C3 
or 600 nmol/L plasminogen in TBS2 as summarised in Table 6. Following 
incubation the plate was washed 3 times with 300 μl per well with TBS2-T prior to 
adding 50 μl per well of either 500 ng/ml tPA, 0.5 mg/ml C3 or 600 nmol/L 
plasminogen in TBS (Table 6) for 90 minutes at 37°C. To the plate, 100 μl of either 
600 nmol/L plasminogen or 500 ng/ml t-PA in the presence of 0.8 mmol/L S-2251 in 
TBS were added per well (Table 6). Plasmin generation was measured using a 
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ELx808 spectrophotometer (Bio-Tek) as described in section 3.9.1. The amount of 
plasmin generated and rate of plasmin generation described in equations 1 and 2.  
 
Table 6: Reaction conditions for the plate based plasmin generation assay.  
Reaction Incubation 1 Incubation 2 Activation 
1 TBS t-PA Plg and S-2251 
2 C3 t-PA Plg and S-2251 
3 t-PA C3 Plg and S-2251 
4 TBS t-PA and C3 Plg and S-2251 
5 TBS Plg t-PA and S-2251 
6 C3 Plg t-PA and S-2251 
7 Plg C3 t-PA and S-2251 
8 TBS Plg and C3 t-PA and S-2251 
Tissue plasminogen activator (t-PA), tris buffer saline (TBS), plasminogen (Plg) 
 
 
3.9.2. Clot based plasmin generation assay 
 To determine whether cross-linking affected plasmin generation, plasmin generation 
(production of pNA) was monitored in a solid clot at 405 nm. The amount of t-PA 
required to allow complete plasmin generation within the four hour incubation period 
was optimised as described in section 3.9.2.1. To a 96 well plate (Greiner), purified 
fibrinogen (final concentration of 0.5 mg/ml) and t-PA (final concentrations 0-172.8 
ng/ml) was added in the presence and absence of purified FXIII (final concentration 
0.0055 mg/ml). TBS was added to a final reaction volume of 70 μl.  The activation 
mix (30 μl) containing 0.025 U/ml final concentration of thrombin and 5 mM final 
concentration of CaCl2 in TBS were added to the fibrinogen mix to initiate fibrin clot 
formation. The absorbance was measured every 12 seconds at 340 nm at 37 °C for 1 
hour in a ELx808 spectrophotometer (Bio-Tek). Following clot formation 50 μl of 
lysis mix containing 0.8 mmol/L of the chromogenic substrate S2251 (Chromogenix) 
and 20 μg/ml plasminogen in TBS were added. The plate was incubated at 37°C and 
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plasmin generation was monitored by the change in absorbance every 48 seconds for 
4 hours at 405 nm using a ELx808 spectrophotometer (Bio-Tek). Plasmin generation 
and rate of plasmin generation were determined using equations 1 and 2 (section 
3.9.1). 
 
3.9.2.1. Optimisation of the clot based plasmin generation assay 
The concentration of t-PA was optimised to determine the amount required to reach 
plateau and therefore the maximum plasmin generation. As shown in Figure 13 all 
the t-PA concentrations were capable of reaching plateau  over the 4 hour incubation 
period whether this was in the presence (Figure 13, Panel A) or absence (Figure 13, 
Panel B) of FXIII. The rate of plasmin generation was unaffected by cross-linking 
(Figure 13, Panel C). A t-PA concentration of 21.6 ng/ml was chosen for future 
experiments as the maximum plasmin generation was reached by 2 hours, using 
higher concentrations the reaction was too fast. 
 
3.9.2.2. Final conditions for the clot based plasmin generation assay 
To a 96 well plate (Greiner), purified fibrinogen (final concentration of 0.5 mg/ml) 
was added in the presence and absence of purified FXIII (final concentration 0.0055 
mg/ml) and in the presence and absence of purified C3 (final concentration 0.5 
mg/ml). Either 21.6 ng/ml t-PA or 20 μg/ml plasminogen were added before clot 
formation. TBS was added to a final reaction volume of 70 μl. Thirty μl of activation 
mix containing 0.025 U/ml final concentration of thrombin and 5 mM final 
concentration of calcium in TBS were added to the fibrinogen mix to initiate fibrin 
clot formation. The absorbance was measured every 12 seconds at 340 nm at 37°C 
for 1 hour in a ELx808 spectrophotometer (Bio-Tek). Following clot formation 50 μl 
of lysis mix containing 0.8 mmol/L of the chromogenic substrate S2251 
(Chromogenix) and either 21.6 ng/ml t-PA or 20 μg/ml plasminogen in TBS were 
added in the opposite orientations to the t-PA and plasminogen incubated within the 
clot. The plate was incubated at 37°C and plasmin generation was monitored by the 
change in absorbance every 48 seconds for 4 hours at 405 nm using a ELx808 
spectrophotometer (Bio-Tek). Plasmin generation and rate of plasmin generation 
were determined using equations 1 and 2 (section 3.9.1).  
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A      B 
  
C 
 
Figure 13: Optimisation of the amount of t-PA required for the clot based 
plasmin generation assay.  
In the presence (Panel A) and absence (Panel B) of FXIII, t-PA at all concentrations 
reached the maximum absorbance in the assay period. (Panel C) Rate of plasmin 
generation was unaffected by the presence (■) or absence (♦) of FXIII.  
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3.10. Relationship between factor H, measures of fibrin 
structure and function and family history of T2DM in South 
Asians 
Dr Riyaz Somani (former Clinical PhD student in DCDR) recruited all the subjects, 
processed all the samples and performed all of the other phenotyping. I analysed 
factor H levels in stored plasma from this study and carried out data analysis for 
factor H (Somani et al. 2012).  
 
3.10.1. Subjects 
Recruitment described in detail in Somani et al (2012). In brief, 119 healthy South 
Asian first degree relatives of patients with T2DM were recruited from West 
Yorkshire, along with 119 healthy South Asian control subjects with no personal or 
family history of T2DM. All subjects gave informed written consent according to 
protocols approved by the Leeds (West) and Bradford NHS research ethics 
committees (Somani et al. 2012). 
 
3.10.2. Blood sampling and analysis of complement factors 
Fifty millilitres of venous blood were taken with a 19-guage needle after a 10 hour 
fast and a 20 minute rest. Blood was taken into iced EDTA to assess the levels of 
C3a-desArg, sC5b-9 and fragment Bb, 0.109 M tri-sodium citrate (pH 8.8) on ice to 
assess the levels of C3, properdin, factor B and turbidimetric analyses and 0.109 M 
tri-sodium citrate (pH 8.8) at room temperature to assess the levels of factor H and 
fibrinogen. Samples were centrifuged at 2560g at 4°C for 30 minutes; the resulting 
plasma was stored at either at -80°C for EDTA plasma or -40°C for tri-sodium citrate 
plasma.  
Complement proteins C3, factor B and properdin were measured using in-
house ELISAs by Dr Somani (Somani et al. 2012). C3a-desArg (QUIDEL), sC5b-9 
(QUIDEL) and fragment Bb (QUIDEL) were measured using commercial ELISAs 
by Dr Somani (Somani et al. 2012). Factor H was analysed by in house ELISA 
(section 3.12.2) by VR Richardson.  Turbidimetric analyses were performed on 
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stored plasma using a method similar to that described in section 3.4.3 (with the 
omission of C3) by Dr Somani (Somani et al. 2012). 
 
3.11. Evaluation of the influence of factor H on fibrin 
structure and function 
3.11.1. Incorporation of Factor H in plasma clots 
Plasma clots were formed by the addition of 50 μl of an activation mix containing 5 
U/ml thrombin, 15 mM CaCl2 (final concentration) in TBS to 250 μl of human 
plasma from 78 individuals who gave informed consent according to a protocol 
approved by the Leeds NHS Trust research ethics committee (Ajjan et al. 2005) and 
incubated at 37°C for 4 hours. Formed clots underwent centrifugation at 13,000 rpm 
for 5 minutes; the serum produced was removed and stored at -40°C. The 
concentrations of factor H in paired plasma and serum were determined by ELISA 
(section 3.12). Factor H incorporation into plasma clots was determined as the 
difference in factor H concentration between plasma and serum expressed as a 
percentage of plasma factor H concentration.  
 
3.12. Factor H ELISA 
An in-house factor H sandwich ELISA was established to analyse the concentration 
of factor H in plasma and serum samples. The factor H ELISA was optimised for 
antibody concentration, standard curve and blocking.  
A 96 welled microtitre plate (Nunc) was coated with 100 μl of primary 
antibody in PBS as described in section 3.12.1.1 for hour at room temperature whilst 
shaking, before storing overnight at 4°C. On the assay day the microtitre plate was 
brought to room temperature and blocked with 3% BSA in PBS-T as described in 
section 3.12.1.2  followed by four washes with 200 μl of PBS-T and blotted onto 
absorbent paper. One hundred μl of PBS-T blank, human plasma diluted 1 in 3000 in 
PBS-T were added to the wells in duplicate along with a standard curve optimisation 
described in section 3.12.1.3 and incubated for 1 hour at room temperature whilst 
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shaking. The microtitre plates were washed four times with 200 μl of PBS-T and 
blotted onto absorbent paper. The plate was incubated with 100 μl of secondary 
antibody in PBS-T as described in section 3.12.1.1 for 1 hour at room temperature 
whilst shaking. The microtitre plates were washed four times with 200 μl of PBS-T 
and blotted onto absorbent paper. The plate was incubated with 100 μl of tertiary 
antibody in PBS-T as described in section 3.12.1.1 for 1 hour at room temperature 
whilst shaking. The microtitre plates were washed four times with 200 μl of PBS-T 
and blotted onto absorbent paper. Activated OPD substrate was prepared by 
dissolving 4 OPD tablets in 12 mls of distilled water and 5 μl of 30% hydrogen 
peroxide (Sigma). One hundred μl of activated OPD substrate were added to the 
wells and allowed to develop for 10 minutes whilst shaking. The reaction was 
stopped by the addition of 100 μl of 1.5 M sulphuric acid (Fisher). The absorbance 
was measured at 490 nm on the DYNEX MRX microtitre plate reader. 
 
3.12.1. Optimisation of the Factor H ELISA 
3.12.1.1. Antibody Optimisation 
The factor H ELISA was initially developed using a grid experiment containing a 
range of capture and detection antibody dilutions using a polyclonal anti-human 
factor H antibody (Quidel) and mouse monoclonal anti-human factor H antibody 
(Quidel) (Figure 14).   
In brief, the orientation of the polyclonal and monoclonal antibody against 
factor H was initially investigated to determine the optimal orientations for capture 
and detection antibodies (Figure 14, Panel A). The plate was coated with a 1:2500 to 
1:20000 dilutions of either polyclonal or monoclonal factor H antibodies in PBS-T, 
followed by incubation with either PBS or room temperature normal pooled plasma 
at a 1 in 3000 dilution with PBS-T. Factor H was detected using a secondary 
detection antibody diluted from 1:2500 to 1:10000 (either the polyclonal or 
monoclonal factor H antibodies in the opposite orientation to the capture antibody) 
and a tertiary HRP conjugated antibody at 1:1000 (either rabbit anti-mouse HRP or 
rabbit anti-goat HRP) and the signal to noise ratio was monitored (equation 3). When 
the plate was coated with the polyclonal factor H antibody the signal to noise ranged 
from 7 – 10. When the plate was coated with the monoclonal factor H antibody using 
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the same antibody dilutions, the signal to noise ratio ranged from <1 – 2, indicating 
the polyclonal factor H antibody should be used as the capture antibody and the 
monoclonal as the detection antibody.  
The antibody concentrations were further optimised to give the best signal to 
noise ratio for the least amount of antibody used (Figure 14, Panel B).  The 
polyclonal capture antibody dilutions were kept the same and the monoclonal 
detection antibody was further diluted from 1:10000 to 1:40000. The signal to noise 
ranged from 5 – 20 across the plate. Higher signal to noise ratios were observed with 
the least amount of antibodies used; however, they gave poor overall absorbances. 
The optimum antibody dilutions were therefore chosen as a 1:10000 capture antibody 
and a 1:20000 detection antibody, as this had good overall absorbencies and a signal 
to noise ratio of 8.  
 
Equation 3 
Signal to noise ratio = Absorbance of normal pool plasma 
                  Absorbance of the PBS blank 
 
3.12.1.2. Blocking step optimisation 
To determine whether factor H bound non-specifically to the ELISA plate in the 
absence of a blocking agent, a blocking step with 3% BSA in PBS-T was compared 
with no blocking step. As shown in Table 7 there was no difference in the 
background (PBS-T blank) absorbance between the blocked and non-blocked wells, 
whereas the absorbance of the normal pooled plasma was higher in the blocked wells 
compared to the non-blocked wells, suggesting factor H does not bind non-
specifically to the ELISA plate. These results suggest a blocking step is not required 
in the final optimised protocol. 
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Table 7: Factor H ELISA performed in the presence and absence of a blocking 
step to determine non-specific binding to the ELISA plate. 
The ELISA plate was blocked with either PBS-T only or 3% BSA in PBS-T. The 
absorbance at 490 nm was measured in wells incubated with a PBS-T blank or 
normal pooled plasma. There was no difference in the PBS-T blank absorbance 
between the blocked and non-blocked wells whereas there was reduced absorbance 
in the non-blocked compared with the blocked when incubated with normal pooled 
plasma.  
 No Blocking Blocking 
PBS-T Blank 0.180 0.181 
Normal pooled plasma 1.293 1.412 
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Figure 14: Grid experiment for the optimisation of the factor H antibodies  
A Grid experiment to determine the optimal orientation of antibodies. Data presented 
as absorbance at 490 nm when the polyclonal or monoclonal ( ) capture antibody 
were used against buffer (PBS-T only) (Purple) or normal pool plasma diluted 1 in 
3000 in PBS-T (White)  B. Grid experiment to determine the optimum 
concentrations of antibody for capture and detection. Data presented as absorbance at 
490 nm when the polyclonal capture antibody and monoclonal detection antibody 
was used.  
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3.12.1.3.  Standard Curve Optimisation 
The standard curve was set up using six serial dilutions of normal pooled plasma 
calibrated against purified factor H (Quidel). The concentration of factor H in the 
normal pool plasma was 219 µg/ml therefore serial dilutions of the normal pool 
plasma resulted in a concentration range of 41.1 μg/ml to 1316.6 μg/ml when plasma 
samples are diluted 1 in 3000. The optimised normal pooled plasma standard curve 
was used in the final ELISA method.  
 
3.12.2. Final conditions for the factor H ELISA 
A 96 welled microtitre plate (Nunc) was coated with 100 μl of 1 in 10,000 diluted 
polyclonal goat anti-human factor H antibody (Quidel) in PBS for 1 hour at room 
temperature whilst shaking, before storing overnight at 4°C. The microtitre plates 
were washed four times with 200 μl of PBS-T and blotted onto absorbent paper. One 
hundred μl of human plasma or serum diluted 1 in 3000 in PBS-T were added to the 
wells in duplicate along with a standard curve diluted 1:500 to 1:16000 using pooled 
normal human plasma calibrated against purified factor H (Quidel) and incubated for 
1 hour at room temperature whilst shaking. The microtitre plates were washed four 
times with 200 μl of PBS-T and blotted onto absorbent paper. The plate was 
incubated with 100 μl of 1 in 20,000 diluted mouse monoclonal anti-human factor H 
antibody (Quidel) in PBS-T for 1 hour at room temperature whilst shaking. The 
microtitre plates were washed four times with 200 μl of PBS-T and blotted onto 
absorbent paper. The plate was incubated with 100 μl of 1 in 1000 diluted rabbit anti-
mouse HRP (DAKO) in PBS-T for 1 hour at room temperature whilst shaking. The 
microtitre plates were washed four times with 200 μl of PBS-T and blotted onto 
absorbent paper. The microtitre plates were developed with OPD substrate and 
stopped with 1.5 M sulphuric acid as described in section 3.12. The absorbance was 
measured at 490 nm on the DYNEX MRX microtitre plate reader and factor H 
concentrations in the samples were automatically read from the standard curve using 
Revelations software (Version 2.02). 
 
 90 
 
3.12.2.1. Spiking and Recovery of Factor H 
Purified factor H was spiked into diluted quality control normal pool plasma (195.9 
µg/ml), to determine the recovery of factor H in the optimised ELISA. The spiking 
recovery results show between 97.5 and 110% recovery across a range of 
concentrations (Table 8). 
 
Table 8: Spiking and recovery of factor H into quality control normal pool 
plasma. 
Spiking of 100 to 350 µg/ml of purified factor H to normal pool plasma (195.9 
µg/ml) resulted in 110 to 97.5% recovery. 
Spike Level 
Expected 
(µg/ml) 
Observed 
(µg/ml) 
Recovery % 
100 µg/ml 295.9 327.3 110.6 
200 µg/ml 395.9 415.7 105 
300 µg/ml 495.9 511.3 103.1 
350 µg/ml 545.9 532.3 97.5 
 
 
3.12.2.2. Effect of freeze/thaw cycles on Factor H levels 
To assess the suitablilty of this assay for measuring plasma samples undergoing 
freeze/thaw cycles, factor H concentration was determined in plasma samples having 
undergone several freeze-thaw cycles (Figure 15). Although the factor H 
concentration remained similar after 2 freeze-thaw cycles, the levels started to 
decrease after three-freeze thaw cycles; suggesting factor H denaturation prevents the 
recognition by the monoclonal secondary antibody. Only samples having undergone 
1 or 2 freeze-thaw cycles were used for subsequent factor H analysis. 
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Figure 15: Factor H levels after repeat freeze/thaw cycles.  
After three freeze/thaw cycles the factor H level begins to decrease. Mean (SEM) of 
2 independent experiments.  
 
 
3.13. Concurrent turbidity and lysis in the presence of factor 
H 
Concurrent turbidity and lysis assay carried out as described in section 3.4.1.3, 
except with the addition of purified factor H (Quidel) to the following final 
concentrations: 0, 25, 50, 75, 100 and 500 µg/ml instead of C3. 
Lysis products produced by the concurrent turbidity and lysis were stored in 4x 
loading buffer (Invitrogen) and 10x reducing agent (Invitrogen) for analysis by gel 
electrophoresis and immunoblotting as described in section 3.2. 
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3.14. Cross-linking of factor H to fibrin 
3.14.1. Cross-linking of factor H in a purified system 
Cross-linking of factor H to fibrin carried out as described in section 3.5.2 except 
with the addition of purified factor H (final concentration, 50 μg/ml) instead of C3. 
Cross-link products were analysed by gel electrophoresis and immunoblotting with a 
goat anti-human factor H antibody and a rabbit anti-fibrinogen antibody as 
previously described in section 3.2.  
 
3.14.2. Cross-linking of factor H in plasma based system 
Cross-linking of factor H to plasma clot components was carried out as described in 
section 3.5.3, except the PVDF membrane was immunoblotted with a goat anti-
human factor H antibody instead of a rabbit anti-human C3c antibody.  
 
3.15. Thrombin and plasmin cleavage of factor H 
Cleavage of factor H by thrombin and plasmin was carried out as described in 
section 3.7, except with the addition of purified factor H (final concentration, 100 
μg/ml) instead of C3. Factor H cleavage products were analysed by gel 
electrophoresis and immunoblotting with goat anti-human factor H antibody as 
described in section 3.2.   
 
3.16. Identification of novel factor XIII substrates 
A functional proteomics based technique was established to identify and characterise 
novel substrates of FXIII in plasma using a method previously established to identify 
substrates of tissue transglutaminase (Fleckenstein et al. 2004;Orru et al. 2003). BP 
was used due to its ability to identify and characterise cross-linking sites within α2-
antiplasmin (Lee et al. 2000;Lee et al. 2001) and the ability to separate cross-linked 
(BP labelled) and non-cross-linked plasma proteins using avidin affinity 
chromatography.   
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3.16.1. Incorporation of BP into plasma proteins 
To optimise the concentrations of BP, FXIII and incubation times, pooled normal 
plasma or fibrinogen depleted plasma (Diagnostic Reagents Ltd) at a final dilution of 
1 in 100 was incubated with final concentrations of 0.022-0.22 mg/ml FXIII, 10-100 
mM BP (Pierce), 5 mM CaCl2 and 1 U/ml thrombin (Calbiochem) and TBS in an 
eppendorf tube, giving a final reaction volume of 1 ml. The sample was mixed and 
incubated for 2-4 hours at 37°C. The negative control was produced using the same 
reaction conditions described above except BP was excluded, whereas in the positive 
control 0.5 mg/ml final concentration of fibrinogen was incubated with 5 mM BP and 
preactivated FXIII as described in section 3.5.1.3.  
 
3.16.2. Removal of excess BP 
3.16.2.1. Removal of excess BP by dialysis 
The 1 ml biotinylated plasma sample was dialysed in a 3.5 KDa molecular weight 
cut-off dialysis membrane against a total of 3-6 litres of TBS for two 1 hour 
incubations and overnight at 4°C.  
 
3.16.2.2. Removal of excess BP by gel filtration 
The biotinylated plasma sample was applied to either a 7 cm (height) by 0.5 cm 
(width) or a 7 cm (height) by 2.5 cm (width) Sephadex G25 course column 
equilibrated in TBS by gravity flow. Proteins and BP were eluted off the column in 
TBS and 1 ml fractions were collected. The absorbance (protein content) was 
monitored at 280 nm using the nanodrop, whilst free BP was monitored by FXIII 
activity assay (Section 3.16.3). 
 
3.16.3. Factor XIII activity assay to monitor BP elutions from the gel 
filtration column 
The FXIII activity assay used previously to assess the incorporation of BP into C3 
(section 3.5.1.1) was adapted to assess BP elution from the gel filtration column 
(section 3.16.2.2). A 96 well microtitre plate (Nunc) was coated with 40 μg/ml 
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fibrinogen and blocked as previously described (section 3.5.1.1). Samples were 
loaded in quadruplicate with 10 μl of 0.022 mg/ml final concentration of purified 
FXIII,  30 μl of TBS1 and either 10 μl of each fraction eluted from the gel filtration 
column (section 3.16.2.2), 10 μl of 3 mM BP positive control or 10 μl TBS1 negative 
control. Incorporation of BP into fibrinogen was initiated upon the addition of 50 μl 
of activation mix containing 20 μl of TBS1, 10 μl of 5 mM final concentration of 
DTT, 10 μl of 10 mM final concentration of CaCl2 and 10 μl of 1 U/ml final 
concentration of thrombin (Calbiochem). The reaction was incubated at room 
temperature for 3 or 10 minutes. Duplicate reactions were stopped with the addition 
of 200 μl of 200 mM EDTA. The plate was washed, incubated with streptavidin 
alkaline phosphatase, developed with p-nitrophenyl-phosphate and absorbance 
measured with a DYNEX MRX microtitre plate reader as previously described in 
section 3.5.1.1.  Incorporation of BP was determined as the difference in absorbance 
between incubations for 3 and 10 minutes. 
 
3.17. Purification of biotinylated plasma proteins by 
monomeric avidin affinity chromatography 
A number of avidin technologies can be employed for the purification of biotinylated 
proteins as outlined in Table 9. Monomeric avidin was chosen as it has a high 
binding capacity with mild elution procedures allowing the re-use of the column. As 
the BP incorporation reaction was performed in TBS an in-house modified method 
was established to purify the BP labelled proteins, and was compared to the 
manufacturers recommended protocol. 
 
3.17.1. The manufacturers recommended protocol for the purification of 
BP containing proteins by monomeric avidin affinity 
chromatography 
A 3 cm (height) by 0.7 cm (width) monomeric avidin (Pierce) column was washed 
with 4 CV of PBS. The non-reversible binding sites were blocked with 3 CV of 2 
mM biotin in PBS. Free biotin was removed from the reversible binding sites upon 
the addition of 6 CV of 0.1 M glycine pH 2.8. The column was equilibrated in PBS. 
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The BP labelled proteins were applied to the column under gravity and incubated on 
the column for 1 hour at room temperature. The column was washed with 6 CV of 
PBS to remove non-bound protein. The bound BP labelled proteins eluted from the 
column in 6 CV of 2 mM biotin in PBS. The column was regenerated with 4 CV of 
0.1 M glycine pH 2.8 and finally equilibrated for storage in PBS. Two ml fractions 
were collected during all steps except for elution fractions which were 1 ml. The 
protein content of the fractions was monitored at 280 nm using a nanodrop (Labtech 
International).  
 
3.17.2. The in-house modified method for the purification of BP 
containing proteins by monomeric avidin affinity chromatography 
A 3 cm (height) by 0.7 cm (width) monomeric avidin (Pierce) column was washed 
with 4 CV of TBS1. The non-reversible binding sites were blocked with 3 CV of 2 
mM biotin in TBS1. Free biotin was removed from the reversible binding sites upon 
the addition of 6 CV of 0.1 M glycine pH 2.8. The column was equilibrated in TBS1. 
The BP labelled proteins were applied to the column under gravity and incubated on 
the column for 1 hour at room temperature. The column was washed with 6 CV of 
TBS1 to remove non-bound protein, followed by a 4 CV 2M salt wash and a 6 CV 
wash in TBS1. The bound BP labelled proteins eluted from the column with 6 CV of 
2 mM biotin elution buffer. The column was regenerated with 4 CV of 0.1 M glycine 
pH 2.8 and finally equilibrated in TBS1. Two ml fractions were collected during all 
steps except for elution fractions which were 1 ml. The protein content of the 
fractions was monitored at 280 nm using a nanodrop (Labtech International).   
 
3.17.3. Optimisation of the monomeric avidin affinity chromatography 
method using biotinylated BSA 
3.17.3.1. Comparison of the elution profiles using the manufacturers 
recommended protocol and an in-house modified method for 
monomeric avidin purificationof BP containing proteins 
The differences in elution profiles between the manufacturer recommended protocol 
and in-house modified methods were examined using commercially available 
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biotinylated BSA, and protein concentrations were determined at 280 nm using a 
nanodrop (Labtech International). The majority of the biotinylated BSA eluted from 
the column during the elution step with a small amount eluting during the 
regeneration step using both methods (Figure 16, Panels A & B). In the in-house 
method a small amount of biotinylated BSA was seen during the initial wash steps 
(Figure 16, Panel B). Fractions from the wash and elution steps were concentrated by 
acetone precipitation and analysed by SDS-PAGE confirming that the majority of 
protein was present in the elution step with small amounts present in the wash 
fractions from both methods (Figure 16, Panels C and D).   
 
3.17.3.2. Identification of the monomeric avidin affinity column 
binding capacity 
As a small amount of biotinylated BSA was eluted from the column during the wash 
step (Figure 16), the column capacity was determined using biotinylated BSA.  
Biotinyated BSA (2.6 mg) was incubated on the monomeric avidin column and the 
elution profiles of the manufacturers and in-house methods were monitored at 280 
nm using a nanodrop (Labtech International). The amount of protein in each elution 
fraction was combined to give a total binding capacity of the column.  The binding 
capacity equalled 1.3 mg for both the manufacturers recommended protocol and the 
in-house modified method, suggesting 2 mls of monomeric avidin can accommodate 
1.3 mg of biotinylated BSA, which was half the binding capacity specified by the 
manufacturer. As there were no obvious differences in elution profiles between the 
two methods and the buffers are compatible with acetone precipitation (section 
3.18.2.1) the in-house modified method containing TBS would be used for further 
purifications of the BP labelled proteins. 
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Table 9: Advantages and disadvantages of avidin affinity chromatography 
Information taken form (Molecular Probes Inc 2001;Thermo fisher scientific Inc 2009;Thermo fisher scientific Inc 2011)      
Isolation 
Method 
Binding affinity Elution Methods Re-usability of 
the 
column/beads 
Non-specific 
binding 
Binding 
Capacity 
Extra Information 
Avidin High Guanidinium 
chloride or SDS-
PAGE  
Unable to re-use High >29 μg biotin/ml 
of gel 
Stable at pH 2-11 and over a 
range of temperatures 
Streptavidin High Guanidinium 
chloride or SDS-
PAGE  
Unable to re-use Lower than 
avidin 
1.3 mg 
biotinylated 
BSA/ml of resin 
Less soluble in water 
compared to avidin. Stable at 
pH 2-11 and is leach 
resistant 
Neutravidin High Guanidinium 
chloride or SDS-
PAGE  
Unable to re-use Low ≥ 20 μg of 
biotin/ml of resin 
Stable at pH 2-11 and is 
leach resistant 
Captavidin Lower than avidin Increasing the pH 
to 10 
Can be used 
multiple times 
Low 10 μg of biotin / 
mg protein 
Biotin binding site altered by 
tyrosine nitration. Free biotin 
is added to eliminate binding 
to non-nitrated tyrosines 
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Isolation 
Method 
Binding affinity Elution Methods Re-usability of 
the 
column/beads 
Non-specific 
binding 
Binding 
Capacity 
Extra Information 
       
Monomeric 
Avidin 
Lower than avidin 2mM free biotin 
or 0.1M glycine 
Maximum of 10 
times, with 2.5% 
decrease in 
binding capacity 
per regeneration 
Low ≥ 1.2 mg 
biotinylated 
BSA/ml of resin 
Binding is reversible allowing 
non-harsh elution conditions 
to be used 
Coated 
Magnetic 
Beads 
High SDS-PAGE 
boiling (harsh 
conditions) 
Single use only Lower than 
avidin 
55 μg biotin / 
mg of beads 
Can separate the biotinylated 
proteins within 5-10 minutes. 
Contains streptavidin coating  
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Figure 16: Purification of biotinylated BSA by monomeric avidin affinity chromatography.  
Purification of biotinylated BSA using (Panel A) Manufacturers recommended method (Panel B) In-house modified method showed that the 
majority of the biotinylated eluted from the monomeric avidin column during the elution step. Analysis of pooled purification products from the 
manufactures recommended method (Panel C) and in-house modified method (Panel D) by coomassie stained gel, confirmed elutions of 
biotinylated BSA in the elution step but also shows biotinylated BSA in the wash steps using both methods.  
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3.18. Acetone Precipitation 
Acetone precipitation was performed to concentrate the eluted protein sample and 
remove any residual salt from the sample prior to LC-MS/MS.  
 
3.18.1. Acetone precipitation of proteins following monomeric avidin 
affinity chromatography 
Four times the sample volume of acetone (Fisher) cooled to -20°C was added to each 
fraction. The sample was mixed and incubated overnight at -20°C. Following 
incubation the sample was spun at 13,400 rpm for 10 minutes, the supernatant was 
removed and the pellet was left to air-dry for 30 minutes. Pellets were stored at -
40°C. 
 
3.18.2. Optimisation of the acetone precipitation method 
3.18.2.1. Buffer compatibility with the acetone precipitation method 
Following avidin affinity chromatography, the fractions required concentration and 
desalting by acetone precipitation. To optimise acetone precipitation, the buffers 
used in the monomeric avidin purification methods were analysed for compatibility 
with the acetone precipitation method. The buffers in the absence of any protein were 
mixed with ice cold acetone and the formation of a precipitate was monitored. 
Glycine formed a precipitate, preventing acetone precipitation of samples containing 
this buffer. In contrast TBS and TBS containing free biotin did not form a 
precipitate, suggesting acetone precipitation can be performed on proteins containing 
these buffers.  
 
3.18.2.2. Protein recoveries after acetone precipitation 
To determine whether protein from the avidin column would be lost during acetone 
precipitation, assuming yields of 210 to 60 µg/ml from the avidin column, plasma 
samples were diluted to appropriate concentrations and were acetone precipitated 
(Table 10). The resulting pellet was air dried to remove remaining acetone; however, 
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the length of time the sample was air dried affected the ability to re-suspend the 
pellet and therefore the recovery of the protein. As expected the protein recoveries 
after acetone precipitation were highest with a higher starting concentration of 
protein and decreased with decreasing initial protein concentrations in all three air 
drying conditions. The percentage protein recovery was highest after air drying for 
30 minutes. Although the protein recoveries after 20 minutes and 40 minutes were 
slightly lower, there was very little difference between the three time points 
assuming a protein recovery of 110 or 60 µg/ml from the avidin column. Air drying 
for thirty minutes was used for future acetone precipitation methods. 
 
 
Table 10: Protein recoveries after acetone precipitation  
Assumed yields of biotinylated plasma proteins from the avidin column were 
incubated in ice cold acetone and the resulting protein recoveries were determined 
after different air drying times. Protein recovery after acetone precipitation was 
improved with increasing initial protein concentration with the optimum air drying 
time of 30 minutes. Mean of three independent experiments.  
Assumed protein 
recovery (µg/ml) 
% recovery after acetone precipitation 
20 minutes 30 minutes 40 minutes 
210 44.8 % 64.5 % 47.9 % 
110 29.3 % 29.5 % 34.8 % 
60 7.9 % 10.4 % 7.2 % 
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3.19. Identification of Factor XIII substrates by SDS-PAGE 
Plasma clots produced from normal pool plasma and FXIII deficient plasma (Affinity  
Biologicals Inc) were formed and perfused as described in section 3.5.3. Cross-link 
formation was stopped with NuPAGE reducing agent and NuPAGE loading buffer as 
described in section 3.2 and clots were heated to either 95°C for 15 minutes or 37°C 
for 1 hour. Reduced clots were run on NuPAGE 3-8% Tris-Acetate gels for 4 hours 
at 150 volts (see section 3.2.1). NuPAGE 3-8% Tris-Acetate gels were stained with 
silver staining (see section 3.19.1) or Coomassie (see section 3.2.2).  
 
3.19.1. Silver staining of plasma clot components 
The 3-8% tris-acetate gels were removed from their plastic covers and immediately 
fixed for one hour whilst shaking in fixing solution. The fixing solution was removed 
and the gel was washed three times with 30% ethanol each for 20 minutes whilst 
shaking. The gels were incubated with 100 ml of 0.02% sodium thiosulphate for 90 
seconds. The gels were washed three times with distilled water, each for 20 seconds, 
and incubated for 20 minutes with 100 ml of silver nitrate solution whilst shaking. 
The silver nitrate solution was removed, gels were washed three times with distilled 
water, each for 20 seconds, and incubated with 100 ml of sodium nitrate developing 
solution for between 2-5 minutes or until a suitable colour had developed. The 
development solution was removed and the gels were washed three times with 
distilled water, each for 20 seconds. The development was finally stopped by the 
addition of 100 ml of 0.05% glycine for 10 minutes whilst shaking. The stopping 
solution was removed and the gels were washed three times with distilled water each 
for 20 seconds. An image was captured using a MultiImage™ Light Cabinet (Alpha 
Innotech Corporation).  
 
3.20. Statistical Analysis 
3.20.1. Analysis of clinical data 
Data was tested for normality using the Shapiro-Wilk test and examination of 
histograms. Normality was assumed if p was >0.05. Data which was not normally 
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distributed was Log10 transformed. Difference in mean values between two groups 
was assessed by the independent sample t-test. Partial correlation was used to assess 
the relationship between factor H, turbidimetric parameters and other complement 
proteins after accounting for age and sex in the South Asian study group. A linear 
regression was performed to determine whether factor H was a predictor of CVD risk 
factors, complement activation after accounting for age and sex and changes in 
turbidimetric parameters, after accounting for age, sex, fibrinogen and PAI-1. 
Statistical significance was determined as a P value of <0.05. All statistical analyses 
were performed in SPSS version 19.  
 
3.20.2. Analysis of in vitro functional study data 
Data was tested for normality using the Shapiro-Wilk test and examination of 
histograms. Normality was assumed if p was >0.05. Data which was not normally 
distributed was Log10 transformed. Difference in mean values between two groups 
was assessed by the independent sample t-test after bonferroni adjustment for 
multiple comparisons. Analysis of the affect of t-PA and plasminogen dose responses 
on fibrin parameters was assessed by one-way ANOVA. Statistical significance was 
determined as a P value of <0.05. All statistical analyses were performed in SPSS 
version 19.  
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Chapter 4 Evaluation of the influence of C3 on fibrin 
structure and function 
C3 has previously been identified in perfused solubilised plasma clots. In FXIII-
depleted plasma clots C3 was present whereas in plasma clots containing FXIII, C3 
was reduced (Appendix A). Plasma clots were also found to contain ~25% of plasma 
C3 and C3 binds to fibrin with high affinity (Howes et al. 2012). These findings may 
suggest that C3 influences fibrin formation and structure and potentially fibrinolysis 
via cross-linking and binding interactions.  Therefore to evaluate the influence of 
complement C3 on fibrin structure and function a series of turbidimetric experiments 
were initially performed to evaluate the effect of C3 on fibrin formation, fibrin 
structure and fibrinolysis.  
 
4.1.    Influence of C3 on fibrin formation and fibrinolysis  
To assess whether complement C3 influences fibrin formation and time to 50% lysis 
in a purified system, a turbidimetric method was performed. A turbidimetric assay 
measures the lag time, a measure of the time taken to form protofibrils and 
maximum absorbance, a measure of lateral aggregation and final fibrin structure 
(Wolberg 2007). Fibrinolysis was measured as the time to 50% lysis following the 
addition of the lysis mix (containing t-PA and plasminogen) overlayed over the 
previously preformed fibrin clot. 
 
4.1.1. Influence of C3 on fibrin clot formation and lysis assessed by 
turbidimetric assay 
 As shown in Figure 17,  there was no significant difference (P= NS) in lag time 
(Panel A) or maximum absorbance (Panel B)  comparing cross-linked fibrin clots 
containing no C3 and those containing increasing concentrations of C3. As shown in 
panel C, increasing C3 concentrations significantly prolonged time to 50% lysis by 
1.5 fold in the presence of 0.55 mg/ml and 0.75 mg/ml C3. These results suggest C3 
does not influence fibrin formation and structure but does prolong lysis. 
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Figure 17: Influence of C3 in the turbidimetric clotting assay followed by 
overlay of t-PA and plasminogen to assess fibrinolysis.  
Using purified proteins, turbidity and lysis overlay were measured in a turbidimetric 
assay at 340 nm.  There was no significant difference in relative lag time (Panel A) 
and relative maximum absorbance (MaxAbs) (Panel B)  comparing cross-linked 
fibrin clots containing no C3 and those containing increasing concentrations of C3. 
Time to 50% lysis (Panel C, D) was significantly increased comparing cross-linked 
fibrin clots containing no C3 and those containing increasing concentrations of C3. 
Data normalised relative to the values obtained in the presence of no C3. Mean of 3 
independent experiments (SEM). * indicates a P value of <0.05 between +/- C3 after 
Bonferroni adjustment. (Howes et al. 2012)  
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Fibrinolysis was significantly prolonged in the presence of increasing 
concentrations of C3. To determine whether the influence of C3 on fibrinolysis was 
dependent on FXIII or protein-protein interactions within fibrin two turbidimetric 
methods were established. The first method was the lysis overlay method which was 
analogous to ex vivo fibrinolysis (Figure 18), whereby pre-formed fibrin clots were 
lysed by t-PA and plasminogen. As shown in Figure 18, Panels A and B, there was 
no significant difference in lag times or maximum absorbance between clots formed 
in the presence of FXIII compared to clots formed in the absence of FXIII. 
Additionally there was no significant difference in lag time and maxiumum 
absorbance with increasing concentrations of C3 in either the presence or absence of 
FXIII. As shown in Figure 18, Panel C, 50% lysis times were significantly longer in 
clots formed in the presence of FXIII compared to clots formed in the absence of 
FXIII, at C3 concentrations of 0.55 and 0.75 mg/ml (P=0.02, P=0.01 respectively). 
Additionally there was a significant difference in 50% lysis times with increasing 
concentrations of C3 in the presence (2.3-fold increase) of FXIII but not in the 
absence of FXIII, which was in agreement with the original turbidity overlay 
experiment which saw a 1.5 fold increase in fibrinolysis rate in the presence of C3. 
These findings suggest there were large batch variations between purified C3 even 
though the reaction conditions and methods were the same. Combined these results 
confirm that C3 does not influence fibrin formation and structure (lag time and 
maximum absorbance) but does prolong fibrinolysis, and the prolongation of 
fibrinolysis was greater in the presence of FXIII compared to in the absence of 
FXIII.  
The second turbidimetric method was the concurrent fibrinolysis method 
which was analogous to in vivo fibrinolysis (Figure 19), whereby fibrin formation 
(thrombin cleavage of fibrinogen) occurs at the same time as fibrinolysis (Plasmin 
cleavage of fibrin(ogen)). As shown in Figure 19, Panel A, lag times were longer in 
clots formed in the presence of FXIII compared to clots formed in the absence of 
FXIII, at all concentrations of C3, although not significant (P=NS). This finding 
suggests there was a difference between the time taken by thrombin to cleave 
fibrinogen only and fibrinogen and FXIII. Shemirani et al (2006) showed that FPA 
cleavage occurs first with the generation of protofibrils, followed by a short lag 
phase whereby FXIII binds the fibrin protofibrils and was subsequently cleaved by 
 107 
 
thrombin. Finally FPB was cleaved to initiate lateral aggregation and leading to an 
increase in turbidity (Shemirani et al. 2006). However as a difference in lag time in 
the presence and absence of FXIII was not observed in the turbidimetric and lysis 
overlay experiment (Figure 18) it suggests the interactions between thrombin with 
fibrinogen and FXIII were affected by the presence of fibrinolytic proteins (t-PA and 
plasminogen). As shown in Figure 19, Panel A there was no significant difference in 
lag time with increasing concentration of C3 in either the presence or absence of 
FXIII, confirming the previous results which suggest C3 does not influence lag time. 
As shown in Figure 19, Panel B, there was no significant difference in maximum 
absorbance between clots formed in the presence or absence of FXIII or between 
clots containing increasing concentrations of C3 in either the presence or absence of 
FXIII, thus confirming the previous results which suggest C3 does not influence the 
final fibrin structure. These findings may be surprising, as C3 is a relatively large 
plasma protein (185 KDa) and although it was unlikely to affect fibrin fibre 
thickness, it may have affected the pore size within the fibrin clot. In other work 
carried out within DCDR, it was found that in the presence of C3 in a purified 
system, the maximum absorbance was increased, suggesting thinner fibres (Hess et 
al. 2011), this was in contrast to the present study and may be accounted for by the 
use of double the amount of fibrinogen (1 mg/ml vs 0.5 mg/ml in the present study 
and a plasma concentration of 2 mg/ml) and a reduced amount of plasminogen (6 
μg/ml vs 20 μg/ml in the present study and a plasma concentration of 200 μg/ml) by 
Hess et al (2011). An increase in fibrinogen concentration has previously been found 
to form a fibrin clot with a dense structure which contains thinner fibrin fibres (Carr 
and Carr 1995). Alternatively, increases in maximum absorbance could have 
occurred to the differences in plasminogen concentration. A previous study found 
that a reduced t-PA concentrations prevented plasmin generation before protofibril 
formation and lateral aggregation, thus prompting an increase in maximum 
absorbance (Bauer et al. 1994). A similar affect on protofibril formation and lateral 
aggregation may occur with a reduced plasminogen concentration leading to an 
increased maximum absorbance. 
As shown in Figure 19, Panel C, 50% lysis times were longer in the clots 
formed in the presence of FXIII (2-fold increase) compared to clots formed in the 
absence of FXIII (1.5-fold increase) (P=NS). Although not significant these findings 
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reflect the FXIII-dependent effect on fibrinolysis in the presence of C3 observed in 
the turbidity and lysis overlay experiment (Figure 18). However as an increase in 
fibrinolysis time was not observed in the absence of FXIII in the turbidimetric and 
lysis overlay experiment (Figure 18) it suggests protein-protein interactions between 
C3, t-PA, plasminogen and plasmin may also influence fibrinolysis.   
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 Figure 18: Evaluation of the influence of C3 in fibrin formation and lysis using 
the turbidity and lysis overlay assay.  
Using purified proteins turbidity and lysis was measured in a turbidimetric assay at 
340 nm in the presence (■) and absence (♦) of FXIII. Three independent experiments 
were performed and error bars are SEM. Panel A: Lag time was not significantly 
different in the presence or absence of FXIII and/or C3. Panel B: Maximum 
absorbance (MaxAbs) was not significantly different in the presence or absence of 
FXIII and/or C3. Panel C: 50% lysis time was significantly longer in the presence of 
FXIII compared to the absence of FXIII at 0.55 and 0.75 mg/ml only (P=<0.02) and 
was significantly increased with increasing C3 concentration in the presence of 
FXIII only. * indicates a P value of <0.05 between + and - C3 after Bonferroni 
adjustment in the presence of FXIII.  
 
* 
* * 
* 
A B 
C 
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Figure 19: Evaluating the influence of C3 in fibrin formation and lysis using the 
concurrent turbidity and lysis assay.  
Using purified proteins turbidity and lysis were measured in a concurrent 
turbidimetric assay at 340 nm in the presence (■) and absence (♦) of FXIII. Three 
independent experiments were performed and error bars are SEM. Panel A: Lag 
time was longer in the presence of FXIII at all C3 concentrations compared to the 
absence of FXIII, with increased C3 concentration not affecting lag time.  Panel B: 
Maximum absorbance (MaxAbs) was not significantly different in the presence and 
absence of FXIII and/or with increasing concentrations of C3. Panel C: 50% lysis 
time was longer in the presence of FXIII with increasing C3 compared to in the 
absence of FXIII. 50% lysis time was significantly longer with increasing C3 
concentration in both the presence and absence of FXIII. * indicates a P value of 
<0.05 between + and- C3 in the presence of FXIII and between + and – C3 in the 
absence of FXIII after Bonferroni adjustment. 
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4.2.    Evaluation of C3 as a substrate for activated FXIII 
Previous work from the DCDR demonstrated that C3 was present in FXIII-depleted 
plasma clots but was reduced in normal pool plasma clots containing FXIII (Howes 
et al. 2012), suggesting C3 was cross-linked. Furthermore the turbidimetric data 
shows that in the presence of C3, cross-linking affects fibrinolysis times, which 
suggests C3 may be cross-linked to fibrin.  To determine whether C3 was a substrate 
for FXIIIa, plate based and gel based assays were performed using the lysine 
analogue, BP.  To determine whether C3 was cross-linked to itself or fibrin during 
clot formation, gel based cross-linking assays were set up using either purified 
proteins or plasma. 
 
4.2.1. Analysis of cross-linking of BP to purified C3 
BP is a lysine analogue which can be cross-linked into the reactive glutamine 
residues within substrates of FXIIIa and tissue transglutaminase. Previous studies 
have used the small primary amine to determine reactive glutamine residues of FXIII 
in α2-antiplasmin (Lee et al. 2000;Lee et al. 2001). Therefore to determine whether 
C3 was a substrate for FXIIIa, a plate-based cross-linking assay was performed 
involving C3 coated plates incubated with BP in the presence of FXIIIa or FXIII-
A2B2. As shown in Figure 20, Panel A, in the presence of FXIIIa, BP was cross-
linked to immobilised C3. As a positive control BP was cross-linked to immobilised 
fibrinogen by FXIIIa. The amount of BP cross-linked to C3 and fibrinogen increased 
with increasing FXIII concentration, however, more BP incorporated into fibrinogen 
than C3. When C3 and fibrinogen were incubated with FXIII-A2B2, no 
incorporation of BP was observed. These results suggest C3 has FXIIIa susceptible 
glutamine residues. 
BP was cross-linked into immobilised C3, however to check that 
immobilisation did not expose non-specific glutamine residues; BP was cross-linked 
to C3 in solution using an alternative assay where C3 was incubated with BP and 
either FXIIIa or FXIII-A2B2, then C3 containing products were captured on anti-C3 
coated plates and BP incorporation was detected by streptavidin HRP. As shown in 
Figure 20, Panel B, in the presence of FXIIIa, there was increased cross-linking of 
BP into C3 over a time course of 1 hour. No time-dependent incorporation of BP 
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into C3 was observed in the presence of FXIII-A2B2, however the background 
incorporation of BP was greater in solution compared to immobilised C3, suggesting 
immobilisation promotes conformational changes which would prevent BP non-
specific binding to C3. These results indicate C3 has FXIIIa susceptible glutamine 
residues which were cross-linked by FXIII in solution. 
To determine which C3 chain contained FXIIIa susceptible glutamine 
residues, cross-linking of BP to C3 in solution was carried out and incorporation was 
analysed by Western blotting with streptavidin HRP.  As shown in Figure 20, Panel 
C, BP was incorporated into both the C3 α and β chains and increased in intensity 
over a 4 hour period, with the greatest amounts of BP cross-linking occurring in the 
C3α chain. Cross-linking of another primary amine, dansylcadaverine into C3 has 
recently been reported (Nikolajsen et al. 2012), thus confirming that C3 was a 
substrate for FXIIIa. The authors further identified glutamine cross-linking sites at 
Gln652 in the C3 β chain and Gln686, 936, 967 and 1317 within the C3 α chain 
using BP. As only one reactive glutamine was present in the C3 β chain compared to 
four in the C3 α chain, it may account for the weaker reaction in the C3 β chain on 
the streptavidin-HRP Western blot in the present study. 
As a negative control, C3 was incubated with BP in the absence of FXIIIa, 
thrombin and calcium; however, incorporation was still observed. As no bands were 
observed when C3 was incubated alone, it suggests that streptavidin HRP did not 
cross-react with C3 (Figure 20, Panel C). One possibility for cross-linking in the 
negative controls could be that the C3 preparation contained small amounts of FXIII 
contamination; however, none were observed by FXIII Western blot (data not 
shown). This finding might suggest that BP incorporates non-specifically into C3 
(via binding) at this concentration of BP (5 mM) and confirms the high background 
observed when C3 was incubated with BP in the presence of FXIIIA2B2 in the plate 
based assay (Figure 20, Panel B). A small amount of dansylcadaverine was 
previously observed in the absence of FXIII-A by Nikolajsen et al (2012) after 1 
hours incubation, however as the negative controls in the present study were 
incubated for 4 hours, it suggests greater incubation times allows greater non-
specific incorporation of BP into C3. 
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To confirm whether BP incorporates non-specifically at 5 mM BP, a positive 
control in the form of fibrinogen was used. In the positive control samples, BP was 
incorporated into the α and γ chains of fibrinogen (Figure 20, Panel D), which were 
mainly present as α-polymers  and γ-dimers, suggesting that fibrin-fibrin cross-links 
were not prevented by BP under these conditions. A small amount was also cross-
linked to the fibrinogen β chain. No cross-linking of BP into fibrinogen was 
observed in the absence of FXIII, suggesting BP does not incorporate non-
specifically into fibrinogen in the absence of cross-linking, however BP was 
incorporated into the fibrinogen β chain in the presence of FXIII, even though no 
cross-linking sites have previously been characterised in the fibrinogen β chain.  
Cross-linking of the fibrinogen β chain has not been previously reported and  as the 
fibrinogen β chain remains at 55 KDa after fibrin cross-linking in previous studies 
(Standeven et al. 2007), it suggests that BP was most likely non-specifically 
incorporated into the β chain. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 114 
 
A      B 
 
 
Figure 20: Cross-linking of BP into purified C3.  
Panel A: Incorporation of BP into immobilised C3 and fibrinogen (Fbg) was 
observed in the presence of FXIIIa and not in the presence of FXIII-A2B2 in a plate 
based FXIII activity assay. Panel B: Incorporation of BP into C3 was observed in 
the presence of FXIIIa in solution as analysed by an ELISA based assay. Mean of 
three independent experiments (SEM). Panel C: BP incubated with C3 in the 
presence of FXIIIa for 0.5-4 hours resulted in increased BP incorporation into the C3 
α and β chains as analysed by streptavidin HRP Western blot, with BP incorporation 
also occurring in the absence of FXIII, thrombin (Thr) and calcium. Panel D: BP 
incubated with fibrinogen for 4 hours resulted in BP incorporation in the presence of 
FXIIIa and not in the absence of FXIIIa as analysed by Western blot with 
streptavidin HRP. Western blots representative of two independent experiments. 
(Richardson et al. 2012)  
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Another possibility could be the non-enzymatic cross-linking of BP to the 
internal glutamyl thioester of cysteine within C3. Lorand (1983) previously showed 
that small primary amines (methylamine and dansylcadaverine) could be non-
enzymatically cross-linked to the internal glutamyl thioester in α2-macroglobulin, 
complement C3 and C4 via a nucleophillic attack by ε-lysine amines. In the case of 
α2-macroglobulin both FXIII-dependent (Mosher 1976;Sottrup-Jensen et al. 1983) 
and non-enzymatic cross-linking (Lorand 1983) was known to occur in the same 
protein, however it was not known whether this can occur simultaneously. The 
mechanisms of action of FXIII-dependent cross-linking and non-enzymatic cross-
linking are illustrated in Figure 21. As the thioester domain is present in the C3 α 
chain this can only account for incorporation in this chain in the absence of FXIIIa.  
 
 
 
Figure 21: Formation of enzymatic and non-enzymatic cross-links. 
Panel A. Cross-linking of glutamine and lysine donor proteins by FXIII. Panel B. 
Non-enzymatic cross-linking of the internal thioester of C3 to a small primary 
amine.   
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4.2.2. Evaluation of cross-linking of complement C3 to fibrin in a 
purified system 
BP was a small substrate of FXIIIa, therefore to determine the physiological 
relevance of C3 cross-linking, C3 cross-linking to itself and cross-linking to fibrin 
was evaluated using purified proteins. To determine whether C3 forms cross-linked 
homodimers, C3 was incubated for 4 hours with thrombin and CaCl2 in the presence 
and absence of FXIII and cross-linked bands were monitored by SDS-PAGE and 
Western blot. As shown in Figure 22, Panels A and B there were no additional high 
molecular weight bands in the presence of FXIIIa compared to without. In addition 
no lower molecular weight bands were observed in the presence of thrombin and 
calcium, suggesting C3 was not cleaved by thrombin under these reaction conditions. 
As a positive control, fibrinogen was analysed under the same reaction conditions 
and as shown in Figure 22, Panels A and C, in the presence of FXIIIa fibrinogen was 
cross-linked to form γ-dimers and numerous α-polymers, with additional high 
molecular weight products present in the loading wells. Fibrin and C3 incubated 
together in the absence of FXIIIa did not produce high molecular weight complexes 
(Figure 22, Panels A-C). These results indicate that C3 did not form cross-linked 
homodimers and therefore does not contain reactive lysine residues for the cross-
linking reaction by FXIIIa. 
Fibrin is the main substrate for FXIIIa and several plasma proteins are cross-
linked to fibrin (See Table 1), therefore to determine whether C3 was cross-linked to 
fibrin during clot formation, C3 was incubated with fibrin in the presence of FXIIIa 
over a time course and cross-linked bands were monitored by SDS-PAGE and 
Western blot. As shown in Figure 23, Panel B, six C3 containing higher molecular 
weight bands (bands a to f) appeared after 5 minutes; two of these same bands cross-
reacted with an anti-fibrinogen antibody (bands a and c) (Figure 23, Panel C) and 
remained over the 24 hour period (Figure 23, Panels B and C). A C3 containing band 
(band h- most likely C3b) was present at time point 0 but was absent at 5 minutes, 
suggesting this C3 containing product could be cross-linked to form one or all of the 
higher molecular weight bands that appeared after 5 minutes. Several of the bands 
(bands a, d, e and f) were not observed at time points later than 5 minutes, suggesting 
they became cross-linked to form higher molecular weight products. A seventh 
higher molecular weight band (g) was observed in the anti-C3c Western blot at the 
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24 hour time point (Figure 23, Panel B). This band did not cross-react with the anti-
fibrinogen antibody (Figure 23, Panel C), suggesting C3 may have cross-linked to 
itself but only after considerable lengths of time. High molecular weight smearing 
(parantheses) and C3 containing products were also observed in the loading wells 
after 4 hours and increased in intensity after 24 hours, suggesting cross-linked C3 
was incorporated into very high molecular weight complexes. Although small 
amounts of C3 were cross-linked to fibrin, the majority of C3 remained non-cross-
linked under these conditions (Figure 23, Panel B), whereas the majority of fibrin γ 
and α chains were cross-linked under these conditions (Figure 23, Panel C). These 
findings suggest that C3 was cross-linked to fibrin within the first 5 minutes, 
however only small amounts of C3 were cross-linked by FXIIIa to fibrin. 
It is known that C3b can non-enzymatically cross-link (intramolecular acyl-
imidazole bond) hydroxyl and amine groups on bacterial surfaces via its internal 
thioester (Law et al. 1997), suggesting the possibility that FXIII-dependent and non-
enzymatic cross-linking of proteins was likely. Therefore to confirm FXIII-
dependent cross-linking of C3 to fibrin, the internal thioester was hydrolysed by 
dialysing purified C3 for 2 one hour incubations and a further week into water, since 
native C3 hydrolyses slowly (186 hours) and C3b spontaneously hydrolyses (30 
psec) (Pangburn and Mullereberhard 1983).  This process will prevent the ability of 
C3 to form intramolecular acyl-imidazole bonds and only allow FXIII-dependent 
cross-linking. Time dependent cross-linking of hydrolysed C3 (C3(H2O)) was 
performed as before and C3(H2O) cross-linked products were monitored by SDS-
PAGE and Western blot. As shown in Figure 24, Panel B, C3(H2O) was cross-linked 
within 5 minutes to form two C3(H2O) containing high molecular weight products 
(bands b and c); these  same bands cross-reacted with anti-fibrinogen antibodies and 
remained over 24 hours (Figure 24, Panel C). These two cross-reactive bands were 
previously observed in the presence of C3 (Figure 23). A fourth band (band g) 
appeared after 10 minutes and remained over 24 hours and a fifth band (band i) 
appeared after 1 hour and increased after 24 hours. High molecular weight C3 
containing complexes were observed in the loading wells after 5 minutes and 
increased over 24 hours. Unlike C3 (Figure 23) band h remained constant throughout 
the assay period. Although small amounts of C3(H2O) were cross-linked to fibrin, 
the majority of C3(H2O) remained non-cross-linked under these conditions (Figure 
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24, Panel B), whereas the majority of fibrin γ and α chains were cross-linked under 
these conditions (Figure 24, Panel C). This observation was the same as in the 
presence of C3 (Figure 23). These results suggest C3(H2O) was as readily cross-
linked to fibrin as C3, however less high molecular weight bands were observed in 
the presence of C3(H2O), suggesting that the C3 containing band (C3b- band h) 
present in the C3 cross-link experiment arose due to intramolecular acyl-imidazole 
bonds with fibrin. Interestingly, these C3b high molecular weight products were only 
observed after the initiation of cross-linking, which suggests that cleavage of the 
FPA and FPB from fibrinogen were required for C3b attachment, possible 
suggesting free hydroxyl or amine groups were exposed following fibrin formation 
which would allow C3b attachment.  These findings also confirm that C3 can 
undergo FXIII-dependent cross-linking and non-enzymatic cross-linking outlined in 
Figure 21 simultaneously within fibrin clots. 
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Figure 22: Analysis of C3 homodimer formation in the presence of FXIIIa.   
C3 and fibrinogen (Fbg) were incubated for 4 hours with combinations of thrombin (Thr), calcium (Ca
2+
) and FXIII and analysed by Coomassie 
stained SDS-PAGE (Panel A) and Western blot with anti-C3c (Panel B) or anti-fibrinogen (Panel C) antibodies. C3 does not form cross-linked 
homodimers, whereas fibrin was fully cross-linked under the same reaction conditions. Representative of two independent experiments. 
(Richardson et al. 2012) 
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Figure 23: Cross-linking of C3 to fibrin over a time course.  
C3 and fibrinogen were incubated with FXIII, thrombin and calcium over a 24 hour period and analysed for cross-link formation by Coomassie 
stained SDS-PAGE (Panel A) and Western blot with anti-C3c (Panel B) and anti-fibrinogen (Panel C) antibodies. Arrows a-g and parentheses 
represent C3 containing cross-linked products. Bands a-f appear after 5 minutes, whilst band g appears after 24 hours, with bands b and c cross-
reacting with the anti-fibrinogen antibody. Band h was present at 0 minutes and disappears at 5 minutes suggesting it was cross-linked into 
higher molecular weight products. Representative of two independent experiments. (Richardson et al. 2012) 
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Figure 24: Cross-linking of hydrolysed C3 to fibrin over a time course 
Hydrolysed C3 and  fibrinogen were incubated with FXIII, thrombin and calcium over a 24 hour period and analysed for cross-link formation by 
Coomassie stained SDS-PAGE (Panel A) and Western blot with anti-C3c (Panel B) and anti-fibrinogen (Panel C) antibodies. Bands b, c, g, i 
represent C3 containing cross-linked products. Bands b and c appear after 5 minutes, whilst band g appears after 10 minutes, with bands b and c 
cross-reacting with the anti-fibrinogen antibody. Band i appears after 1 hour. Band h remains constant over the 24 hours. Representative of one 
experiment. 
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4.2.3. Influence of plasma C3 incorporation into plasma clots on 
fibrinolysis and cross-linking 
In a purified system C3 did not influence fibrin structure but did prolong lysis and 
this was found to be FXIII dependent. Therefore to determine whether C3 influences 
fibrin formation and fibrinolysis in a plasma milieu purified C3 at concentrations 
between 0.5 and 2 mg/ml were spiked into plasma and plasma clot formation and 
lysis were analysed using the concurrent turbidity/lysis assay. As shown in Figure 
25, Panel A, lag time was significantly decreased with increasing C3 concentration, 
at all C3 concentrations, suggesting the time required for protofibril formation was 
shorter. As shown in Figure 25, Panel B maximum absorbance was significantly 
decreased with increasing C3 concentration, at all C3 concentrations, suggesting the 
final fibrin structure was less dense. As shown in Figure 25, Panel C lysis time was 
significantly increased with increasing C3 concentration. At the highest C3 
concentration lysis time was 2.7 fold longer than in the absence of added C3. This 
was significantly lower than the 9-fold increase in lysis time in the presence of the 
known plasmin inhibitor α2-AP (Fraser et al. 2011). Since C3 prolonged fibrinolysis 
in the presence of known fibrinolysis inhibitors which are cross-linked, such as α2-
AP, it suggests C3 may play a key role in prolonging fibrinolysis in plasma clots. In 
the plasma clots a decrease in maximum absorbance  was also observed in the 
presence of C3, suggesting the fibrin structure has a higher fiber density with thinner 
fibers, which would normally promote fibrinolysis in a plasma system (Carr and 
Alving 1995), suggesting the effect of C3 on fibrinolysis was important in plasma 
clots. Several previous studies in DCDR have observed an association between 
complement C3 and prolonging lysis time in plasma clots (Hess et al. 
2011;Schroeder et al. 2010). These findings were consistent with the increase in 
fibrinolysis times observed in the present study.  To fully appreciate the effect of C3 
and FXIII on plasma fibrinolysis rates future experiments need to compare 
fibrinolysis rates in normal pool plasma and FXIII depleted plasma spiked with C3 
to determine the influence of FXIII on lysis. Alternatively fibrinolysis rates could be 
compared between C3 depleted plasma and FXIII depleted plasma to determine the 
importance of both proteins in fibrinolysis. 
In a purified system C3 was cross-linked to fibrin, however during plasma 
clot formation a number of other plasma proteins may compete with C3 for cross-
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linking to fibrin, therefore a series of experiments were established to determine 
whether C3 was cross-linked in plasma clots, and whether C3 was cross-linked to 
fibrin during plasma clot formation. Plasma clots were formed by the addition of 
thrombin and CaCl2 to plasma and left to clot in a humidified incubator for 4 hours. 
Non-incorporated proteins were removed by perfusion with either TBS to remove all 
non-bound proteins or a 2M NaCl wash to remove any bound proteins and C3 
incorporation/cross-linking was assessed by Western blot (Figure 26, Panels A). C3 
α and β chains were observed in TBS washed plasma clots, but were absent in NaCl 
washed plasma clots. However higher molecular weight products reactive with anti-
C3 antibodies were observed in the loading wells of both TBS and NaCl washed 
plasma clots (Figure 26, Panel A). As a positive control, α2-AP was analysed in the 
same washed plasma clots. No bands were observed at the molecular weight of α2-
antiplasmin; however, numerous higher molecular weight bands were observed in 
both the TBS and NaCl washed plasma clots characteristic of α2-AP incorporation 
into fibrin α-multimers (Figure 26, Panel B). Band intensity in the α2-AP Western 
blot was the same in the presence of both the TBS and NaCl washed plasma clots 
suggesting the differences observed in the C3 Western blot was not the result of 
loading differences between the lanes. These findings suggest C3 binds and cross-
links to plasma clot components, whereas α2-antiplasmin was only cross-linked. 
This data was also consistent with the presence of high molecular weight complexes 
containing C3 in the purified cross-linking experiments. This data was also 
consistent with previous findings that show C3 binds to fibrinogen with high affinity, 
with 2 binding sites on fibrin(ogen) for C3 (Howes et al. 2012) which was replicated 
by (Hess et al. 2011). Furthermore, in unpublished data generated in collaboration 
with Dr Kerrie Smith (Post-doc in DCDR) a recombinant fragment of the αC domain 
of fibrinogen was found to bind to immobilised C3 (Appendix D, Figure 69).  
To evaluate plasma C3 cross-linking over a time course, non-perfused plasma 
clots were reduced with SDS buffers and run on 3-8% tris acetate gels before 
Western blotting with anti-C3 and anti-fibrinogen antibodies (Figure 26, Panels C 
and D). Four C3 containing higher molecular weight products were observed after 5 
minutes (Figure 26, Panel C, arrows) and remained present over the four hour period 
(bands b-e). Bands b to d present in the C3 Western blot cross-reacted with similar 
molecular weight bands present in the anti-fibrinogen Western blot (Figure 26, Panel 
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D, arrows). C3 reactive high molecular weight products were observed in the loading 
wells and in weak higher molecular weight products after 10 minutes, suggesting C3 
was actively cross-linked to plasma proteins in particular fibrin. Although similar 
fibrinogen containing high molecular weight products were observed in the plasma 
cross-linking assay, cross-linking to other plasma proteins cannot be ruled out. 
Nikolajsen et al (2012) also found that C3 was cross-linked in plasma clots but did 
not specify any plasma proteins which were cross-linked to C3, whereas in the 
present study fibrin was identified as a substrate for FXIII dependent cross-linking to 
C3 (Richardson et al. 2012). Similar to the purified system the majority of C3 
remained non-cross-linked after 4 hours. This observation was in agreement with 
Nikolajsen et al (2012) who found that only 5% of C3 was cross-linked to plasma 
clots proportional to α2-AP cross-linking. Several possibilities could account for the 
low amount of C3 cross-linking within fibrin clots. For example, C3 may be 
incorporated into fibrin via alternative mechanisms such as binding which was 
previously observed in the perfused plasma clots (Figure 26, Panel A) and has 
previously been observed using surface plasmon resonance (Howes et al. 2012; Hess 
et al. 2011). Alternatively the small amount of C3 cross-linking to fibrin may be 
because FXIII has a higher substrate specificity for other plasma proteins such as 
fibrin and α2-AP, thus FXIII promotes fibrin-fibrin and fibrin-α2-AP cross-linking 
instead of C3-fibrin cross-linking. This was supported by the immobilised plate 
based assay, in which more BP was cross-linked to fibrinogen than C3. Substrate 
specificity of FXIII has been found to be dependent on not only the reactive 
glutamine but also the surrounding amino acids which bind to the active site of FXIII 
(Cleary and Maurer 2006), suggesting that C3 has weaker interactions between C3 
and FXIII-A compared to fibrin.  These results in both purified proteins and plasma 
suggest C3 was actively incorporated into plasma clots through FXIII-dependent 
cross-linking to fibrin. The most likely site for C3 cross-linking on fibrin was within 
the alpha chain, as highlighted in Table 1, previous plasma proteins α2-AP, TAFI, 
PAI-2, von Willebrand factor, thrombospondin-1 and fibronectin have been found to 
cross-link this region of fibrin.  A recent study  found that fibrin α–α cross-linking 
occurs between four glutamine residues (Gln223, Gln237, Gln366, Gln563) and five 
lysine residues (Lys 418, Lys508, Lys539,Lys556, Lys601) in the formation of nine 
cross-link combinations (Wang 2011), with previous studies identifying many more 
available lysine residues for cross-linking including; Lys580, Lys448, Lys606, 
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Lys427, Lys429, Lys208, Lys224 and Lys219 (Matsuka et al. 1996;Sobel et al. 
1996), which provides the opportunity for C3 to cross-link the fibrin α-chain. 
Previous studies have shown that α chain cross-linking was important in protecting 
against fibrinolysis (Siebenlist et al. 1994) and cross-linking of fibrinolysis inhibitors 
such as α2-AP to the α chain further prevents the ability of the clot to be broken 
down by plasmin (Fraser et al. 2011). If C3 cross-linking to the fibrin α-chain were 
to occur it might suggest a possible mechanism for prolonging fibrinolysis, due to 
the ability of α-chain cross-linking to protect against fibrinolysis. Further 
experiments need to be performed to confirm cross-linking of C3 to the fibrin α-
chain and to determine the potential cross-linking sites on fibrin. Another important 
mechanism for C3 cross-linking to fibrin may be in localising C3 to the site of fibrin 
clot formation where complement activation is required to combat invading 
pathogens as part of the innate immune response.   
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Figure 25: Evaluation of the influence of C3 in plasma clot formation and lysis.  
Purified C3 at 0.5 to 2 mg/ml, was spiked into plasma (C3 concentration of 1 mg/ml) 
and analysed by concurrent turbidimetric assay at 340 nm for relative lag time 
(Panel A) which showed a significant decrease with increasing C3 concentration, 
suggesting a shorter time for protofibril formation; relative maximum absorbance 
(MaxAbs) (Panel B) which showed a significant decrease with increasing C3 
concentration, suggesting the fibrin clots were less dense;  relative lysis time (Panel 
C) which showed a significantly increased with increasing C3 concentration, 
suggesting fibrinolysis was prolonged. Mean of three independent experiments 
(SEM). Data normalised relative to the values obtained in the presence of no added 
C3. * indicates a P value of <0.05 comparing +/- C3 after Bonferroni adjustment. 
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Figure 26: Cross-linking of C3 to plasma clot components.  
Panels A & B Plasma clots formed in a humidified chamber for 4 hours were 
perfused with tris buffered saline (TBS) or 2 M NaCl, solubilised and analysed by 
Western blot with anti-C3c (Panel A) and anti-α2-APantibodies (Panel B). C3 was 
incorporated into TBS perfused clots and C3 containing high molecular weight 
products in the loading wells in TBS and salt perfused clots. α2-AP containing high 
molecular weight products were observed in both TBS and salt perfused clots. 
Panels C & D Non-perfused plasma clot formation stopped at time points between 
0-4 hours by SDS buffers were analysed by Western blot with anti-C3c (Panel C) 
and anti-fibrinogen (Panel D) antibodies. Four C3 containing higher molecular 
weight products were observed at 5 minutes and C3 containing products in the 
loading wells were observed at 10 minutes. Bands b-d cross-reacted with similar 
molecular weight products present in the anti-fibrinogen Western blot. 
Representative of two independent experiments. (Richardson et al. 2012)  
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4.3.    The influence of C3 on protein-protein interactions 
involved in fibrinolysis 
In the turbidimetric and lysis overlay assay C3 was found to prolong lysis in the 
presence of FXIII only, and C3 was confirmed to be a substrate for FXIII and was 
cross-linked to fibrin. Whereas in the concurrent turbidimetric assay C3 prolonged 
lysis in the presence and absence of FXIII, suggesting C3 interacts with other fibrin 
clot components to prolong lysis. Therefore the interactions between C3 and 
thrombin, plasmin, t-PA and plasminogen were investigated. To determine whether 
C3 was a substrate for proteolysis, C3 influenced the interactions between t-PA and 
plasminogen on the fibrin surface and C3 influenced plasmin generation. 
 
4.3.1.    Proteolysis of C3 within cross-linked fibrin clots 
To determine whether C3 undergoes proteolysis by thrombin and plasmin during 
fibrin formation and lysis, clots formed and lysed in the overlay experiments 
(Section 4.1.1) were analysed by SDS-PAGE and Western blot for the presence of 
possible C3 cleavage products (Figure 27, Panels A-D). Fibrin cleavage in the 
presence and absence of C3 resulted in the same cleavage products at all C3 
concentrations (Figure 27, Panels A). This suggests that C3 does not influence the 
final cleavage products of fibrin, but this experiment was unable to determine 
whether C3 influenced cleavage of fibrin over time.  
  A number of additional bands were observed (labelled a to l) when 
comparing clots containing no C3 and those containing increasing concentrations of 
C3. The majority of these bands were confirmed as C3 containing bands by Western 
blotting with an anti-C3c antibody (Figure 27, Panel B). The C3 cleavage products 
also increased in intensity with increasing concentration of C3. To confirm the 
identity of the C3 cleavage products bands a to l were excised from a Coomassie 
stained SDS-PAGE gel (Figure 27, Panel C) and analysed by MALDI-MS. Table 11 
shows that a number of the C3 cleavage products were consistent with known 
cleavage products of the C3 α chain generated by conventional complement 
activation/inhibition (a; C3b, f; C3c α chain fragment 2, g; C3d, h; C3c α chain 
fragment 1) with bands d, j and k containing un-known cleavage of the C3 β chain. 
Nagasawa and Stroud (1977) had previously shown that C3b and not zymogen C3 
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was cleaved by plasmin in the β chain, resulting in two products of 58KDa and 
17KDa. These products reflect the approximate molecular weights observed by SDS-
PAGE seen in the present study.  Several of the bands (b and i) produced peptide 
patterns consistent with known C3 products (Table 11); however, their molecular 
weight by SDS-PAGE suggests they underwent additional cleavage resulting in 
minor products. These results suggest C3 was cleaved within lysed fibrin clots, with 
the generation of known cleavage products of the C3 α chain and several un-known 
cleavage products of the C3 β chain. A recent study found that C3a was produced by 
thrombin and plasmin cleavage of C3 and that the C3a produced was functionally 
active and capable of chemoattraction of mast cells and neutrophils (Amara et al. 
2010), suggesting that protease cleavage of C3 results in fragments that are still 
capable of complement specific functions. However, Amara et al (2010) failed to 
identify the additional thrombin and plasmin cleavage products of C3 observed in the 
present study. As this experiment evaluating concentration dependent cleavage of C3 
contained two serine proteases, thrombin and plasmin, capable of cleaving C3, 
cleavage of C3 by thrombin and plasmin was evaluated further.   
 
 
 
 
 130 
 
 
Figure 27: Concentration dependent cleavage of C3 within fibrin clots.  
Clots formed and lysed in overlay experiments (Figure 17) were analysed for C3 
cleavage by Coomassie stained SDS-PAGE (Panel A) and Western blotting with an 
anti-C3c antibody (Panel B). Fibrin cleavage products were the same at all C3 
concentrations. Whereas C3 was cleaved resulting in bands a-l, which increased in 
intensity with increasing C3. Bands a to l were excised from a Coomassie stained gel 
(Panel C) and analysed by MALDI-MS (identity in Table 11). Representative of 
three independent experiments.  
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Table 11: Characterisation of complement C3 lysis products analysed by 
MALDI-TOF-MS peptide mass fingerprinting 
Band 
Protein 
Identified 
Accession 
number 
pI 
MW 
(KDa) 
MOWSE 
score
* 
Expected 
value 
Number 
of 
peptide 
matches 
Sequence 
coverage 
(%) 
a 
Complement 
C3b α chain 
gi 
118137965 
5.18 103.8 173
†
 1.2e-12 47 46 
b 
Complement 
C3b α chain 
gi 
118137965 
5.18 103.8 104
†
 9.3e-06 37 36 
c 
Complement 
C3 α chain 
gi 
78101268 
5.5 112 59
†
 0.31 32 28 
d 
Complement 
C3 β chain 
gi 
78101267 
6.82 71.1 117
†
 4.7e-07 33 55 
e 
Complement 
C3 
P01024 6.02 187 94 7.5e-06 47 28 
f 
Complement 
C3c α chain 
fragment 2 
gi 
78101271 
4.79 39.4 75
†
 0.0079 26 62 
g 
Complement 
component 
C3d 
gi 
157830512 
6.34 32.8 69
†
 0.032 16 41 
h 
Complement 
C3c α chain 
fragment 1 
gi 
78101270 
5.84 21.4 94
†
 0.0001 14 59 
i 
Complement 
C3c α chain 
fragment 1 
gi 
78101270 
5.84 21.4 62
†
 0.13 11 52 
j 
Complement 
C3 β chain 
gi 
78101267 
6.82 71.1 109
†
 3e-06 32 58 
k 
Complement 
C3 β chain 
gi 
78101267 
6.82 71.1 93
†
 0.00013 25 48 
l 
None 
identified 
       
*MASCOT MOWSE search score is -10 log (p), where p is the probability that the 
observed match is a random event. Search scores >56 indicate identity at the p< 0.05 
level. pI and MW are theoretical values.  
†
Analysis using NCBI database indicated splice variants and truncated polypeptides 
of relevance with highly significant scores.  
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4.3.2. Proteolysis of complement C3 by thrombin 
In the previous experiment evaluating concentration dependent cleavage of C3 the 
reaction contained two serine proteases, thrombin and plasmin which were possibly 
capable of C3 cleavage. Previous studies have also shown that C3 was cleaved by 
thrombin at 1 U/ml (Amara et al. 2010) and 18 U/ml (Clark et al. 2008). Therefore to 
determine whether thrombin at 0.025 U/ml was capable of cleaving C3 and to 
confirm cleavage of C3 at higher thrombin concentrations, purified C3 was 
incubated with thrombin at different concentrations for 4 hours. In the presence of 
thrombin (Figure 28) purified C3 was only cleaved when 5 U/ml thrombin or greater 
was present, with the generation of C3b (band a), C3a (band l) and a small amount of 
C3c (band h). Cleavage products of C3 by thrombin are illustrated in Figure 30. 
Since the turbidimetric assays were performed using 0.025 U/ml of thrombin it 
suggests that C3 was not cleaved by thrombin during fibrin formation or lysis. This 
result confirms the previous observation in the cross-linking experiment which found 
no lower molecular weight products after purified C3 was incubated with thrombin 
and calcium. In the context of in vivo fibrin clot formation, this data suggests that C3 
may be cleaved by thrombin during the thrombin burst when the greatest amount of 
thrombin was generated at around 7.2-28.8 U/ml (Brummel-Ziedins et al. 2005). 
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Figure 28: Thrombin cleavage of complement C3 
Complement C3 was incubated with different concentrations of thrombin for 4 hours 
and C3 cleavage products were analysed by Coomassie stained SDS-PAGE. C3 was 
cleaved by thrombin at 5 U/ml or above resulting in three products (bands a, h, l), 
labels based on Table 11 products. 
 
 
4.3.3. Proteolysis of complement C3 by plasmin  
In the previous experiment evaluating concentration dependent cleavage of C3 the 
reaction contained two serine proteases, thrombin and plasmin. As shown in the 
previous experiment thrombin did not cleave C3 at the concentration used in the 
turbidimetric assay, which suggests plasmin might be cleaving C3. Amara et al 
(2010) previously observed C3 cleavage with the generation of C3a at 2 μg/ml 
plasmin, whereas Nagasawa and stroud (1977) observed cleavage of C3b by plasmin 
at a plasmin to C3 ratio of 15:1 (w/w). To determine whether C3 was a substrate for 
plasmin in the turbidimetric assay (complete conversion of plasminogen to plasmin 
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in the turbidimetric assay would result in 17 μg/ml plasmin), plasmin was incubated 
with purified C3 for 4 hours at different concentrations. In the presence of 10-44 
µg/ml plasmin (Figure 29, Panel A) the same cleavage products were observed as 
those in the concentration dependent experiment (bands a-l, labels based on Table 11 
products). Cleavage products of C3 by plasmin are illustrated in Figure 30. These 
results suggest C3 was a substrate for both thrombin and plasmin however in the 
concentration dependent experiments C3 was cleaved by plasmin only, as the 
cleavage products reflect those seen when purified C3 was cleaved by plasmin and 
since no cleavage of C3 by thrombin was observed at 0.025 U/ml thrombin (the 
concentration used in the concentration dependent experiment).  
To analyse the plasmin-generated C3 β chain cleavage products further, 
bands d and k were excised from a Coomassie stained SDS-PAGE (Figure 29, Panel 
A) and were analysed by MALDI-MS/MS and LC-MS/MS to localise the plasmin 
cleavage site (Figure 29, Panel B). MALDI-MS/MS and LC-MS/MS confirmed that 
the cleavage products were indeed C3 β chain with peptide coverage of band d at the 
carboxyl terminus of the C3 β chain and peptide coverage of band k at the amino 
terminus of the C3 β chain, suggesting the site of cleavage was between residues 60 
and 109, with possible plasmin cleavage sites at residues 65, 66, 73, 97, 100 and 104. 
Trypsin cleavage of the C3 β chain was previously observed at position Lys100 
(Eggertsen et al. 1985). Backes et al (2000) found that plasmin requires an aromatic 
amino acid at position 2 amino terminally from the cleavage site by screening a 
peptide library (Backes et al. 2000). Taking into consideration this study, a possible 
candidate cleavage site in the C3 β chain based on this principle could be at Lys97. 
Both Lys100 and Lys97 lie within the region of residues 60-109, which was 
observed by MALDI-MS/MS and LC-MS/MS in the present study, suggesting they 
are likely candidate sites for plasmin cleavage of the β chain. In the present study, 
peptide coverage by MALDI-MS/MS and LC-MS/MS show that the cleavage site 
was most likely at the amino terminus, leading to the production of two peptides. 
However, as complete peptide coverage at the carboxyl terminus was not achieved 
by either MALDI-MS/MS or LC-MS/MS, additional cleavage at the carboxyl 
terminus cannot be ruled out.    
In the present study MALDI-MS/MS and LC-MS/MS identified the region of 
plasmin cleavage within the β chain between 60 and 109. This region lies within 
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macroglobulin domain 1 (Janssen et al. 2005). Nagasawa and Stroud (1977) found 
that C3b and not zymogen C3 could be cleaved within the β chain, suggesting 
structural changes are required to allow access to the cleavage site within 
macroglobulin domain 1. Indeed  large conformational changes occurred in the 
generation of C3b, with the thioester containing domain dropping down to come into 
contact with macroglobulin domain 1 (Janssen et al. 2006). Very few roles have been 
identified for the C3 β chain, however free C3 β chain has been shown to have 
eosinophil cytotoxic inhibitor activities (Minkoff et al. 1991), which suggests the C3 
β chain supports a feedback mechanism to prevent further inflammation. 
In summary, this series of results show that thrombin and plasmin cleave C3, 
however cleavage of C3 within fibrin clots was most likely the result of plasmin and 
not thrombin. These experiments were unable to determine whether C3 and fibrin 
compete for plasmin mediated cleavage over time and therefore act as competitive 
substrates to prolong fibrinolysis.   
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Figure 29: Plasmin cleavage of purified complement C3 
Panel A, Complement C3 was incubated with plasmin for 4 hours and C3 cleavage 
products were analysed by SDS-PAGE. C3 was cleaved by plasmin (at all plasmin 
concentrations) resulted in numerous products (bands a-l) labels based on Table 11 
products. Bands d and k were excised (as they were unknown cleavage products of 
the C3 β chain), digested with Asp-N and trypsin and analysed by MALDI-TOF-
MS/MS and LC-MS/MS. Panel B, Sequence coverage of band d (red) and band k 
(green) show that the possible cleavage site in the C3 β chain lies between residues 
60-109 with possible lysine cleavage sites highlighted (yellow).   
     1 MGPTSGPSLL LLLLTHLPLA LGSPMYSIIT PNILRLESEE TMVLEAHDAQ  
    51 GDVPVTVTVH DFPGKKLVLS SEKTVLTPAT NHMGNVTFTI PANREFKSEK  
   101 GRNKFVTVQA TFGTQVVEKV VLVSLQSGYL FIQTDKTIYT PGSTVLYRIF  
   151 TVNHKLLPVG RTVMVNIENP EGIPVKQDSL SSQNQLGVLP LSWDIPELVN  
   201 MGQWKIRAYY ENSPQQVFST EFEVKEYVLP SFEVIVEPTE KFYYIYNEKG  
   251 LEVTITARFL YGKKVEGTAF VIFGIQDGEQ RISLPESLKR IPIEDGSGEV  
   301 VLSRKVLLDG VQNPRAEDLV GKSLYVSATV ILHSGSDMVQ AERSGIPIVT  
   351 SPYQIHFTKT PKYFKPGMPF DLMVFVTNPD GSPAYRVPVA VQGEDTVQSL  
   401 TQGDGVAKLS INTHPSQKPL SITVRTKKQE LSEAEQATRT MQALPYSTVG  
   451 NSNNYLHLSV LRTELRPGET LNVNFLLRMD RAHEAKIRYY TYLIMNKGRL  
   501 LKAGRQVREP GQDLVVLPLS ITTDFIPSFR LVAYYTLIGA SGQREVVADS  
   551 VWVDVKDSCV GSLVVKSGQS EDRQPVPGQQ MTLKIEGDHG ARVVLVAVDK  
   601 GVFVLNKKNK LTQSKIWDVV EKADIGCTPG SGKDYAGVFS DAGLTFTSSS  
   651 GQQTAQRAEL QCPQPAAR  
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Figure 30: Diagrammatic representation of C3 cleavage by plasmin and 
thrombin 
Panel A. Cleavage of the C3 alpha chain by thrombin and plasmin results in the 
generation of C3b, C3c, C3d and C3g. Panel B. Cleavage of the C3 beta chain by 
plasmin resulting in two products. Arrows indicate cleavage sites by thrombin (Thr) 
and plasmin (Pln) including the amino acid residues resulting from cleavage during 
complement activation.  
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4.3.4. Time-dependent cleavage of purified C3 and fibrin clots 
containing C3 by plasmin generated as a result of t-PA cleavage of 
plasminogen 
In the previous series of experiments C3 was found to be cleaved by plasmin and 
plasmin cleavage of C3 occurred in cross-linked fibrin clots. In addition the final 
fibrin degradation products were unaffected by C3. However previous experiments 
were unable to determine whether C3 alters fibrin cleavage products during 
fibrinolysis and would therefore act as a competitive substrate for plasmin to prolong 
fibrinolysis. In the first instance time-dependent cleavage of purified C3 in the 
absence of fibrin by plasmin generated as a result of t-PA cleavage of plasminogen 
was monitored over 24 hour period by SDS-PAGE and Western blotting to 
determine the rate of C3 cleavage. As shown in Figure 31, Panels A-C, at 2 hours, 
C3b (band a) and C3c (bands f and h) were generated and increased in intensity by 
24 hours; cleavage of the C3 β chain was also observed (band d) at 2 hours and 
increased in intensity over the 24 hours. Band e also appeared at 2 hours but was 
nearly absent at 24 hours, suggesting that this band was further cleaved, possibly to 
produce the minor lower molecular weight bands i and j which appeared at 24 hours 
(Figure 31, Panel B). These results suggest in the absence of fibrin, C3 was cleaved 
by plasmin by 2 hours; the cleavage products produced were the same as in the 
previous experiment where fibrin was present. 
 To determine the effect of t-PA mediated plasmin generation on C3 and 
fibrin cleavage over time, purified C3 was incubated with fibrinogen, thrombin and 
CaCl2 in the absence (Figure 32) and presence (Figure 33) of FXIII for 1 hour to 
allow clot formation. Lysis was initiated following the addition of t-PA and 
plasminogen, and cleavage products of C3 and fibrin were monitored over a time 
course by SDS-PAGE and Western blot. In non-cross-linked fibrin clots containing 
C3 (Figure 32, Panel C), the C3 α chain was cleaved by 30 minutes generating C3b 
(band a) and C3c α chain fragment 2 (bands f) along with cleavage of the C3 β chain 
(band d), all of which increased in intensity over time; however, C3b and C3c α 
chain fragment 2 were nearly absent after 24 hours, suggesting they were 
additionally cleaved. C3c α chain fragment 1 (band h and band i) was generated after 
1 hour; however, only band h increased in intensity over time. C3d (band g) and 
lower molecular weight C3 β chain cleavage products (bands j and k) were present at 
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24 hours only. These results suggest in the presence of non-cross-linked fibrin 
cleavage of C3 was quicker than in the presence of purified C3 alone. One 
possibility for this was that increased plasmin generation occurred due to the 
presence of fibrin, since fibrin has previously been found to be cofactor for 
plasminogen cleavage by t-PA (Fredenburgh and Nesheim 1992;Horrevoets et al. 
1997;Hoylaerts et al. 1982). 
The banding patterns for fibrin cleavage were similar in the presence and 
absence of C3 (Figure 32, Panels A and B), with complete cleavage of the non-cross-
linked fibrin chains (α, β, γ) by 4 hours in both the presence and absence of C3 to 
form α’, α-chain remnants, β’ and γ’. These results suggest fibrin cleavage was un-
affected by the presence of C3 and confirms the previous observation in the 
turbidimetric and lysis overlay experiment which found no significant difference in 
fibrinolysis in non-cross-linked fibrin clots in the presence of C3.  
 
 
Figure 31: Time-dependent cleavage of purified C3 in the absence of fibrin by 
plasmin generated as a result of t-PA cleavage of plasminogen.  
Purified C3 was incubated with t-PA and plasminogen (to generate plasmin) over a 
time course and cleavage products were monitored by Coomassie stained SDS-
PAGE (Panel A) and Western blotting with anti-C3c antibody (Panel B). C3 was 
cleaved (bands a-k) by plasmin within 2 hours and C3 cleavage products increase 
over the 24 hour period. Labels a-k based on Table 11 products. Representative of 
two independent experiments. 
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Figure 32: Time dependent cleavage of non-cross-linked fibrin clots containing 
C3 by plasmin generated as a result of t-PA cleavage of plasminogen.  
Non-cross-linked fibrin clots formed in the absence (Panel A) and presence (Panel 
B & C) of C3 for 1 hour were overlayed with t-PA and plasminogen over 24 hours 
and cleavage products were monitored by Coomassie stained SDS-PAGE (Panels A 
& B) and Western blot with anti-C3c antibody (Panel C). Arrows indicate C3 
cleavage products (bands a-l based on Table 11 products), with C3 cleavage 
occurring by 30 minutes. * indicates complete cleavage of fibrinogen chains in the 
presence and absence of C3 by 4 hours. Representative of two independent 
experiments.  
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In cross-linked fibrin clots containing C3 (Figure 33) the C3 α chain and C3 
β chain were cleaved within 30 minutes, resulting in C3b and β chain cleavage 
product (bands a and d). Full length C3 α and β chains were completely cleaved after 
24 hours, resulting in lower molecular weight products. C3c α chain fragment 2 
(band f) was generated after 30 minutes and increased in intensity over time, whereas 
C3c α chain fragment 1 (band h) decreased over time. C3d (band g) was present after 
4 hours and increased at 24 hours. Lower molecular weight bands i and j were 
present after 4 hours and remained constant at 24 hours. These results suggest 
cleavage of C3 by plasmin in the presence of cross-linked fibrin clots was faster than 
in the presence of purified C3 alone but not different to cleavage of C3 within non-
cross-linked fibrin clots. 
As shown in Figure 33, at time point 0 minutes all the γ chains were cross-
linked forming γ-dimers, however some fibrinogen α chains remained in both the 
presence and absence of C3. This finding was consistent with the previous cross-
linking assay which found fibrinogen α chains remained after 1 hour and was 
consistent with a previous study which found that un-cross-linked fibrinogen α 
chains remained after 2 hours (Pizzo et al. 1973). Interestingly fewer higher 
molecular weight α-polymers were observed in the presence of C3, however it was 
possible that very high molecular weight fibrin products may be present in the 
loading wells, as the previous cross-linking experiments contained fibrin high 
molecular weight complexes in the loading wells after 1 hour incubation. Analysis of 
the production of cross-linked fibrin degradation products by t-PA mediated plasmin 
generation (Figure 33, Panels A and B) over the time course showed many of the 
same cleavage patterns in the presence and absence of C3; however, in the presence 
of C3 fewer higher molecular weight fibrin cross-links (above 150 KDa) were 
formed, therefore allowing these to be cleaved at a faster rate (within 1 hour) 
compared to cross-linked fibrin in the absence of C3, where high molecular weight 
fibrin cross-linked products remained at 2 hours.  Cleavage of the γ dimers was 
similar between fibrin clots in the presence and absence of C3. Cleavage of the fibrin 
β chain to β’ was faster in the presence of C3 with complete cleavage by 2 hours 
compared to 24 hours in the absence of C3. In the presence of C3 non-cross-linked 
α-chains were cleaved to form α’ at a similar rate compared to in the absence of C3, 
however after 24 hours this product was further cleaved to form α-chain remnants in 
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the absence of C3, whereas the majority of this chain remained at 24 hours in the 
presence of C3, which may account for why there were fewer α-chain remnants 
(bands 4 and 5) in the presence of C3. A number of additional bands were observed 
in the presence of C3 which were not observed in the absence of C3 (bands 1-3) 
these most likely represent α-polymer fragments that contain cross-linked C3. As 
previously discussed cross-linking of C3 to fibrin was most likely to occur in the 
fibrin α-chain as many lysine residues are available for FXIII-dependent cross-
linking. These results suggest C3 may be important in protecting α chain cleavage 
products from further plasmin cleavage. Previous studies have shown that FXIII-
dependent cross-linking may prevent plasmin mediated degradation of fibrin by 
reduced the numbers of carboxyl terminal lysine residues required for the 
amplification of plasmin generation (Fleury and Anglescano 1991).  Furthermore, 
resistance of the fibrin clot to plasmin-mediated fibrinolysis was found to be 
dependent on the formation of γ-dimers or highly complex α-multimers which 
conferred increased resistance to fibrinolysis (Siebenlist et al. 1994). These results 
were not expected, as it would be expected that adding another plasmin substrate in 
the form of C3 would decrease the effective plasmin concentration available for 
fibrin cleavage. It is possible that the plasmin concentration generated as a result of 
t-PA dependent cleavage of plasminogen was sufficient in these clots to not have a 
substrate competition effect between fibrin and C3. These findings were also the 
opposite to what was expected, based on the results of the turbidimetric overlay 
experiment, which observed prolonged fibrinolysis in the presence of C3 and FXIII 
compared to in the absence of C3.  
To compare the rate of C3 chain cleavage in the presence and absence of 
fibrin and FXIII, C3 chain cleavage was analysed by densitometry of Western blots. 
As shown in Figure 34, both C3 α and β chains were cleaved over the 24 hour 
period; however, the C3 α-chain was cleaved to a greater extent than the C3 β-chain 
(Figure 34, Panels A and B) in the presence of purified C3 alone, cross-linked and 
non-cross-linked fibrin. In the presence of cross-linked fibrin clots the C3 α and β 
chains were nearly completely cleaved after 24 hours. In the presence of non-cross-
linked fibrin approximately 25% and 60% of the C3 α and β chains remained intact 
after 24 hours (P= NS comparing cross-linked and non-cross-linked fibrin clots), 
similar to the cleavage of purified C3 alone with approximately 30% and 40% 
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respectively. These results confirm that C3 was a substrate for plasmin and further 
show that the C3 β chain appeared to be more resistant to cleavage over the first 2 
hours in cross-linked and non-cross-linked fibrin clots.  
In summary, these results show that C3 was cleaved by plasmin at a similar 
rate between cross-linked and non-cross-linked fibrin clots and cleavage of C3 
occured at the same time as cleavage of fibrin, which suggests C3 was not a 
competitive substrate for plasmin under these reaction conditions, however as fewer 
lower molecular weight fibrin α-chain remnants were observed in the presence of C3 
in cross-linked fibrin clots it suggests C3 might protect cleavage of fibrin α-chains 
by plasmin.  
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Figure 33: Time dependent cleavage of cross-linked fibrin clots containing C3 
by plasmin generated as a result of t-PA cleavage of plasminogen.  
Cross-linked fibrin clots formed in the absence (Panel A) and presence (Panel B & 
C) of C3 for 1 hour were overlayed with t-PA and plasminogen over 24 hours and 
cleavage products were monitored by Coomassie stained SDS-PAGE (Panels A & 
B) and Western blot with anti-C3c antibody (Panel C). Arrows indicate C3 cleavage 
products (bands a-l based on Table 11 products), with C3 cleavage occurring by 30 
minutes (Panels B & C). High molecular weight cross-linked fibrin α polymers were 
cleaved faster in the presence of C3 (Panel B) compared to the absence of C3 (Panel 
A), with low molecular weight bands (bands 1-5) differentially produced in the 
presence of C3 compared to in the absence of C3. Representative of two independent 
experiments.  
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Figure 34: Densitometry analysis of C3 α and β chain cleavage over time.  
Band intensity of the intact C3 α (Panel A) and C3 β (Panel B) chains measured by 
densitometry from Western blots, blotted with an anti-C3c antibody over a 24 hour 
period in purified C3 (■), non-cross-linked fibrin clot containing C3 (♦) and cross-
linked fibrin clot containing C3 (▲) which have undergone t-PA mediated 
plasminogen cleavage. Band intensity was converted to a percentage of intact C3 α 
and β chains at time point 0. At 24 hours the C3 α and β chains were nearly 
completely cleaved in cross-linked fibrin clots, however in non-cross-linked fibrin 
clots and in purified C3, 25 and 30% of the C3 α chain remained and 60 and 40% of 
the C3 β chain remained. Mean of two independent experiments (SEM). 
 
 
4.3.5.     The influence of C3 on t-PA and plasminogen interactions 
involved in plasmin generation 
In the concurrent turbidimetric assay C3 was found to significantly prolong 
fibrinolysis in the presence and absence of FXIII, suggesting C3 may interact with 
proteins involved in fibrinolysis. Furthermore C3 was found to interact with plasmin 
and was cleaved by plasmin within fibrin clots at the same rate as fibrin cleavage by 
plasmin, suggesting C3 was not a competitive substrate for plasmin. Therefore to 
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series of experiments were established to determine the effect of C3 on plasminogen 
cleavage, fibrinolysis in response to plasminogen/t-PA concentration and plasmin 
generation. 
 
4.3.5.1. Analysis of the influence of C3 on plasminogen cleavage 
To determine whether C3 influences plasminogen cleavage in the absence of fibrin, 
purified C3 and/or purified fibrinogen were incubated with t-PA and plasminogen 
over a time course and plasminogen cleavage products were monitored by Western 
blot. As shown in Figure 35, Panel A, when t-PA and plasminogen were incubated 
alone, plasminogen was not converted to plasmin over the 24 hour time course. As 
shown in Figure 35, Panel B, when t-PA and plasminogen were incubated with 
purified C3 a small amount of plasminogen was converted to plasmin with the 
majority remaining as plasminogen after 24 hours. Two additional lower molecular 
weight products (bands a and b) were present at 24 hours only. This finding suggests 
that C3 forms a surface for t-PA mediated plasmin generation. As shown in Figure 
35, Panel C, when t-PA and plasminogen were incubated with purified fibrinogen, 
plasminogen was converted to plasmin as a decrease in band intensity was observed 
over the 24 hours, with the majority of plasminogen cleaved by 24 hours. Two 
additional lower molecular weight products (bands a and b) were present at 24 hours 
only. When purified C3 and fibrinogen were incubated together with t-PA and 
plasminogen (Figure 35, Panel D) plasminogen was converted to plasmin as a 
decrease in band intensity was observed over 24 hours, with the majority of 
plasminogen cleaved by 24 hours. Three additional lower molecular weight products 
(bands a-c) were present at 24 hours only. Plasminogen was cleaved by t-PA to a 
greater extent in the presence of fibrin(ogen) compared to in the absence of 
fibrin(ogen), thus confirming previous studies which found that fibrinogen and fibrin 
promoted plasmin generation greater than t-PA and plasminogen alone (Eastman et 
al. 1992). Combined these results suggest C3 provides a surface for plasminogen 
cleavage; however fibrinogen was more efficient for plasminogen cleavage over the 
24 hours, with C3 not affecting plasminogen cleavage when incubated with 
fibrinogen.  
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To determine whether C3 influences plasminogen cleavage in the presence of 
fibrin, fibrin clots were formed in the presence and absence of C3 for 1 hour. Fibrin 
clots were overlayed with t-PA and plasminogen over a time course and plasminogen 
cleavage products were monitored by Western blot. As shown in Figure 35, Panel E, 
when t-PA and plasminogen were incubated with non-cross-linked fibrin clots in the 
absence of C3, plasminogen was converted to plasmin with the plasminogen band 
decreasing over the 24 period however a small amount of plasminogen remained at 
24 hours, whilst the plasmin band increased over the 24 hours, similar to the 
observations in purified fibrinogen. There was no difference in plasminogen 
cleavage in the presence of fibrinogen or fibrin, possibly as both have been shown to 
be cofactors for plasminogen activation by t-PA (Fredenburgh et al. 1992;Horrevoets 
et al. 1997;Hoylaerts et al. 1982). In fibrin clots in the absence of C3, lower 
molecular weight band a appeared at 2 hours and increased in intensity over time. 
Similar to the observations in fibrin clots in the absence of C3, when t-PA and 
plasminogen were incubated with non-cross-linked fibrin clots in the presence of C3 
(Figure 35, Panel F), plasminogen decreased over time with a small amount of 
plasminogen remaining at 24 hours, whilst the plasmin band increased in intensity 
over time. This result suggests there was no difference in plasminogen cleavage and 
plasmin generation between non-cross-linked fibrin clots in the presence and absence 
of C3. Whereas in non-cross-linked fibrin clot in the presence of C3 (Figure 35, 
Panel F), three lower molecular weight bands were observed, the first (band a) 
appeared at 1 hour and increased in intensity over time, whilst bands b and c were 
observed at 24 hours only. This suggests that plasmin autodigestion was enhanced in 
the presence of C3 in non-cross-linked fibrin clots. 
To determine whether C3 influences plasminogen cleavage in the presence of 
cross-linked fibrin, cross-linked fibrin clots were formed in the presence and absence 
of C3 for 1 hour. Cross-linked fibrin clots were overlayed with t-PA and 
plasminogen over a time course and plasminogen cleavage products were monitored 
by Western blot. As shown in Figure 35, Panel G, when t-PA and plasminogen were 
incubated with cross-linked fibrin clots in the absence of C3, the plasminogen band 
remained constant over the first 4 hours and only decreased slightly after 24 hours 
with the majority remaining after 24 hours, this finding was in contrast to non-cross-
linked fibrin clots in the absence of C3 where lower levels of plasminogen remained 
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after 24 hours (Panel E). In cross-linked fibrin clots (Panel G), the plasmin band 
increased over the 24 hour period, similar to the increase in the plasmin band in the 
presence of non-cross-linked fibrin (Panel E). In cross-linked fibrin clots (Panel G), 
only one lower molecular weight band (band a) was observed at 4 hours and 
increased in intensity after 24 hours, this was a similar observation to non-cross-
linked fibrin (Panel E). As shown in Figure 35, Panel H, when t-PA and plasminogen 
were incubated with cross-linked fibrin in the presence of C3, the plasminogen band 
remained constant over the first 4 hours and only decreased after 24 hours with the 
majority remaining after 24 hours. This finding was similar to the observation in 
cross-linked fibrin in the absence of C3 (Panel G). This finding in cross-linked fibrin 
in the presence of C3 contrasts with the observation in non-cross-linked fibrin 
containing C3 (Panel F), where plasminogen cleavage steadily declined over the 24 
hours. In the cross-linked fibrin clots containing C3 the plasmin band increased in 
intensity for the first 2 hours before decreasing slightly at 24 hours. This observation 
was in direct contrast to cross-linked fibrin in the absence of C3 (Panel G) and non-
cross-linked fibrin in the presence of C3 (Panel F), where the plasmin band steadily 
increased over the 24 hours. In cross-linked fibrin clots containing C3, three low 
molecular weight bands were observed, bands a and b appearing at 30 minutes and 
both increase in intensity over the 24 hours whereas band c was present at 24 hours 
only. In cross-linked fibrin in the presence of C3, more low molecular weight bands 
appeared than in cross-linked fibrin in the absence of C3 (Panel G) and appeared 
sooner than the low molecular weight bands in non-cross-linked fibrin in the 
presence of C3 (Panel F). These findings show, less plasminogen cleavage in the 
presence of cross-linked fibrin clots compared to non-cross-linked fibrin clots, 
suggesting FXIII plays a role in plasmin generation. It has previously been shown 
that cross-linking hides the high affinity binding sites for t-PA, preventing t-PA 
binding and plasminogen cleavage (Husain et al. 1989) and therefore reducing 
plasmin generation. Less plasmin was also generated in cross-linked fibrin clots 
containing C3 compared to in the absence of C3 and the plasmin generated in cross-
linked fibrin clots containing C3 underwent autodigestion to form more angiostatins 
which appeared sooner compared to cross-linked fibrin in the absence of C3.  
As a small amount of plasmin was observed at time point 0 in the Western 
blots, to more clearly evaluate plasmin generation the amount of plasmin generation 
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over time was compared to time point 0 using densitometry. As shown in Figure 36, 
in the presence of fibrin the intensity of the plasmin band increased over time with a 
large increase at 24 hours, however in the presence of fibrin clots containing C3 the 
intensity of the plasmin band increased at a faster rate until 2 hours before plateauing 
for the remainder of the time course. In the presence of cross-linked fibrin the 
intensity of the plasmin band matched that of fibrin clots containing C3, except for 
an increase in band intensity at 24 hours. In the presence of cross-linked fibrin clots 
containing C3 the plasmin band was the least intense, with only a slight increase in 
band intensity over the first 4 hours before a decrease at 24 hours. The differences                              
between the amount of plasmin generated in fibrin clots in the presence and absence 
of C3 and FXIII did not reach statistical significance at any time point. 
When plasminogen was converted to plasmin in these Western blots a 
number of additional fragmentation bands were also observed.  These fragmentation 
products were the same as those observed when plasminogen and t-PA were 
incubated with non-lysine analogues which promote plasminogen activation and 
autodigestion (Ohyama et al. 2004). In all experiments which led to plasmin 
generation, the fragmentation product at ~60 KDa was observed. This fragment most 
likely represents A61, an angiostatin made up of chain A (kringle domains 1-4 and 
part of kringle domain 5), which was produced by plasmin autodigestion (Kassam et 
al. 2001). The alternative fragments also likely represent minor angiostatins, 
angiostatin4.5 (52 KDa) and angiostatin (38 KDa) (Soff 2000). In cross-linked and 
non-cross-linked fibrin clots containing C3, more angiostatins were identified 
compared to in the absence of C3, angiostatins were also identified sooner in cross-
linked fibrin clots containing C3 compared to non-cross-linked fibrin clots 
containing C3. This suggests that plasmin generated as a result of t-PA mediated 
plasminogen cleavage was broken down to more angiostatins and sooner following 
plasminogen cleavage, which would reduce the amount of plasmin available for 
fibrin clot lysis. Angiostatins are responsible for preventing angiogenesis and cell 
proliferation.  However recently angiostatins have also been found to prolong 
fibrinolysis times by binding to fibrin and preventing t-PA mediated plasminogen 
activation (Ahn et al. 2011). Stack et al (1999) also found that angiostatin bound to t-
PA preventing t-PA mediated plasminogen activation (Stack et al. 1999). These 
findings are consistent with the turbidimetric data which shows prolonged 
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fibrinolysis in cross-linked fibrin clots containing C3 compared to in the absence of 
C3 and FXIII, and highlights the possibility that angiostatin production may be a 
mechanism for prolonging fibrinolysis in the presence of C3. Alternatively 
angiostatins play a role in preventing excessive inflammation by preventing 
monocyte and neutrophil chemotaxis (Benelli et al. 2001). Angiostatin binds 
leukocyte β1 and β2 integrins thus preventing leukocyte attachment to the 
endothelium and extracellular matrix proteins and angiostatins bind Mac-1 a ligand 
responsible for leukocyte-fibrinogen binding (Chavakis et al. 2005). In this study, 
angiostatins also prevented the expression of tissue factor. These findings suggest 
that C3 promotes production of angiostatins required for preventing excessive 
inflammation and preventing further thrombus formation, whilst maintaining the 
current fibrin clot from fibrinolysis by plasmin.  
In summary, these results suggest that in cross-linked fibrin clots, 
plasminogen cleavage remained similar in the presence and absence of C3, however 
less plasmin and increased numbers of lower molecular weight products were 
observed in the presence of C3, suggesting the plasmin generated underwent 
autodigestion to form A61, angiostatin4.5 and angiostatin. When comparing C3 
containing fibrin clots in the presence and absence of FXIII, less plasminogen was 
cleaved and less plasmin was generated in the presence of FXIII. These findings 
support the results of the turbidity overlay experiment which showed that C3 
prolongs fibrinolysis and prolonged fibrinolysis was dependent on FXIII-dependent 
cross-linking.   
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Figure 35: Time dependent t-PA mediated generation of plasmin in the 
presence and absence of C3, fibrin and FXIII.  
Analysis of plasminogen cleavage by t-PA over a time course analysed by Western 
blot with an anti-plasminogen antibody. No plasminogen was cleaved by t-PA alone 
(Panel A). In the presence of C3 a small amount of plasminogen was cleaved to 
form plasmin (Panel B). In the presence of fibrinogen (Panel C) and C3 with 
fibrinogen (Panel D) the majority of plasminogen was cleaved to form plasmin at 24 
hours. In the presence of non-cross-linked fibrin in the presence and absence of C3 
the majority plasminogen was cleaved to plasmin at 24 hours (Panel E and F). In 
the presence of cross-linked fibrin (Panel G) and cross-linked fibrin containing C3 
(Panel H) plasminogen cleavage remained constant over 4 hours with only a small 
amount cleaved at 24 hours. Red arrows (bands a-c) represent angiostatin production 
in all Western blots that have produced plasmin. Western blots representative of two 
independent experiments.  
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Figure 36: Densitometry analysis of plasmin generation over a 24 hour time 
course 
Band intensity of plasmin measured from anti-plasminogen Western blot over a 24 
hour period. Relative plasmin generation was calculated as difference in band 
intensity from time point 0 mins. Relative plasmin generation increasing over time in 
the presence of fibrin, but plateauing at 2 hours in the presence of fibrin clots 
containing C3. In the presence of cross-linked fibrin relative plasmin generation 
steadily increased over the 24 hours, however in the presence of cross-linked fibrin 
clots containing C3 relative plasmin generation increased slowly until 4 hours before 
decreasing at 24 hours. Mean of two independent experiments.  
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4.3.5.2. The influence of C3 on fibrin structure and fibrinolysis 
dependent on t-PA and plasminogen concentration 
In the previous concurrent turbidimetric assay C3 was found to prolong fibrinolysis 
but not affect fibrin structure, suggesting C3 may interact with t-PA and/or 
plasminogen to prolong fibrinolysis. A concurrent turbidimetric assay was therefore 
performed to determine whether t-PA and plasminogen concentration influenced 
fibrin structure and fibrinolysis in the absence of C3 and to determine whether C3 
had an additive affect on fibrin structure and fibrinolysis at reduced t-PA and 
plasminogen concentrations, which might suggest C3 interacts with t-PA and 
plasminogen. A concurrent turbidimetric assay was performed in the presence and 
absence of C3 with t-PA (Figure 37) and plasminogen (Figure 38) dose responses. 
As shown in Figure 37, in the absence of C3, maximum absorbance (Panel A) was 
significantly higher (P=0.002) and lysis time (Panel B) was significantly prolonged 
(P=0.001) with a decreased concentration of t-PA. As shown in Figure 37, panel C, 
in the presence of C3, maximum absorbance was significantly higher than in the 
absence of C3 at 5 and 10 ng/ml of t-PA but not at 50 ng/ml t-PA. Lysis time (Figure 
37, Panel D) was significantly prolonged in the presence of C3 at all t-PA 
concentrations.  
As shown in Figure 38, in the absence of C3, maximum absorbance (Figure 
38, Panel A) was significantly higher (P=0.0001) and lysis time (Figure 38, Panel B) 
was significantly prolonged (P=0.0001) with a decrease in plasminogen 
concentration. As shown in Figure 38, Panel C, maximum absorbance was 
significantly higher in the presence of C3 compared to the absence of C3 at both 0.2 
and 2 μg/ml of plasminogen but not at 20 µg/ml. Lysis time (Figure 38, Panel D) 
was significantly prolonged in the presence of C3 compared to the absence of C3 at 
all plasminogen concentrations, with lysis times prolonged by up to 1.5 fold at the 
lowest plasminogen concentration. Combined these findings suggest, that altering 
the t-PA and plasminogen concentration affects the overall clot structure in the 
absence of C3, resulting in a fibrin clots composed of thicker fibres and larger pores 
that takes longer to lyse. The increase in maximum absorbance observed with 
reduced t-PA and plasminogen was the opposite result previously observed in the C3 
concentration-dependent turbidimetric assays. This finding may reflect the lower 
concentrations of t-PA and plasminogen used in this series of experiments (5-50 
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ng/ml t-PA incubated with 0.2-20 µg/ml plasminogen) compared to the previous 
turbidimetric experiments (100 ng/ml t-PA with 20 µg/ml plasminogen). Hess et al 
(2011) previously found that maximum absorbance was increased in the presence of 
C3 when using a lower plasminogen concentration (6 µg/ml). The increase in 
maximum absorbance observed in both the t-PA and plasminogen dose responses as 
a result of C3 could be accounted for by the temporal relationship between fibrin 
formation and fibrinolysis. Bauer et al (1994) found that with reduced t-PA 
concentrations, the time for protofibril formation and lateral aggregation of the fibrin 
fibres was increased, with plasmin generation occurring after lateral aggregation, 
whereas at higher concentrations plasmin generation occurs before lateral 
aggregation leading to fibrin breakdown and a reduced maximum absorbance (Bauer 
et al. 1994). Additionally, when clot formation and lysis occur concurrently adding 
another substrate in the form of C3 would decrease the effective plasmin 
concentration available for cleavage of fibrin thus increasing the maximum 
absorbance. These data suggest that in reduced t-PA and plasminogen 
concentrations, C3 further prevents early plasmin generation, allowing effective 
protofibril and lateral aggregation of the fibrin fibres to increase the maximum 
absorbance and in turn prolong fibrinolysis.  
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Figure 37: The effect of t-PA dose response on the influence of C3 in fibrin 
structure and lysis 
Turbidimetric measurements at 340 nm were made using the concurrent assay in the 
presence of decreasing t-PA concentration in the presence and absence of C3. 
Relative maximum absorbance (MaxAbs) and lysis time was calculated as the 
difference between +/- C3 at each individual t-PA concentration. Maximum 
absorbance was significantly increased in the absence of C3 with decreasing t-PA 
(P=0.002) (Panel A), whereas maxiumum absorbance in fibrin clots containing C3 
was significantly higher (t-PA 10 and 5 ng/ml) compared to fibrin clots in the 
absence of C3 (Panel C). Lysis time was significantly increased in the absence of C3 
with decreasing t-PA (P=0.001) (Panel B), whereas lysis time was significantly 
longer in fibrin clots containing C3 at all t-PA concentrations (Panel D). Mean of 
three independent experiments. * indicates P = <0.05 after bonferroni adjustment 
when comparing +/- C3 at each individual t-PA concentration.  
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Figure 38: The effect of a plasminogen dose response on the influence of C3 in 
fibrin structure and lysis 
Turbidimetric measurements at 340 nm were made using the concurrent assay in the 
presence of decreasing plasminogen concentration in the presence and absence of 
C3. Relative maximum absorbance (MaxAbs) and lysis time was calculated as the 
difference between +/- C3 at each individual plasminogen concentration. Maximum 
absorbance was significantly increased in the absence of C3 with decreasing 
plasminogen (P=0.0001) (Panel A), whereas maxiumum absorbance in fibrin clots 
containing C3 was significantly higher (plasminogen 2 and 0.2 μg/ml) compared to 
fibrin clots in the absence of C3 (Panel C). Lysis time was significantly increased in 
the absence of C3 with decreasing plasminogen (P=0.0001) (Panel B), whereas lysis 
time was significantly longer in fibrin clots containing C3 at all plasminogen 
concentrations (Panel D). Mean of three independent experiments. * indicates P = 
<0.05 after bonferroni adjustment when comparing +/- C3 at each individual 
plasminogen concentration. 
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4.3.6. The influence of C3 on the interactions between t-PA and 
plasminogen on a fibrin surface involved in plasmin generation 
In the concurrent turbidimetric assay, C3 prolonged fibrinolysis in the presence and 
absence of FXIII. Furthermore, in the t-PA and plasminogen dose response 
experiments, C3 further enhanced the effect of t-PA and/or plasminogen on their 
own to prevent early plasmin generation and therefore prolong fibrinolysis, 
suggesting C3 may influence the interactions between t-PA, plasminogen and fibrin 
required for effective plasmin generation. In the absence of C3, fibrin acts as both a 
surface for plasmin generation and a substrate for generated plasmin.  Plasmin 
generation requires interactions between fibrin, t-PA and plasminogen. Plasminogen 
and t-PA bind to fibrin within the D regions Aα140-160 and γ312-324 respectively 
(Bosma et al. 1988;Schielen et al. 1991) and also within the αC domain Aα221-610 
(Tsurupa et al. 2001). Binding within the αC domain was high affinity (Kd 
Plasminogen 32 nM and tPA 33 nM) (Tsurupa et al. 2001) compared to the D 
regions (Kd ~ 1 µM for both tPA and plasminogen) (Yakovlev et al. 2000), 
suggesting the αC domain was essential in the initiation of fibrinolysis.  
To determine whether C3 affects plasmin generation on a fibrin surface, 
fibrin was immobilised onto a 96 well plate and incubated with different orientations 
of t-PA, plasminogen and C3, each for 90 minutes. Plasmin generation was 
monitored by the cleavage of a chromogenic substrate S-2251. When t-PA was pre-
incubated on the fibrin surface prior to plasminogen and S-2251, the maximum 
plasmin generation occurred after ~ 2½ hours (Figure 39, Panel A). Although the 
amount of plasmin generated at 4 hours between the different orientations did not 
significantly differ (P= NS) (Figure 39, Panel C), the rate of plasmin generation was 
reduced when C3 was incubated following a pre-incubation with t-PA and prior to 
plasminogen and S-2251 compared with t-PA pre-incubated on the fibrin surface 
prior to plasminogen and S-2251 although not significant (P=NS) (Figure 39, Panel 
D). This result suggests that C3 and t-PA bind to fibrin on separate sites, since C3 
incubated first on the fibrin surface did not prevent t-PA mediated plasmin 
generation (Figure 40, Panel C). In unpublished data produced by Dr Kerrie Smith 
(section 9.4) using surface plasmon resonance a recombinant fragment of the αC 
domain (Aα233-425) bound to immobilised C3 with high affinity (Kd ~2.4 nM), 
which suggests that C3 binds within the region of t-PA and plasminogen binding, 
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however as no affect of C3 on plasmin generation was observed it suggests there was 
sufficient space on the αC domain to prevent steric hindrance when all three proteins 
were bound. Whereas when t-PA was incubated on the fibrin surface first, C3 
prevented t-PA mediated plasmin generation. One possibility for this finding could 
be that conformational changes occur in t-PA which exposes a binding site for C3. 
This binding then prevents the formation of the ternary complex between t-PA, 
plasminogen and fibrin (Figure 40, Panel B). A recent study found that t-PA binds to 
fibrin first by the finger domain, resulting in exposure of a cryptic domain that was 
able to bind plasminogen (Kim et al. 2011), resulting in plasmin generation, if C3 
were able to bind this cryptic site in t-PA it would prevent plasmin generation by 
preventing plasminogen binding to the t-PA. Whereas no decrease in the rate of 
plasmin generation was observed when t-PA and C3 were pre-incubated together on 
the fibrin surface suggesting that t-PA and C3 bind to fibrin at their separate sites 
with equal affinity, thus preventing the time required for conformational changes to 
occur in t-PA that exposes the C3 binding site (Figure 40, Panel D).  To fully 
determine whether the effect of C3 on plasmin generation was dependent on binding 
to t-PA following fibrin binding, further experiments need to be performed using u-
PA which does not have a fibrin-dependent effect.  
When plasminogen was pre-incubated on the fibrin surface prior to t-PA and 
S-2251, the maximum plasmin generation was not reached within the 4 hour assay 
period, suggesting the reaction was significantly slower than that of t-PA when pre-
incubated on the fibrin surface prior to the addition of plasminogen and S-2251, even 
though the concentration of proteins used in this experiment were the same as those 
used when t-PA was incubated on the fibrin surface (Figure 39, Panel B). The 
amount of plasmin generated (Figure 39, Panel E) and the rate of plasmin generation 
(Figure 39, Panel F) was reduced/slower when C3 was incubated on the fibrin 
surface following a pre-incubation with plasminogen and prior to the addition of t-
PA and S-2251 or when C3 and plasminogen were incubated together on the fibrin 
surface prior to the addition of t-PA and S-2251 compared to plasminogen incubated 
on the fibrin surface prior to the addition of t-PA and S-2251, although not 
significant (P=NS). These findings suggest the amount and rate of plasmin 
generation was dependent on the orientation of when C3 was pre-incubated on the 
fibrin coated plates. Previous studies have shown that plasminogen can bind to two 
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fibrin monomers, suggesting plasminogen has two binding sites (Fears 1989), 
therefore plasminogen might bind both C3 and fibrin, with binding of C3 to 
plasminogen preventing the appropriate t-PA mediated interactions with 
plasminogen and fibrin required for plasmin generation (Figure 41, Panel B). When 
C3 was incubated on the fibrin surface first, C3 binds to a separate site on fibrin 
compared to t-PA and plasminogen, thus allowing t-PA and plasminogen to form the 
tertiary complex (Figure 41, Panel C), with no affect on plasmin generation, as 
suggested previously this result suggests C3, t-PA and plasminogen are able to bind 
to fibrin without steric hindrance. When plasminogen and C3 were incubated on the 
fibrin surface together a decrease in plasmin generation was observed suggesting C3 
and plasminogen form a complex in solution which prevents plasminogen binding to 
fibrin and therefore decreases t-PA mediated cleavage of plasminogen at the fibrin 
surface (Figure 41, Panel D). In a recent study by Barthel et al (2012a) C3 and C3 
cleavage products C3b, C3c and C3d were found to bind to plasminogen in solution 
and this binding interaction was found to be lysine dependent as a lysine analogue 
(εACA) inhibited binding of C3d by 75% (Barthel et al. 2012a). Since binding of 
plasminogen to fibrin was also dependent on lysine residues (Fears 1989) it suggests 
that C3 competes with fibrin for plasminogen binding via lysine residues and thus 
decreases plasmin generation. Barthel et al (2012a) did not suggest whether C3 
bound to plasminogen will prevent plasminogen cleavage by t-PA. However if this 
was to occur it would suggest that C3 and C3 activation products produced by 
plasmin cleavage would form a positive feedback loop to regulate plasminogen 
activation. Since plasminogen binds to C3 in solution it was also possible that C3 
may have been lost during the C3 purification at the lysine sepharose stage, however 
this must only account for a small amount of C3 due to the significantly lower 
plasminogen concentration in plasma compared to C3.    
Combined these results suggest C3 binds to fibrin bound t-PA, C3 binds to 
fibrin bound plasminogen and C3 binds plasminogen in solution to prevent plasmin 
generation. These findings confirm the previous observations in the concurrent 
turbidimetric assay that show C3 prolongs fibrinolysis in the absence of FXIII and 
suggests a possible mechanism might be reduced plasmin generation as a result of 
interactions between C3 and plasminogen and between C3 and t-PA.  
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Figure 39: Plasmin generation in a plate based assay.   
S-2251 cleavage monitored by changes in absorbance at 405 nm when t-PA (Panel 
A) or plasminogen (Panel B) were pre-incubated on an immobilised fibrin surface 
before, after or at the same time as C3. Panel C, the amount of plasmin generated at 
4 hours, when t-PA was pre-incubated on an immobilised fibrin surface, showed no 
significant difference in the amount of plasmin between the orientations. Panel D, 
the rate of plasmin generation between 0-2 hours when t-PA was pre-incubated on an 
immobilised fibrin surface, showed a reduced rate when C3 was incubated following 
a pre-incubation with t-PA. Panel E and D, the amount of plasmin generated and the 
rate of plasmin generation at 4 hours, when plasminogen was pre-incubated on an 
immobilised fibrin surface, was reduced when C3 was incubated following a pre-
incubation with plasminogen and when plasminogen and C3 were incubated 
together. Mean of three independent experiments (SEM).  
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Figure 40: The interactions between C3 and t-PA that influence plasmin 
generation in the plate based assay 
Panel A. t-PA and plasminogen (Plg) bind to fibrin in the formation of a tertiary 
complex, responsible for activating plasminogen to form plasmin (Pln). Panel B. 
When t-PA was incubated on the fibrin surface first this allows conformational 
changes to occur which exposes a binding site for C3. C3 once bound to t-PA 
prevents plasminogen binding to form the tertiary complex, thus plasmin generation 
was decreased. Panel C. When C3 was incubated on the fibrin surface first, C3 binds 
to a separate site on fibrin compared to t-PA and plasminogen, thus allowing t-PA 
and plasminogen to form the tertiary complex, with no affect on plasmin generation. 
Panel D. When t-PA and C3 were incubated on the fibrin surface together no affect 
on plasmin generation was observed suggesting C3 and t-PA bind to fibrin at 
separate sites and that C3 bound to fibrin before conformational changes occurred in 
t-PA which exposed a binding site for C3. 
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Figure 41: The interactions between C3 and plasminogen that influence plasmin 
generation in the plate based assay 
Panel A. t-PA and plasminogen (Plg) bind to fibrin in the formation of a tertiary 
complex, responsible for activating plasminogen to form plasmin (Pln). Panel B. 
Plasminogen has two binding sites, therefore plasminogen can bind both C3 and 
fibrin, however binding of C3 to plasminogen prevents t-PA mediated interactions 
with plasminogen and fibrin resulting in reduced plasmin generation. Panel C. When 
C3 was incubated on the fibrin surface first, C3 binds to a separate site on fibrin 
compared to t-PA and plasminogen, thus allowing t-PA and plasminogen to form the 
tertiary complex, with no affect on plasmin generation. Panel D. When plasminogen 
and C3 were incubated on the fibrin surface together a decrease in plasmin 
generation was observed suggesting C3 and plasminogen form a complex in solution 
which prevents plasminogen binding to fibrin and therefore decreases t-PA mediated 
cleavage of plasminogen at the fibrin surface. 
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4.3.6.1. The influence of C3 on plasmin generation on the surface of 
fibrin clots incubated with t-PA and plasminogen 
In section 4.2, C3 was shown to cross-link to fibrin and C3 within cross-linked fibrin 
clots was found to influence fibrinolysis rates in turbidimetric assays (Section 4.1.1), 
suggesting that C3 cross-linking may influence plasmin generation. To examine this 
possibility, plasmin generation was analysed by the cleavage of the chromogenic 
substrate S-2251 on the surface of fibrin clots containing +/- C3 and +/- FXIII, when 
either t-PA or plasminogen was incubated within the fibrin clot by monitoring the 
absorbance changes at 405 nm upon the addition of either t-PA or plasminogen to 
initite lysis.  Previous optimisation experiments found there was no difference in 
plasmin generation between fibrin clots in the presence and absence of FXIII (Figure 
13), suggesting plasmin generation was not FXIII-dependent.  
When t-PA was incubated in the solid fibrin clots (Figure 42, Panels A-C), 
there was no significant difference in plasmin maximum absorbance, plasmin 
generation and rate of plasmin generation between cross-linked fibrin clots and non-
cross-linked fibrin clots whether in the presence or absence of C3 (P = NS). There 
was a lower plasmin maximum absorbance, less plasmin generated and reduced rate 
of plasmin generation (Figure 42, Panels A-C) in cross-linked fibrin clots containing 
C3 compared in the absence of C3 although not significant (P=NS) There was a 
lower plasmin maximum absorbance, less plasmin generated and reduced rate of 
plasmin generation (Figure 42, Panels A-C) between non-cross-linked fibrin clots 
containing C3 compared to in the absence of C3 (Plasmin generation P=0.003, Rate 
of plasmin generation P=NS). These results confirm the optimisation experiment 
which shows that FXIII does not influence plasmin generation and further shows that 
C3 prevents plasmin generation on the surface of a fibrin clot. As outlined in Figure 
40, Panel B, plasmin generation was reduced due to C3 binding conformationally 
changed t-PA, which prevents plasminogen binding, plasminogen cleavage and 
reduced plasmin generation. As C3 was incubated with t-PA and fibrin for an hour 
before plasminogen was added it suggests that this mechanism could have occurred, 
thus preventing the added plasminogen from binding t-PA and generating plasmin. 
This mechanism accounts for the affect of C3 in both the presence and absence of 
FXIII. 
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In the concurrent turbidimetric assay, C3 was found to prolong fibrinolysis in 
the presence of C3 and FXIII when plasminogen was incubated in the fibrin clot. 
Therefore the solid fibrin clot based plasmin generation assay was performed in 
fibrin clots incubated with plasminogen in the presence and absence of C3 and 
FXIII. As shown in Figure 43, Panels A & B there was a lower plasmin maximum 
absorbance and plasmin generation in cross-linked fibrin clots containing C3 and 
non-cross-linked fibrin clots containing C3 compared to cross-linked and non-cross-
linked fibrin clots in the absence of C3. (P=0.02, P=NS respectively). There was no 
significant difference in plasmin maximum absorbance and plasmin generation 
between cross-linked fibrin clots containing C3 compared to non-cross-linked fibrin 
clots containing C3 or between cross-linked fibrin and non-cross-linked fibrin clots 
in the absence of C3 (P=NS). As shown in Figure 43, Panel C, the rate of plasmin 
generation reflected the final plasmin generation with lower rates of plasmin 
generation observed in cross-linked fibrin clots containing C3 and non-cross-linked 
fibrin clots containing C3 compared to cross-linked and non-cross-linked fibrin clots 
in the absence of C3 altough not significant (P=NS). There was no significant 
difference in rate of plasmin generation between cross-linked clots in cross-linked 
fibrin clots containing C3 compared to non-cross-linked fibrin clots containing C3 or 
between cross-linked fibrin and non-cross-linked fibrin clots in the absence of C3 
(P=NS).  These results confirm the optimisation of the solid clot based plasmin 
generation assay which found that FXIII does not affect plasmin generation (Figure 
13) and further supports a role for C3 in the prevention of plasmin generation on the 
surface of a fibrin clot. As outlined in Figure 41, Panel B, plasmin generation was 
reduced when plasminogen bound to fibrin and C3 preventing t-PA mediated 
cleavage, whereas in Figure 41, Panel D, plasmin generation was reduced by 
plasminogen binding C3 in solution preventing plasmin attachment to fibrin and t-
PA mediated cleavage of plasminogen. Both of these mechanisms may account for 
the reduced plasmin generation observed in the presence and absence of FXIII.  
These findings support the observations in the concurrent turbidimetric assay which 
suggest that C3 prolongs fibrinolysis in the presence and absence of FXIII. As the 
solid clots in these experiments contained either t-PA or plasminogen they don’t 
reflect the differences observed in the turbidity overlay experiment which contained 
no t-PA and plasminogen during clot formation, which may account for why there 
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was not a larger difference in plasmin generation between cross-linked and non-
cross-linked fibrin clots containing C3.  
 
 
 
Figure 42: Plasmin generation in the presence of C3 and FXIII within a solid 
fibrin clot containing t-PA.   
Fibrin clots containing t-PA in the presence and absence of C3 and FXIII were 
formed. Plasmin generation was monitored at 405 nm (change in absorbance) when 
plasminogen and S-2251 were overlayed on the fibrin clot (Panel A). Panel B: The 
amount of plasmin generated at 4 hours was reduced in cross-linked fibrin clots 
containing C3 and in non-cross-linked fibrin clots containing C3. No difference was 
observed between cross-linked fibrin clots compared to non-cross-linked fibrin clots 
containing C3 and between cross-linked fibrin clots and non-cross-linked fibrin clots 
in the absence of C3. Panel C. The rate of plasmin generation between 0-2 hours 
was reduced in cross-linked fibrin clots containing C3 although not significant.  
Mean of three independent experiments (SEM). * P=<0.05 between +/- C3 in the 
absence of FXIII. 
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Figure 43: Plasmin generation in the presence of C3 and FXIII within a solid 
clot containing plasminogen.  
Fibrin clots containing plasminogen in the presence and absence of C3 and FXIII 
were formed. Plasmin generation was monitored at 405 nm (change in absorbance) 
when t-PA and S-2251 were overlayed on the fibrin clot (Panel A). Panel B. The 
amount of plasmin generated at 4 hours was reduced in cross-linked fibrin clots 
containing C3 and non-cross-linked fibrin clots containing C3. No difference in 
plasmin generation was observed in cross-linked and non-cross-linked fibrin clots in 
either the presence or absence of C3. Panel C. The rate of plasmin generation 
between 0-2 hours was reduced in cross-linked fibrin clots containing C3 and non-
cross-linked fibrin clots containing C3. No difference in the rate of plasmin 
generation was observed in cross-linked and non-cross-linked fibrin clots in either 
the presence or absence of C3. Mean of three independent experiments (SEM). * 
P=<0.05 between +/- C3 in the presence of FXIII.  
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In summary, the present study has confirmed previous clinical study 
findings that suggest C3 prolongs fibrinolysis in both a purified and plasma based 
system. Although fibrin structure was unaffected by the presence of C3, C3 was 
found to cross-link the small primary amine of BP and C3 was cross-linked to fibrin 
in both purified and plasma clots. In addition, C3b was able to form non-enzymatic 
cross-links via its internal thioester with fibrin during the cross-linking process. C3 
was also found to bind to fibrin in plasma clots. This study has also investigated 
potential mechanisms for prolonged fibrinolysis. C3 was found to be a substrate for 
plasmin with the generation of complement activation products of the C3 α chain and 
an unknown cleavage product of the C3 β chain, however as cleavage of C3 occured 
at a similar rate to fibrin cleavage it suggests C3 was not a competitive substrate for 
plasmin in fibrin clots. Alternatively C3 was found to influence plasminogen 
cleavage, plasmin generation and angiostatin production in cross-linked and non-
cross-linked fibrin clots. This study has highlighted possible mechanisms for 
prolonging fibrinolysis which include binding of C3 to conformationally changed t-
PA which prevents plasminogen binding and binding of C3 to plasminogen on the 
fibrin surface or in solution to prevent t-PA mediated plasminogen cleavage. These 
findings suggest C3 was an active component of fibrin clots and was localised to 
fibrin via cross-linking and binding and C3 prolongs fibrinolysis via several 
mechanisms most likely to prevent pathogen invasion.  
.
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Chapter 5 Evaluating the influence of factor H on CVD risk 
and fibrin structure and function 
Complement factor H was previously identified as a clot component in perfused 
solubilised plasma clots (Howes et al. 2012) and as shown by the previous chapter, 
incorporation of C3 into fibrin clots had a functional effect on fibrinolysis. Therefore 
the functional effects of factor H on fibrin structure and function were investigated. 
A factor H ELISA was therefore established to evaluate the percentage incorporation 
of factor H into plasma clots. In a study examining CVD risk in South Asian 
relatives of patients with T2DM compared with healthy South Asian controls, 
increased complement activation (formation of sC5b-9) was observed (Somani et al. 
2012), suggesting the down regulation of an inhibitor in complement activation, 
therefore factor H was proposed as a potential CVD risk factor.  In this study group 
factor H was measured to evaluate the relationship between factor H and CVD risk 
factors, complement activation and fibrin structure and function in South Asian 
relatives and controls.  
 
5.1.   Incorporation of factor H into plasma clots 
Factor H has previously been identified as a plasma clot component (Howes et al. 
2012). To establish the quantity of plasma factor H incorporated into plasma clots, 
factor H concentrations were compared in paired plasma and plasma-derived serum 
samples (n=78). As shown in Figure 44 the concentration of factor H within the clot 
increased with increasing plasma factor H concentration; however, the proportion of 
factor H incorporated into plasma clots varied between individuals from 0% to 34%, 
with a mean incorporation of 11.4% (SD 8.01). Since the concentration of factor H 
within plasma clots varied widely it suggests factor H may play a role in plasma clot 
structure and function. 
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Figure 44: Incorporation of complement factor H into ex vivo plasma clots.  
Factor H was measured by ELISA in paired plasma and plasma derived serum 
samples (n=78). Clot factor H was calculated as the difference between the serum 
concentration of factor H and the plasma concentration of factor H. Panel A: The 
concentration of factor H within plasma clots increased with increasing plasma factor 
H concentration.  
 
5.2.   Relationship between factor H and family history of T2DM 
in South Asians 
5.2.1. Relationship between factor H and conventional risk factors for 
T2DM and CVD in South Asian relatives and controls 
Factor H is a regulator of complement activation and as such alterations in the level 
of factor H may play a role in the inflammatory aspects of T2DM and CVD, 
therefore the relationship between factor H and conventional risk factors of T2DM 
and CVD were investigated. In South Asian relatives and controls (Table 12), plasma 
factor H correlated with the following T2DM and CVD risk factors: BMI, insulin, 
CRP and fibrinogen. Additionally in South Asian controls plasma factor H correlated 
with triglycerides, glucose and HOMA-IR. In linear regression analyses, BMI (1.8% 
variance) was an independent predictor of factor H in South Asian controls and CRP 
(3.6% variance) was an independent predictor of factor H in South Asian relatives. 
R² = 0.3955 
-20 
0 
20 
40 
60 
80 
100 
120 
140 
160 
100 300 500 C
lo
t 
F
a
c
to
r 
H
 (
μ
g
/m
l)
 
Plasma Factor H (μg/ml) 
 170 
 
 
Table 12 : Age and sex adjusted correlation coefficients between factor H and 
conventional risk factors for T2DM and CVD in South Asian controls and 
relatives 
Factor H was significantly correlated with BMI, Insulin, CRP and fibrinogen in 
South Asian controls and relatives. Additionally factor H was significantly correlated 
with triglycerides, glucose and homeostatic model assessment of insulin resistance 
(HOMA-IR) in South Asian controls. HDL: High-density lipoprotein; LDL: Low-
density lipoprotein. 
 South Asian Controls South Asian Relatives 
T2DM and CVD risk factors   
BMI 0.516† 0.368† 
Cholesterol 0.153 0.040 
HDL -0.100 0.096 
LDL 0.155 0.024 
Triglycerides 0.284* 0.005 
Glucose 0.203* -0.069 
Insulin 0.401† 0.221* 
HOMA-IR 0.415† 0.189 
CRP 0.588† 0.522† 
Fibrinogen 0.474† 0.584† 
Significant correlations: *P<0.05, †P<0.001 
 
 
5.2.2. Relationship between factor H and complement components in 
South Asian relatives and controls 
In previous work by Dr Somani, sC5b-9 was found to be significantly (P= <0.0001) 
higher in South Asian relatives compared to South Asian controls (Somani et al. 
2012) and this was not entirely explained by other complement components, 
therefore factor H was analysed to determine if this explained the increase in 
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complement activation. There was no significant difference in factor H levels (P= 
0.46) between South Asian relatives and the South Asian controls (Figure 45). 
Plasma levels of factor H correlated with zymogen complement components 
(Table 13) C3, factor B and properdin (P= <0.001) in both South Asian relatives and 
controls, with no correlation observed between factor H and activated complement 
components fragment Bb, C3a-desArg and sC5b-9 in South Asian relatives; 
however, sC5b-9 was negatively correlated in South Asian controls (P= <0.05). In 
linear regression analyses, C3 and factor B were independent predictors of factor H 
in both South Asian controls (44.1% and 10.9% variance respectively) and South 
Asian relatives (25.5% and 9.2% variance respectively).  
 
 
 
Figure 45: Complement factor H in South Asian relatives of subjects with 
T2DM compared with South Asian controls with no family history. 
Factor H measured by ELISA was not significantly different between 119 South 
Asian relatives (SAR) and 119 South Asian controls (SAC). 
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Table 13: Age and sex adjusted correlation coefficients between factor H and 
complement components in South Asian controls and relatives. 
Factor H was significantly correlated with C3, properdin and factor B in South Asian 
controls and relatives and was negatively correlated with sC5b-9 in South Asian 
controls.  
 South Asian Controls South Asian Relatives  
Complement Components   
C3 0.686† 0.533† 
sC5b-9 -0.230* 0.157 
C3a-desArg 0.041 0.020 
Properdin 0.370† 0.349† 
Factor B 0.638† 0.509† 
Bb -0.098 -0.129 
Significant correlations: *P<0.05, †P<0.001 
 
5.2.3. Relationship between factor H and fibrin structure and function 
in South Asian relatives and controls 
Factor H has been found to be plasma clot component and incorporation of factor H 
within plasma clots varied between individuals suggesting factor H may influence 
plasma clot structure and function. In the South Asian study group, plasma clot 
formation and lysis parameters were previously analysed by Dr Somani (Somani et 
al. 2012, unpublished data), who identified increased maximum absorbance 
(turbidity analysis and concurrent analysis) and reduced fibrinolysis times in South 
Asian relatives compared with controls (see appendix Table 18). Therefore the 
associations between factor H and ex vivo clot parameters were evaluated in this 
study. Initially, the combined study group was split into quartiles according to their 
plasma concentration of factor H. As shown in Figure 46, Panels A-D with 
increasing quartiles of factor H, lag times were significantly reduced and maximum 
absorbance was significantly increased. There was no significant difference in lysis 
times between the highest and lowest quartiles of factor H (Panel E); however, the 
area under the lysis curve was significantly increased with increasing factor H 
quartiles (Panel F).    
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Figure 46: Role of factor H in plasma fibrin formation and lysis. 
The combined South Asian relative and control study group was split into quartiles 
based on plasma factor H concentration and were analysed for turbidimetric clotting 
assay parameters (Panels A & B) and turbidimetric fibrinolysis assay parameters 
(Panels C-F). Panels A & C: Lag time decreased with increasing quartiles of factor 
H. Panels B & D: Maximum absorbance (MaxAbs) increased with increasing 
quartiles of factor H. Panel E: Time to 50% lysis was unaffected by factor H 
quartiles. Panel F: Area under the lysis curve (AUC) increased with increasing 
quartiles of factor H. Error bars are SEM. *P = <0.05. when compared to quartile 1.  
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The age and sex adjusted correlations between factor H and turbidimetric parameters 
in South Asian relatives and controls are presented in Table 14. Factor H was 
significantly correlated with maximum absorbance (turbidity analysis and concurrent 
lysis analysis) and area under the lysis curve in both South Asian relatives and South 
Asian controls and with lysis time in South Asian controls. Factor H was 
significantly inversely correlated with lag time (concurrent analysis) in South Asian 
relatives and South Asian controls and lag time (turbidity analysis) in South Asian 
relatives only. In linear regression analyses, including adjustment for age, sex, 
fibrinogen, and PAI-1, factor H was independently  associated with maximum 
absorbance (turbidity analysis) (P=0.005), 50% lysis time (P=0.006) and area under 
the lysis curve (P=0.041) in South Asian controls however, factor H was not 
independently associated with any fibrin parameter in South Asian relatives. The 
independent associations between factor H and fibrin parameters in healthy controls 
suggested that factor H may influence fibrin clot density and fibrinolysis. Therefore 
additional in vitro experiments were carried out to evaluate the role of complement 
factor H on fibrin formation and fibrinolysis, cross-linking and the interaction with 
the coagulation proteases thrombin and plasmin.  
 
 
 
 
 
 
 
 
 
 175 
 
Table 14: Age and sex adjusted correlation coeffcients between factor H and 
turbidimetric parameters in South Asian relatives and controls 
In South Asian controls, factor H was significantly correlated with maximum 
absorbance (T), maximum absorbance (F), lysis time, area under the lysis curve and 
was negatively correlated with lag time (F). In South Asian relatives, factor H was 
correlated with maximum absorbance (T), maximum absorbance (F), area under the 
lysis curve and was negatively correlated with lag time (F). 
 South Asian Controls South Asian Relatives 
Turbidity clotting analysis   
Lag time (T) -0.118 -0.278* 
Maximum Absorbance (T) 0.546† 0.408† 
   
Concurrent fibrinolysis 
analysis 
  
Lag time (F) -0.238*
 
-0.306† 
Maximum Absorbance (F) 0.477† 0.479† 
Lysis time 0.425† 0.021 
Area under the lysis curve 0.566† 0.445† 
Significant correlations *P = <0.05, † P = <0.001    
 
5.3.   Evaluating the influence of factor H on fibrin formation and 
lysis 
In the South Asian controls, factor H was independently associated with maximum 
absorbance, 50% lysis time and area under the lysis curve, suggesting factor H may 
influence fibrin clot structure and function in healthy individuals. To further clarify 
the clinical observations a turbidimetric assay was performed using purified proteins, 
to assess whether incorporated factor H influences fibrin formation and fibrinolysis. 
There was no significant (P= NS) difference in lag times (Figure 47, Panel A), 
maximum absorbance (Figure 47, Panel B) or 50% lysis times (Figure 47, Panel C) 
between fibrin clots containing no factor H and those containing increasing 
concentrations of factor H up to 100 μg/ml. At supraphysiological concentrations of 
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factor H (500 µg/ml) lag time was significantly longer (P= 0.001); however, 
maximum absorbance and lysis time were not affected by factor H (P= NS). These 
findings in a purified system suggest factor H plays little or no role in fibrin structure 
and function, except at supraphysiological concentrations of factor H, when lag time 
was prolonged, suggesting factor H may compete with fibrinogen and FXIII for 
thrombin cleavage. Since the observations in a purified system suggest factor H plays 
little or no role in fibrin formation and lysis it suggests the clinical observation in the 
South Asian study group may be due to other haemostatic determinants such as 
FXIII.  
 
5.4.   Evaluation of factor H cross-linking to fibrin 
5.4.1. Cross-linking of factor H to fibrin in a purified system 
As shown in appendix A, factor H was present in FXIII-depleted plasma clots but 
was nearly absent in normal pool plasma clots containing FXIII, suggesting factor H 
may be cross-linked to form higher molecular weigh products (Howes et al. 2012), 
therefore to determine whether factor H (procured from Quidel) was cross-linked to 
itself or to fibrin during clot formation, cross-linking assays were set up using 
purified proteins. To determine whether factor H forms cross-links with itself, factor 
H bands were monitored by SDS-PAGE and Western blotting with factor H antibody 
after an incubation of 4 hours in the presence and absence of FXIIIa. As shown in 
Figure 48, panel B there was no difference between the high molecular weight 
smearing/bands between purified factor H alone and purified factor H incubated with 
FXIIIa.  As a positive control fibrinogen was analysed under the same conditions. As 
shown in Figure 48, panels A and C that in the presence of FXIIIa, fibrinogen was 
cross-linked to form γ-dimers and numerous α-polymers, with high molecular weight 
products present in the loading wells. Fibrin and factor H incubated together in the 
presence of FXIIIa for 4 hours produced the same factor H high molecular weight 
bands/smearing compared to in the absence of fibrinogen (Figure 48, Panels B). 
Figure 48, Panel B also shows that in the presence of thrombin a number of factor H 
containing lower molecular weight bands were produced, suggesting either that 
factor H was cleaved by thrombin or factor H was degraded during storage.   
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Figure 47: Evaluating the influence of factor H on fibrin formation and lysis.  
Using purified proteins concurrent clot formation and lysis was measured in a 
turbidimetric assay at 340 nm. Relative lag time, maximum absorbance (MaxAbs) 
and lysis time were calculated as the normalised data to no factor H. Panel A: Lag 
time was increased at supraphysiological concentrations of factor H. Panels B & C: 
Maximum absorbance and lysis time were unaffected by factor H. Three independent 
experiments were performed (SEM). *P = <0.05 after Bonferroni adjustment when 
comparing +/- factor H. 
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Figure 48: Analysis of factor H cross-linking to fibrin in a purified system.  
Factor H and fibrinogen (Fbg) were incubated for 4 hours with thrombin (Thr), calcium (Ca
2+
) and FXIII and analysed by Coomassie stained 
SDS-PAGE (Panel A) and Western blot with anti-factor H (Panel B) and anti-fibrinogen (Panel C) antibodies. Mean of two independent 
experiments. Parentheses indicate high molecular weight factor H products which appear to be present in the purified factor H and are unlikely to 
be FXIII-dependent cross-linked products.Numerous lower molecular weight cleavage products were also observed when factor H was incubated 
with thrombin.
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5.4.2. Cross-linking of factor H to plasma clot components 
Using purified proteins factor H was not cross-linked to fibrin, therefore to determine 
whether factor H was cross-linked to plasma proteins, plasma clots perfused with 
either TBS to remove non-bound proteins or with 2M NaCl to remove bound 
proteins were assessed by Western blot for factor H cross-linking (Figure 49). Factor 
H was observed in the TBS wash, and to a lesser degree in the NaCl wash, with no 
high molecular weight bands present in either the TBS or NaCl washed plasma clots 
(Figure 49, Panel A), suggesting that in plasma factor H was not cross-linked, 
however was capable of binding plasma clot components. As a positive control α2-
AP was analysed in the same plasma clots. No bands were observed at the molecular 
weight of α2-AP; however, numerous high molecular weight bands were observed in 
both the TBS and NaCl wash (Figure 49, Panel B) suggesting α2-AP was cross-
linked. Combined these results suggest factor H was cross-linked to form 
homodimers and factor H binds to plasma clot components.  
 
5.5.   Analysis of factor H cleavage by thrombin and plasmin 
In a purified system factor H did not affect fibrin structure (maximum absorbance) or 
fibrinolysis, but did prolong lag time at supraphysiological concentrations of factor 
H, suggesting thrombin might cleave factor H. Furthermore in the cross-linking 
experiments low molecular weight bands were observed when factor H was 
incubated with thrombin and calcium. Clots formed and lysed in the concurrent 
turbidimetric analysis were analysed by SDS-PAGE and Western blotting to 
determine whether factor H was cleaved during fibrin clot formation/lysis. As shown 
in Figure 50 factor H was cleaved resulting in five cleavage products of ~ 140, 100, 
70, 45 and 37 KDa, with all five cleavage products increasing in intensity with 
increasing factor H (25-100 µg/ml).  
To determine whether thrombin was responsible for cleavage of factor H, 
purified factor H (obtained from Quidel) was incubated with increasing 
concentrations of thrombin for 4 hours and analysed by SDS-PAGE and Western 
blot. As shown in Figure 51 thrombin cleaves factor H into six products of ~140, 
100, ~75, 60, 45 and ~32 KDa; however, the majority of factor H remained in its full 
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length form even at the highest thrombin concentration. Although these factor H 
cleavage products were observed in the cross-linking experiments in the presence of 
thrombin, several other products were also observed suggesting that factor H was 
also degraded. At the concentration of thrombin (0.025 U/ml) used in the concurrent 
turbidimetric assay only two of the cleavage products were observed, which suggests 
factor H was also cleaved by plasmin during fibrinolysis.  
 Since the lysed fibrin clots containing factor H analysed in Figure 50 also 
contained plasmin along with thrombin and a number of the bands were not 
accounted for by thrombin cleavage, purified factor H (obtained from Quidel) was 
incubated with increasing concentrations of plasmin for 4 hours and analysed for 
cleavage products by SDS-PAGE and Western blot. Plasmin cleaved factor H into 
numerous products of ~140, 100, ~75, 60, 45, 37, 24, 20 and 15 KDa. At the highest 
plasmin concentration the majority of full length factor H was cleaved to lower 
molecular weight products. This confirms that plasmin also cleaves factor H, 
however many of the cleavage products observed here were not observed in lysed 
cross-linked fibrin clots containing factor H, suggesting plasmin may have a higher 
affinity for cleaving fibrin rather than factor H, which may account for why no 
difference in fibrinolysis time was observed in the presence of increasing factor H 
concentrations.  
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Figure 49: Analysis of factor H cross-linking in plasma clots.  
Plasma clots formed in a humidified chamber were washed with either Tris buffered 
saline (TBS) or a 2 M NaCl wash for 4 hours. Plasma clots were solubilised and 
analysed by Western blot with anti-factor H (Panel A) and anti-α2-AP (Panel B) 
antibodies. Purified factor H (FH) and α2-antiplasmin (α2-AP) were included as 
controls. Western blots representative of two independent experiments. Western blots 
show that factor H was not cross-linked but does bind plasma clot components, 
whereas α2-AP was cross-linked forming high molecular weight products.
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Figure 50: Concentration dependent cleavage of factor H within purified fibrin 
clots.   
Purified clots produced during the concurrent turbidimetric and lysis analysis were 
analysed for factor H cleavage products by Coomassie stained SDS-PAGE (Panel A) 
and Western blot with an anti-factor H antibody (Panel B). Arrows indicate cleavage 
of factor H with products of ~ 140, 100, 70, 45 and 37 KDa. 
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Figure 51: Cleavage of factor H by thrombin and plasmin.  
Purified factor H was incubated with thrombin or plasmin for 4 hours at 37°C. The resulting cleavage products were analysed by Coomassie 
stained SDS-PAGE (Panel A) and Western blot with an anti-factor H antibody (Panel B). Arrows indicate cleavage products of factor H of 
~140, 100, ~75, 60, 45, 37, ~32, 24, 20 and 15 KDa by thrombin and plasmin.
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5.6.   Discussion 
Factor H was identified by mass spectrometry in perfused solubilised plasma clots by 
Dr Howes (Appendix A). To determine the amount of factor H incorporated into 
plasma clots during clot formation, paired plasma and plasma-derived serum were 
compared using ELISA. Eleven percent of plasma factor H was incorporated into a 
plasma clot, which was well below the 25% incorporation of C3 previously 
determined in the same plasma samples (Howes et al. 2012) and also below the level 
of α2-antiplasmin incorporation of 24-42% (Carter et al. 1999;Cederholm-Williams 
1981;Sakata and Aoki 1980), which is known to be actively incorporated into fibrin 
clots by FXIII-dependent cross-linking (Fraser et al. 2011;Ichinose et al. 
1983;Kimura et al. 1985a;Kimura and Aoki 1986). However as incorporation of 
factor H varied widely between individuals it may suggest that factor H was not 
actively being incorporated during clot formation but instead becomes trapped as a 
result of clot formation or it may play an active role in fibrin structure and function.  
Several studies have investigated the role of the factor H polymorphism 
Tyr402His in CVD risk, with contradictory results (Kardys et al. 2006;Koeijvoets et 
al. 2009;Pai et al. 2007;Zee et al. 2006) Factor H can also be found in atherosclerotic 
lesions, with reduced levels present in areas containing C5b-9 (Seifert et al. 1989). In 
the superficial layer of early atherosclerotic plaques factor H binds to proteoglycans, 
thus limiting complement activation at the C3 convertase stage, whereas deeper in 
the intima factor H was absent enabling full activation of complement cascade and 
the generation of C5b-9 (Oksjoki et al. 2003), suggesting factor H plays a protective 
role in atherosclerosis. Correlation analyses were therefore performed between factor 
H and conventional risk factors for T2DM and CVD in the South Asian study group. 
In both the South Asian controls and South Asian relatives, factor H was positively 
correlated with BMI and insulin. Moreno-Navarrete et al (2010) also found that 
circulating levels of factor H expressed in omental fat deposits were associated with 
obesity, insulin resistance and metabolic parameters. Weight loss or improved insulin 
resistance caused a decrease in factor H levels (Moreno-Navarrete et al. 2010), which 
suggests that factor H was upregulated to help prevent uncontrolled alternative 
pathway activation observed in obesity and diabetes. Factor H was also secreted from 
pancreatic β cells and, as a result, inhibits insulin secretion when combined with 
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adrenomedullin, which could suggest that factor H acts as a chaperone protein for 
adrenomedullin in the regulation of insulin secretion (Martinez et al. 2001). Factor H 
was also positively correlated with the acute phase reactants CRP and fibrinogen in 
both South Asian controls and South Asian relatives, which might suggest 
underlying inflammation in these individuals.  
Factor H is a regulator of the alternative complement pathway by acting as a 
cofactor for factor I in the cleavage of C3b to iC3b, aiding dissociation of the C3 
convertase and competing with factor B for C3b binding (de Cordoba and de Jorge 
2008). As a result, reduced levels of factor H may lead to increased levels of 
complement activation products. Therefore, factor H levels in South Asian relatives 
and controls were investigated to account for the increase in the complement 
activation product soluble C5b-9. However, no difference was observed between the 
South Asian controls and South Asian relatives, suggesting that inhibition of the 
alternative complement pathway by factor H was unaffected. This might suggest that 
reduced expression or function of other complement inhibitors contributes to the 
increased soluble C5b-9. For example the membrane-bound complement inhibitors 
CD55 and CD59 are responsible for preventing the assembly of the alternative 
pathway C3 convertase and the membrane attack complex respectively. In diabetic 
individuals CD55 and CD59 expression is down-regulated in peripheral blood 
leukocytes (Ma et al. 2009). Inactivation of CD59 by glycation leads to uncontrolled 
deposition of the membrane attack complex (Qin et al. 2004), suggesting that down-
regulation of these inhibitors makes them likely candidates for the increase in soluble 
C5b-9 observed in the South Asian relatives. Factor H was positively correlated with 
zymogen complement components C3, properdin and factor B in both South Asian 
controls and South Asian relatives. This might reflect the general synthesis of acute 
phase reactants (complement C3 and factor B) by the liver as a result of TNFα 
stimulation of gene expression (Perlmutter et al. 1986). Factor H was negatively 
correlated with soluble C5b-9 in South Asian controls only; this was expected, as a 
change in the amount of inhibitor would reflect an opposite change in the amount of 
activation product and suggests normal control of complment activation in South 
Asian controls.  
Fibrin formation and final fibrin structure has been found to be a major 
determinant in CVD risk. As patients with MI have altered fibrin architecture, with 
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stiffer fibrin clots and smaller pores, decreased permeability and slower lysis times 
(Collet et al. 2006;Fatah et al. 1996). Furthermore the fibrin structure of plasma clots 
significantly differs to purified fibrin clots (Carr 1988) suggesting plasma proteins 
contribute to the alterations in fibrin structure. To determine whether factor H alters 
fibrin formation and structure, turbidimetric parameters were compared across factor 
H quartiles in the South Asian study group. With increasing quartiles of factor H, the 
time for fibrin protofibril formation was shorter and the final fibrin structure was 
denser. In previous studies, increased fibrin density was associated with prolonged 
fibrinolysis (Collet et al. 2000;Collet et al. 2006), however in the present study there 
was no significant difference in lysis time between the lowest and highest quartiles of 
factor H, although in correlation analyses factor H correlated with inceased fibrin 
clot density and increased lysis times in the South Asian controls. Factor H was 
negatively correlated with time required for protofibril formation and positively 
correlated with fibrin density in South Asian controls and relatives, however after 
accounting for age, sex, fibrinogen and PAI-1, factor H was independently associated 
with maximum absorbance, 50% lysis time and area under the lysis curve in healthy 
individuals only, suggesting factor H may influence fibrin formation and lysis 
parameters. However these analyses can not exclude the affect of other haemostatic 
determinants which may affect fibrin formation and lysis.   
To determine whether factor H plays a functional role in fibrin clot formation 
a turbidimetric assay was performed using purified proteins. Factor H was found not 
to influence the fibrin clot formation and fibrinolysis parameters investigated under 
physiologically relevant concentrations, suggesting that clot structure was unaffected 
by factor H. However, factor H present at supraphysiological concentrations 
significantly prolonged the time taken for protofibril formation (lag time), one 
possibility for this increase in lag time was the observation that factor H was cleaved 
by thrombin in the present study and by a previous study (Ohtsuka et al. 1993). As 
factor H was cleaved by thrombin, it might suggest that lag times should be affected 
by increased factor H over the physiological range; however, this was not observed. 
This could be due to the relatively low concentration of thrombin present in the 
reaction as well as the addition of fibrinogen and FXIII, which are major (and likely 
preferred) substrates for thrombin. These findings in the purified system suggest that 
factor H plays no functional role in fibrin formation and structure.  
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Previously incorporated proteins such as α2-AP have been found to be 
actively cross-linked to fibrin clots by FXIIIa (Fraser et al. 2011;Ichinose et al. 
1983;Kimura et al. 1985a;Kimura et al. 1986). Therefore to determine whether factor 
H was actively incorporated into fibrin clots by FXIIIa-dependent cross-linking, 
cross-linking in purified and plasma based fibrin clots was investigated by SDS-
PAGE and Western blot. Factor H incubated with FXIIIa in the absence of fibrin 
produced no additional high molecular weight products compared to purified factor 
H aloneThe same banding pattern was observed when factor H was incubated with 
fibrin in the presence of FXIIIa. No additional high molecular weight cross-linked 
bands were observed above 300 KDa, suggesting factor H was not cross-linked to 
high molecular weight fibrin α-chain products. Factor H has previously been 
identified to form non-covalent dimers and oligomers in plasma, which may account 
for the high molecular weight products observed in the purified factor H. 
Interestingly, recombinant fragments of factor H; SCR 6-8 and SCR 16-20 form 
dimers (Nan et al. 2008;Okemefuna et al. 2008) with the polymorphism His402 in 
SCR 6-8, promoting dimer formation (Fernando et al. 2007). Pangburn et al (2009) 
found that factor H dimer and oligomer formation was promoted in the presence of 
heparin and dextran sulphate. Factor H oligomer formation promoted binding to C3b, 
which resulted in increased cofactor activity and decay acceleration and therefore 
suppression of complement activation (Pangburn et al. 2009). These studies highlight 
the possibility that factor H and sections of the SCR which form dimers or oligomers, 
which function in complement regulation.  
Similar to the purified cross-linking experiments, the perfused plasma clots 
were also incubated for 4 hours; however no factor H homodimers or cross-linking 
between cleavage products were observed, unlike the positive control α2-
antiplasmin, which was actively cross-linked within plasma clots to provide 
protection against fibrinolysis (Kimura et al. 1985a;Kimura et al. 1985b;Sakata and 
Aoki 1982). This might suggest that in a complex mix of proteins such as plasma, 
factor H may have to compete with other substrates of FXIII for cross-linking. 
Alternatively since factor H was not cross-linked to fibrin, it might be lost from the 
plasma clots during perfusion. A small amount of factor H remained in the washed 
plasma clots, suggesting that although factor H was not actively cross-linked to 
fibrin, it was possible that factor H can bind to a plasma clot component. One 
 188 
 
possibility may be that factor H may bind to fibrin as factor H contains structural 
homology with the coagulation protein FXIII B chain (Reycampos et al. 1990). FXIII 
B chain was found to bind fibrinogen via the γ’ chain (Siebenlist et al. 1996) and the 
αC region (Smith et al. 2011), allowing the transport of FXIII to the site of active 
fibrin clot formation. If binding of factor H to fibrin were to occur then this would 
localise factor H to the site of coagulation and therefore the site of complement 
activation however binding studies are required in the future to confirm factor H 
binding to fibrin.  
As a number of low molecular weight products were present in the cross-
linking analyses, cleavage of factor H within fibrin clots was investigated. Analysis 
of lysed fibrin clots by SDS-PAGE showed that a small amount of factor H was 
cleaved under these reaction conditions. To determine whether this was due to 
thrombin or plasmin purified factor H was incubated with increasing concentrations 
of these enzymes. Thrombin cleaved factor H to form six products of ~140, 100, ~75, 
60, 45 and ~32 KDa; with factor H cleavage occurring at a thrombin concentration as 
low as 0.025 µg/ml, suggesting that prolongation of lag time at supraphysiological 
concentrations of factor H could be due to thrombin cleavage. However, the majority 
of the factor H remained intact after 4 hours even at the highest factor H 
concentration of 18 µg/ml. Ohtsuka et al (1993) found that factor H was cleaved by 
thrombin forming one product of similar molecular weight to intact factor H after 5 
minutes with the majority cleaved after 2 hours by high-performance liquid 
chromatography. As the amino terminus was the same as intact factor H, Ohtsuka et 
al (1993) suggested that the carboxyl terminus was the site of cleavage, in the 
formation of a hydrophobic factor H molecule with monocyte chemotactic activity 
(Ohtsuka et al. 1993). As the molecular weight of this hydrophobic factor H 
molecule and intact factor H appear the same it may account for why the majority of 
factor H appeared to be uncleaved after 4 hours by SDS-PAGE and Western blot in 
the present study. The additional cleavage products of factor H may be due to the 
high thrombin concentration (18 µg/ml compared with 5 µg/ml used by Ohtsuka et 
al. 1993) and longer incubation times used in the cleavage experiment.   
Factor H was also cleaved in the present study by plasmin producing 
numerous products (~140, ~80, 60, 37, 24, 20 and 15 KDa). A similar cleavage 
pattern was observed with trypsin cleavage of factor H by Sim et al (1982) who 
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demonstrated within 25 minutes trypsin cleaved factor H to products of 141 and 34 
KDa, whereas after 90 minutes trypsin further cleaved the 141 KDa chain to form 
products of 88, 26 and 24 KDa (Sim and Discipio 1982). Fontaine et al (1989) found 
that plasmin cleaved plasma factor H to form truncated factor H products on reduced 
gels of 43 and 40 KDa (Fontaine et al. 1989). In the presence of fibrin clots five 
factor H cleavage products were observed in the present study; three of the same 
cleavage products were observed after thrombin (0.025 µg/ml) cleavage of purified 
factor H, whereas all five cleavage products were observed after plasmin cleavage of 
purified factor H, suggesting that cleavage was the result of plasmin and thrombin 
proteolysis. 
In the case of factor H, cleavage by thrombin results in a cleavage product 
which has monocyte chemotactic activity, whilst maintaining the inhibitory activity 
of intact factor H for C3bBb (C3 convertase) and C3b in the production of iC3b 
(Ohtsuka et al. 1993). Ohtsuka et al (1993) did not show the same product after 
plasmin cleavage of factor H; however, factor H fragmentation resulting from 
plasmin cleavage of factor H was previously identified in plasma and these 
fragments also retained cofactor activity for C3b (Fontaine et al. 1989;Sim et al. 
1982). Factor H cleavage either as the result of thrombin and/or plasmin occurred in 
fibrin clots; however, this did not affect lag or lysis times over the physiological 
range, suggesting incorporated factor H may play an important role in controlling 
complement activation and the immune response within the clot rather than 
modulating clot structure or function. The function of factor H in the inhibition of 
complement activation within whole blood clots was highlighted by the ability of 
factor H to bind to activated platelets via receptors GPIIb/IIIa or thrombospondin-1 
(Vaziri-Sani et al. 2005), and preventing C3 activation by aiding factor I mediated 
cleavage of C3 (Hamad et al. 2010). Without this control in complement activation 
by factor H on the surface of platelets, full complement activation and the formation 
of the membrane attack complex would lead to stimulation of α-granule release of 
FV and promote a pro-thrombotic state (Wiedmer et al. 1986). In patients with 
aHUS, platelet surface levels of factor H are significantly decreased; resulting in 
complement component deposition and platelet microparticle release (Stahl et al. 
2008). As platelet microparticles are known to be pro-thrombotic (Keuren et al. 
2006), this study suggests a protective role of factor H in thrombosis. The importance 
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of factor H in controlling complement within a clot was highlighted by the ability of 
thrombin and plasmin cleaved factor H to still retain cofactor activity for cleavage of 
C3b by factor I (Fontaine et al. 1989;Ohtsuka et al. 1993;Sim et al. 1982). Thrombin 
cleaved factor H may further aid the immune response by chemotaxis of monocytes 
for pathogen removal by phagocytosis (Ohtsuka et al. 1993). Since the present study 
has shown that factor H does not affect fibrin structure or function, it suggests factor 
H plays a regulatory role within the clot in regards to complement activation.  
 
In summary, the present study confirmed that factor H was a plasma clot 
component, and showed that only small amounts were incorporated into plasma 
clots. The present study has shown that levels of factor H are not significantly 
different between individuals with a family history of T2DM and healthy controls 
suggesting complement activation in these individuals was the result of down-
regulation of alternative complement inhibitors; however the correlation between 
factor H and acute phase reactants suggest factor H was a marker of ongoing 
inflammation in these individuals. In plasma clots factor H was associated with 
increased clot density and  prolonged lysis in healthy individuals, however the in 
vitro data suggests factor H plays minor roles in fibrin formation and overall fibrin 
structure and lysis even though factor H was found to be cross-linked and cleaved by 
thrombin and plasmin. Previous studies have shown that factor H oligomer 
formation, and cleavage products of factor H remain functionally active, suggesting 
factor H may play a protective role in fibrin clots by preventing uncontrolled 
complement activation rather than modulating fibrin clot structure and function.  
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Chapter 6 Identification of novel FXIII substrates using a 
functional proteomics approach 
In several recent studies the cellular substrates of tissue transglutaminase have been 
identified using BP, the biotin labelled lysine analogue commonly utilised to identify 
reactive glutamine residues (Fleckenstein et al. 2004;Orru et al. 2003). In this study, 
the method was adapted to identify novel substrates of FXIII in plasma as 
summarized in Figure 52. Initially, BP was cross-linked to proteins in fibrinogen 
depleted plasma by FXIIIa. The biotin labelled plasma proteins were purified from 
non-biotin labelled plasma proteins by avidin affinity chromatography prior to MS 
identification of the parent protein and reactive glutamine residues.  
 
 
Figure 52: Proposed method for the identification of novel FXIII substrates in 
plasma 
BP was incubated in fibrinogen depleted plasma in the presence and absence of 
FXIII. BP labelled proteins were separated from non-BP labelled proteins by avidin 
affinity chromatography prior to MS identification of the parent protein. Reactive 
glutamine residues were identified by MS following an additional avidin affinity 
chromatography of the BP containing peptides. 
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6.1.   FXIII-dependent cross-linking of BP into plasma proteins 
6.1.1. Optimisation of the BP cross-linking reaction in normal pool 
plasma  
Cross-linking of BP into plasma proteins by FXIIIa was assessed by Western blotting 
with streptavidin HRP in the following sections. Initial optimisation experiments 
were performed to determine: (1) the optimum concentration of BP and (2) the 
optimum concentration of FXIII, to maximise incorporation of BP and to minimise 
the number of protein-protein cross-links. Normal pooled plasma was initially used 
for these optimisation steps to enable monitoring of FXIII-dependent cross-linking of 
fibrinogen, therefore allowing the assessment of protein-protein cross-link formation.  
Cross-linking of BP into plasma proteins was found to be concentration 
dependent (Figure 53, Panel A) with increased band intensity with increasing BP. At 
10 mM and 25 mM BP a number of high molecular weight bands were observed, 
suggesting protein-protein cross-linking was still taking place. These protein-protein 
cross-links were confirmed to be fibrin cross-linking bands as shown in Figure 53, 
panel B. To determine whether FXIII concentration was a rate-limiting factor in the 
cross-linking reactions, 100-fold excess and 1000-fold excess FXIII (plasma 
concentration of FXIII, 0.022 mg/ml) relative to the concentration of other plasma 
proteins in the reaction were compared. Although the banding pattern for both FXIII 
concentrations were similar, there appeared to be a greater amount of protein-protein 
cross-links formed especially in the presence of either 10 mM or 25 mM BP (Figure 
53, Panel A), which were confirmed as protein-protein cross-links in the fibrinogen 
Western blot (Figure 53, Panel B).  
To enable maximal cross-linking in reactions, samples were required to 
contain excess BP; therefore BP was removed from the samples by centrifugation 
using a 3 KDa molecular weight cut off spin column. The flow-through was 
incubated with FXIII, thrombin and calcium on fibrinogen coated plates and cross-
linking of residual BP was assessed by streptavidin alkaline phosphatase. As shown 
in Figure 53, Panel C in all of the reactions, BP was present in excess; with residual 
BP cross-linking onto the fibrinogen coated plates in a concentration dependent 
manner. The amount of excess BP was independent of FXIII concentration (Figure 
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53, Panel C). Final concentrations of 100 mM BP and 0.022 mg/ml FXIII were 
chosen for subsequent analyses.  
 
 
 
Figure 53: Concentration dependent cross-linking of BP to plasma proteins 
BP (10-100 mM) was incorporated into normal pooled plasma in the presence of 
0.022 mg/ml or 0.22 mg/ml FXIII as analysed by streptavidin HRP Western blot 
(Panel A). High molecular weight fibrin cross-linked products were confirmed by 
anti-fibrinogen (Panel B) Western blot. Panel C. Analysis of excess BP by FXIII 
activity assay. Excess BP from the cross-linking reaction with 0.022 mg/ml FXIII 
(black) and 0.22 mg/ml FXIII (white) was removed by de-salting spin column 
(Millipore) and analysed by FXIII activity assay, with concentration-dependent 
cross-linking of BP to fibrinogen coated plates. Data presented as mean of triplicate 
experiments (SEM). 
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6.1.2. Optimisation of the incubation time for the BP cross-linking 
reaction in fibrinogen depleted plasma  
The optimum concentration of BP and FXIII were determined in normal pooled 
plasma; however, as fibrinogen is a major substrate of FXIII and is relatively 
abundant in plasma (~ 2 mg/ml), fibrinogen depleted plasma was used to facilitate 
the identification of less abundant FXIII substrates. Fibrinogen depleted plasma was 
confirmed to be fibrinogen free by the Clauss fibrinogen assay, which found no 
clotting after 30 minutes. Diluted normal pooled plasma and fibrinogen depleted 
plasma (1 in 100 dilution) were also examined by Western blot for the presence of 
fibrinogen. Although a small amount of fibrinogen was present in the fibrinogen 
depleted plasma, this was significantly less than that observed in normal pooled 
plasma (Figure 54). These experiments confirm that fibrinogen was almost 
completely depleted and residual fibrinogen was insufficient for clot formation.  
 
 
Figure 54: Depletion of fibrinogen in fibrinogen depleted plasma 
Western blot (anti-fibrinogen antibody) of normal pooled plasma (NP) and 
fibrinogen depleted plasma (FDP) show that FDP contains a small amount of 
fibrinogen compared to NP. 
 
 In the previous optimisation steps described in section 6.1.1 BP cross-linking 
reactions were incubated for two hours only. Incubation time was optimised in 
fibrinogen depleted plasma (Figure 55). Although the banding patterns observed 
between the three time points were similar, there was a greater intensity of 
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biotinylated proteins after three hours as observed by streptavidin HRP, with no 
additional increase in band intensity after four hours. This experiment also confirmed 
the use of 100 mM BP in fibrinogen depleted plasma with the greatest intensity of 
biotinylated proteins (Figure 55, Panel A). Excess BP was also assessed by FXIII 
activity assay. At all three time points BP was in excess (Figure 55, Panel B); 
however, with increasing time a reduced amount of BP at 50 mM and 75 mM BP 
was observed. At 100 mM BP the levels remained similar over the three incubation 
time points, thus confirming the use of 100 mM BP in fibrinogen depleted plasma. 
The optimum incubation time of three hours was chosen for subsequent experiments. 
 
 
Figure 55: Time dependent cross-linking of BP to FXIII substrates in fibrinogen 
depleted plasma.   
Panel A. Streptavidin HRP Western blot of BP (50-100 mM) incorporation into 
plasma proteins by FXIIIa over time. Three hours was considered the optimum 
incubation time. Panel B. Excess BP from the cross-linking reaction at 2 hours 
(black) 3 hours (grey) 4 hours (white) was removed by de-salting spin column 
(Millipore) and analysed by FXIII activity assay. Reduced excess BP was observed 
with increasing incubation times in the presence of 50-75 mM BP with no difference 
in excess BP in the presence of 100 mM. Data presented as mean of triplicate 
experiments (SEM).  
 196 
 
6.1.3. Establishment of the positive and negative controls for mass 
spectrometry analysis. 
Once the optimal conditions were established, the negative and positive controls 
were assessed by streptavidin HRP for BP incorporation. FXIII-B subunit binds to 
the alternatively spliced variant of γ-fibrinogen, γ’ (Siebenlist et al. 1996), which 
represents up to ~15% of plasma fibrinogen (Moaddel et al. 2000). FXIII-A2B2 also 
binds to the αC region of fibrinogen specifically between residues 371-425 (Smith et 
al. 2011). These findings confirm a proposal that FXIII might circulate in plasma 
bound to fibrinogen (Greenberg and Shuman 1982), suggesting a possibility that 
fibrinogen depleted plasma would also be depleted of FXIII. To test this theory BP 
incorporation into plasma proteins was compared in the presence and absence of 
exogenous FXIII. Biotinylated plasma proteins were observed under both conditions 
(Figure 56, Panel A). Western blotting therefore confirmed that fibrinogen depleted 
plasma was not free of FXIII or other transglutaminases such as tissue 
trasglutaminase (TG2) and was therefore not a suitable negative control for MS 
analyses. As a negative control for the non-specific interactions with the avidin 
affinity chromatography column, fibrinogen depleted plasma incubated in the 
absence of BP was assessed. As expected, no bands in either the normal pooled 
plasma, fibrinogen depleted plasma or purified fibrinogen were observed in the 
absence of BP (Figure 56, Panels A and B).  
As a positive control for the proteomic investigation, purified fibrinogen was 
used, as the cross-linking sites have been well characterised by previous 
investigators. Cross-linking of BP occurred in the fibrinogen α and γ chains, with a 
small amount of biotinylation in the fibrinogen β chain (Figure 56, Panel B).  BP was 
also cross-linked to a small number of high molecular weight proteins (Figure 56, 
Panel B), which corresponded to BP incorporation into high molecular weight 
protein contamination of either purified fibrinogen or purified FXIII (Figure 56, 
Panel C, arrows). The positive control of purified fibrinogen and the negative control 
of fibrinogen depleted plasma in the absence of BP were chosen for subsequent 
experiments.   
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Figure 56: Evaluation of the positive and negative controls for mass spectrometry.  
Streptavidin HRP Western blot of BP incorporation into plasma proteins (Panel A) and purified fibrinogen (Panel B) in the presence and 
absence of FXIII, with no BP incorporation in the absence of BP. Panel C. Coomassie stained gel of purified fibrinogen and purified FXIII. 
Arrows indicate possible high molecular weight contamination in the fibrinogen and FXIII preparations that could be cross-linked in panel B.
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6.2.   Purification of BP labelled plasma proteins by monomeric 
avdin affinity chromatography 
To remove BP labelled plasma proteins from non-labelled plasma proteins, 
monomeric avidin was used due to its ability to bind biotin within the BP. 
Monomeric avidin was chosen over other avidin techniques due to its high binding 
capacity, low non-specific binding and reusability.  
 
6.2.1. Removal of free BP by dialysis 
Non-incorporated BP can interact with the avidin column, preventing binding of BP 
labelled proteins to the column and therefore reducing the maximum protein binding 
capacity of the column. Several methods for removal of free BP were evaluated. Two 
different dialysis conditions were explored; firstly BP labelled protein samples were 
dialysed three times for 30 minutes in a total of 3 litres of TBS, secondly for two 
times 1 hour and overnight in a total of 6 litres of TBS using a 3 KDa molecular 
weight cut off membrane, and then applied to the avidin column. The protein 
concentration was monitored at 280 nm. Protein containing fractions were 
concentrated by acetone precipitation and analysed for the presence of biotinylated 
proteins by Western blotting with streptavidin HRP. As shown in Figure 57, panels A 
& C, the majority of the protein was washed from the column in the first few 
fractions, and these fractions did contain biotinylated plasma proteins (Figure 57, 
Panels B & D), suggesting insufficient removal of free BP. A small amount of 
biotinylated protein was eluted from the column during the elution step, fractions 17-
26 (Figure 57, Panels C & D), suggesting that a proportion of BP labelled proteins 
bound to the avidin column, but sufficient free BP prevented the majority of BP 
labelled protein from binding to the avidin column. These experiments suggest that 
the samples would require long periods of dialysis and large volumes of buffer for 
the effective removal of BP and that dialysis was an inefficient method for the 
removal of free BP from BP labelled proteins.   
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Figure 57: Removal of free BP by dialysis.  
Panels A & B. Dialysis in 3 litres of TBS for a total of 90 minutes. Panels C & D. 
Dialysis in 6 litres of TBS for a total of 14 hours.  Panels A & C. Chromatogram of 
the monomeric avidin affinity purification shows that the majority of the protein 
eluted during the first few fractions (arrows represent a change in buffer). Panels B 
& D. Acetone precipitation and analysis of fractions by streptavidin HRP Western 
blot, confirms that BP labelled proteins were washed from the column in the first few 
fractions, with a small amount in the elution factions (Panel D) only.  
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6.2.2. Removal of free BP by gel filtration 
Gel filtration separates components via size exclusion, therefore, as BP was 
relatively small at 328.47 Da compared to plasma proteins, it was expected that this 
method would separate free BP from the BP labelled proteins. Two different 
Sephadex G25 columns were evaluated, one of 7 cm by 0.5 cm and one of 7 cm by 
2.5 cm as shown in Figure 58. Protein content of the fractions was monitored at 280 
nm and BP content of the fractions was monitored by FXIII activity assay. In the first 
column the elution profiles of BP and protein overlap, with fibrinogen and plasma 
proteins eluting between fractions 3-13, whereas BP elutes between fractions 6-30 
(Figure 58, Panels A & B). In the second column peak separation was improved, 
with fibrinogen and plasma proteins eluting between fractions 10-20 and BP eluting 
between fractions 19-45 (Figure 58, Panel C & D). This suggested that the 7 cm by 
2.5 cm Sephadex G25 column gave adequate separation for subsequent experiments.   
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Figure 58: Removal of free BP by gel filtration.  
Using a sephadex G25 column of height 7 cm by width 0.5 cm (Panels A & B) 
plasma proteins (blue), purified fibrinogen (green) eluted between fractions 3-13 as 
monitored at 280 nm, whereas BP (pink) eluted between fractions 6-30 as monitored 
by FXIII activity assay. Using a sephadex G25 column of height 7 cm by width 2.5 
cm (Panels C & D) plasma proteins (blue) and purified fibrinogen (green) eluted 
between fractions 10-20, whereas BP (pink) eluted between fractions 19-45. The 
sephadex G25 column height 7 cm by width 2.5 cm was used for subsequent 
experiments. 
 
 
 
 
 
A B 
C D 
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6.2.3. Purification of BP labelled proteins and negative control by gel 
filtration and monomeric avidin affinity chromatography 
The negative control (fibrinogen depleted plasma incubated with FXIIIa in the 
absence of BP), positive control (fibrinogen incubated with FXIIIa and BP) and BP 
labelled fibrinogen depleted plasma samples were purified by gel filtration to remove 
excess BP label. Although the negative control did not contain BP, it underwent gel 
filtration to replicate the conditions under which the BP labelled plasma sample were 
treated. Protein was eluted from the gel filtration column between fractions 9 and 22 
(Figure 59, Panel A, C & E) and BP eluted from the gel filtration column between 
fractions 16 and 45. Fractions 9 to 19 were pooled, concentrated in a 3 KDa 
molecular weight spin column and applied to the monomeric avidin affinity column. 
Following an incubation of one hour on the monomeric avidin column, the protein 
was eluted from the column using the optimised in-house method of purification 
(Section 3.17.2). In the negative control, the majority of the protein was washed from 
the column between fractions 1 and 5 with a small amount of protein observed in the 
salt wash and additional TBS wash step (Figure 59, Panel B). As expected, no 
protein eluted from the column during the elution or regeneration steps. In the 
positive control, a small amount of protein was washed from the column between 
fractions 1 to 15, with the majority eluting during the elution step between fractions 
16 and 28 (Figure 59, Panel D). In the BP labelled plasma protein sample, the 
majority of the protein eluted during the initial wash step between fractions 1 and 8. 
A smaller amount of protein was eluted from the avidin column during the elution 
step between fractions 16 and 22 and also during the regeneration step between 
fractions 23 to 26 (Panel F). The elution fractions from all three samples underwent 
acetone precipitation and were stored for MS analysis. A small amount of the BP 
labelled plasma sample was also analysed for BP labelled proteins by Western blot 
with streptavidin HRP. As shown in Figure 59, panel G the majority of the protein 
washed from the column during the initial TBS wash was non-biotinylated, with only 
a small presence of biotinylated proteins. On the other hand, proteins present in the 
elution fractions were biotinylated, with the greatest amount of biotinylated proteins 
present in fractions 18-19. 
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Figure 59: Purification of BP labelled plasma proteins, positive and negative 
controls by monomeric avidin affinity chromatography 
Panels A, C & E: Protein eluted from the gel filtration column monitored at 280 nm 
(blue) between fractions 9 and 22 and BP eluted from the gel filtration column 
monitored by FXIII activity assay (pink) between fractions 16 to 45. Panels B, D & 
F: Chromatogram of the avidin affinity column purifications monitored at 280 nm 
with non-BP labelled proteins removed during the wash steps and BP labelled 
proteins eluted during the elution fractions. Arrows represent the buffer changes 
specified in Panel B. Panels A & B: Negative control. Panels C & D: Positive 
control. Panels E & F: BP labelled plasma proteins. Panel G: Streptavidin HRP 
Western blot of concentrated fractions from Panel F confirm purification of BP 
labelled proteins 
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6.3.   Identification of BP labelled proteins by mass spectrometry 
The acetone precipitated BP-labelled plasma proteins obtained from the avidin 
affinity column were trypsin digested and analysed by LC-MS/MS to identify both 
the parent protein and the glutamine site of BP incorporation. The resulting peptide 
matches were directly analysed in MASCOT to help identify the parent proteins. The 
negative control was analysed first and, as expected, no proteins were identified. The 
positive control was then analysed with no detection of fibrinogen, as there was 
insufficient protein for identification. The biotinylated plasma protein sample was 
analysed last, with the identification of human serum albumin only (Table 15), 
however no BP labelled peptides were identified within the human serum albumin. 
Failure to identify the positive control and any known plasma substrates of FXIII 
resulted from the strong presence of human serum albumin in the sample and 
insufficient protein concentration; therefore, the following modifications to the 
method were evaluated (a) reduce the monomeric avidin column size to help prevent 
sample dilution (b) increase the protein concentration (c) reduce BP to prevent non-
specific incorporation into albumin (d) performing the acetone precipitation at York 
University immediately prior to MS analysis. 
 
 
Table 15: Characterisation of BP labelled plasma proteins analysed by LC-
MS/MS peptide mass fingerprinting 
Protein Identified 
Accession 
number 
MW 
(KDa) 
MOWSE 
Score 
Expected 
value 
Number of 
peptide 
matches 
Human Serum 
albumin 
gi|6013427 70.7 184 3.9e-05 4 
*MASCOT MOWSE search score is -10 log (p), where p is the probability that the observed 
match is a random event. Search scores >56 indicate identity at the p< 0.05 level.   
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6.4.   Further optimisation of the monomeric avidin purification 
method 
To increase the protein yield obtained during monomeric avidin affinity 
chromatography, several modifications to the previous method were performed 
including reducing the monomeric avidin column size to prevent sample dilution, 
increasing the initial protein concentration of the sample and reducing the BP 
concentration to reduce non-specific binding to albumin.  
 
6.4.1. Establishment of the column size for the purification of BP 
labelled proteins 
To help prevent sample dilution, the column volume of the avidin column was 
reduced from 2 mls to 0.5 mls in the first instance. To check whether the binding 
capacity of the avidin column was affected by column volume, biotinylated BSA was 
applied to the column and protein concentration was monitored at 280 nm. As shown 
in Figure 60, panel A the majority of the biotinylated BSA was washed from the 
column between fractions 0 to 5 with a maximum concentration of 0.12 mg/ml in 
fraction 2. A smaller amount of biotinylated BSA eluted between fractions 7 and 10 
during the elution step, suggesting the binding capacity of the column was 
significantly impaired. The column volume was therefore increased to 1 ml and once 
again the biotinylated BSA elution was monitored at 280 nm. As shown in Figure 60, 
panel B the majority of the biotinylated BSA eluted during the elution step between 
fractions 7 and 13 with a maximum concentration of 0.09 mg/ml in fraction 9. A 
small amount of biotinylated BSA was washed from the column between fractions 1 
and 3; however, these levels were significantly improved compared to the 0.5 ml 
column volume. A column volume of 1 ml was therefore considered to be the 
minimum for future purification of biotinylated plasma proteins.  
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Figure 60: Evaluation of binding capacity of the monomeric avidin column after 
a reduction in column volume.  
Biotinylated BSA elution chromatogram from the avidin affinity column monitored 
at 280 nm. A column volume of 0.5 ml (Panel A) had a binding capacity of 140 μg 
whereas a column colume of 1 ml (Panel B) had a binding capacity of 330 μg. 
Arrows represent changes in buffers.  
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6.4.2. Optimisation of the initial protein concentration 
The initial protein concentration was low due to the initial dilution of the plasma, 
which may have prevented the capture of sufficient plasma proteins by avidin 
affinity chromatography; therefore resulting in insufficient protein for MS. A 10-fold 
(2.05 mg/ml) and 30-fold (9.38 mg/ml) increase in fibrinogen depleted plasma 
protein concentration was incubated in the presence and absence of BP for BP 
labelling as previously described in section 6.1. Fractions 10 to 19 from the gel 
filtration column were pooled, concentrated for each control and BP labelled sample 
and applied to the monomeric avidin column. For both negative controls, plasma 
proteins were washed from the avidin column between fractions 1 and 4 (Figure 61, 
Panels A & D). No protein was eluted during the elution step. 
 For the 10-fold BP labelled sample, plasma proteins were washed from the 
column between fractions 0 and 3 with a maximum concentration of 0.8 mg/ml in 
fraction 1. No protein was eluted during the elution step (Figure 61, Panel B). To 
determine whether biotinylated proteins were present in the initial wash fractions, 
fraction 1 was acetone precipitated and analysed by Western blot with streptavidin 
HRP. As shown in Figure 61, panel C the wash fractions did indeed contain 
biotinylated proteins that were not purified from the non-biotinylated plasma 
proteins. As a greater proportion of BP labelled proteins was expected in the 30-fold 
plasma sample, it was also purified by monomeric avidin. The plasma proteins were 
washed from the column between fractions 1 and 3, with a maximum concentration 
of 3.5 mg/ml in fraction 1. A small amount of protein was eluted during the 
regeneration step only (Figure 61, Panel E).  
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Figure 61: Purification of negative control and BP labelled plasma proteins by monomeric avidin affinity chromatography after an 
increase in the inital protein concentration.  
Chromatogram of protein elutions monitored at 280 nm for the negative control (Panels A & D) and BP labelled plasma (Panels B & E) after an 
incubation with a 10-fold (Panels A & B) and 30-fold (Panels D & E) increase in initial plasma concentration. In all chromatograms protein 
elutes from the monomeric avidin column in the wash step. Arrows indicate the buffer changes outlined in panel A. Panel C. Fraction 1 of panel 
B was acetone precipitated and analysed by streptavidin HRP Western blot and was found to contain BP labelled plasma proteins. 
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As no purified BP labelled proteins were obtained after changing the column 
volume or increasing the initial plasma concentration using the previously optimised 
method, five reactions were combined and purified by monomeric avidin 
chromatography. Five negative control reactions containing 1 in 100 dilutions of 
fibrinogen depleted plasma (total protein content of 0.7 mg/ml) in the presence of 
FXIIIa  and five test samples containing 1 in 100 dilutions of fibrinogen depleted 
plasma (total protein content of 0.7 mg/ml), 5 mM BP and FXIIIa were set up. Each 
reaction was individually gel-filtered as described previously. Fractions 10 to 19 
from all five reactions were pooled, concentrated and applied to the monomeric 
avidin column, with the negative control purified first. As shown in Figure 62, Panel 
A, the majority of the plasma proteins were washed from the column between 
fractions 1 and 3 with a maximum concentration of 1.55 mg/ml in fraction 2. A small 
amount was also washed from the column during the salt wash. As shown in Figure 
62, Panel B, the majority of BP labelled protein was washed from the column 
between fractions 1 and 4, with a maximum protein concentration of 0.75 mg/ml in 
fraction 2. A smaller amount of protein was washed from the column during the salt 
wash; however, no protein was eluted from the column during the elution step.  
 
6.4.3. Establishment of BP concentration to reduce human serum 
albumin labelling 
Human serum albumin was the only protein to be identified by MS, however no BP 
labelled peptides from human serum albumin were determined, suggesting BP may 
be non-specific at high concentrations, therefore BP incorporation into albumin was 
monitored over a range of BP concentrations by streptavidin HRP Western blot and 
compared with an anti-albumin Western blot. In reactions using 5 mM and 10 mM 
BP, the amount of biotinylated albumin was significantly reduced compared to the 50 
mM and 100 mM BP reactions (Figure 63, Panel A), however BP containing high 
molecular weight bands were also found to contain albumin (Figure 63, Panel B), 
suggesting human serum albumin was cross-linked by FXIIIa to form multimers. 
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Figure 62: Purification of pooled BP labelled plasma reactions by monomeric avidin affinity chromatography.  
Panel A. Purification of the negative control resulted in all the protein washing from the column during the wash steps. Panel B. Purification of 
the biotinylated plasma protein samples resulted in all the protein washing from the column during the wash steps.  Protein elution was 
monitored at 280 nm. Arrows represent changes in buffer steps outlined in panel A.  
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Figure 63: Identification of BP labelling of albumin at reduced BP 
concentrations 
BP from 5 mM to 100 mM was incubated with fibrinogen depleted plasma in the 
presence of FXIIIa. BP labelled plasma proteins were observed by streptavidin HRP 
Western blot (Panel A) and compared to an anti-albumin Western blot (Panel B). At 
all concentrations of BP, BP was incorporated into albumin and albumin multimers. 
 
 
This series of optimisation experiments show an inability to optimise the 
monomeric avidin method further as the binding capacity of the monomeric avidin 
column was checked and found to be unaltered from that specified in section 3.17.3.2 
and no excess BP was observed in the BP labelled plasma samples by FXIII activity 
assay (data not shown). Furthermore, BP incorporates into human serum albumin at 
reduced BP concentrations forming albumin multimers, therefore any further series 
of experiments would require starting plasma depleted in both fibrinogen and human 
serum albumin. Therefore a gel based approach to identifying FXIII substrates in 
plasma clots was established. 
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6.5.   Identification of plasma FXIII substrates by SDS-PAGE 
As an alternative method for the identification of FXIII substrates, normal pooled 
plasma clots and FXIII deficient plasma clots formed in a humidified incubator and 
perfused with buffer were compared by SDS-PAGE. The resulting plasma clots were 
reduced in 100 mM DTT, separated by electrophoresis on 3-8 % tris-acetate gels and 
silver stained; the resulting bands in the normal pooled plasma were compared to the 
FXIII deficient plasma to determine possible FXIII substrates. The normal pooled 
plasma clots contained a large number of high molecular weight proteins that were 
poorly resolved under these conditions (Figure 64). Although the FXIII deficient 
plasma clots were better resolved, the band intensity was insufficient for MS 
identification of plasma proteins.  
 
 
Figure 64: SDS-PAGE of a silver stained, perfused, solubilised plasma clots.  
Normal pooled plasma and FXIII depleted plasma clots were perfused with either tris 
buffered saline (TBS) or a salt wash and analysed by SDS-PAGE on 3-8% tris-
acetate gels (silver stained) show poor resolution in the high molecular weight range 
and insufficient protein in the FXIII depleted plasma clots. Gel representative of 
three independent experiments. 
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 Following the poor resolution of the higher molecular weight proteins, 
different temperature and staining conditions were evaluated. Figure 65 panel A, 
shows that higher molecular weight proteins stained with silver were poorly resolved 
whether undergoing a 15 minute treatment at 95°C or one hour at 37°C. However, 
the lower molecular weight bands appeared to be better resolved at 37°C (1 hour) 
compared to the 95°C (15 minutes). Although silver staining was highly sensitive 
and allowed the identification of a large numbers of protein bands, the experiments 
described above suggest it was impossible to distinguish bands in the high molecular 
weight range by SDS-PAGE. As an alternative, reduced plasma clots were analysed 
by SDS-PAGE and stained with coomassie. As shown in Figure 65, panel B, there 
was insufficient protein bands observed from the plasma clots having undergone 
incubation at 95°C. Whereas at 37°C the protein bands were poorly resolved and 
showed protein smearing, possibly suggesting the protein was not reduced 
completely. Due to the time constraints of this project, further evaluation of this 
method was not established; however future progression of this method could include 
the evaluation of different reducing agents (Urea), the amount of protein loaded onto 
the gels or the amount of time the gels were run for.  
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Figure 65: Temperature dependent reduction of solubilised plasma clots  
Panels A & B. Normal pooled plasma clots solubilised by 100 mM DTT and loading 
buffer at 95°C for 15 minutes (Panels A & B) or at 37°C for 1 hour (Panel A) or 1-
24 hours (Panel B). Plasma proteins seperated by SDS-PAGE on a 3-8% Tris 
Acetate gel and were either silver stained (Panel A) or Coomassie stained (Panel B). 
Panel A shows that the plasma proteins were insufficiently resolved within the high 
molecular weight range, whereas panel B shows insufficient protein and protein 
which was poorly reduced. 
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6.6.   Discussion  
The plasma proteome is dynamic and as such contains a large number (~106) and 
range of protein concentrations (55 000 000 000 pM, albumin to 1-5 pM, IL-6) 
(Hortin and Sviridov 2010). For example, the top 10 most concentrated proteins 
make up ~90% of the protein in plasma (Anderson et al. 2004). For this reason it was 
important to investigate subproteomes which perform specific functions within 
plasma, to maximise the yield and analyse the sample in depth. Several processing 
techniques including protein depletion, fractionation and selection for specific 
protein-protein interactions can be used to reduce protein complexity and allow the 
identification of greater numbers of proteins with lower protein concentrations. To 
facilitate identification of FXIII substrates, a combination of the above techniques 
were employed. Protein depletion of fibrinogen from plasma was essential in the 
identification of less abundant substrates. Fibrinogen is one of the ten most abundant 
plasma proteins at a concentration of around 2 mg/ml and is the main substrate for 
FXIIIa. Selection for specific protein-protein interactions was carried out using the 
biotinylated probe, BP. This is a lysine analogue that can be cross-linked by FXIIIa 
to reactive glutamine residues within substrates and, as a result, could form an 
effective probe for the isolation and evaluation of FXIII substrates by avidin affinity 
chromatography. BP was cross-linked into the reactive glutamine residues of a 
number of plasma proteins with protein molecular weights ranging from ~15 KDa 
through to >300 KDa. The optimum BP concentration was determined to be 100 
mM, as it produced the largest proportion of biotinylated proteins whilst reducing 
protein-protein cross-linking interactions. The BP concentration used in the present 
study was significantly higher than the reported 10 mM BP used  for cross-linking 
purified α2-antiplasmin (Lee et al. 2000); however, it was deemed appropriate to use 
higher concentration of BP to allow the maximum number of cross-linking reactions 
to occur within a complex mixture of proteins. The optimum FXIII concentration 
was examined to determine whether FXIII was a rate limiting factor in the cross-
linking reaction. No obvious differences were observed for 100-fold and 1000-fold 
excess FXIII concentrations, possibly as the ratio of FXIII to other plasma proteins 
was already 100 fold greater. The cross-linking of BP into plasma substrates of FXIII 
was also examined over time. A three hour incubation time was considered optimum 
as the greatest intensity of bands was observed. Although FXIII substrates such as 
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fibrin (Standeven et al. 2007) and α2 antiplasmin (Lee et al. 2001) are known to 
cross-link more rapidly to fibrin, von Willebrand factor required an incubation time 
of three hours to cross-link to fibrin in plasma (Hada et al. 1986), suggesting for the 
purpose of identifying potential novel substrates longer incubation times were 
appropriate. 
Fibrinogen depleted plasma with no exogenous FXIII was initially evaluated 
as a negative control, since FXIII can bind to fibrin(ogen) by several identified 
interactions it was possible that FXIII was also depleted from the fibrinogen depleted 
plasma. To test this proposal, FXIII depletion in fibrinogen depleted plasma was 
evaluated by incubating fibrinogen depleted plasma and BP in the absence of added 
FXIII. As cross-linking of BP to plasma proteins was observed, this suggests that 
plasma FXIII may not be bound exclusively to fibrinogen in plasma.  
Immunodepletion of FXIII from the fibrinogen depleted plasma was considered; 
however, this would require prolonged sample handling, possible sample dilution 
and no guarantee that all the FXIII would be removed. Alternatively incorporation of 
BP into fibrinogen depleted plasma proteins may be the result of other members of 
the transglutaminase family such as TG2. Erythrocytes are a known source of plasma 
TG2 and TG2 has previously been found to cross-link fibrin in thrombi (Mutch et al 
2010). Therefore, an alternative negative control containing fibrinogen depleted 
plasma in the absence of BP was investigated. This negative control would allow the 
cross-linking reactions to take place; however, due to the absence of the biotinylated 
probe, the proteins would be eliminated during avidin affinity chromatography. This 
would therefore allow the analysis of non-specific binding of streptavidin HRP to 
plasma proteins and the non-specific binding of proteins to the monomeric avidin 
affinity column. No bands were observed in the absence of BP, suggesting 
streptavidin does not bind non-specifically to the plasma proteins.  
FXIIIa cross-links fibrin to provide the strength and rigidity to a clot. FXIII 
initially cross-links the fibrin γ chain between Lys406 of one γ chain and either 
Gln398 or Gln399 on a neighbouring γ chain to form γ-dimers (Purves et al. 1987). 
FXIII also forms cross-links between fibrin α chains involving Gln221, Gln237, 
Gln328, Gln366 (Cottrell et al. 1979) and Lys508, Lys556, Lys539, Lys580, Lys583, 
Lys418, Lys448, Lys601, Lys606, Lys427, Lys446, Lys429, lys208, Lys224 and 
Lys219 to form α-polymers (Sobel et al. 1996). Therefore, as fibrinogen was a major 
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substrate of FXIII and the glutamine cross-linking sites have been previously 
characterised, fibrinogen was chosen as an appropriate positive control to determine 
the specificity of BP cross-linking. As expected BP, was cross-linked to both the α 
and γ chains of fibrinogen, which confirms previous findings that suggest the α and γ 
chains are the only chains to be cross-linked (Standeven et al. 2007). The intensity of 
the α chain band was greater than that of the γ chain, possibly because there are four 
reactive glutamine residues within the α chain, compared to only two known reactive 
glutamine residues within the γ chain. A small amount of cross-linking of BP was 
also observed in the fibrinogen β chain that has not been previously reported 
(Standeven et al. 2007). This either suggests that the small size of the biotin probe 
allows it to be bound non-specifically to the β chain or that the biotin probe has been 
cross-linked to a currently unknown glutamine site. However as the fibrinogen β 
chain remains at 55 KDa after fibrin cross-linking in previous studies (Standeven et 
al. 2007), it suggests that BP was most likely non-specifically incorporated into the β 
chain. BP was also cross-linked into a number of high molecular weight complexes 
by FXIIIa in purified fibrinogen. These bands represent the formation of γ-dimers, 
suggesting protein-protein cross-linking occurred, as the γ-chain contains more than 
one reactive glutamine residue, additionally higher molecular weight bands represent 
cross-linking of contaminating proteins that were not removed from the purified 
fibrinogen and purified FXIII or high molecular weight cross-linked fibrin α chains. 
Incorporation of BP into plasma proteins was optimised to maximise the number of 
protein identifications, therefore validation of any cross-linking sites identified by 
MS would be required to exclude proteins which are non-specifically identified. 
Avidin affinity chromatography was employed to allow the separation of 
non-BP labelled plasma proteins from FXIII substrates which contained the BP label. 
Several avidin purification methods are summarised in Table 9. Monomeric avidin 
was chosen as the purification method of choice due to its high binding capacity, low 
non-specific binding and lower binding affinity, allowing the avidin-biotin 
interaction to be reversible with 2 mM free biotin. Commercial biotinylated BSA was 
used to check the purification method and the overall binding capacity. As expected, 
the biotinylated BSA bound to the monomeric avidin column and eluted during the 
elution step using both the manufacturers and alternative methods with a binding 
capacity of 1.3 mg of biotinylated BSA per 2 mls of monomeric avidin. The binding 
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capacity was significantly lower than the specified 2.4 mg of biotinylated BSA per 2 
mls of monomeric avidin quoted by the manufacturer (Thermo fisher scientific Inc 
2011). In the first series of experiments, the protein concentration applied to the 
column was significantly lower than the binding capacity of the column (summarised 
in Table 16), to allow the capture of all BP labelled proteins in the plasma sample.   
 As free BP contains the biotin tag, it is also able to attach to the monomeric 
avidin column, thus preventing the attachment of BP labelled plasma proteins. Also, 
due to its small size, attachment to the avidin column may be more accessible 
compared to large proteins containing only one or a few cross-linked BP molecules. 
To remove excess BP from the plasma sample, dialysis was evaluated using a 3.5 
KDa molecular weight cut off membrane, which was significantly larger than the 
328.47 Da of the BP. However, BP- labelled plasma proteins were observed in the 
wash fractions from the monomeric avidin column and were only observed in the 
elution fractions after significantly longer dialysis times with increasing levels of 
buffer, suggesting BP still remained in the sample. This could be due to the high 
starting concentration of BP or insufficient buffer exchange. Dialysis was therefore 
considered ineffective for the removal of BP, as large volumes of buffer would be 
required with increased sample handling time, which might lead to protein 
degradation. Gel filtration was considered as an alternative to the removal of BP. Gel 
filtration separates components via their size, with larger proteins unable to penetrate 
the matrix pores and therefore eluting first, whereas smaller proteins/contaminants 
penetrate the matrix pores and elute later (Hagel 2001). Therefore BP can be readily 
separated from much larger plasma proteins. This technique has been previously 
described for the removal of free BP from cross-linked tissue transglutaminase 
substrates (Fleckenstein et al. 2004;Orru et al. 2003). An additional benefit of using 
this technique was that BP elution from the column can be fully monitored using the 
FXIII activity assay, therefore ensuring the efficient removal of BP from the plasma 
sample. A Sephadex G25 column was selected to separate the plasma proteins from 
the BP, since the exclusion limit of 5000 Da (Hagel 2001) would prevent any protein 
over 5000 Da being retained on the column, with other lower molecular weight 
proteins and BP retained by interactions with the matrix pores of the column to elute 
later. Fleckenstein et al (2004) used a Sephadex G50 superfine column for the 
removal of free BP from biotinylated proteins. Sephadex G50 has an exclusion limit 
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of 30,000 Da (Hagel 2001) and was considered inappropriate for plasma samples, as 
low molecular weight plasma proteins would be excluded with the BP and would 
therefore minimise peak separation. Column dimensions were shown to have a large 
influence on the separation of protein from BP, with peak separation significantly 
improved with a wider column diameter. One explanation for this could be that the 
surface area of the column was increased allowing increased penetration of the BP 
into the matrix pores resulting in improved peak seperation. Gel filtration was 
therefore used in the separation of BP from all biotinylated samples.  
 Once the free BP had been successfully removed, biotinylated purified 
fibrinogen and biotinylated plasma samples were successfully separated from non-
biotinylated proteins by monomeric avidin affinity chromatography. Elution fractions 
were acetone precipitated to remove salt from the samples and to concentrate the 
proteins for MS analysis. Protein samples were analysed by MS using a bottom-up 
approach, whereby the proteins were digested with trypsin before mass analysis 
using an HCTultra ETD II ion trap mass spectrometer. The bottom-up approach is 
known to be particularly effective in the analysis of complex samples and in the 
identification of chemical modifications within peptides (Yates et al. 2009) such as 
the cross-linking of BP to reactive glutamine residues of FXIII substrates. The 
HCTultra ETD II ion trap mass spectrometer used for the analysis of the BP labelled 
proteins was a tandem mass spectrometer that combines electrospray ionisation with 
either collision induced dissociation or electron transfer dissociation. Collision 
induced dissociation is known to be particularly effective for sequence information; 
however, fragmentation by this technique usually occurs at the weakest bond, usually 
at the site of a post-translational modification, such as the BP incorporation site, 
whereas electron transfer dissociation is known to be particularly effective at 
detecting post-translational modifications; however, it results in multiply charged 
fragments (Hartmer et al. 2008;Yates et al. 2009), making it harder to identify the 
parent protein and its sequence using protein databases (Sharma et al. 2010).  This 
mass spectrometer was therefore used to combine the advantages of collision induced 
dissociation with those of electron transfer dissociation in the identification of BP 
labelled plasma proteins due to the posttranslational modification. Human serum 
albumin was the only plasma protein to be identified in the MS analysis. Human 
serum albumin has not been previously characterised as a FXIII substrate; however, 
 220 
 
has been previously found to be cross-linked by tissue transglutaminase forming 
dimers and high molecular weight polymers (Thung et al. 1989). Gupta et al. (2007) 
further showed that BP could be cross-linked to human serum albumin by tissue 
transglutaminase in atherosclerotic plaque tissue (Gupta et al. 2007); however the 
reactive glutamine residues were not identified by this study. As FXIII and tissue 
transglutaminase come from the same enzymatic family, there is a possibility the 
FXIII may also cross-link human serum albumin; however, no BP labels were 
identified in the MS analyses, suggesting that either human serum albumin bound 
non-specifically to the monomeric avidin during the purification stages or the MS 
was unable to pick up the BP label. Subsequent experiments confirmed BP 
incorporation into human serum albumin monomers and polymers which cross-
reacted with both an anti-albumin antibody and streptavidin-HRP, thus confirming 
the observation of human serum albumin polymer formation previously observed in 
the presence of tissue transglutaminase (Thung et al. 1989). Human serum albumin is 
highly abundant in plasma and therefore all the cross-linked bands containing BP 
were also found to contain albumin at both high and low BP levels. Depletion of 
albumin from the fibrinogen depleted plasma was considered, however although 
depletion of albumin from serum was good at over 90% (Bjorhall et al. 2005) 
depletion of albumin from plasma was lower at 72%, with significant loss of low 
abundance proteins (cytokines) observed in this study (Granger et al. 2005). Analysis 
of albumin depleted from serum, identified 67 proteins which were also depleted 
along with the albumin, 57 of these proteins were either of low molecular weight or 
low abundance (Zhou et al. 2004). These studies suggest albumin will most likely 
remain in the plasma sample after depletion, with possible depletion of unknown 
FXIII substrates during the depletion steps.  
 Several issues were identified from the MS analysis; firstly the protein 
concentration of the samples was too low, due to the loss of protein at each step as 
highlighted in Figure 66.  Initially the starting plasma sample was depleted of 
fibrinogen. It was possible that during the immunodepletion procedure plasma 
substrates of FXIII were also depleted, due to binding to fibrinogen or non-
specifically to the immunodepletion column. Another reason could be that the initial 
starting concentration of protein was not sufficient for BP labelling, preventing the 
capture of enough FXIII substrates by avidin affinity chromatography. Although the 
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avidin affinity column was able to purify BP labelled plasma proteins, these were in 
small quantities compared to non-BP labelled proteins. Alterations to the BP 
labelling method were evaluated to help increase the initial protein concentration  
however, this resulted in no BP labelled proteins eluting from the monomeric avidin 
column even though BP labelled proteins were present in the sample by streptavidin 
Western blot. One possibility for the absence of BP labelled proteins in the elution 
step could be that FXIII substrates are present in plasma at relatively low 
concentrations with possibly only one or two reactive glutamine sites available for 
BP labelling per protein, therefore making it harder to attach to the avidin sites from 
within a complex mixture of proteins such as plasma where the majority would not 
be labelled. This may account for why the BP labelled BSA attached to the avidin 
column readily, as the whole sample was BP labelled with eight moles of biotin per 
mole of BSA. This may account for why previous studies have used DTT to reduce 
protein disulphide bonds, during the BP incorporation method to identify substrates 
of tissue transglutaminase (Orru et al. 2003;Ruoppolo et al. 2003), however reducing 
proteins into their component chains may lead to the identification of BP labelled 
proteins by FXIII which would not be otherwise cross-linked in plasma. Finally the 
loss of protein could be due to the acetone precipitation method. Proteins only 
precipitate in ice cold acetone; therefore the absence of a cold centrifuge for 
centrifugation of samples from the freezer would allow the sample to warm during 
centrifugation and in turn cause the re-suspension of the proteins and overall loss of 
yield. Although numerous changes had been made to the reaction conditions, 
removal of free BP and the avidin column itself (changes highlighted in Table 16), 
BP labelled plasma proteins of sufficient quantity was not obtained to allow the 
identification of any proteins other than human serum albumin by MS 
Alternatively, the low yield could be due to the need of a large interaction 
time between the biotinylated protein and the monomeric avidin. According to the 
manufacturer’s instructions, an interaction time of one hour was advised between the 
monomeric avidin and BP labelled proteins (Thermo fisher scientific Inc 2011). 
Whereas a recent study found that even after an interaction time of three hours, 
biotinylated cytochrome C remained in the supernatant following monomeric avidin 
affinity chromatography (Spross and Sinz 2012). Chromatography techniques such 
as avidin affinity chromatography will evolve, allowing for greater sensitivity in the 
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future. For example, in a recent study  monomeric avidin attached to a monolithic 
stationary phase column was found to have a higher binding capacity (7.1 mg of 
BSA/ml of column), better enrichment of biotinylated proteins and required a 
reduced interaction time between the biotinylated protein and the column of 132 
seconds (Spross et al. 2012) compared to commercially sourced monomeric avidin 
(Thermo fisher scientific Inc 2011). Alternatively, avidin or streptavidin could be 
used more extensively in the future due to the design of cleavable linker regions 
within biotin probes (Landi et al. 2010).  
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Figure 66: Stages representing the loss of protein in the proteomics approach 
1. Protein loss during immunodepletion of fibrinogen from plasma could have 
occurred by the non-specific binding to the immunodepletion column or to 
fibrinogen. 2. The starting concentration of proteins in the BP cross-linking reaction 
was insufficient. 3. Due to the exclusion limit of the gel filtration column, proteins of 
<5000 KDa may have been lost during purification. 4. As observed in the following 
series of experiments, BP labelled proteins had difficulty binding to the monomeric 
avidin column. 5. Due to the absence of a cold centrifuge proteins may have 
remained in solution during the acetone precipitation method.  
 
 
 As an alternative method for the identification of FXIII substrates, perfused 
plasma clots and perfused FXIII-deficient clots were compared. The plasma clot 
proteome encompasses proteins which either bind and/or are cross-linked by FXIIIa 
during fibrin clot formation. By perfusing plasma clots with TBS all non-
incorporated plasma proteins were removed, whereas perfusion with a salt wash 
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enabled the removal of bound proteins. Protein bands from perfused solubilised 
normal pooled plasma clots were compared with perfused solubilised FXIII deficient 
plasma clots by SDS-PAGE to determine possible FXIII substrates. Previously Dr 
JM Howes used this technique to identify complement C3, factor H and fibronectin 
as FXIIIa dependent cross-linked substrates (Howes et al. 2012). Therefore, to 
identify additional plasma proteins, 100 μl of plasma were used to form the clots 
compared to only 50 μl previously used (Howes et al. 2012). However, this resulted 
in poor resolution of the high molecular weight bands in the plasma clot. One 
possibility for this could be the accumulation of un-resolved fibrin α-polymers in the 
high molecular weight range, as fibrin polymer formation was also identified 
previously in 2-DE polyacrylamide gels (Howes et al. 2012). Secondly, there was 
insufficient protein within the bands to allow the effective identification by MS. 
Different staining techniques were investigated; silver staining was highly sensitive, 
allowing the identification of larger numbers of proteins; however, due to this 
sensitivity band intensity was insufficient for protein identification by MS. 
Coomassie blue stain was less sensitive than silver stain and as a result less abundant 
proteins were not picked up; however, due to its reduced sensitivity clear bands on a 
Coomassie stained gel usually indicate sufficient protein for MS analysis. In the 
future, alternative denaturing reagents could be used, to provide better separation of 
the higher molecular weight products within fibrin clots. In a recent study, plasma 
clots were washed with a mixture of urea, thiourea and CHAPS (3-[(3-
cholamidopropyl)diethylammonio]-1-propanesulfonate) to remove all non-covalently 
bound proteins for analysis by MS (Talens et al. 2012). This study only identified 
bound proteins (proteins in the supernatant); however this technique could be used in 
the future to identify the cross-linked components of the clot. 
The plasma clot subproteome has previously been investigated by comparing 
the differences in plasma and plasma derived serum samples. Proteins known to be 
involved in coagulation were lower in serum compared to plasma. Whereas 
complement proteins (complement C3 and factor H) were also found to be reduced in 
serum (Misek et al. 2005), suggesting they are incorporated into a plasma clot. 
Analysis of the low molecular weight peptidome of serum identified coagulation 
proteins (prothrombin and fibrinogen) and complement proteins (C3 and C4) with 
peptides most likely produced by cleavage by proteases during plasma clot formation 
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(Tammen et al. 2005).  Niessen et al (2011) not only found that complement proteins 
were present in plasma and whole blood clots but also found that complement 
proteins C1q, C5, C6 and C9 are actively cleaved by proteases using proteomics by 
comparing the changes in molecular weight (Niessen et al. 2011). These studies 
highlight the importance of coagulation and complement proteins in ex vivo 
thrombus formation. The identification of complement proteins within plasma clots 
using proteomics shows that complement activation occurs during thrombus 
formation; however proteomics is unable to determine the functional role of 
complement in thrombus formation, thus supporting the need for in vitro studies to 
validate the proteomic observations.   
 
In summary, the present study has established a functional proteomics based 
method for the identification of reactive glutamine containing substrates of FXIIIa 
using BP. Using this method, human serum albumin was identified as a potential 
substrate and was confirmed to form cross-links with itself in the formation of human 
serum albumin multimers. Although further alterations to the method were made, the 
purification of BP labelled proteins by monomeric avidin proved to be the problem, 
which prevented the present study identifying more FXIII substrates. Further 
advances in avidin purification and MS technology may make this technique possible 
in the future. As an alternative method for the identification of FXIII substrates, a gel 
based approach proved just as problematic with insufficient protein and poor 
resolution within the high molecular range; however future optimisation could 
include trying different reducing agents to improve high molecular weight bands and 
combining numerous clots to increase the protein content.  
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Table 16: Methods evaluated for the purification of BP labelled plasma proteins by monomeric avidin affinity chromatography.  
Highlighted in yellow are the changes made.  
Reaction 
Number 
1 2 3 4 5 6 
Plasma 
Concentration 
0.81 mg/ml 0.72 mg/ml 0.73 mg/ml 2.05 mg/ml 8.64 mg/ml ~0.67 mg/ml per 
sample 
BP 100 mM 100 mM  100 mM 100 mM 100 mM 5 mM 
Reaction Volume 
in TBS 
1 ml 1 ml 1 ml 500 μl 500 μl 5x 1 ml 
Method of 
removal of 
excess BPNH2 
3.5 KDa Dialysis 
3x 30 min in 1 
Litre of TBS 
3.5 KDa dialysis 
2x 1 hour and 
overnight each in 
2 litres of TBS 
7cm by 2.5cm 
sephadex G25 
column followed 
by concentration 
in 3 KDa vivaspin 
column 
7cm by 2.5cm 
sephadex G25 
column followed 
by concentration 
in 3 KDa vivaspin 
column 
7cm by 2.5cm 
sephadex G25 
column followed 
by concentration 
in 3 KDa vivaspin 
column 
7cm by 2.5cm 
sephadex G25 
column followed 
by concentration 
in 3 KDa vivaspin 
column 
Protein applied 
to avidin column  
0.63 mg/ml 0.34 mg/ml 0.31 mg/ml 
 
1.53 mg/ml 
 
5.62 mg/ml 2.26 mg/ml 
Avidin column 
volume 
2 mls 2 mls 2 mls 1 ml 1 ml 2 mls 
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Chapter 7 Conclusions 
Complement and coagulation cascades are derived from common ancestral genes 
(Krem et al. 2002) and are activated to prevent blood loss and pathogen invasion, 
and, as a result, are required to co-localise at the injury site. In previous work 
performed in DCDR, complement proteins C3 and factor H were identified as novel 
plasma clot components using a proteomics based technique (Howes et al. 2012). 
Therefore, these complement proteins were analysed to determine their role in fibrin 
formation and fibrinolysis.  
Complement and coagulation/fibrinolysis proteins interact at numerous levels 
as highlighted in Figure 67. During coagulation thrombin cleaves fibrinogen and 
FXIII to initiate clot formation, whilst thrombin cleavage of C3 results in the 
generation of C3b and C3a at high concentrations, most probably during the 
thrombin burst, when the greatest thrombin concentration is generated (Brummel-
Ziedins et al. 2005). C3a is an anaphylotoxin that attracts phagocytes for the targeted 
destruction (phagocytosis) of pathogens. To prevent excess inflammation as a result 
of anaphylatoxin (C3a and C5a) production, TAFIa, a fibrinolysis inhibitor, 
inactivates C3a and C5a by cleaving the carboxyl terminal lysine or arginine residues 
(Campbell et al. 2001;Leung et al. 2008). Complement activation may also result 
from thrombin generated C3b in the production of the alternative pathway C3 
convertase in the presence of factor B and factor D, ultimately resulting in more C3a, 
C3b and the generation of the membrane attack complex (C5b-9). This could occur 
in fibrin clots as C3b can non-covalently attach to fibrin during cross-linked fibrin 
formation. Factor H may form a protective role in fibrin clots against excessive 
complement activation with thrombin and plasmin cleaved factor H still retaining 
cofactor activity for cleavage of C3b by factor I (Fontaine et al. 1989;Ohtsuka et al. 
1993;Sim et al. 1982). Complement activation in whole blood thrombi was suggested 
by (Distelmaier et al. 2009) by comparing systemic plasma to coronary thrombi. 
Within coronary thrombi levels of C3c, C3a and C5a were significantly increased; 
alternatively, thrombi levels of factor B decreased compared to systemic plasma 
factor B levels, suggesting factor B is consumed in the formation of the alternative 
pathway C3 convertase within thrombi, which was confirmed by the localised 
deposition of C5b-9. The main role for the membrane attack complex within thrombi 
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is in the effective removal of pathogens by cell lysis as part of the innate immune 
response. The importance of complement activation within fibrin clots is highlighted 
by several recent studies which found that FXIIIa dependent entrapment of E.coli 
and S.aureus within fibrin clots helped to prevent systemic infection (Wang et al. 
2010). Whereas Loof et al (2011) found that the intrinsic pathway of coagulation was 
activated on the surface of S.pyogenes bacteria, resulting in FXIIIa dependent 
immobilisation within fibrin clots and the prevention of bacterial release (Loof et al. 
2011). The present study has also shown that complement C3 is incorporated into 
fibrin clots through binding and cross-linking reactions, which would allow C3 to 
localise to the site of active pathogen invasion, furthermore in the presence of C3 and 
FXIII fibrinolysis was significantly prolonged, suggesting complement C3 and FXIII 
play important roles in the prevention of pathogen invasion. Since systemic infection 
was prevented in these studies it suggests that bacterial killing must take place within 
the fibrin clot and therefore suggests a role for complement activation and FXIII in 
this process. Once such mechanism of pathogen removal is phagocytosis, both C3a 
and thrombin cleaved factor H provide chemotaxis of monocytes for pathogen 
removal by phagocytosis (Ohtsuka et al. 1993;Sarma et al. 2011). Phagocytes bind to 
the opsonins C3b and iC3b via CR1, 3 and 4 (Gros et al. 2008;Hatano et al. 2009) 
and as shown in the cross-linking experiments in the present study, C3b is active and 
able to bind to free hydroxyl and amine groups via its internal thioester within fibrin 
clots.  
An alternative mechanism for the formation of the membrane attack complex 
may be in platelet activation. C3b has been shown to bind P-selectin on the surface 
of activated platelets, resulting in the generation of the C3 convertase following 
factor B recruitment and therefore the generation of C3a and C5b-9 (Del, I et al. 
2005). C5b-9 produced as a result of complement activation on activated platelets 
promotes the pro-thrombotic state by aiding factor V release from α granules and the 
formation of the prothrombinase complex on the platelet surface (Wiedmer et al. 
1986). The function of factor H in the inhibition of complement activation within 
whole blood clots is highlighted by the ability of factor H to bind to activated 
platelets via receptors GPIIb/IIIa or thrombospondin-1 (Vaziri-Sani et al. 2005), and 
preventing C3 activation by aiding factor I mediated cleavage of C3 (Hamad et al. 
2010). In patients with aHUS, platelet surface levels of factor H are significantly 
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decreased; resulting in complement component deposition and platelet microparticle 
release (Stahl et al. 2008). As platelet microparticles are known to be pro-thrombotic 
(Keuren et al. 2006), this study suggests a protective role of factor H in thrombosis. 
Hamad et al (2010) found that C3(H2O) bound to activated platelets, which in the 
presence of factor I was cleaved to form iC3(H2O). The resulting iC3(H2O) was able 
to bind complement receptor 1, suggesting a role for iC3(H2O) in the attachment of 
monocytes and neutrophils to platelets and therefore the site of potential 
phagocytosis (Hamad et al. 2010). The formation and role of platelet-leukocyte 
(monocytes or neutrophils) complexes in thrombosis has previously been examined 
in an in vivo baboon model following an arteriovenus shunt. Whereby activated 
platelets expressed P-selectin on their surface which when bound to leukocytes 
promoted leukocyte accumulation within a thrombus and promoted the deposition of 
fibrin (Palabrica et al. 1992). Scholz et al (2002) has since shown that tissue factor 
bound to platelet microparticles is transferred to the monocyte surface in a CD62P 
dependent manner (Scholz et al. 2002), thus promoting the initiation of coagulation 
resulting in fibrin formation.  Furthermore, platelet microparticles bound to 
neutrophils, promoted the expression of CD11b (which in complex with CD18 forms 
CR3) and the phogocytic activity of the neutrophils (Jy et al. 1995).  
Alternatively, during fibrinolysis the process of complement activation may 
be controlled by the coagulation protease plasmin along with conventional 
complement inhibitors to help prevent host tissue damage. In the present study 
plasmin cleaved C3 into C3b and C3a and further cleaved C3b into C3c, C3d and 
cleavage products of the β chain, all of which prevent the formation of the C3 
convertase and therefore complement activation in favour of phagocytosis by the 
attachment of C3b, iC3b and C3c to opsonise pathogens and promote the immediate 
clearance via complement receptor 1 on neutrophils and eosinophils (Gros et al. 
2008;Hatano et al. 2009) or the secondary effect by promoting the adaptive immune 
response in the stimulation of the B cell response via complement receptor 2 
attachment to C3dg or C3d (Sarrias et al. 2001). Amara et al (2010) recently 
confirmed plasmin cleavage of C3 in the generation of C3a and further showed C3a 
recruited neutrophils. Furthermore in a purified system plasmin at physiological 
levels has recently been shown to inhibit the alternative pathway C3 convertase by 
40% and production of the membrane attack complex by 40% (Barthel et al. 2012a); 
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however, C3b degradation by plasmin was inhibited by α2-antiplasmin (Barthel et al. 
2012a), suggesting α2-antiplasmin promotes complement activation and the 
formation of the C3 convertase, however it is unknown whether α2-antiplasmin plays 
a similar role in plasma clots. As shown in the present study C3 prolongs fibrinolysis 
rates via several possible mechanisms including substrate competition, plasmin 
generation and angiostatin production as described in Chapter 4, possibly to prevent 
systemic pathogen invasion. The importance of this is highlighted by the number of 
pathogens that exploit the fibrinolytic system to evade fibrin entrapment and the 
immune system (Summarised in Table 17), with mechanisms including recruitment 
of t-PA or plasminogen, cleavage of fibrinolysis inhibitors or by the production of 
proteins with similar effects to the human fibrinolytic proteins. Several of the 
pathogens summarised in Table 17, recruit/bind plasminogen on their surfaces to 
evade the immune system and fibrin entrapment. Interestingly, C3 also binds 
plasminogen, as discussed above, suggesting C3 may prevent pathogen 
binding/recruitment of plasminogen, thus protecting the fibrin clot from plasmin 
degradation and preventing systemic pathogen invasion. 
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Figure 67: Interaction between C3, factor H and components of the coagulation/fibrinolytic cascades.  
Tissue damage results in the initiation of coagulation, resulting in fibrin clot formation and complement activation. During fibrin formation 
complement C3 binds and is cross-linked to the forming fibrin and pathogens are trapped in the forming clot.  C3 is cleaved within fibrin clots 
either by the C3 convertase or by thrombin/plasmin cleavage. C3 and its cleavage products also bind to plasminogen, possibly to prevent 
recruitment of plasminogen by pathogens. The C3 cleavage product C3a binds to the C3a receptor (C3aR), which initiates thrombomodulin 
shedding, responsible for increased fibrin formation and platelet clumping. Thrombin activatable fibrinolysis inhibitor (TAFI) inhibits this 
process by cleaving C3a into C3a-desArg. Cleavage products C3b recruit the remaining complement components in the formation of the 
membrane attack complex (MAC), which lyse both pathogens within the fibrin clot and platelets. Platelets release factor V from α granules, 
aiding the formation of the prothrombinase complex and therefore coagulation by the production of thrombin. Platelets are protected from this 
lysis by the complement inhibitor factor H. C3a promotes chemotaxis of white blood cells to the clot site, whilst opsonisation by C3b and iC3b of 
the clot may promote white blood cell phagocytosis of pathogens within fibrin clots.
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Table 17: The mode of exploitation of the fibrinolytic system by pathogens 
Pathogen Mode of action Reference 
H.influenzae Binds plasminogen via protein E on its surface, 
cleavage by u-PA resulted in cleavage of fibrin 
and C3b 
(Barthel et al. 
2012b) 
B. burgdorferi Binds plasminogen via lipoprotein A on its 
surface, activated by host plasminogen 
activators. Plasmin produced is protected from 
α2-antiplasmin 
(Fuchs et al. 1994) 
B. burgdorferi Binds plasminogen via ErpP, ErpA, ErpC on 
its surface, activated to plasmin by u-PA 
(Brissette et al. 
2009) 
Y. pestis and  
S. enterica 
Membrane bound proteases, Omptins, 
inactivate PAI-1 
(Haiko et al. 2010) 
M. fermentans Binds plasminogen via two sites on its surface, 
cleavage by u-PA results in host cell invasion 
(Yavlovich et al. 
2001) 
Streptococci  Bind plasminogen via M proteins on its 
surface, activated by streptokinase produced 
by the streptococci 
(Bennasr et al. 
1994) 
Staphylococci Produce the plasminogen activator 
staphylokinase; however, a small amount of 
plasmin is required for full activation 
(Grella and 
Castellino 1997) 
Y. pestis Pla is a plasminogen activator and inactivates 
α2-antiplasmin 
(Kukkonen et al. 
2001) 
 
 
 
In the context of cardiovascular disease, increased fibrinolysis times and 
decreased plasmin generation lead to a pro-thrombotic state, eventually leading to the 
development of occlusive thrombi and ultimately MI or a stroke. Increased 
fibrinolysis times as a result of C3 is particularly important in CVD, as individuals 
with CVD and T2DM have higher plasma levels of C3 compared with healthy 
controls, with increased C3 levels pre-dating disease presentation. (Ajjan et al. 
2005;Carter et al. 2009;Muscari et al. 2000;Onat et al. 2005;Somani et al. 2006). In 
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relatives with a family history of diabetes, levels of C3 were significantly higher than 
healthy controls, with a significant association of C3 with prolonged fibrinolysis 
times observed in these individuals (Schroeder et al. 2010). Hess et al (2011) also 
found that fibrinolysis times were prolonged in type 1 diabetic children compared 
with controls and this correlated with plasma levels of C3 in these individuals (Hess 
et al. 2011), suggesting C3 is pro-thrombotic and may contribute to increased CVD 
risk. A recent study demonstrated that C3b deposition on endothelial cells as a result 
of P-selectin binding was responsible for microvascular thrombosis (Morigi et al. 
2011). Once bound to P-selectin C3b recruited factor B to form the C3 convertase 
and generated C3a. C3a once bound to C3aR on the endothelial cells, was 
responsible for thrombomodulin shedding from the endothelial cells and therefore 
resulting in increased fibrin deposition and platelet clumping. Thrombomodulin is an 
important cofactor in the thrombin mediated activation of the anticoagulant protein C 
and the fibrinolysis inhibitor TAFI (Van de Wouwer and Conway 2004), and 
therefore has anti-coagulant functions, however as highlighted by Morigi et al (2011) 
thrombomodulin shedding resulted in a pro-thrombotic state. The importance of this 
study in cardiovascular thrombosis is highlighted by the increased expression of P-
selection on endothelial cells at the site of active atherosclerotic plaque formation 
(Johnson-Tidey et al. 1994) and increased deposition of complement activation 
products C3b on endothelial cells during atherosclerotic plaque development (Yin et 
al. 2007) suggesting these events might lead to a pro-thrombotic state as a result of 
thrombomodulin shedding. Alternatively, TAFI may be important in inhibiting this 
process, as TAFI can inactivate C3a and C5a by cleaving the carboxyl terminal 
lysine or arginine residues (Campbell et al. 2001;Leung et al. 2008) in the formation 
of C3a desArg. Unlike C3a, C3a desArg formed as a result of carboxypeptidase B 
cleavage was unable to bind C3aR (Wilken et al. 1999). This suggests that TAFI may 
prevent thrombomodulin shedding and the resulting fibrin formation and platelet 
clumping observed in the presence of intact C3a, however if thrombomodulin 
shedding were to occur then activation of TAFI would be prevented and the 
protective mechanisms of TAFI would also be lost. 
In the context of CVD, proteomics is only starting to be fully appreciated in 
the discovery of biomarkers. By comparing plasma from patients with coronary 
artery stenosis with controls with normal arteries, 95 proteins were differentially 
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expressed, with up-regulation of proteins from the following protein groups: 
complement (C1, C3, C4, C5a and factor B), coagulation (fibrinogen γ chain, 
prothrombin) and fibrinolysis (α2 antiplasmin) (Donahue et al. 2006). A decrease in 
α-antitrypsin isoforms and increase in fibrinogen γ isoforms was observed in patients 
with acute coronary syndrome compared with healthy controls (Mateos-Caceres et al. 
2004). A recent study comparing systemic plasma to plasma from an atherosclerotic 
plaque rupture site from MI patients, found that the latter contained 9 proteins which 
were differentially expressed including an increase in complement factor H related 
protein 2 and a decrease in complement factor B, C5, C7, carboxypeptidase N, 
plasminogen, protein S, pigment epithelial derived factor and matrix metalloprotease 
9 (Distelmaier et al. 2012). This study has highlighted the local complement 
activation and potential regulation (complement factor H related protein 2) that 
occurs at coronary atherosclerotic plaque rupture sites. These studies have 
highlighted the role of complement as a marker of CVD and further showed that 
complement was involved in disease pathogenesis, which confirms the role of 
complement in disease pathogenesis previously observed in the in vitro data.  
Proteomic studies have also highlighted the importance of complement and 
coagulation factors during plasma clot formation. In a proteomic study by 
Distelmaier et al (2009), complement activation was observed in the coronary 
thrombi from patients with acute MI, with increased levels of C3c, C3a and C5a and 
deposition of the activation products C3d and C5b-9. As a result of anaphylatoxin 
production, neutrophils were actively recruited to the thrombus site, suggesting 
complement activation either as a result of the conventional pathways or as a result 
of thrombin and plasmin generation potentiate the detrimental effects of complement 
in MI. Several studies have compared plasma to plasma derived serum, with 
components of the coagulation and complement cascades found to be depleted in 
serum compared to plasma. Interestingly, C3 and clusterin were found to have 
molecular weights matching cleavage products in serum with C3 cleavage resulting 
in C3b and C3dg (Misek et al. 2005). Analysis of the serum peptidome (low 
molecular weight peptides) found fibrinogen, prothrombin, albumin, apolipoprotein 
A1, collagen, C4, C3 and several cellular components (Tammen et al. 2005). These 
studies suggest C3 is cleaved and confirms the cleavage products of C3 observed in 
the present study following plasmin cleavage of C3. Initiation of coagulation in 
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plasma and whole blood by the addition of tissue factor and calcium, removed the 
fibrin clot, and then monitored cleavage products of coagulation and complement 
proteins (changes in molecular weight) in the supernatant compared to plasma 
controls. This method observed the majority of coagulation and complement 
proteins, however cleavage only occured in FX, FV, prothrombin, protein S, 
fibrinogen, FXIII, complement C1r, C5, C6 and C9(Niessen et al. 2011). 
Complement C3 cleavage in this study was not identified however this could be 
because they measured components in the supernatant and not the actual thrombi. 
Whereas the direct analysis of perfused solubilised plasma thrombi identified 
complement proteins C3 and factor H along with proteins involved in coagulation 
(fibrin α, β and γ chains, FXIII, α2-macroglobulin, kininogen) protein inhibition 
(inter-alpha-trypsin inhibitor) and binding proteins (fibronectin) (Howes et al. 2012). 
These studies have not only highlighted the importance of complement and 
coagulation proteins in plasma clot formation, but also highlighted the ability of 
complement proteins to be cleaved and potentially activated within plasma clots. In 
the future, proteomics could be used to profile protein production and protein 
cleavage resulting from CVD processes, allowing quick and cheap diagnostic tests to 
be developed for the identification of at risk patients. For example, in the case of MI, 
sera from MI patients compared with normal individuals were found to produce 
increased levels of C3f and FpA, both of which underwent additional amino terminal 
truncation in the formation of a distinct peptide pattern (Marshall et al. 2003). 
Alternatively, proteomics could be used to determine the changing protein profile of 
CVD patients following treatment, allowing practitioners to determine the best 
treatment profile for different stages of the disease.  
 
In conclusion, this study has shown that complement C3 and factor H are not only 
substrates of coagulation specific enzymes (FXIII, thrombin and plasmin), but in the 
case of C3 are also involved in fibrin function by influencing the interactions and 
functions of fibrinolytic proteins.  These effects may be important in preventing 
pathogen invasion whilst promoting the complement response within the fibrin clot 
required for pathogen removal. Whilst factor H did not have the same effects within 
fibrin clots as C3, its function within fibrin clots is likely protective, to prevent 
uncontrolled complement activation and tissue damage. This study has added to the 
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growing body of evidence which suggests complement and coagulation pathways 
interact for the purposes of blood loss and pathogen removal. This study has also 
highlighted the importance of identifying proteins involved in plasma clot formation 
by proteomics and validating their roles in fibrin formation. In the context of CVD, 
understanding the mechanisms involved in fibrin formation and lysis are important in 
determining at risk individuals. 
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Chapter 9 Appendices   
9.1.   Appendix A: Identification of complement proteins in 
perfused, solubilised plasma clots 
 
 
Figure 68: Identification of complement proteins in perfused, solubilised plasma 
clots.  
SDS-PAGE of normal pool plasma clots (PC) and FXIII depleted plasma clots (PC) 
on a 3-8% Tris- acetate gel (Work carried out by Dr JM Howes) Factor H and C3 
identified by MALDI-MS of trypsin digested bands. 
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9.2.   Appendix B: Buffers and Solutions 
C3 PURIFICATION 
PEG I (pH 7.4) 15% PEG 4000 
100 mM Sodium phosphate 
15 mM EDTA 
150 mM NaCl 
0.5 mM PMSF 
PEG II (pH 7.4) 26% PEG 4000 
100 mM Sodium phosphate 
15 mM EDTA 
150 mM NaCl 
0.5 mM PMSF 
Lysine Sepharose I (pH 7.4) 100 mM Sodium phosphate 
15 mM EDTA 
150 mM NaCl 
0.5 mM PMSF 
Lysine Sepharose II (pH 7.4) 100 mM Sodium phosphate 
15 mM EDTA 
150 mM NaCl 
200 mM ε-aminocaproic acid (εACA) 
0.5 mM PMSF 
Ion Exchange I (pH 7.0) 25 mM Sodium phosphate 
5 mM EDTA 
Ion Exchange II (pH 7.0) 25 mM Sodium phosphate 
5 mM EDTA 
25 mM NaCl 
Ion Exchange III (pH 7.0) 25 mM Sodium phosphate 
5 mM EDTA 
300 mM NaCl 
Gel Filtration Buffer (pH 7.4) 100 mM Sodium phosphate 
5 mM EDTA 
150 mM NaCl 
50 mM εACA 
0.5 mM PMSF 
Potassium Phosphate Dialysis Buffer (pH 7.4) 25 mM Potassium phosphate 
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100 mM KCl 
50 mM εACA 
C5 Elution Buffer (pH 7.4) 25 mM Potassium phosphate 
2 M KCl 
C3 Elution Buffer I (pH 7.4) 250 mM Potassium phosphate 
100 mM KCl 
C3 Elution Buffer II (pH7.4) 400 mM Potassium phosphate 
100 mM KCl 
TBS (pH 7.4) 100 mM NaCl 
50 mM Tris 
 
FIBRINOGEN AND FXIII PURIFICATION 
Fibrinogen Equilibration Buffer (pH 7.4) 20 mM Tris 
300 mM NaCl 
1 mM CaCl2 
Fibrinogen Wash Buffer I (pH 7.4) 20 mM Tris 
1 M NaCl 
1 mM CaCl2 
Fibrinogen Wash Buffer II (pH 6.0) 50 mM Na-Acetate 
300 mM NaCl 
1 mM CaCl2 
Fibrinogen Elution Buffer (pH 7.4) 20 mM Tris 
300 mM NaCl 
5 mM EDTA 
TBS (pH 7.4) 100 mM NaCl 
50 mM Tris 
ASSAY BASED BUFFERS 
Transfer Buffer 190 mM Glycine 
20 mM Tris  
40% Methanol 
PBS (pH 7.2) 100 mM Sodium phosphate 
140 mM NaCl 
PBS-Tween (pH 7.2) 100 mM Sodium phosphate 
500 mM NaCl 
 277 
 
0.002% Tween 20 
TBS (pH 7.4) 100 mM NaCl 
50 mM Tris 
TBS1 (pH 7.4) 140 mM NaCl 
40 mM Tris 
TBS1-BSA (pH 7.4) 140 mM NaCl 
40 mM Tris 
1% BSA 
TBS1-T (pH 7.4) 140 mM NaCl 
40 mM Tris 
0.01% Tween 
Diethanolamine Buffer (pH 9.8) 1M Diethanolamine 
0.5 mM MgCl2 
TBS2 (pH 7.4) 110 mM NaCl 
50 mM Tris 
TBS2-T (pH 7.4) 110 mM NaCl 
50 mM Tris 
0.01% Tween 
TBS2-blocking buffer (pH 7.4) 140 mM NaCl 
50 mM Tris 
0.01% Tween 
3% BSA 
Plasmin assay high salt buffer (pH 7.4) 750 mM NaCl 
50 mM Tris 
Fixing solution 40% Methanol 
10% Acetic acid 
Silver nitrate solution 2 mg/ml Silver nitrate 
0.02% Formaldehyde 
Silver nitrate developing solution 30 mg/ml Sodium carbonate 
8.75 µg/ml Pentahydrate sodium 
thiosulphate 
0.05% Formaldehyde 
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9.3.   Appendix C: Letter of ethical approval 
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9.4.   Appendix D: Binding of C3 to fibrin 
 
 
 
Figure 69: Binding interactions between C3 and fibrinogen.  
Experiments performed by Dr Kerrie Smith. Panel A. Binding of C3 to immobilised 
fibrin Panel B. Binding of a recombinant αC fragment (233-425) to immobilised C3 
analysed by SPR using a Biacore 3000.  
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9.5.    Appendix E: Turbidity and lysis measurements in South 
Asian first degree relatives of patients with T2DM and South 
Asian controls with no family history 
 
Table 18: Plasma clot turbidity and lysis measurements in South Asian first 
degree relatives of patients with T2DM and South Asian controls with no family 
history 
Experiments and data analysis performed by Dr Riyaz Somani. Data presented as 
mean and 95% confidence intervals. Differences between the two groups were 
assessed using the Students t-test and were found to have an increase in maximum 
absorbances (MaxAbs) and a decrease in lysis time in South Asian relatives 
compared with South Asian controls.  
 South Asian Controls 
(n=119) 
South Asian Relatives 
(n=119) 
P Value 
Turbidity    
Lag time 338 (319, 357) 337 (318, 356) 0.949 
MaxAbs 0.369 (0.351, 0.386) 0.399 (0.378, 0.419) 0.033 
Concurrent 
turbidity and lysis 
   
Lag time 375 (357, 393) 360 (343, 377) 0.241 
MaxAbs 0.254 (0.239, 0.271) 0.291 (0.272, 0.311) 0.004 
Lysis time 1658 (1625, 1691) 1566 (1530, 1603) 0.001 
AUC 242 (222, 263) 258 (238, 278) 0.287 
AUC (area under the lysis curve) 
